

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 9/00</b>		A2	(11) International Publication Number: <b>WO 99/66028</b> (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: <b>PCT/EP99/04171</b>		[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US).	
(22) International Filing Date: 16 June 1999 (16.06.99)		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	
(30) Priority Data: 09/099,504 18 June 1998 (18.06.98) US 60/101,631 24 September 1998 (24.09.98) US 60/118,906 5 February 1999 (05.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except AT/US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). LIGON, James, Madison [US/US]; 3616 South Pointe Drive, Apex, NC 27502 (US). MOLNAR, Istvan [HU/US]; 4004 Branchwood Drive, Durham, NC 27705 (US). ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, Raleigh, NC 27612 (US). GÖRLACH, Jörn [DE/US]; 3907 King Charles Road, Durham, NC 27707 (US). CYR, Devon			
(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES			
(57) Abstract			
Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

### FIELD OF THE INVENTION

The present invention relates generally to polyketides and genes for their synthesis. In particular, the present invention relates to the isolation and characterization of novel polyketide synthase and nonribosomal peptide synthetase genes from *Sorangium cellulosum* that are necessary for the biosynthesis of epothilones A and B.

### BACKGROUND OF THE INVENTION

Polyketides are compounds synthesized from two-carbon building blocks, the  $\beta$ -carbon of which always carries a keto group, thus the name polyketide. These compounds include many important antibiotics, immunosuppressants, cancer chemotherapeutic agents, and other compounds possessing a broad range of biological properties. The tremendous structural diversity derives from the different lengths of the polyketide chain, the different side-chains introduced (either as part of the two-carbon building blocks or after the polyketide backbone is formed), and the stereochemistry of such groups. The keto groups may also be reduced to hydroxyls, enoyls, or removed altogether. Each round of two-carbon addition is carried out by a complex of enzymes called the polyketide synthase (PKS) in a manner similar to fatty acid biosynthesis.

The biosynthetic genes for an increasing number of polyketides have been isolated and sequenced. For example, see U.S. Patent Nos. 5,639,949, 5,693,774, and 5,716,849, all of which are incorporated herein by reference, which describe genes for the biosynthesis of soraphen. See also, Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998) and WO 98/07868, which describe genes for the biosynthesis of rifamycin, and U.S. Patent No. 5,876,991, which describes genes for the biosynthesis of tylactone, all of which are incorporated herein by reference. The encoded proteins generally fall into two types: type I and type II. Type I proteins are polyfunctional, with several catalytic domains carrying out different enzymatic steps covalently linked together (e.g. PKS for erythromycin, soraphen, rifamycin, and avermectin (MacNeil *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C.

- 2 -


pp. 245-256 (1993)); whereas type II proteins are monofunctional (Hutchinson *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C. pp. 203-216 (1993)).

For the simpler polyketides such as actinorhodin (produced by *Streptomyces coelicolor*), the several rounds of two-carbon additions are carried out iteratively on PKS enzymes encoded by one set of PKS genes. In contrast, synthesis of the more complicated compounds such as erythromycin and soraphen involves PKS enzymes that are organized into modules, whereby each module carries out one round of two-carbon addition (for review, see Hopwood *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C., pp. 267-275 (1993)).

Complex polyketides and secondary metabolites in general may contain substructures that are derived from amino acids instead of simple carboxylic acids. Incorporations of these building blocks are accomplished by non-ribosomal polypeptide synthetases (NRPSs). NRPSs are multienzymes that are organized in modules. Each module is responsible for the addition (and the additional processing, if required) of one amino acid building block. NRPSs activate amino acids by forming aminoacyl-adenylates, and capture the activated amino acids on thiol groups of phosphopantetheinyl prosthetic groups on peptidyl carrier protein domains. Further, NRPSs modify the amino acids by epimerization, N-methylation, or cyclization if necessary, and catalyse the formation of peptide bonds between the enzyme-bound amino acids. NRPSs are responsible for the biosynthesis of peptide secondary metabolites like cyclosporin, could provide polyketide chain terminator units as in rapamycin, or form mixed systems with PKSs as in yersiniabactin biosynthesis.

Epothilones A and B are 16-membered macrocyclic polyketides with an acylcysteine-derived starter unit that are produced by the bacterium *Sorangium cellulosum* strain Sce90 (Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), incorporated herein by reference). The structure of epothilone A and B wherein R signifies hydrogen (epothilone A) or methyl (epothilone B) is:

- 3 -



The epothilones have a narrow antifungal spectrum and especially show a high cytotoxicity in animal cell cultures (see, Höfle *et al.*, Patent DE 4138042 (1993), incorporated herein by reference). Of significant importance, epothilones mimic the biological effects of taxol, both *in vivo* and in cultured cells (Bollag *et al.*, *Cancer Research* 55: 2325-2333 (1995), incorporated herein by reference). Taxol and taxotere, which stabilize cellular microtubules, are cancer chemotherapeutic agents with significant activity against various human solid tumors (Rowinsky *et al.*, *J. Natl. Cancer Inst.* 83: 1778-1781 (1991)). Competition studies have revealed that epothilones act as competitive inhibitors of taxol binding to microtubules, consistent with the interpretation that they share the same microtubule-binding site and possess a similar microtubule affinity as taxol. However, epothilones enjoy a significant advantage over taxol in that epothilones exhibit a much lower drop in potency compared to taxol against a multiple drug-resistant cell line (Bollag *et al.* (1995)). Furthermore, epothilones are considerably less efficiently exported from the cells by P-glycoprotein than is taxol (Gerth *et al.* (1996)). In addition, several epothilone analogs have been synthesized that have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules (WO 98/25929, incorporated herein by reference).

Despite the promise shown by the epothilones as anticancer agents, problems pertaining to the production of these compounds presently limit their commercial potential. The compounds are too complex for industrial-scale chemical synthesis and so must be produced by fermentation. Techniques for the genetic manipulation of myxobacteria such as *Sorangium cellulosum* are described in U.S. Patent No. 5,686,295, incorporated herein by reference. However, *Sorangium cellulosum* is notoriously difficult to ferment and production levels of epothilones are therefore low. Recombinant production of epothilones in heterologous hosts that are more amenable to fermentation could solve current production problems. However, the genes that encode the polypeptides responsible for epothilone bio-

synthesis have heretofore not been isolated. Furthermore, the strain that produces epothilones, i.e. So ce90, also produces at least one additional polyketide, spirangien, which would be expected to greatly complicate the isolation of the genes particularly responsible for epothilone biosynthesis.

Therefore, in view of the foregoing, one object of the present invention is to isolate the genes that are involved in the synthesis of epothilones, particularly the genes that are involved in the synthesis of epothilones A and B in myxobacteria of the Sorangium-/Polyangium group, i.e., *Sorangium cellulosum* strain So ce90. A further object of the invention is to provide a method for the recombinant production of epothilones for application in anticancer formulations.

#### SUMMARY OF THE INVENTION

In furtherance of the aforementioned and other objects, the present invention unexpectedly overcomes the difficulties set forth above to provide for the first time a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone. In a preferred embodiment, the nucleotide sequence is isolated from a species belonging to *Myxobacteria*, most preferably *Sorangium cellulosum*.

In another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID

- 5 -

NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In a more preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684

- 6 -

of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1,

- 7 -

nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In an especially preferred embodiment, the present invention provides a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of

- 8 -

SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

- 9 -

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1.

- 10 -

NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene, wherein the vector is capable of being stably transformed into a host cell. Still further, the present invention provides a recombinant host cell comprising such a chimeric gene, wherein the host cell is capable of expressing the nucleotide sequence that encodes at least one polypeptide necessary for the biosynthesis of an epothilone. In a preferred embodiment, the recombinant host cell is a bacterium belonging to the order *Actinomycetales*, and in a more preferred embodiment the recombinant host cell is a strain of *Streptomyces*. In other embodiments, the recombinant host cell is any other bacterium amenable to fermentation, such as a pseudomonad or *E. coli*. Even further, the present invention provides a Bac clone comprising a nucleic acid molecule of the invention, preferably Bac clone pEPO15.

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a  $\beta$ -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment, said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids

- 11 -

3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino

- 12 -

acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of

- 13 -

SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40,

- 14 -

45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1,

- 15 -

nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

According to yet another embodiment, the epothilone synthase domain is a  $\beta$ -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

According to an additional embodiment, the epothilone synthase domain is a methyltransferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 51534-52657 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 51534-52657 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 61427-62254 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 61427-62254 of SEQ ID NO:1.

In still another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. According to this

embodiment, said non-ribosomal peptide synthetase preferably comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-

12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

The present invention further provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-23.

In accordance with another aspect, the present invention also provides methods for the recombinant production of polyketides such as epothilones in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer. A specific advantage of these production methods is the chirality of the molecules produced; production in transgenic organisms avoids the generation of populations of racemic mixtures, within which some enantiomers may have reduced activity. In particular, the present invention provides a method for heterologous expression of epothilone in a recombinant host, comprising: (a) introducing into a host a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention that comprises a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone; and (b) growing the host in conditions that allow biosynthesis of epothilone in the host. The present invention also provides a method for producing epothilone, comprising: (a) expressing epothilone in a recombinant host by the aforementioned method; and (b) extracting epothilone from the recombinant host.

According to still another aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a  $\beta$ -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment,

- 19 -

said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, and amino acids 32-450 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of

SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

According to yet another embodiment, the epothilone synthase domain is a  $\beta$ -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

According to an additional embodiment, the epothilone synthase domain is a methyl-transferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6.

- 21 -

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

#### DEFINITIONS

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

**Associated With / Operatively Linked:** Refers to two DNA sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

**Chimeric Gene:** A recombinant DNA sequence in which a promoter or regulatory DNA sequence is operatively linked to, or associated with, a DNA sequence that codes for an mRNA or which is expressed as a protein, such that the regulator DNA sequence is able to regulate transcription or expression of the associated DNA sequence. The regulator DNA sequence of the chimeric gene is not normally operatively linked to the associated DNA sequence as found in nature.

**Coding DNA Sequence:** A DNA sequence that is translated in an organism to produce a protein.

**Domain:** That part of a polyketide synthase necessary for a given distinct activity. Examples include acyl carrier protein (ACP),  $\beta$ -ketosynthase (KS), acyltransferase (AT),  $\beta$ -ketoreductase (KR), dehydratase (DH), enoylreductase (ER), and thioesterase (TE) domains.

**Epothilones:** 16-membered macrocyclic polyketides naturally produced by the bacterium *Sorangium cellulosum* strain So ce90, which mimic the biological effects of taxol. In this application, "epothilone" refers to the class of polyketides that includes epothilone A and epothilone B, as well as analogs thereof such as those described in WO 98/25929.

- 22 -

**Epothilone Synthase:** A polyketide synthase responsible for the biosynthesis of epothilone.

**Gene:** A defined region that is located within a genome and that, besides the aforementioned coding DNA sequence, comprises other, primarily regulatory, DNA sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion.

**Heterologous DNA Sequence:** A DNA sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring DNA sequence.

**Homologous DNA Sequence:** A DNA sequence naturally associated with a host cell into which it is introduced.

**Homologous Recombination:** Reciprocal exchange of DNA fragments between homologous DNA molecules.

**Isolated:** In the context of the present invention, an isolated nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

**Module:** A genetic element encoding all of the distinct activities required in a single round of polyketide biosynthesis, i.e., one condensation step and all the  $\beta$ -carbonyl processing steps associated therewith. Each module encodes an ACP, a KS, and an AT activity to accomplish the condensation portion of the biosynthesis, and selected post-condensation activities to effect the  $\beta$ -carbonyl processing.

**NRPS:** A non-ribosomal polypeptide synthetase, which is a complex of enzymatic activities responsible for the incorporation of amino acids into secondary metabolites including, for example, amino acid adenylation, epimerization, N-methylation, cyclization, peptidyl carrier protein, and condensation domains. A functional NRPS is one that catalyzes the incorporation of an amino acid into a secondary metabolite.

**NRPS gene:** One or more genes encoding NRPSs for producing functional secondary metabolites, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

**Nucleic Acid Molecule:** A linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

**ORF:** Open Reading Frame.

**PKS:** A polyketide synthase, which is a complex of enzymatic activities (domains) responsible for the biosynthesis of polyketides including, for example, ketoreductase, dehydratase, acyl carrier protein, enoylreductase, ketoacyl ACP synthase, and acyltransferase. A functional PKS is one that catalyzes the synthesis of a polyketide.

**PKS Genes:** One or more genes encoding various polypeptides required for producing functional polyketides, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

**Substantially Similar:** With respect to nucleic acids, a nucleic acid molecule that has at least 60 percent sequence identity with a reference nucleic acid molecule. In a preferred embodiment, a substantially similar DNA sequence is at least 80% identical to a reference DNA sequence; in a more preferred embodiment, a substantially similar DNA sequence is at least 90% identical to a reference DNA sequence; and in a most preferred embodiment, a substantially similar DNA sequence is at least 95% identical to a reference DNA sequence. A substantially similar DNA sequence preferably encodes a protein or peptide having substantially the same activity as the protein or peptide encoded by the reference DNA sequence. A substantially similar nucleotide sequence typically hybridizes to a reference nucleic acid molecule, or fragments thereof, under the following conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub> pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C. With respect to proteins or peptides, a substantially similar amino acid sequence is an amino acid sequence that is at least 90% identical to the amino acid sequence of a reference protein or peptide and has substantially the same activity as the reference protein or peptide.

**Transformation:** A process for introducing heterologous nucleic acid into a host cell or organism.

**Transformed / Transgenic / Recombinant:** Refers to a host organism such as a bacterium into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to

- 24 -

encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, i.e., a bacterium, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.

#### DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is the nucleotide sequence of a 68750 bp contig containing 22 open reading frames (ORFs), which comprises the epothilone biosynthesis genes.

SEQ ID NO:2 is the protein sequence of a type I polyketide synthase (EPOS A) encoded by *epoA* (nucleotides 7610-11875 of SEQ ID NO:1).

SEQ ID NO:3 is the protein sequence of a non-ribosomal peptide synthetase (EPOS P) encoded by *epoP* (nucleotides 11872-16104 of SEQ ID NO:1).

SEQ ID NO:4 is the protein sequence of a type I polyketide synthase (EPOS B) encoded by *epoB* (nucleotides 16251-21749 of SEQ ID NO:1).

SEQ ID NO:5 is the protein sequence of a type I polyketide synthase (EPOS C) encoded by *epoC* (nucleotides 21746-43519 of SEQ ID NO:1).

SEQ ID NO:6 is the protein sequence of a type I polyketide synthase (EPOS D) encoded by *epoD* (nucleotides 43524-54920 of SEQ ID NO:1).

SEQ ID NO:7 is the protein sequence of a type I polyketide synthase (EPOS E) encoded by *epoE* (nucleotides 54935-62254 of SEQ ID NO:1).

SEQ ID NO:8 is the protein sequence of a cytochrome P450 oxygenase homologue (EPOS F) encoded by *epoF* (nucleotides 62369-63628 of SEQ ID NO:1).

SEQ ID NO:9 is a partial protein sequence (partial Orf 1) encoded by *orf1* (nucleotides 1-1826 of SEQ ID NO:1).

- 25 -

SEQ ID NO:10 is a protein sequence (Orf 2) encoded by *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:11 is a protein sequence (Orf 3) encoded by *orf3* (nucleotides 3415-5556 of SEQ ID NO:1).

SEQ ID NO:12 is a protein sequence (Orf 4) encoded by *orf4* (nucleotides 5992-5612 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:13 is a protein sequence (Orf 5) encoded by *orf5* (nucleotides 6226-6675 of SEQ ID NO:1).

SEQ ID NO:14 is a protein sequence (Orf 6) encoded by *orf6* (nucleotides 63779-64333 of SEQ ID NO:1).

SEQ ID NO:15 is a protein sequence (Orf 7) encoded by *orf7* (nucleotides 64290-63853 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:16 is a protein sequence (Orf 8) encoded by *orf8* (nucleotides 64363-64920 of SEQ ID NO:1).

SEQ ID NO:17 is a protein sequence (Orf 9) encoded by *orf9* (nucleotides 64727-64287 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:18 is a protein sequence (Orf 10) encoded by *orf10* (nucleotides 65063-65767 of SEQ ID NO:1).

SEQ ID NO:19 is a protein sequence (Orf 11) encoded by *orf11* (nucleotides 65874-65008 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:20 is a protein sequence (Orf 12) encoded by *orf12* (nucleotides 66338-65871 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:21 is a protein sequence (Orf 13) encoded by *orf13* (nucleotides 66667-67137 of SEQ ID NO:1).

SEQ ID NO:22 is a protein sequence (Orf 14) encoded by *orf14* (nucleotides 67334-68251 of SEQ ID NO:1).

SEQ ID NO:23 is a partial protein sequence (partial Orf 15) encoded by *orf15* (nucleotides 68346-68750 of SEQ ID NO:1).

SEQ ID NO:24 is the universal reverse PCR primer sequence.

SEQ ID NO:25 is the universal forward PCR primer sequence.

SEQ ID NO:26 is the NH24 end "B" PCR primer sequence.

SEQ ID NO:27 is the NH2 end "A" PCR primer sequence.

SEQ ID NO:28 is the NH2 end "B" PCR primer sequence.

- 26 -

SEQ ID NO:29 is the pEPO15-NH6 end "B" PCR primer sequence.

SEQ ID NO:30 is the pEPO15-H2.7 end "A" PCR primer sequence.

#### DEPOSIT INFORMATION

The following material has been deposited with the Agricultural Research Service, Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. All restrictions on the availability of the deposited material will be irrevocably removed upon the granting of a patent.

<u>Deposited Material</u>	<u>Accession Number</u>	<u>Deposit Date</u>
pEPO15	NRRL B-30033	June 11, 1998
pEPO32	NRRL B-30119	April 16, 1999

#### DETAILED DESCRIPTION OF THE INVENTION

The genes involved in the biosynthesis of epothilones can be isolated using the techniques according to the present invention. The preferable procedure for the isolation of epothilone biosynthesis genes requires the isolation of genomic DNA from an organism identified as producing epothilones A and B, and the transfer of the isolated DNA on a suitable plasmid or vector to a host organism that does not normally produce the polyketide, followed by the identification of transformed host colonies to which the epothilone-producing ability has been conferred. Using a technique such as  $\lambda$ ::Tn5 transposon mutagenesis (de Bruijn & Lupski, *Gene* 27: 131-149 (1984)), the exact region of the transforming epothilone-conferring DNA can be more precisely defined. Alternatively or additionally, the transforming epothilone-conferring DNA can be cleaved into smaller fragments and the smallest that maintains the epothilone-conferring ability further characterized. Whereas the host organism lacking the ability to produce epothilone may be a different species from the organism from which the polyketide derives, a variation of this technique involves the transformation of host DNA into the same host that has had its epothilone-producing ability disrupted by mutagenesis. In this method, an epothilone-producing organism is mutated and non-epothilone-producing mutants are isolated. These are then complemented by genomic DNA isolated from the epothilone-producing parent strain.

A further example of a technique that can be used to isolate genes required for epothilone biosynthesis is the use of transposon mutagenesis to generate mutants of an epothilone-producing organism that, after mutagenesis, fails to produce the polyketide. Thus, the region of the host genome responsible for epothilone production is tagged by the transposon and can be recovered and used as a probe to isolate the native genes from the parent strain. PKS genes that are required for the synthesis of polyketides and that are similar to known PKS genes may be isolated by virtue of their sequence homology to the biosynthetic genes for which the sequence is known, such as those for the biosynthesis of rifamycin or soraphen. Techniques suitable for isolation by homology include standard library screening by DNA hybridization.

Preferred for use as a probe molecule is a DNA fragment that is obtainable from a gene or another DNA sequence that plays a part in the synthesis of a known polyketide. A preferred probe molecule comprises a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen PKS (U.S. Patent No. 5,716,849), and a more preferred probe molecule comprises the  $\beta$ -ketoacyl synthase domains from the first and second modules of the rifamycin PKS (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998)). These can be used to probe a gene library of an epothilone-producing microorganism to isolate the PKS genes responsible for epothilone biosynthesis.

Despite the well-known difficulties with PKS gene isolation in general and despite the difficulties expected to be encountered with the isolation of epothilone biosynthesis genes in particular, by using the methods described in the instant specification, biosynthetic genes for epothilones A and B can surprisingly be cloned from a microorganism that produces that polyketide. Using the methods of gene manipulation and recombinant production described in this specification, the cloned PKS genes can be modified and expressed in transgenic host organisms.

The isolated epothilone biosynthetic genes can be expressed in heterologous hosts to enable the production of the polyketide with greater efficiency than might be possible from native hosts. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, heterologous genes can be expressed in *Streptomyces* and other actinomycetes using techniques such as those described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994), both of which are incorporated herein by reference. See also, Rowe *et al.*, *Gene*

216: 215-223 (1998); Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), all of which are incorporated herein by reference.

Alternately, genes responsible for polyketide biosynthesis, i.e., epothilone biosynthetic genes, can also be expressed in other host organisms such as pseudomonads and *E. coli*. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, PKS genes have been successfully expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985), incorporated herein by reference. In addition, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the tac or trc promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al.*, in: *Industrial Microorganisms: Basic and Applied Molecular Genetics*, Eds. Baltz *et al.*, American Society for Microbiology, Washington (1993)).

Other expression systems that may be used with the epothilone biosynthetic genes of the invention include yeast and baculovirus expression systems. See, for example, "The Expression of Recombinant Proteins in Yeasts," Sudbery, P. E., *Curr. Opin. Biotechnol.* 7(5): 517-524 (1996); "Methods for Expressing Recombinant Proteins in Yeast," Mackay, et al., Editor(s): Carey, Paul R., *Protein Eng. Des.* 105-153, Publisher: Academic, San Diego, Calif (1996); "Expression of heterologous gene products in yeast," Pichuantes, et al., Editor(s): Cleland, J. L., Craik, C. S., *Protein Eng.* 129-161, Publisher: Wiley-Liss, New York, N. Y (1996); WO 98/27203; Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998); "Insect Cell Culture: Recent Advances, Bioengineering Challenges And Implications In Protein Production," Palomares, et al., Editor(s): Galindo, Enrique; Ramirez, Octavio T., *Adv. Bioprocess Eng.* Vol. II, Invited Pap. Int. Symp., 2nd (1998) 25-52, Publisher: Kluwer, Dordrecht, Neth; "Baculovirus Expression Vectors," Jarvis, Donald L., Editor(s): Miller, Lois K., *Baculoviruses* 389-431, Publisher: Plenum, New York, N. Y. (1997); "Production Of Heterologous Proteins Using The Baculovirus/Insect Expression System," Grittiths, et al., *Methods Mol. Biol.* (Totowa, N. J.) 75 (Basic Cell Culture Protocols (2nd Edition)) 427-440 (1997); and "Insect Cell Expression Technology," Luckow, Verne A., *Protein Eng.* 183-218,

Publisher: Wiley-Liss, New York, N. Y. (1996); all of which are incorporated herein by reference.

Another consideration for expression of PKS genes in heterologous hosts is the requirement of enzymes for posttranslational modification of PKS enzymes by phosphopantetheinylation before they can synthesize polyketides. However, the enzymes responsible for this modification of type I PKS enzymes, phosphopantetheinyl (P-pant) transferases are not normally present in many hosts such as *E. coli*. This problem can be solved by coexpression of a P-pant transferase with the PKS genes in the heterologous host, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998), incorporated herein by reference.

Therefore, for the purposes of polyketide production, the significant criteria in the choice of host organism are its ease of manipulation, rapidity of growth (*i.e.* fermentation), possession or the proper molecular machinery for processes such as posttranslational modification, and its lack of susceptibility to the polyketide being overproduced. Most preferred host organisms are actinomycetes such as strains of *Streptomyces*. Other preferred host organisms are pseudomonads and *E. coli*. The above-described methods of polyketide production have significant advantages over the technology currently used in the preparation of the compounds. These advantages include the cheaper cost of production, the ability to produce greater quantities of the compounds, and the ability to produce compounds of a preferred biological enantiomer, as opposed to racemic mixtures inevitably generated by organic synthesis. Compounds produced by heterologous hosts can be used in medical (*e.g.* cancer treatment in the case of epothilones) as well as agricultural applications.

---

## EXPERIMENTAL

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

### Example 1: Cultivation of an Epothilone-Producing Strain of *Sorangium cellulosum*

*Sorangium cellulosum* strain 90 (DSM 6773, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig) is streaked out and grown (30°C) on an agar plate of SolE medium (0.35% glucose, 0.05% tryptone, 0.15% MgSO<sub>4</sub> x 7H<sub>2</sub>O, 0.05% ammonium sulfate, 0.1% CaCl<sub>2</sub>, 0.006% K<sub>2</sub>HPO<sub>4</sub>, 0.01% sodium dithionite, 0.0008% Fe-EDTA, 1.2% HEPES, 3.5% [vol/vol] supernatant of sterilized stationary *S. cellulosum* culture) pH ad. 7.4. Cells from about 1 square cm are picked and inoculated into 5 mls of G51t liquid medium (0.2% glucose, 0.5% starch, 0.2% tryptone, 0.1% probion S, 0.05% CaCl<sub>2</sub>x2H<sub>2</sub>O, 0.05% MgSO<sub>4</sub>x7H<sub>2</sub>O, 1.2% HEPES, pH ad. 7.4) and incubated at 30°C with shaking at 225 rpm. After 4 days, the culture is transferred into 50 mls of G51t and incubated as above for 5 days. This culture is used to inoculate 500 mls of G51t and incubated as above for 6 days. The culture is centrifuged for 10 minutes at 4000 rpm and the cell pellet is resuspended in 50 mls of G51t.

### Example 2: Generation of a Bacterial Artificial Chromosome (Bac) Library

To generate a Bac library, *S. cellulosum* cells cultivated as described in Example 1 above are embedded into agarose blocks, lysed, and the liberated genomic DNA is partially digested by the restriction enzyme *Hind*III. The digested DNA is separated on an agarose gel by pulsed-field electrophoresis. Large (approximately 90-150 kb) DNA fragments are

isolated from the agarose gel and ligated into the vector pBelobacII. pBelobacII contains a gene encoding chloramphenicol resistance, a multiple cloning site in the *lacZ* gene providing for blue/white selection on appropriate medium, as well as the genes required for the replication and maintenance of the plasmid at one or two copies per cell. The ligation mixture is used to transform *Escherichia coli* DH10B electrocompetent cells using standard electroporation techniques. Chloramphenicol-resistant recombinant (white, *lacZ* mutant) colonies are transferred to a positively charged nylon membrane filter in 384 3X3 grid format. The clones are lysed and the DNA is cross-linked to the filters. The same clones are also preserved as liquid cultures at -80°C.

Example 3: Screening the Bac Library of *Sorangium cellulosum* 90 for the Presence of Type I Polyketide Synthase-Related Sequences

The Bac library filters are probed by standard Southern hybridization procedures. The DNA probes used encode β-ketoacyl synthase domains from the first and second modules of the rifamycin polyketide synthase (Schupp et al., *FEMS Microbiology Letters* 159: 201-207 (1998)). The probe DNAs are generated by PCR with primers flanking each ketosynthase domain using the plasmid pNE95 as the template (pNE95 equals cosmid 2 described in Schupp et al. (1998)). 25 ng of PCR-amplified DNA is isolated from a 0.5% agarose gel and labeled with <sup>32</sup>P-dCTP using a random primer labeling kit (Gibco-BRL, Bethesda MD, USA) according to the manufacturer's instructions. Hybridization is at 65°C for 36 hours and membranes are washed at high stringency (3 times with 0.1x SSC and 0.5% SDS for 20 min at 65°C). The labeled blot is exposed on a phosphorescent screen and the signals are detected on a Phospholmager 445SI (screen and 445SI from Molecular Dynamics). This results in strong hybridization of certain Bac clones to the probes. These clones are selected and cultured overnight in 5 mls of Luria broth (LB) at 37°C. Bac DNA from the Bac clones of interest is isolated by a typical miniprep procedure. The cells are resuspended in 200 µl lysozyme solution (50mM glucose, 10 mM EDTA, 25 mM Tris-HCl, 5mg/ml lysozyme), lysed in 400 µl lysis solution (0.2 N NaOH and 2% SDS), the proteins are precipitated (3.0 M potassium acetate, adjusted to pH5.2 with acetic acid), and the Bac DNA is precipitated with isopropanol. The DNA is resuspended in 20µl of nuclease-free distilled water, restricted with *Bam*HI (New England Biolabs, Inc.) and separated on a 0.7% agarose gel. The gel is blotted by Southern hybridization as described above and probed

under conditions described above, with a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen polyketide synthase as the probe (see, U.S. Patent No. 5,716,849). Five different hybridization patterns are observed. One clone representing each of the five patterns is selected and named pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33, respectively.

**Example 4: Subcloning of *Bam*HI Fragments from pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33**

The DNA of the five selected Bac clones is digested with *Bam*HI and random fragments are subcloned into pBluescript II SK+ (Stratagene) at the *Bam*HI site. Subclones carrying inserts between 2 and 10 kb in size are selected for sequencing of the flanking ends of the inserts and also probed with the 1.2 *Sma*I probe as described above. Subclones that show a high degree of sequence homology to known polyketide synthases and/or strong hybridization to the soraphen ketosynthase domain are used for gene disruption experiments.

**Example 5: Preparation of Streptomycin-Resistant Spontaneous Mutants of *Sorangium cellulosum* strain So ce90**

0.1 ml of a three day old culture of *Sorangium cellulosum* strain So ce90, which is raised in liquid medium G52-H (0.2% yeast extract, 0.2% soyameal defatted, 0.8% potato starch, 0.2% glucose, 0.1% MgSO<sub>4</sub> x7H<sub>2</sub>O, 0.1% CaCl<sub>2</sub> x2H<sub>2</sub>O, 0.008% Fe-EDTA, pH ad 7.4 with KOH), is plated out on agar plates with SoIE medium supplemented with 100 µg/ml streptomycin. The plates are incubated at 30°C for 2 weeks. The colonies growing on this medium are streptomycin-resistant mutants, which are streaked out and cultivated once more on the same agar medium with streptomycin for purification. One of these streptomycin-resistant mutants is selected and is called BCE28/2.

Example 6: Gene Disruptions in *Sorangium cellulosum* BCE28/2 Using the Subcloned *Bam*HI Fragments

The *Bam*HI inserts of the subclones generated from the five selected Bac clones as described above are isolated and ligated into the unique *Bam*HI site of plasmid pCIB132 (see, U.S. Patent No. 5,716,849). The pCIB132 derivatives carrying the inserts are transformed into *Escherichia coli* ED8767 containing the helper plasmid pUZ8 (Hedges and Matthew, *Plasmid* 2: 269-278 (1979)). The transformants are used as donors in conjugation experiments with *Sorangium cellulosum* BCE28/2 as recipient. For the conjugation, 5-10 x 10<sup>9</sup> cells of *Sorangium cellulosum* BCE28/2 from an early stationary phase culture (reaching about 5 x 10<sup>8</sup> cells/ml) grown at 30°C in liquid medium G51b (G51b equals medium G51t with tryptone replaced by peptone) are mixed in a 1:1 cellular ratio with a late-log phase culture (in LB liquid medium) of *E. coli* ED8767 containing pCIB132 derivatives carrying the subcloned *Bam*HI fragments and the helper plasmid pUZ8. The mixed cells are then centrifuged at 4000 rpm for 10 minutes and resuspended in 0.5 ml G51b medium. This cell suspension is then plated as a drop in the center of a plate with So1E agar containing 50 mg/l kanamycin. The cells obtained after incubation for 24 hours at 30°C are harvested and resuspended in 0.8 ml of G51b medium, and 0.1 to 0.3 ml of this suspension is plated out on a selective So1E solid medium containing phleomycin (30 mg/l), streptomycin (300 mg/l), and kanamycin (50 mg/l). The counterselection of the donor *Escherichia coli* strain takes place with the aid of streptomycin. The colonies that grow on this selective medium after an incubation time of 8-12 days at a temperature of 30°C are isolated with a plastic loop and streaked out and cultivated on the same agar medium for a second round of selection and purification. The colony-derived cultures that grow on this selective agar medium after 7 days at a temperature of 30°C are transconjugants of *Sorangium cellulosum* BCE28/2 that have acquired phleomycin resistance by conjugative transfer of the pCIB132 derivatives carrying the subcloned *Bam*HI fragments.

Integration of the pCIB132-derived plasmids into the chromosome of *Sorangium cellulosum* BCE28/2 by homologous recombination is verified by Southern hybridization. For this experiment, complete DNA from 5-10 transconjugants per transferred *Bam*HI fragment is isolated (from 10 ml cultures grown in medium G52-H for three days) applying the method described by Pospiech and Neumann, *Trends Genet.* 11: 217 (1995). For the Southern blot, the DNA isolated as described above is cleaved either with the restriction

enzymes *Bg*II, *Cla*I, or *Not*I, and the respective *Bam*HI inserts or pCIB132 are used as 32P labelled probes.

**Example 7: Analysis of the Effect of the Integrated *Bam*HI Fragments on Epothilone Production by *Sorangium cellulosum* After Gene Disruption**

Transconjugant cells grown on about 1 square cm surface of the selective So1E plates of the second round of selection (see Example 6) are transferred by a sterile plastic loop into 10 ml of medium G52-H in an 50 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 3 days, the culture is transferred into 50 ml of medium G52-H in an 200 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 4-5 days, 10 ml of this culture is transferred into 50 ml of medium 23B3 (0.2 % glucose, 2 % potato starch, 1.6 % soya meal defatted, 0.0008 % Fe-EDTA Sodium salt, 0.5 % HEPES (4-(2-hydroxyethyl)-piperazine-1-ethane-sulfonic-acid), 2 % vol/vol polystyrene resin XAD16 (Rohm & Haas), pH adjusted to 7.8 with NaOH) in an 200 ml Erlenmeyer flask.

Quantitative determination of the epothilone produced takes place after incubation of the cultures at 30°C and 180 rpm for 7 days. The complete culture broth is filtered by suction through a 150 µm nylon filter. The resin remaining on the filter is then resuspended in 10 ml isopropanol and extracted by shaking the suspension at 180 rpm for 1 hour. 1 ml is removed from this suspension and centrifuged at 12,000 rpm in an Eppendorff Microfuge. The amount of epothilones A and B therein is determined by means of an HPLC and detection at 250 nm with a UV\_DAD detector (HPLC with Waters -Symetry C18 column and a gradient of 0.02 % phosphoric acid 60%-0% and acetonitril 40%-100%).

Transconjugants with three different integrated *Bam*HI fragments subcloned from pEPO15, namely transconjugants with the *Bam*HI fragment of plasmid pEPO15-21, transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-5, and transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-1, are tested in the manner described above. HPLC analysis reveals that all transconjugants no longer produce epothilone A or B. By contrast, epothilone A and B are detectable in a concentration of 2-4 mg/l in transconjugants with *Bam*HI fragments integrated that are derived from pEPO20, pEPO30, pEPO31, pEPO33, and in the parental strain BCE28/2.

**Example 8: Nucleotide Sequence Determination of the Cloned Fragments and Construction of Contigs**

**A. BamHI Insert of Plasmid pEPO15-21**

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-21], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-21 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs. Both strands are entirely sequenced, and every nucleotide is sequenced at least two times. The nucleotide sequence is compiled using the program Sequencher vers. 3.0 (Gene Codes Corporation), and analyzed using the University of Wisconsin Genetics Computer Group programs. The nucleotide sequence of the 2213-bp insert corresponds to nucleotides 20779-22991 of SEQ ID NO:1.

**B. BamHI Insert of Plasmid pEPO15-4-1**

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-1], and the nucleotide sequence of the 3.9-kb *Bam*HI insert in pEPO15-4-1 is determined as described in (A) above. The nucleotide sequence of the 3909-bp insert corresponds to nucleotides 16876-20784 of SEQ ID NO:1.

**C. BamHI Insert of Plasmid pEPO15-4-5**

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-5], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-4-5 is determined as described in (A) above. The nucleotide sequence of the 2233-bp insert corresponds to nucleotides 42528-44760 of SEQ ID NO:1.

- 36 -

**Example 9: Subcloning and Ordering of DNA Fragments from pEPO15 Containing Epothilone Biosynthesis Genes**

pEPO15 is digested to completion with the restriction enzyme *Hind*III and the resulting fragments are subcloned into pBluescript II SK- or pNEB193 (New England Biolabs) that has been cut with *Hind*III and dephosphorylated with calf intestinal alkaline phosphatase. Six different clones are generated and named pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24 (all based on pNEB193), and pEPO15-H2.7 and pEPO15-H3.0 (both based on pBluescript II SK-).

The *Bam*HI insert of pEPO15-21 is isolated and DIG-labeled (Non-radioactive DNA labeling and detection system, Boehringer Mannheim), and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH24, indicating that pEPO15-21 is contained within pEPO15-NH24.

The *Bam*HI insert of pEPO15-4-1 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH24 and pEPO15-H2.7. Nucleotide sequence data generated from one end each of pEPO15-NH24 and pEPO15-H2.7 are also in complete agreement with the previously determined sequence of the *Bam*HI insert of pEPO15-4-1. These experiments demonstrate that pEPO15-4-1 (which contains one internal *Hind*III site) overlaps pEPO15-H2.7 and pEPO15-NH24, and that pEPO15-H2.7 and pEPO15-NH24, in this order, are contiguous.

The *Bam*HI insert of pEPO15-4-5 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH2, indicating that pEPO15-21 is contained within pEPO15-NH2.

Nucleotide sequence data is generated from both ends of pEPO15-NH2 and from the end of pEPO15-NH24 that does not overlap with pEPO15-4-1. PCR primers NH24 end "B": GTGACTGGCGCCTGGAATCTGCATGAGC (SEQ ID NO:26), NH2 end "A": AGCGGGAGCTTGCTAGACATTCTGTTTC (SEQ ID NO:27), and NH2 end "B": GACGCGCCTCGGGCAGCGCCCCAA (SEQ ID NO:28), pointing towards the *Hind*III sites,

are designed based on these sequences and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair NH24 end "B" and NH2 end "A" with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH24 and pEPO15-NH2, fused at the *Hind*III site, establishing that the *Hind*III fragments of pEPO15-NH2 and pEPO15-NH24 are, in this order, contiguous.

The *Hind*III insert of pEPO15-H2.7 is isolated and DIG-labeled as above, and used as a probe in a DNA hybridization experiment at high stringency against pEPO15 digested by *Not*I. A *Not*I fragment of about 9 kb in size shows a strong a hybridization, and is further subcloned into pBluescript II SK- that has been digested with *Not*I and dephosphorylated with calf intestinal alkaline phosphatase, to yield pEPO15-N9-16. The *Not*I insert of pEPO15-N9-16 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH6, and also for the expected clones pEPO15-H2.7 and pEPO15-NH24. Nucleotide sequence data is generated from both ends of pEPO15-NH6 and from the end of pEPO15-H2.7 that does not overlap with pEPO15-4-1. PCR primers are designed pointing towards the *Hind*III sites and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair pEPO15-NH6 end "B": CACCGAAGCGTCGATCTGGTCCATC (SEQ ID NO:29) and pEPO15-H2.7 end "A": CGGTCAAGATCGACGACGGGCTTC (SEQ ID NO:30) with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH6 and pEPO15-H2.7, fused at the *Hind*III site, establishing that the *Hind*III fragments of pEPO15-NH6 and pEPO15-H2.7 are, in this order, contiguous.

All of these experiments, taken together, establish a contig of *Hind*III fragments covering a region of about 55 kb and consisting of the *Hind*III inserts of pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, and pEPO15-NH2, in this order. The inserts of the remaining two *Hind*III subclones, namely pEPO15-NH1 and pEPO15-H3.0, are not found to be parts of this contig.

**Example 10: Further Extension of the Subclone Contig Covering the Epothilone Biosynthesis Genes**

An approximately 2.2 kb *Bam*HI – *Hind*III fragment derived from the downstream end of the insert of pEPO15-NH2 and thus representing the downstream end of the subclone contig described in Example 9 is isolated, DIG-labeled, and used in Southern hybridization experiments against pEPO15 and pEPO15-NH2 DNAs digested with several enzymes. The strongly hybridizing bands are always found to be the same in size between the two target DNAs indicating that the *Sorangium cellulosum* So ce90 genomic DNA fragment cloned into pEPO15 ends with the *Hind*III site at the downstream end of pEPO15-NH2.

A cosmid DNA library of *Sorangium cellulosum* So ce90 is generated, using established procedures, in pScosTriplex-II (Ji, et al., *Genomics* 31: 185-192 (1996)). Briefly, high-molecular weight genomic DNA of *Sorangium cellulosum* So ce90 is partially digested with the restriction enzyme *Sau*3AI to provide fragments with average sizes of about 40 kb, and ligated to *Bam*HI and *Xba*I digested pScosTriplex-II. The ligation mix is packaged with Gigapack III XL (Stratagene) and used to transfet *E. coli* XL1 Blue MR cells.

The cosmid library is screened with the approximately 2.2 kb *Bam*HI – *Hind*III fragment, derived from the downstream end of the insert of pEPO15-NH2, used as a probe in colony hybridization. A strongly hybridizing clone, named pEPO4E7 is selected.

pEPO4E7 DNA is isolated, digested with several restriction endonucleases, and probed in Southern hybridization experiments with the 2.2 kb *Bam*HI – *Hind*III fragment. A strongly hybridizing *Nor*I fragment of approximately 9 kb in size is selected and subcloned into pBluescript II SK- to yield pEPO4E7-N9-8. Further Southern hybridization experiments reveal that the approximately 9 kb *Nor*I insert of pEPO4E7-N9-8 overlaps pEPO15-NH2 over 6 kb in a *Nor*I – *Hind*III fragment, while the remaining approximately 3 kb *Hind*III – *Nor*I fragment would extend the subclone contig described in Example 9. End sequencing reveals, however, that the downstream end of the insert of pEPO4E7-N9-8 contains the *Bam*HI – *Nor*I polylinker of pScosTriplex-II, thereby indicating that the genomic DNA insert of pEPO4E7 ends at a *Sau*3AI site within the extending *Hind*III – *Nor*I fragment and that the *Nor*I site is derived from pScosTriplex-II.

An approximately 1.6 kb *Pst*I – *Sal*I fragment derived from the approximately 3 kb extending *Hind*III – *Nor*I subfragment of pEPO4E7-N9-8, containing only *Sorangium*

*cellulosum* So ce90-derived sequences free of vector, is used as a probe against the bacterial artificial chromosome library described in Example 2. Besides the previously-isolated EPO15, a Bac clone, named EPO32, is found to strongly hybridize to the probe. pEPO32 is isolated, digested with several restriction endonucleases, and hybridized with the approximately 1.6 kb *Pst*I – *Sal*I probe. A *Hind*III – *Eco*RV fragment of about 13 kb in size is found to strongly hybridize to the probe, and is subcloned into pBluescript II SK-digested with *Hind*III and *Hinc*II to yield pEPO32-HEV15.

Oligonucleotide primers are designed based on the downstream end sequence of pEPO15-NH2 and on the upstream (*Hind*III) end sequence derived from pEPO32-HEV15, and used in sequencing reactions with pEPO4E7-N9-8 as the template. The sequences reveal the existence of a small *Hind*III fragment (EPO4E7-H0.02) of 24 bp, undetectable in standard restriction analysis, separating the *Hind*III site at the downstream end of pEPO15-NH2 from the *Hind*III site at the upstream end of pEPO32-HEV15.

Thus, the subclone contig described in Example 9 is extended to include the *Hind*III fragment EPO4E7-H0.02 and the insert of pEPO32-HEV15, and constitutes the inserts of: pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, pEPO15-NH2, EPO4E7-H0.02 and pEPO32-HEV15, in this order.

**Example 11: Nucleotide Sequence Determination of the Subclone Contig Covering the Epothilone Biosynthesis Genes**

The nucleotide sequence of the subclone contig described in Example 10 is determined as follows.

pEPO15-H2.7. Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-H2.7], and the nucleotide sequence of the 2.7-kb *Bam*HI insert in pEPO15-H2.7 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs.

- 40 -

pEPO15-NH6, pEPO15-NH24 and pEPO15-NH2. The *Hind*III inserts of these plasmids are isolated, and subjected to random fragmentation using a Hydroshear apparatus (Genomic Instrumentation Services, Inc.) to yield an average fragment size of 1-2 kb. The fragments are end-repaired using T4 DNA Polymerase and Klenow DNA Polymerase enzymes in the presence of desoxynucleotide triphosphates, and phosphorylated with T4 DNA Kinase in the presence of ribo-ATP. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *Eco*RV and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

pEPO32-HEV15. pEPO32-HEV15 is digested with *Hind*III and *Ssp*I, the approximately 13.3 kb fragment containing the ~13 kb *Hind*III – *Eco*RV insert from *So. cellulosum* Sce90 and a 0.3 kb *Hinc*II – *Ssp*I fragment from pBluescript II SK- is isolated, and partially digested with *Hae*III to yield fragments with an average size of 1-2 kb. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *Eco*RV and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

The chromatograms are analyzed and assembled into contigs with the Phred, Phrap and Consed programs (Ewing, et al., *Genome Res.* 8(3): 175-185 (1998); Ewing, et al., *Genome Res.* 8(3): 186-194 (1998); Gordon, et al., *Genome Res.* 8(3): 195-202 (1998)). Contig gaps are filled, sequence discrepancies are resolved, and low-quality regions are resequenced using custom-designed oligonucleotide primers for sequencing on either the original subclones or selected clones from the random subclone libraries. Both strands are completely sequenced, and every basepair is covered with at least a minimum aggregated Phred score of 40 (confidence level of 99.99%).

The nucleotide sequence of the 68750 bp contig is shown as SEQ ID NO:1.

**Example 12: Nucleotide Sequence Analysis of the Epothilone Biosynthesis Genes**

SEQ ID NO:1 is found to contain 22 ORFs as detailed below in Table 1:

**Table 1**

ORF	Start codon	Stop codon	Homology of deduced protein	Proposed function of deduced protein
<i>orf1</i>	outside of sequenced range	1826		
<i>orf2</i> *	3171	1900	Hypothetical protein SP: Q11037; DD-peptidase SP:P15555	
<i>orf3</i>	3415	5556	<i>Na/H antiporter</i> PID: D1017724	<i>Transport</i>
<i>orf4</i> *	5992	5612		
<i>orf5</i>	6226	6675		
<i>epoA</i>	7610	11875	Type I polyketide synthase	Epothilone synthase: Thiazole ring formation
<i>epoP</i>	11872	16104	Non-ribosomal peptide synthetase	Epothilone synthase: Thiazole ring formation
<i>epoB</i>	16251	21749	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoC</i>	21746	43519	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoD</i>	43524	54920	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoE</i>	54935	62254	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoF</i>	62369	63628	Cytochrome P450	Epothilone macrolactone oxidase
<i>orf6</i>	63779	64333		
<i>orf7</i> *	64290	63853		
<i>orf8</i>	64363	64920		
<i>orf9</i> *	64727	64287		
<i>orf10</i>	65063	65767		
<i>orf11</i> *	65874	65008		
<i>orf12</i> *	66338	65871		
<i>orf13</i>	66667	67137		
<i>orf14</i>	67334	68251	Hypothetical protein GI:3293544; Cation efflux system protein GI:2623026	<i>Transport</i>
<i>orf15</i>	68346	outside of sequenced range		

\* On the reverse complementer strand. Numbering according to SEQ ID NO:1.

*epoA* (nucleotides 7610-11875 of SEQ ID NO:1) codes for EPOS A (SEQ ID NO:2), a type I polyketide synthase consisting of a single module, and harboring the following domains:  $\beta$ -ketoacyl-synthase (KS) (nucleotides 7643-8920 of SEQ ID NO:1, amino acids 11-

437 of SEQ ID NO:2); acyltransferase (AT) (nucleotides 9236-10201 of SEQ ID NO:1; amino acids 543-864 of SEQ ID NO:2); enoyl reductase (ER) (nucleotides 10529-11428 of SEQ ID NO:1, amino acids 974-1273 of SEQ ID NO:2); and acyl carrier protein homologous domain (ACP) (nucleotides 11549-11764 of SEQ ID NO:1, amino acids 1314-1385 of SEQ ID NO:2). Sequence comparisons and motif analysis (Haydock, et al. *FEBS Lett.* 374: 246-248 (1995); Tang, et al., *Gene* 216: 255-265 (1998)) reveal that the AT encoded by EPOS A is specific for malonyl-CoA. EPOS A should be involved in the initiation of epothilone biosynthesis by loading the acetate unit to the multienzyme complex that will eventually form part of the 2-methylthiazole ring (C26 and C20).

*epoP* (nucleotides 11872-16104 of SEQ ID NO:1) codes for EPOS P (SEQ ID NO:3), a non-ribosomal peptide synthetase containing one module. EPOS P harbors the following domains:

- peptide bond formation domain, as delineated by motif K (amino acids 72-81 [FPLTDIQESY] of SEQ ID NO:3, corresponding to nucleotide positions 12085-12114 of SEQ ID NO:1); motif L (amino acids 118-125 [VVARHDML] of SEQ ID NO:3, corresponding to nucleotide positions 12223-12246 of SEQ ID NO:1); motif M (amino acids 199-212 [SIDLINVDLGSLSI] of SEQ ID NO:3, corresponding to nucleotide positions 12466-12507 of SEQ ID NO:1); and motif O (amino acids 353-363 [GDFTSMVLLDI] of SEQ ID NO:3, corresponding to nucleotide positions 12928-12960 of SEQ ID NO:1);
- aminoacyl adenylate formation domain, as delineated by motif A (amino acids 549-565 [LTYEELSRRSRRLGARL] of SEQ ID NO:3, corresponding to nucleotide positions 13516-13566 of SEQ ID NO:1); motif B (amino acids 588-603 [VAVLAVLESGAAYVPI] of SEQ ID NO:3, corresponding to nucleotide positions 13633-13680 of SEQ ID NO:1); motif C (amino acids 669-684 [AYVIYTSGSTGLPKGV] of SEQ ID NO:3, corresponding to nucleotide positions 13876-13923 of SEQ ID NO:1); motif D (amino acids 815-821 [SLGGATE] of SEQ ID NO:3, corresponding to nucleotide positions 14313-14334 of SEQ ID NO:1); motif E (amino acids 868-892 [GQLYIGGVGLALGYWRDEEKTRKSF] of SEQ ID NO:3, corresponding to nucleotide positions 14473-14547 of SEQ ID NO:1); motif F (amino acids 903-912 [YKTGDLGRYL] of SEQ ID NO:3, corresponding to nucleotide positions 14578-14607 of SEQ ID NO:1); motif G (amino acids 918-940 [EFMGREDNQIKLRGYRVELGEIE] of SEQ ID NO:3, corresponding to nucleotide positions 14623-14692 of SEQ ID NO:1); motif H (amino acids 1268-1274 [LPEYMPV] of SEQ ID NO:3, corresponding to nucleotide positions 15673-15693 of SEQ ID NO:1); and

- 43 -

motif I (amino acids 1285-1297 [LTSNGKVDRKALR] of SEQ ID NO:3, corresponding to nucleotide positions 15724-15762 of SEQ ID NO:1);

- an unknown domain, inserted between motifs G and H of the aminoacyl adenylate formation domain (amino acids 973-1256 of SEQ ID NO:3, corresponding to nucleotide positions 14788-15639 of SEQ ID NO:1); and
- a peptidyl carrier protein homologous domain (PCP), delineated by motif J (amino acids 1344-1351 [GATSIHIV] of SEQ ID NO:3, corresponding to nucleotide positions 15901-15924 of SEQ ID NO:1).

It is proposed that EPOS P is involved in the activation of a cysteine by adenylation, binding the activated cysteine as an aminoacyl-S-PCP, forming a peptide bond between the enzyme-bound cysteine and the acetyl-S-ACP supplied by EPOS A, and the formation of the initial thiazoline ring by intramolecular heterocyclization. The unknown domain of EPOS P displays very weak homologies to NAD(P)H oxidases and reductases from *Bacillus* species. Thus, this unknown domain and/or the ER domain of EPOS A may be involved in the oxidation of the initial 2-methylthiazoline ring to a 2-methylthiazole.

*epoB* (nucleotides 16251-21749 of SEQ ID NO:1) codes for EPOS B (SEQ ID NO:4), a type I polyketide synthase consisting of a single module, and harboring the following domains: KS (nucleotides 16269-17546 of SEQ ID NO:1, amino acids 7-432 of SEQ ID NO:4); AT (nucleotides 17865-18827 of SEQ ID NO:1, amino acids 539-859 of SEQ ID NO:4); dehydratase (DH) (nucleotides 18855-19361 of SEQ ID NO:1, amino acids 869-1037 of SEQ ID NO:4);  $\beta$ -ketoreductase (KR) (nucleotides 20565-21302 of SEQ ID NO:1, amino acids 1439-1684 of SEQ ID NO:4); and ACP (nucleotides 21414-21626 of SEQ ID NO:1, amino acids 1722-1792 of SEQ ID NO:4). Sequence comparisons and motif analysis reveal that the AT encoded by EPOS B is specific for methylmalonyl-CoA. EPOS A should be involved in the first polyketide chain extension by catalysing the Claisen-like condensation of the 2-methyl-4-thiazolecarboxyl-S-PCP starter group with the methylmalonyl-S-ACP, and the concomitant reduction of the  $\beta$ -keto group of C17 to an enoyl.

*epoC* (nucleotides 21746-43519 of SEQ ID NO:1) codes for EPOS C (SEQ ID NO:5), a type I polyketide synthase consisting of 4 modules. The first module harbors a KS (nucleotides 21860-23116 of SEQ ID NO:1, amino acids 39-457 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 23431-24397 of SEQ ID NO:1, amino acids 563-884 of SEQ ID NO:5); a KR (nucleotides 25184-25942 of SEQ ID NO:1, amino acids 1147-1399 of SEQ ID NO:5); and an ACP (nucleotides 26045-26263 of SEQ ID NO:1, amino acids 1434-1506 of

- 44 -

SEQ ID NO:5). This module incorporates an acetate extender unit (C14-C13) and reduces the  $\beta$ -keto group at C15 to the hydroxyl group that takes part in the final lactonization of the epothilone macrolactone ring. The second module of EPOS C harbors a KS (nucleotides 26318-27595 of SEQ ID NO:1, amino acids 1524-1950 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 27911-28876 of SEQ ID NO:1, amino acids 2056-2377 of SEQ ID NO:5); a KR (nucleotides 29678-30429 of SEQ ID NO:1, amino acids 2645-2895 of SEQ ID NO:5); and an ACP (nucleotides 30539-30759 of SEQ ID NO:1, amino acids 2932-3005 of SEQ ID NO:5). This module incorporates an acetate extender unit (C12-C11) and reduces the  $\beta$ -keto group at C13 to a hydroxyl group. Thus, the nascent polyketide chain of epothilone corresponds to epothilone A, and the incorporation of the methyl side chain at C12 in epothilone B would require a post-PKS C-methyltransferase activity. The formation of the epoxi ring at C13-C12 would also require a post-PKS oxidation step. The third module of EPOS C harbors a KS (nucleotides 30815-32092 of SEQ ID NO:1, amino acids 3024-3449 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 32408-33373 of SEQ ID NO:1, amino acids 3555-3876 of SEQ ID NO:5); a DH (nucleotides 33401-33889 of SEQ ID NO:1, amino acids 3886-4048 of SEQ ID NO:5); an ER (nucleotides 35042-35902 of SEQ ID NO:1, amino acids 4433-4719 of SEQ ID NO:5); a KR (nucleotides 35930-36667 of SEQ ID NO:1, amino acids 4729-4974 of SEQ ID NO:5); and an ACP (nucleotides 36773-36991 of SEQ ID NO:1, amino acids 5010-5082 of SEQ ID NO:5). This module incorporates an acetate extender unit (C10-C9) and fully reduces the  $\beta$ -keto group at C11. The fourth module of EPOS C harbors a KS (nucleotides 37052-38320 of SEQ ID NO:1, amino acids 5103-5525 of SEQ ID NO:5); a methylmalonyl CoA-specific AT (nucleotides 38636-39598 of SEQ ID NO:1, amino acids 5631-5951 of SEQ ID NO:5); a DH (nucleotides 39635-40141 of SEQ ID NO:1, amino acids 5964-6132 of SEQ ID NO:5); an ER (nucleotides 41369-42256 of SEQ ID NO:1, amino acids 6542-6837 of SEQ ID NO:5); a KR (nucleotides 42314-43048 of SEQ ID NO:1, amino acids 6857-7101 of SEQ ID NO:5); and an ACP (nucleotides 43163-43378 of SEQ ID NO:1, amino acids 7140-7211 of SEQ ID NO:5). This module incorporates a propionate extender unit (C24 and C8-C7) and fully reduces the  $\beta$ -keto group at C9.

*epoD* (nucleotides 43524-54920 of SEQ ID NO:1) codes for EPOS D (SEQ ID NO:6), a type I polyketide synthase consisting of 2 modules. The first module harbors a KS (nucleotides 43626-44885 of SEQ ID NO:1, amino acids 35-454 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 45204-46166 of SEQ ID NO:1, amino acids 561-881 of SEQ ID NO:6); a KR (nucleotides 46950-47702 of SEQ ID NO:1, amino acids

- 45 -

1143-1393 of SEQ ID NO:6); and an ACP (nucleotides 47811-48032 of SEQ ID NO:1, amino acids 1430-1503 of SEQ ID NO:6). This module incorporates a propionate extender unit (C23 and C6-C5) and reduces the  $\beta$ -keto group at C7 to a hydroxyl group. The second module harbors a KS (nucleotides 48087-49361 of SEQ ID NO:1, amino acids 1522-1946 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 49680-50642 of SEQ ID NO:1, amino acids 2053-2373 of SEQ ID NO:6); a DH (nucleotides 50670-51176 of SEQ ID NO:1, amino acids 2383-2551 of SEQ ID NO:6); a methyltransferase (MT, nucleotides 51534-52657 of SEQ ID NO:1, amino acids 2671-3045 of SEQ ID NO:6); a KR (nucleotides 53697-54431 of SEQ ID NO:1, amino acids 3392-3636 of SEQ ID NO:6); and an ACP (nucleotides 54540-54758 of SEQ ID NO:1, amino acids 3673-3745 of SEQ ID NO:6). This module incorporates a propionate extender unit (C21 or C22 and C4-C3) and reduces the  $\beta$ -keto group at C5 to a hydroxyl group. This reduction is somewhat unexpected, since epothilones contain a keto group at C5. Discrepancies of this kind between the deduced reductive capabilities of PKS modules and the redox state of the corresponding positions in the final polyketide products have been, however, reported in the literature (see, for example, Schwecke, et al., *Proc. Natl. Acad. Sci. USA* 92: 7839-7843 (1995) and Schupp, et al., *FEMS Microbiology Letters* 159: 201-207 (1998)). An important feature of epothilones is the presence of gem-methyl side groups at C4 (C21 and C22). The second module of EPOS D is predicted to incorporate a propionate unit into the growing polyketide chain, providing one methyl side chain at C4. This module also contains a methyltransferase domain integrated into the PKS between the DH and the KR domains, in an arrangement similar to the one seen in the HMWP1 yersiniabactin synthase (Gehring, A.M., DeMoll, E., Fetherston, J.D., Mori, I., Mayhew, G.F., Blattner, F.R., Walsh, C.T., and Perry, R.D.: Iron acquisition in plague: modular logic in enzymatic biogenesis of yersiniabactin by Yersinia pestis. *Chem. Biol.* 5, 573-586, 1998). This MT domain in EPOS D is proposed to be responsible for the incorporation of the second methyl side group (C21 or C22) at C4.

*epoE* (nucleotides 54935-62254 of SEQ ID NO:1) codes for EPOS E (SEQ ID NO:7), a type I polyketide synthase consisting of one module, harboring a KS (nucleotides 55028-56284 of SEQ ID NO:1, amino acids 32-450 of SEQ ID NO:7); a malonyl CoA-specific AT (nucleotides 56600-57565 of SEQ ID NO:1, amino acids 556-877 of SEQ ID NO:7); a DH (nucleotides 57593-58087 of SEQ ID NO:1, amino acids 887-1051 of SEQ ID NO:7); a probably nonfunctional ER (nucleotides 59366-60304 of SEQ ID NO:1, amino acids 1478-1790 of SEQ ID NO:7); a KR (nucleotides 60362-61099 of SEQ ID NO:1, amino acids 1810-2055

- 46 -

of SEQ ID NO:7); an ACP (nucleotides 61211-61426 of SEQ ID NO:1, amino acids 2093-2164 of SEQ ID NO:7); and a thioesterase (TE) (nucleotides 61427-62254 of SEQ ID NO:1, amino acids 2165-2439 of SEQ ID NO:7). The ER domain in this module harbors an active site motif with some highly unusual amino acid substitutions that probably render this domain inactive. The module incorporates an acetate extender unit (C2-C1), and reduces the  $\beta$ -keto at C3 to an enoyl group. Epothilones contain a hydroxyl group at C3, so this reduction also appears to be excessive as discussed for the second module of EPOS D. The TE domain of EPOS E takes part in the release and cyclization of the grown polyketide chain via lactonization between the carboxyl group of C1 and the hydroxyl group of C15.

Five ORFs are detected upstream of *epoA* in the sequenced region. The partially sequenced *orf1* has no homologues in the sequence databanks. The deduced protein product (Orf 2, SEQ ID NO:10) of *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1) shows strong similarities to hypothetical ORFs from *Mycobacterium* and *Streptomyces coelicolor*, and more distant similarities to carboxypeptidases and DD-peptidases of different bacteria. The deduced protein product of *orf3* (nucleotides 3415-5556 of SEQ ID NO:1), Orf 3 (SEQ ID NO:11), shows homologies to Na/H antiporters of different bacteria. Orf 3 might take part in the export of epothilones from the producer strain. *orf4* and *orf5* have no homologues in the sequence databanks.

Eleven ORFs are found downstream of *epoE* in the sequenced region. *epoF* (nucleotides 62369-63628 of SEQ ID NO:1) codes for EPOS F (SEQ ID NO:8), a deduced protein with strong sequence similarities to cytochrome P450 oxygenases. EPOS F may take part in the adjustment of the redox state of the carbons C12, C5, and/or C3. The deduced protein product of *orf14* (nucleotides 67334-68251 of SEQ ID NO:1), Orf 14 (SEQ ID NO:22) shows strong similarities to GI:3293544, a hypothetical protein with no proposed function from *Streptomyces coelicolor*, and also to GI:2654559, the human embryonic lung protein. It is also more distantly related to cation efflux system proteins like GI:2623026 from *Methanobacterium thermoautotrophicum*, so it might also take part in the export of epothilones from the producing cells. The remaining ORFs (*orf6*-*orf13* and *orf15*) show no homologies to entries in the sequence databanks.

#### Example 13: Recombinant Expression of Epothilone Biosynthesis Genes

Epothilone synthase genes according to the present invention are expressed in heterologous organisms for the purposes of epothilone production at greater quantities than can be accomplished by fermentation of *Sorangium cellulosum*. A preferable host for heterologous expression is *Streptomyces*, e.g. *Streptomyces coelicolor*, which natively produces the polyketide actinorhodin. Techniques for recombinant PKS gene expression in this host are described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994). See also, Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), as well as U.S. Patent Nos. 5,521,077, 5,672,491, and 5,712,146, which are incorporated herein by reference.

According to one method, the heterologous host strain is engineered to contain a chromosomal deletion of the actinorhodin (*act*) gene cluster. Expression plasmids containing the epothilone synthase genes of the invention are constructed by transferring DNA from a temperature-sensitive donor plasmid to a recipient shuttle vector in *E. coli* (McDaniel *et al.* (1993) and Kao *et al.* (1994)), such that the synthase genes are built-up by homologous recombination within the vector. Alternatively, the epothilone synthase gene cluster is introduced into the vector by restriction fragment ligation. Following selection, e.g. as described in Kao *et al.* (1994), DNA from the vector is introduced into the *act*-minus *Streptomyces coelicolor* strain according to protocols set forth in Hopwood *et al.*, *Genetic Manipulation of Streptomyces. A Laboratory Manual* (John Innes Foundation, Norwich, United Kingdom, 1985), incorporated herein by reference. The recombinant *Streptomyces* strain is grown on R2YE medium (Hopwood *et al.* (1985)) and produces epothilones. Alternatively, the epothilone synthase genes according to the present invention are expressed in other host organisms such as pseudomonads, *Bacillus*, yeast, insect cells and/or *E. coli*. PKS and NRPS genes are preferably expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985). In another embodiment, the expression vectors pKK223-3 and pKK223-2 are used to express PKS and NRPS genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. Expression of PKS and NRPS genes in heterologous hosts, which do not naturally have the phosphopantetheinyl (P-pant) transferases needed for post-translational modification of PKS enzymes, requires the coexpression in the host of a P-pant transferase, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998).

**Example 14: Isolation of Epothilones from Producing Strains**

Examples of cultivation, fermentation, and extraction procedures for polyketide isolation, which are useful for extracting epothilones from both native and recombinant hosts according to the present invention, are given in WO 93/10121, incorporated herein by reference, in Example 57 of U.S. Patent No. 5,639,949, in Gerth et al., *J. Antibiotics* 49: 560-563 (1996), and in Swiss patent application no. 396/98, filed February 19, 1998, and U.S. patent application no. 09/248,910 (that discloses also preferred mutant strains of *Sorangium cellulosum*), both of which are incorporated herein by reference. The following are procedures that are useful for isolating epothilones from cultured *Sorangium cellulosum* strains such as So ce90, and may also be used for the isolation of epothilone from recombinant hosts.

**A: Cultivation of epothilone-producing strains:**

Strain: *Sorangium cellulosum* Soce-90 or a recombinant host strain according to the present invention.

Preservation of the strain: In liquid N<sub>2</sub>.

Media: Precultures and intermediate cultures: G52  
Main culture: 1B12

**G52 Medium:**

yeast extract, low in salt (BioSpringer, Maison Alfort, France)	2 g/l
MgSO <sub>4</sub> (7 H <sub>2</sub> O)	1 g/l
CaCl <sub>2</sub> (2 H <sub>2</sub> O)	1 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	2 g/l
potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	8 g/l
glucose anhydrous	2 g/l
EDTA-Fe(III)-Na salt (8 g/l)	1 ml/l

- 49 -

pH 7.4, corrected with KOH

Sterilisation: 20 mins. 120 °C

1B12 Medium:

potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	20 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	11 g/l
EDTA-Fe(III)-Na salt	8 mg/l
pH 7.8, corrected with KOH	
Sterilisation: 20 mins. 120 °C	

Addition of cyclodextrins and cyclodextrin derivatives:

Cyclodextrins (Fluka, Buchs, Switzerland, or Wacker Chemie,  
Munich, Germany) in different concentrations are sterilised  
separately and added to the 1B12 medium prior to seeding.

Cultivation: 1 ml of the suspension of *Sorangium cellulosum* Soce-90 from a liquid N<sub>2</sub> ampoule is transferred to 10 ml of G52 medium (in a 50 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 5 ml of this culture is added to 45 ml of G52 medium (in a 200 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 50 ml of this culture is then added to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Maintenance culture: The culture is overseeded every 3-4 days, by adding 50 ml of culture to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask). All experiments and fermentations are carried out by starting with this maintenance culture.

Tests in a flask:

(I) Preculture in an agitating flask:

- 50 -

Starting with the 500 ml of maintenance culture, 1 x 450 ml of G52 medium are seeded with 50 ml of the maintenance culture and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

(ii) Main culture in the agitating flask:

40 ml of 1B12 medium plus 5 g/l 4-morpholine-propane-sulfonic acid (= MOPS) powder (in a 200 ml Erlenmeyer flask) are mixed with 5 ml of a 10x concentrated cyclodextrin solution, seeded with 10 ml of preculture and incubated for 5 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Fermentation: Fermentations are carried out on a scale of 10 litres, 100 litres and 500 litres. 20 litre and 100 litre fermentations serve as an intermediate culture step. Whereas the pre-cultures and intermediate cultures are seeded as the maintenance culture 10% (v/v), the main cultures are seeded with 20% (v/v) of the intermediate culture. Important: In contrast to the agitating cultures, the ingredients of the media for the fermentation are calculated on the final culture volume including the inoculum. If, for example, 18 litres of medium + 2 litres of inoculum are combined, then substances for 20 litres are weighed in, but are only mixed with 18 litres.

Preculture in an agitating flask:

Starting with the 500 ml maintenance culture, 4 x 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) are each seeded with 50 ml thereof, and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Intermediate culture, 20 litres or 100 litres:

20 litres: 18 litres of G52 medium in a fermenter having a total volume of 30 litres are seeded with 2 litres of the preculture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.


100 litres: 90 litres of G52 medium in a fermenter having a total volume of 150 litres are seeded with 10 litres of the 20 litre intermediate culture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 150 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.

- 51 -

Main culture, 10 litres, 100 litres or 500 litres:

10 litres: The media substances for 10 litres of 1B12 medium are sterilised in 7 litres of water, then 1 litre of a sterile 10% 2-(hydroxypropyl) - $\beta$ -cyclodextrin solution are added, and seeded with 2 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre of liquid per min., 0.5 bars excess pressure, pH control with H<sub>2</sub>SO<sub>4</sub>/KOH to pH 7.6 +/- 0.5 (i.e. no control between pH 7.1 and 8.1).

100 litres: The media substances for 100 litres of 1B12 medium are sterilised in 70 litres of water, then 10 litres of a sterile 10% 2-(hydroxypropyl) - $\beta$ -cyclodextrin solution are added, and seeded with 20 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 200 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H<sub>2</sub>SO<sub>4</sub>/KOH to pH 7.6 +/- 0.5. The chain of seeding for a 100 litre fermentation is shown schematically as follows:



500 litres: The media substances for 500 litres of 1B12 medium are sterilised in 350 litres of water, then 50 litres of a sterile 10% 2-(hydroxypropyl) - $\beta$ -cyclodextrin solution are added, and seeded with 100 litres of a 100 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 120 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H<sub>2</sub>SO<sub>4</sub>/KOH to pH 7.6 +/- 0.5.

Product analysis:

Preparation of the sample:

- 52 -

50 ml samples are mixed with 2 ml of polystyrene resin Amberlite XAD16 (Rohm + Haas, Frankfurt, Germany) and shaken at 180 rpm for one hour at 30°C. The resin is subsequently filtered using a 150 µm nylon sieve, washed with a little water and then added together with the filter to a 15 ml Nunc tube.

Elution of the product from the resin:

10 ml of isopropanol (>99%) are added to the tube with the filter and the resin. Afterwards, the sealed tube is shaken for 30 minutes at room temperature on a Rota-Mixer (Labinco BV, Netherlands). Then, 2 ml of the liquid are centrifuged off and the supernatant is added using a pipette to HPLC tubes.

HPLC analysis:

Column:	Waters-Symetry C18, 100 x 4 mm, 3.5 µm WAT066220 + preliminary column 3.9 x 20 mm WAT054225
Solvents:	A: 0.02 % phosphoric acid B: Acetonitrile (HPLC-Quality)
Gradient:	41% B from 0 to 7 min. 100% B from 7.2 to 7.8 min. 41% B from 8 to 12 min.
Oven temp.:	30°C
Detection:	250 nm, UV-DAD detection
Injection vol.:	10 µl
Retention time:	Epo A: 4.30 min      Epo B: 5.38 min

B: Effect of the addition of cyclodextrin and cyclodextrin derivatives to the epothilone concentrations attained.


Cyclodextrins are cyclic ( $\alpha$ -1,4)-linked oligosaccharides of  $\alpha$ -D-glucopyranose with a relatively hydrophobic central cavity and a hydrophilic external surface area.

The following are distinguished in particular (the figures in parenthesis give the number of glucose units per molecule):  $\alpha$ -cyclodextrin (6),  $\beta$ -cyclodextrin (7),  $\gamma$ -cyclodextrin (8),  $\delta$ -cyclodextrin (9),  $\varepsilon$ -cyclodextrin (10),  $\zeta$ -cyclodextrin (11),  $\eta$ -cyclodextrin (12), and  $\theta$ -cyclodextrin (13). Especially preferred are  $\delta$ -cyclodextrin and in particular  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin, or mixtures thereof.

Cyclodextrin derivatives are primarily derivatives of the above-mentioned cyclodextrins, especially of  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin, primarily those in which one or more up to all of the hydroxy groups (3 per glucose radical) are etherified or esterified. Ethers are primarily alkyl ethers, especially lower alkyl, such as methyl or ethyl ether, also propyl or butyl ether; the aryl-hydroxyalkyl ethers, such as phenyl-hydroxy-lower-alkyl, especially phenyl-hydroxyethyl ether; the hydroxyalkyl ethers, in particular hydroxy-lower-alkyl ethers, especially 2-hydroxyethyl, hydroxypropyl such as 2-hydroxypropyl or hydroxybutyl such as 2-hydroxybutyl ether; the carboxyalkyl ethers, in particular carboxy-lower-alkyl ethers, especially carboxymethyl or carboxyethyl ether; derivatised carboxyalkyl ethers, in particular derivatised carboxy-lower-alkyl ether in which the derivatised carboxy is etherified or amidated carboxy (primarily aminocarbonyl, mono- or di-lower-alkyl-aminocarbonyl, morpholino-, piperidino-, pyrrolidino- or piperazino-carbonyl, or alkyloxycarbonyl), in particular lower alkyloxycarbonyl-lower-alkyl ether, for example methyloxycarbonylpropyl ether or ethyloxycarbonylpropyl ether; the sulfoalkyl ethers, in particular sulfo-lower-alkyl ethers, especially sulfobutyl ether; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein alk is alkyl, especially lower alkyl, and n is a whole number from 2 to 12, especially 2 to 5, in particular 2 or 3; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein R' is hydrogen, hydroxy,  $-\text{O-(alk-O)}_z\text{-H}$ ,  $-\text{O-(alk(-R)-O)}_p\text{-H}$  or  $-\text{O-(alk(-R)-O)}_q\text{-alk-CO-Y}$ ; alk in all cases is alkyl, especially lower alkyl; m, n, p, q and z are a whole number from 1 to 12, preferably 1 to 5, in particular 1 to 3; and Y is OR<sub>1</sub> or NR<sub>2</sub>R<sub>3</sub>, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> independently of one another, are hydrogen or lower alkyl, or R<sub>2</sub> and R<sub>3</sub> combined together with the linking nitrogen signify morpholino, piperidino, pyrrolidino or piperazino; or branched cyclodextrins, in which etherifications or acetals with other sugar molecules are present, especially glucosyl-, diglucosyl- ( $G_2\text{-}\beta$ -cyclodextrin), maltosyl- or dimaltosyl-cyclodextrin, or N-acetylglucosaminyl-, glucosaminyl-, N-acetylgalactosaminyl- or galactosaminyl-cyclodextrin.

Esters are primarily alkanoyl esters, in particular lower alkanoyl esters, such as acetyl esters of cyclodextrins.

It is also possible to have cyclodextrins in which two or more different said ether and ester groups are present at the same time.

Mixtures of two or more of the said cyclodextrins and/or cyclodextrin derivatives may also exist.

Preference is given in particular to  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrins or the lower alkyl ethers thereof, such as methyl- $\beta$ -cyclodextrin or in particular 2,6-di-O-methyl- $\beta$ -cyclodextrin, or in particular the hydroxy lower alkyl ethers thereof, such as 2-hydroxypropyl- $\alpha$ -, 2-hydroxypropyl- $\beta$ - or 2-hydroxypropyl- $\gamma$ -cyclodextrin.

The cyclodextrins or cyclodextrin derivatives are added to the culture medium preferably in a concentration of 0.02 to 10, preferably 0.05 to 5, especially 0.1 to 4, for example 0.1 to 2 percent by weight (w/v).

Cyclodextrins or cyclodextrin derivatives are known or may be produced by known processes (see for example US 3,459,731; US 4,383,992; US 4,535,152; US 4,659,696; EP 0 094 157; EP 0 149 197; EP 0 197 571; EP 0 300 526; EP 0 320 032; EP 0 499 322; EP 0 503 710; EP 0 818 469; WO 90/12035; WO 91/11200; WO 93/19061; WO 95/08993; WO 96/14090; GB 2,189,245; DE 3,118,218; DE 3,317,064 and the references mentioned therein, which also refer to the synthesis of cyclodextrins or cyclodextrin derivatives, or also: T. Loftsson and M.E. Brewster (1996): Pharmaceutical Applications of Cyclodextrins: Drug Solubilization and Stabilisation: *Journal of Pharmaceutical Science* 85 (10):1017-1025; R.A. Rajewski and V.J. Stella(1996): Pharmaceutical Applications of Cyclodextrins: In Vivo Drug Delivery: *Journal of Pharmaceutical Science* 85 (11): 1142-1169).

All the cyclodextrin derivatives tested here are obtainable from the company Fluka, Buchs, CH. The tests are carried out in 200 ml agitating flasks with 50 ml culture volume. As controls, flasks with adsorber resin Amberlite XAD-16 (Rohm & Haas, Frankfurt, Germany) and without any adsorber addition are used. After incubation for 5 days, the following epothilone titres can be determined by HPLC:

Table 2:

Addition	order No.	Conc [%w/v] <sup>1</sup>	Ep A [mg/l]	Ep B [mg/l]
Amberlite XAD-16 (v/v)		2.0 (%v/v)	9.2	3.8

- 55 -

Addition	order No.	Conc [%w/v] <sup>1</sup>	Epo A [mg/l]	Epo B [mg/l]
2-hydroxypropyl-β-cyclodextrin	56332	0.1	2.7	1.7
2-hydroxypropyl-β-cyclodextrin	"	0.5	4.7	3.3
2-hydroxypropyl-β-cyclodextrin	"	1.0	4.7	3.4
2-hydroxypropyl-β-cyclodextrin	"	2.0	4.7	4.1
2-hydroxypropyl-β-cyclodextrin	"	5.0	1.7	0.5
2-hydroxypropyl-α-cyclodextrin	56330	0.5	1.2	1.2
2-hydroxypropyl-α-cyclodextrin	"	1.0	1.2	1.2
2-hydroxypropyl-α-cyclodextrin	"	5.0	2.5	2.3
β-cyclodextrin	28707	0.1	1.6	1.3
β-cyclodextrin	"	0.5	3.6	2.5
β-cyclodextrin	"	1.0	4.8	3.7
β-cyclodextrin	"	2.0	4.8	2.9
β-cyclodextrin	"	5.0	1.1	0.4
methyl-β-cyclodextrin	66292	0.5	0.8	<0.3
methyl-β-cyclodextrin	"	1.0	<0.3	<0.3
methyl-β-cyclodextrin	"	2.0	<0.3	<0.3
2,6 di-o-methyl-β-cyclodextrin	39915	1.0	<0.3	<0.3
2-hydroxypropyl-γ-cyclodextrin	56334	0.1	0.3	<0.3
2-hydroxypropyl-γ-cyclodextrin	"	0.5	0.9	0.8
2-hydroxypropyl-γ-cyclodextrin	"	1.0	1.1	0.7
2-hydroxypropyl-γ-cyclodextrin	"	2.0	2.6	0.7
2-hydroxypropyl-γ-cyclodextrin	"	5.0	5.0	1.1
no addition			0.5	0.5

<sup>1</sup>) Apart from Amberlite (%v/v), all percentages are by weight (%w/v).

Few of the cyclodextrins tested (2,6-di-o-methyl-β-cyclodextrin, methyl-β-cyclodextrin) display no effect or a negative effect on epothilone production at the concentrations used. 1-2% 2-hydroxy-propyl-β-cyclodextrin and β-cyclodextrin increase epothilone production in the examples by 6 to 8 times compared with production using no cyclodextrins.

- 56 -

**C: 10 litre fermentation with 1% 2-(hydroxypropyl)- $\beta$ -cyclodextrin):**

Fermentation is carried out in a 15 litre glass fermenter. The medium contains 10 g/l of 2-(hydroxypropyl)- $\beta$ -cyclodextrin from Wacker Chemie, Munich, Germany. The progress of fermentation is illustrated in Table 3. Fermentation is ended after 6 days and working up takes place.

**Table 3:** Progress of a 10 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.5	0.3
3	1.8	2.5
4	3.0	5.1
5	3.7	5.9
6	3.6	5.7

**D: 100 litre fermentation with 1% 2-(hydroxypropyl)- $\beta$ -cyclodextrin):**

Fermentation is carried out in a 150 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- $\beta$ -cyclodextrin. The progress of fermentation is illustrated in Table 4. The fermentation is harvested after 7 days and worked up.

**Table 4:** Progress of a 100 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.3	0

- 57 -

3	0.9	1.1
4	1.5	2.3
5	1.6	3.3
6	1.8	3.7
7	1.8	3.5

**E: 500 litre fermentation with 1% 2-(hydroxypropyl)- $\beta$ -cyclodextrin:**

Fermentation is carried out in a 750 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- $\beta$ -cyclodextrin. The progress of fermentation is illustrated in Table 5. The fermentation is harvested after 7 days and worked up.

**Table 5: Progress of a 500 litre fermentation**

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0.6	0.6
4	1.7	2.2
5	3.1	4.5
6	3.1	5.1

**F: Comparison example 10 litre fermentation without adding an adsorber:**

Fermentation is carried out in a 15 litre glass fermenter. The medium does not contain any cyclodextrin or other adsorber. The progress of fermentation is illustrated in Table 6. The fermentation is not harvested and worked up.

**Table 6: Progress of a 10 litre fermentation without adsorber.**

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0	0
4	0.7	0.7
5	0.7	1.0
6	0.8	1.3

**G: Working up of the epothilones: Isolation from a 500 litre main culture:**

The volume of harvest from the 500 litre main culture of example 2D is 450 litres and is separated using a Westfalia clarifying separator Type SA-20-06 (rpm = 6500) into the liquid phase (centrifugate + rinsing water = 650 litres) and solid phase (cells = ca. 15 kg). The main part of the epothilones are found in the centrifugate. The centrifuged cell pulp contains < 15% of the determined epothilone portion and is not further processed. The 650 litre centrifugate is then placed in a 4000 litre stirring vessel, mixed with 10 litres of Amberlite XAD-16 (centrifugate:resin volume = 65:1) and stirred. After a period of contact of ca. 2 hours, the resin is centrifuged away in a Heine overflow centrifuge (basket content 40 litres; rpm = 2800). The resin is discharged from the centrifuge and washed with 10-15 litres of deionised water. Desorption is effected by stirring the resin twice, each time in portions with 30 litres of isopropanol in 30 litre glass stirring vessels for 30 minutes. Separation of the isopropanol phase from the resin takes place using a suction filter. The isopropanol is then removed from the combined isopropanol phases by adding 15-20 litres of water in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and the resulting water phase of ca. 10 litres is extracted 3x each time with 10 litres of ethyl acetate. Extraction is effected in 30 litre glass stirring vessels. The ethyl acetate extract is concentrated to 3-5 litres in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and afterwards concentrated to dryness in a rotary evaporator (Büchi type) under vacuum. The result is an ethyl acetate extract of 50.2 g. The ethyl acetate extract is dissolved in

500 ml of methanol, the insoluble portions filtered off using a folded filter, and the solution added to a 10 kg Sephadex LH 20 column (Pharmacia, Uppsala, Sweden) (column diameter 20 cm, filling level ca. 1.2 m). Elution is effected with methanol as eluant. Epothilone A and B is present predominantly in fractions 21-23 (at a fraction size of 1 litre). These fractions are concentrated to dryness in a vacuum on a rotary evaporator (total weight 9.0 g). These Sephadex peak fractions (9.0 g) are thereafter dissolved in 92 ml of acetonitrile:-water:-methylene chloride = 50:40:2, the solution filtered through a folded filter and added to a RP column (equipment Prepbar 200, Merck; 2.0 kg LiChrospher RP-18 Merck, grain size 12 $\mu$ m, column diameter 10 cm, filling level 42 cm; Merck, Darmstadt, Germany). Elution is effected with acetonitrile:water = 3:7 (flow rate = 500 ml/min.; retention time of epothilone A = ca. 51-59 mins.; retention time of epothilone B = ca. 60-69 mins.). Fractionation is monitored with a UV detector at 250 nm. The fractions are concentrated to dryness under vacuum on a Büchi-Rotavapor rotary evaporator. The weight of the epothilone A peak fraction is 700 mg, and according to HPLC (external standard) it has a content of 75.1%. That of the epothilone B peak fraction is 1980 mg, and the content according to HPLC (external standard) is 86.6%. Finally, the epothilone A fraction (700 mg) is crystallised from 5 ml of ethyl acetate:toluene = 2:3, and yields 170 mg of epothilone A pure crystallisate [content according to HPLC (% of area) = 94.3%]. Crystallisation of the epothilone B fraction (1980 mg) is effected from 18 ml of methanol and yields 1440 mg of epothilone B pure crystallisate [content according to HPLC (% of area) = 99.2%]. m.p. (Epothilone B): e.g. 124-125 °C;  $^1$ H-NMR data for Epothilone B:

500 MHz-NMR, solvent: DMSO-d6. Chemical displacement  $\delta$  in ppm relative to TMS. s = singlet; d = doublet; m = multiplet

$\delta$ (Multiplicity)	Integral (number of H)
7.34 (s)	1
6.50 (s)	1
5.28 (d)	1
5.08 (d)	1
4.46 (d)	1
4.08 (m)	1

- 60 -

3.47 (m)	1
3.11 (m)	1
2.83 (dd)	1
2.64 (s)	3
2.36 (m)	2
2.09 (s)	3
2.04 (m)	1
1.83 (m)	1
1.61 (m)	1
1.47 - 1.24 (m)	4
1.18 (s)	6
1.13 (m)	2
1.06 (d)	3
0.89 (d + s, overlapping)	6

$\Sigma = 41$

#### Example 15: Medical Uses of Recombinantly Produced Epothilones

Pharmaceutical preparations or compositions comprising epothilones are used for example in the treatment of cancerous diseases, such as various human solid tumors. Such anticancer formulations comprise, for example, an active amount of an epothilone together with one or more organic or inorganic, liquid or solid, pharmaceutically suitable carrier materials. Such formulations are delivered, for example, enterally, nasally, rectally, orally, or parenterally, particularly intramuscularly or intravenously. The dosage of the active ingredient is dependent upon the weight, age, and physical and pharmacokinetical condition of the patient and is further dependent upon the method of delivery. Because epothilones mimic the biological effects of taxol, epothilones may be substituted for taxol in compositions and methods utilizing taxol in the treatment of cancer. See, for example, U.S.

Patent Nos. 5,496,804, 5,565,478, and 5,641,803, all of which are incorporated herein by reference.

For example, for treatments, epothilone B is supplied in individual 2 ml glass vials formulated as 1 mg/1 ml of clear, colorless intravenous concentrate. The substance is formulated in polyethylene glycol 300 (PEG 300) and diluted with 50 or 100 ml 0.9% Sodium Chloride Injection, USP, to achieve the desired final concentration of the drug for infusion. It is administered as a single 30-minute intravenous infusion every 21 days (treatment three-weekly) for six cycles, or as a single 30-minute intravenous infusion every 7 days (weekly treatment).

Preferably, for weekly treatment, the dose is between about 0.1 and about 6, preferably about 0.1 and about 5 mg/m<sup>2</sup>, more preferably about 0.1 and about 3 mg/m<sup>2</sup>, even more preferably 0.1 and 1.7 mg/m<sup>2</sup>, most preferably about 0.3 and about 1 mg/m<sup>2</sup>; for three-weekly treatment (treatment every three weeks or every third week) the dose is between about 0.3 and about 18 mg/m<sup>2</sup>, preferably about 0.3 and about 15 mg/m<sup>2</sup>, more preferably about 0.3 and about 12 mg/m<sup>2</sup>, even more preferably about 0.3 and about 7.5 mg/m<sup>2</sup>, still more preferably about 0.3 and about 5 mg/m<sup>2</sup>, most preferably about 1.0 and about 3.0 mg/m<sup>2</sup>. This dose is preferably administered to the human by intravenous (i.v.) administration during 2 to 180 min, preferably 2 to 120 min, more preferably during about 5 to about 30 min, most preferably during about 10 to about 30 min, e.g. during about 30 min.

While the present invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the present invention.


**BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSE OF PATENT PROCEDURES**

**INTERNATIONAL FORM**

TO  
 Novartis AG  
 Novartis Corporation  
 Patent and Trademark Dept.  
 3054 Cornwallis Rd.  
 Research Triangle Park, NC 27709

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT**  
 issued pursuant to Rule 7.1 by the  
**INTERNATIONAL DEPOSITORY AUTHORITY**  
 identified at the bottom of this page

**NAME AND ADDRESS  
OF DEPOSITOR**

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:	Accession number given by the <b>INTERNATIONAL DEPOSITORY AUTHORITY:</b>
Escherichia coli DH10B (pEPO15)	NRRL B-30033
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I. above was accompanied by:  <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation  <small>(Mark with a cross where applicable)</small>	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depository Authority accepts the microorganism identified under I. above, which was received by it on June 11, 1998 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I. above was received by this International Depository Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
<b>V. INTERNATIONAL DEPOSITORY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depository Authority	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s):   Date: 7-1-98
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	

<sup>1</sup> Where Rule 6.6(d) applies, such date is the date on which the status of international depository authority was acquired.

**BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSE OF PATENT PROCEDURES**

**INTERNATIONAL FORM**

**TO**  
 Novartis AG  
 c/o Novartis Agricultural Biotechnology  
 Research, Inc.  
 Patent & Trademark Department  
 3054 Cornwallis Road  
 Research Triangle Park, NC 27709

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT**  
 issued pursuant to Rule 7.1 by the  
**INTERNATIONAL DEPOSITORY AUTHORITY**  
 identified at the bottom of this page

**NAME AND ADDRESS  
OF DEPOSITOR**

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <i>Escherichia coli DH10B [pEPO32]</i>	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: <i>NRRL B-30119</i>
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
<p>The microorganism identified under I. above was accompanied by:</p> <p><input type="checkbox"/> a scientific description</p> <p><input checked="" type="checkbox"/> a proposed taxonomic designation</p> <p>(Mark with a cross where applicable)</p>	
<b>III. RECEIPT AND ACCEPTANCE</b>	
<p>This International Depository Authority accepts the microorganism identified under I. above, which was received by it on April 16, 1999 (date of the original deposit)<sup>1</sup></p>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
<p>The microorganism identified under I. above was received by this International Depository Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).</p>	
<b>V. INTERNATIONAL DEPOSITORY AUTHORITY</b>	
<p>Name: Agricultural Research Culture Collection (NRRL)    International Depository Authority</p> <p>Address: 1815 N. University Street    Peoria, Illinois 61604 U.S.A.</p>	<p>Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s):  <i>J. L. Sny</i></p> <p>Date: 5-16-99</p>

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depository authority was acquired.

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone.
2. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is isolated from a myxobacterium.
3. An isolated nucleic acid molecule according to claim 2, wherein said myxobacterium is *Sorangium cellulosum*.
4. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 1.
5. A recombinant vector comprising a chimeric gene according to claim 4.
6. A recombinant host cell comprising a chimeric gene according to claim 4.
7. The recombinant host cell of claim 6, which is a bacteria.
8. The recombinant host cell of claim 7, which is an Actinomycete.
9. The recombinant host cell of claim 8, which is *Streptomyces*.
10. A Bac clone comprising a nucleic acid molecule according to claim 1.
11. The Bac clone of claim 10, which is pEPO15.
12. An isolated nucleic acid molecule according to claim 1, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids

118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

13. An isolated nucleic acid molecule according to claim 12, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino

acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

14. An isolated nucleic acid molecule according to claim 12, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ

ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

15. A nucleic acid molecule according to claim 12, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1.

NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

16. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 12.

17. A recombinant vector comprising a chimeric gene according to claim 16.

18. A recombinant host cell comprising a chimeric gene according to claim 16.

19. The recombinant host cell of claim 18, which is a bacteria.

20. The recombinant host cell of claim 19, which is an Actinomycete.

21. The recombinant host cell of claim 20, which is *Streptomyces*.

22. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1.

NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

23. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 22.

24. A recombinant vector comprising a chimeric gene according to claim 23.

25. A recombinant host cell comprising a chimeric gene according to claim 23.

26. The recombinant host cell of claim 25, which is a bacteria.

27. The recombinant host cell of claim 26, which is an Actinomycete.

28. The recombinant host cell of claim 27, which is *Streptomyces*.

29. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one epothilone synthase domain.

30. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a  $\beta$ -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

31. An isolated nucleic acid molecule according to claim 30, wherein said  $\beta$ -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

32. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

33. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

34. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

35. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

36. An isolated nucleic acid molecule according to claim 35, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

37. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

38. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

39. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

40. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

41. An isolated nucleic acid molecule according to claim 40, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting

of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

42. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

43. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

44. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

45. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an acyl carrier protein domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

46. An isolated nucleic acid molecule according to claim 45, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID

NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

47. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

48. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

49. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

50. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of:

amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

51. An isolated nucleic acid molecule according to claim 50, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

52. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

53. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

54. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

55. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a  $\beta$ -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino

acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

56. An isolated nucleic acid molecule according to claim 55, wherein said  $\beta$ -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

57. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

58. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

59. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID

NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

60. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

61. An isolated nucleic acid molecule according to claim 60, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

62. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1.

63. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 51534-52657 of SEQ ID NO:1.

64. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is nucleotides 51534-52657 of SEQ ID NO:1.

65. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

66. An isolated nucleic acid molecule according to claim 65, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

67. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1.

68. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 61427-62254 of SEQ ID NO:1.

69. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is nucleotides 61427-62254 of SEQ ID NO:1.

70. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

71. An isolated nucleic acid molecule according to claim 70, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

72. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1.

NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

73. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

74. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

75. A method for heterologous expression of epothilone in a recombinant host, comprising:

- (a) introducing a chimeric gene according to claim 4 into a host; and
- (b) growing the host in conditions that allow biosynthesis of epothilone in the host.

76. A method for producing epothilone, comprising:

- (a) expressing epothilone in a recombinant host by the method of claim 75; and
- (b) extracting epothilone from the recombinant host.

77. An isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

78. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a  $\beta$ -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

79. An isolated polypeptide according to claim 78, wherein said  $\beta$ -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

80. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

81. An isolated polypeptide according to claim 80, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino

acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

82. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

83. An isolated polypeptide according to claim 82, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

84. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyl carrier protein domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

85. An isolated polypeptide according to claim 84, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

86. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

87. An isolated polypeptide according to claim 86, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

88. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a  $\beta$ -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

89. An isolated polypeptide according to claim 88, wherein said  $\beta$ -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

90. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

91. An isolated polypeptide according to claim 90, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

92. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

93. An isolated polypeptide according to claim 77, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

- 1 -

## SEQUENCE LISTING

<110> Novartis AG

<120> GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

<130> 4-30582A

<140>

<141>

<160> 30

<170> PatentIn Ver. 2.0

<210> 1

<211> 68750

<212> DNA

<213> Sorangium cellulosum

<400> 1

aagcttcgtc cgacgccttc ttgcgcccgc ccacccctgc ccgtgtgtc gatgtggcc 60  
acggccgggc cacggaggcg catgtgtcgc cggaggcgcc cggatcgag gaccccccgc 120  
ccctccgaga gcaccccccgc atccaggaaag gggggccgtc ctttactgc atgtgcctcg 180  
gcgaccgtac ggtggaggtc ctgcgcacac accagcccc cggatccatc agttccacc 240  
atgccccgcg cctgaggacac cccgacttga cctccggacgc gatgtgtcgc gacggccccc 300  
cgctcgctcg gtggctcgcc ggcgcggcg cggccgggtcc cttccgcgag tacgaagagg 360  
agcgcgagcg agcccgaaacc ggcgcaggagg cgaggccctt ggggtctcgcc gccgcgcgc 420  
cctgttcgtc gccccatctg ccccgcttcg aggacgcacca acggggctg cgcgtcgcc 480  
cgatgtcgcc tgaagtcgccc gaggccgagc ggcgcctcccg cgcctcgatc gcaactcccg 540  
agctcgctcg tgccgcgtc ctgcgttcgtc tcgggacgggg cgggggtccc tggtccggat 600  
atcccgcta cgagatgtcg ccagagaatc tgcgttcgtc ttggggccctc cgcacccgca 660  
tcgcgcggcc ctccgcggccc ggcacatcg aggcccttcg cgcggcgccgca ggcgggtgt 720  
tcgccttcgtc ggaggatcgta tcgagcaaga agagccatc cggcaacatc cccgaaggccc 780  
tgtggggagcc gtcggcgacgc atcggtccgcg cgatgggcaa tgccgacaac ctcttcgtc 840  
tcgacgcgcg cggggcgatc gggggggagg tgcggccctc ggcgcacag cggggccct 900  
tcgccccgggg cggccggctcg ggggttccttc gaggccgggg ctctcgccgg 960  
tcgtgaccga cggagacgca ttgtacttcg ggcacggcaa cgcacatcgat atgttccaaac 1020  
ccggccggat ctgcggcggtc gtgtgtcgcc cggcaaccgc tcccttcgtc gagtcgcac 1080  
cgccccctcg ccagatgtcc ttcgtcgcc acgcacacgc gggcaccatc tccaagggtcc 1140  
tgacggaaagg cggcccccgc atcgatgtcg caaaaacca ggcgcgacccg atgagctcg 1200  
tccacgtcg cgggttcatcg ggcgtggatca accaggccat ggtggccgac cccgagccgg 1260  
gcgcgcctt cgccgtcccg cgctcgacca tcatggaaatt cgagcacccc acgcctcggt 1320  
gtctccacga gccccggggc agcgcttcgt ccctcgccgt cgacgaggag caccctctact 1380  
ggtgcgagct ttcggctggc cggatcgacg tatggcgcaca cccgcaccatc cggccggcg 1440  
ccccgagcc ttcgcgtac ctggcgacgc accccattgc ggcgcacccgt taccctcgcc 1500  
tcacccctcaa tgccgacccac gtgtgtggg ccggccctga tcgcggggcc atccctcgccgg 1560  
tcgacaagcg caccggcgta gagccatcg tcctcgccga gacgcgcacat ccccgccgc 1620  
acgtcggtc cgaggacccg gacatctcg cgcgttcccg acagcccgac tcccgcaact 1680  
ggcacgtcga gcacatccgc tccggccct ccaccgtcg ggcgcactac cagcgccagc 1740  
tatgggaccg ccctgacatg gtgtcaatc ggcgcggcccttccatc acgaacgcacc 1800  
gcacccctcgac gtcgtcgcc acgtgacatc gtcgtcgcc gggccgtca tcggaggccgc 1860  
ccggacccgag ctggcgaccc gccgtggcg ggcgcacccgt cgcgtcgccat cgggtggcgac 1920  
gttagacgtc gcccaggaaac gtcgtcgacg ccccgagaac aggaagccgg cggatttgt 1980  
catcgcgtc cccatcgatc cggggcccg atcattgtac caggacgtcc cgaacccgac 2040  
gtcccaacca tagccggccg gacccctcgac gaccgcgtcc ggcgcggcgatccac 2100  
cccaataaccc cagccgtcgcc ttcgtcgaccc gccccggaaa aacgaggacgc cgccttcgt 2160  
ggccggcggt aggtgtatcg cgcgtatctc ggcgcacccgt ggcgcgtca agagccgc 2220  
gccctcggtc acaccgcgtc tcatgtacat ggcgcgcacccgt cggatccaccgt 2280  
cgacacgacg cccggccggcgc cccggggaa cggccggccgg cttggatccatagg cgcgtcgcc 2340  
cccgatcgca tccatcgccgt tttctccccc cttgtcgatcg tcggatccatagg aaccgcacccgt 2400  
cgcaaccgatc ggcgtcgatcg cggccggccgtc gtcggatccatagg cgcgtcgcc 2460  
cgccggatcg cgcgtcgccatc cggccgtcgatcg gtcggatccatagg cgcgtcgcc 2520  
caccctcgatc accaggatcg cccgtcgatcg catccactgc gccccccggatccatagg gatgcacccgt 2580  
cggeacccgtc cggacccgtc ggatccatcg gtcggatccatagg cgcgtcgcc 2640

- 2 -

ctgcgcgttg acgagcccga gctcgatcgat ggccccgtgg atcggcgacg atgcgtcgaa 2700  
 cgagattccg aagcccatcg tgaacgtcat caggcgccgc accgtatcg gccgcgtccgc 2760  
 gggaccgtc tcgtcgatcg gaccatcgat gcgcgccgc accttccggt tcgcgagctc 2820  
 cggcaaccat cggtcgacgg gggagtcgag gtcgagcttgc ctttcctcgat cgagcatcat 2880  
 caccggcgta gcggtgaccc cggtcgatcat cgaggcgatc cgaaagatcg tgccccggcg 2940  
 catggcgcg ctgccccggc gtcgggtcac gcccacccgc tccacgtgca cgtcgccgccc 3000  
 gcgcgcgacc agccagaccc ctccccggat ctgccccggc gccacccctcg ccgcacatcac 3060  
 ctcgcgcgct ggcgcgcagcg cggcgcccccc cggtcttcgc cttggctgcc cttccctcc 3120  
 ggccccaccc aacgcgcacc cggcgcccccc caccgtatcgaa aagctccca taaaactcccg 3180  
 ctttcctcatg accgtcgatcg ctttcctcgag cggggcgccc tgccccgtcc gagagcactg 3240  
 actgcgcgcg cccgaaaaaaa tcatcggtgc cccgtcacga tcgcccggc gggtggctcc 3300  
 gccccggccgc ccgctcgggc gccccccct ggacgagcaa agctcgcccccc cccgcgccta 3360  
 gcaacggccgt tggcatgtcc ggcgtcgacc cacacggagg agccacccac cctgtatgcac 3420  
 ggccctcaccg agcggcaggc cttgtcttcgc ctcgtcaccgc tcgctgtatcg cttcgatcg 3480  
 ggcgcgcgcct cggcgagct cccctccgtc gtccggcgcc tcgccccggg gttccatcgaa 3600  
 ttccggcgcg tcgtcgatgggg ggtcggggtc gtgtctcgatcg gataggcgcg 3660  
 gcccccttcc aggagccggc ttccttcgtc tgcgtatggc gggatcgatcgatccctcg 3720  
 cggccctgggg cgctcgccgc tcggccgc tccctccgtcg gatcgatcgatccctcg 3780  
 ttttcggcgcc tcgtcgatcgatcg gatcgatcgatcgatccctcg gatcgatcgatccctcg 3840  
 tcgggtacgg cgttcagatcg agtatcgatcgatcgatccctcg gatgcgcgcgc 3900  
 gatcgatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 3960  
 gatcgatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4020  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4080  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4140  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4200  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4260  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4320  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4380  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4440  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4500  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4560  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4620  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4680  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4740  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4800  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4860  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4920  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 4980  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5040  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5100  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5160  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5220  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5280  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5340  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5400  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5460  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5520  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5580  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5640  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5700  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5760  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5820  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5880  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 5940  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6000  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6060  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6120  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6180  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6240  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6300  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6360  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6420  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6480  
 gatcgatcgatcgatcgatcgatccctcg gatcgatcgatccctcg 6540

gacagccgaa	gaggcaagct	ggcccggagacg	accgtgcctgt	atgcacaactt	cgagctgcctc	6600
atcaccgccc	agaagcagag	cagccccctcag	tgcgcattcgt	ctgcccggct	catcggggccg	6660
acgtctgtcg	ggtgacatcg	cgcatacgc	agcgctgagc	ccgcccagcag	gcccccagggc	6720
cctgcctcga	tggcccttccc	catcacccct	gcccactctt	ccagcgcacgg	ccgcccgcgcg	6780
acggccgcgt	ccaagcaacc	gcccgtgcgg	cgccggcttca	cgccgcgcgc	aggcgagcgt	6840
cctggcgcgg	cctgtgcgttc	gcttggaaagga	tcggggagac	atggatagag	aatcgaggat	6900
cgcgcatttt	gttgcctatcg	cagccaaacgt	ggcgatcgcg	gccccgtcaagt	tcatcgccgc	6960
cggccgtgacc	ggcagctcggt	cgaggcgttt	gcccacttcg	gccccgttccc	gegcgtgcgt	7020
ctctacgaca	acctaacaagag	cgccgtcgctc	gagcgcacacg	gccccgtcgat	ccgggttccac	7080
cccacgctgc	tggctctgtc	ggcgcatcattac	cgcttcgagc	cgccgcggccgt	cgccgtcgcc	7140
cgcggcaacg	agaaggggccg	cgtccagcgc	gccatcacgg	cgtggacgcac	atggcgcgga	7200
aacgtctgtcg	taaccggccca	gcaatgtcat	ggggatggcc	cccccttgag	7260	
ggggctggcc	gggggtcgacg	atatcgccgc	atctcccccgt	caatctcccg	tggtaaaaaga	7320
aaaatttgc	atagatcgta	agctgtgata	gtggctctgtc	ttacgttgcg	tcttccgcac	7380
ctcgagcgag	tttctctggaa	taactttcaa	ttttttcgag	ggggggcttgg	tctctgggttc	7440
ctcaggaagc	ctgatcgggaa	cgagctaatt	cccatccatt	tttttgaggc	tctgctcaaa	7500
gggatttagat	cgagtggagac	agttcttttgc	cagtgcgcga	agaacacctggg	cctcgaccgg	7560
aggacgatcg	acgtccgcga	gccccgtcage	cgctggaggat	gtggccgtcg	tggcgatccg	7620
tccccatcgag	cgccgcagccg	aagatcccg	tgcgcattcgt	ggagcgcgt	gccgtcgcc	7680
cgggtggcgtg	atcgatctga	gccccgttcgt	gacgccttc	gaggggctcgc	gccccgtcg	7740
cggggcagtc	cccgccgaac	gctggggatgc	agcagcgtgg	tttgcattccg	accccgatgc	7800
cccggggaag	acgcccgtta	cgccgcgcata	tttccctgagc	gacgttagcc	gtttcgacgc	7860
ctcccttc	ggcatctcg	ctcgcaagc	gctgcggatg	gacccctgcac	atcgactctt	7920
gctggagggt	tgcgtggagg	cgctggagaa	cgccgcgcatt	gttccatcg	cgctcgctgg	7980
tacggaaaacg	ggagtgttca	tcgggatcgg	ccccgtccaa	tatggaggccg	cgctgcccga	8040
agecgccggc	tccgcagaga	tcgacgcgtca	tgggggtcgt	ggggacgtatgc	ccagcgtcg	8100
agcggggcga	atctcgatgt	ccctcggttgc	gccccgtccg	tgttgcgcgg	tggataccgg	8160
ctatttcgtcc	tcgctgggtgg	cggttcatct	ggccgtgtcag	agcttgcgt	ccggggaaatg	8220
ctccacggcc	ctggctgggt	gggtatcgct	gatgttgcg	ccgagcacc	tctgtgtggc	8280
ctcgaqaacc	cgggcgtctgg	ccagggacgg	tcgcgtcaag	gcatttttgcg	cggaggccga	8340
tgggttccgga	cgaggcgaag	gggtgcggct	cgtgggttcc	aacggcgttca	gtggagcccc	8400
cgccgacggc	gatcgatata	tggcggtat	tcgaggatcc	gcatcaatc	acgacgggtc	8460
gagcagcgggt	tcgaccgtgtc	cgaaacgggg	ccccaaagaa	atcggtgt	aacggggccct	8520
ggcggcgcga	ggctgcgcgg	cgcttcgtgt	gggttatgtc	gagggcacacg	gcacgggcac	8580
gacgccttgg	gaccccatcg	aaatccaa	tctgaatgcg	gtatacggcc	tctggcgaga	8640
tgtcgccacg	ccgcgtgtcgt	tcgggtcggt	gaagaccaac	tttggccatc	ctgagtatgc	8700
gtcgffffatc	acttgggtcgtc	tgaagggtcgt	tttgccttctt	cagcacgggc	agattccgtc	8760
gcacccctccac	gcccgcggcgc	tgaacccccc	gatcttcatgg	gggtatcttc	ggctgaccgt	8820
cacgcgcgc	cgacacccgt	ggccggactgt	gaatacgcgg	cgacggggcgg	gggtgagcc	8880
gttcggatcg	agcggggatca	acgcgcacgt	ggtgtgtggaa	ggggcgcgg	cggcgacgt	8940
cacaccggcc	gccccggcgc	gaccggcaga	gctgtgtgg	ctgtcgccaa	ggaccgcgtc	9000
agccctggat	gcaacaggcgg	cgccgtcg	cgaccatctg	gagacctacc	cttcgcagtc	9060
tctggggcgt	gttgcgttca	gtctggcgtac	gacgcgcagc	gcatgtggagc	accggctcgc	9120
ggtggggcgg	acgtcgaggg	aggggctcg	ggcagccctgt	gacgctgcgg	cgcaggggaca	9180
gacgtcgccc	ggtgcgggtgc	gcagatcg	cgatcttc	cgccgtttct	9240	
cttcacccgga	caggggggcgc	agacgtgtgg	catggggcgt	gggtgttacg	atgtatgtc	9300
cgcgtttccgc	gagggttccgt	acctgtgtcgt	gagggtgttc	aacccaggagc	tgcaccggcc	9360
gctcccgcg	gtgtatgtggg	ccgaacccggc	cagcgctcgac	gcccgcgtgc	tgcaccagac	9420
agccttcacc	cagccggcgc	tgttcaccc	cgaatatgcg	ctcgcccg	tgtggcggtc	9480
gtgggggtgt	gagccggagat	tgggtcgccgg	ccatagatcg	gggtgagctgg	tggctgcctg	9540
cgtggggcgc	gtgttctcg	ttgaggacgc	gggtttcttgc	gtggctgcgc	gccccggccct	9600
gatgcaggcg	ctggccggccg	ggggggcgat	gggtgtcgatc	gagggcgcgg	aggccgtatgt	9660
ggctgtcg	ggggccggcc	acgcagcgtc	gggtgtcgatc	cgccgggtca	acgcctccgga	9720
ccagggtgg	atcgccggcc	ccggggcaacc	cgtgcattcg	atcgccgg	cgatggccgc	9780
gccccggcc	cgaaaaagg	cgctccacgt	ctcgcatcg	ttccactac	cgctcatggc	9840
cccgtatcg	gaggcggttc	ggcggtgtgg	cgagtcgtgt	agcttccggc	ggccgtcgat	9900
cgccctgg	agcaatctga	cggggaaggc	ttgcacagac	gagggtgagct	cgccgggcta	9960
ttgggtgc	cacgcgcgag	aggtgggtcg	tttcgcggat	ggagtgtaa	cgctgcacgc	10020
ggccgggtcg	ggcaccttc	tcgagggtcg	tccggaaatcg	acgtctgtcg	gcctgggtgccc	10080
tgcctgc	atcgccggcc	ggccggcgct	gttcgcattcg	tcgcgcgtcg	ggcggtacga	10140
gccccggc	gttcccgagg	cgctcggtcg	gttctggggc	gtcggtggcc	tggctctctg	10200
ggccggcc	tcccccctcag	ggggggcgccg	gggtggccgt	ccccacgtacc	tctggcagcg	10260
cgagcgctac	tggatcgaca	cgaaagccga	cgacgcggcg	cgtggcgacc	gccgtgtcc	10320
gggagcggtt	cacgacgagg	tcgaggaggg	ggggcgcgg	cgccggcggcg	accggcgcag	10380
cgctcggtc	gaccatccgc	cgccccagag	cgacgcggcc	gagaagggtc	aggccggccgg	10440

cgaccgtccg ttccggctcg agatcgatga gccaggcgtg cttgatcacc tcgtgctcg 10500  
 ggtcacggag cggcgcgccc ctggctggg cgagggtcgag atcgccgtcg acgcggcggg 10560  
 gtcacgttc aatgtatgtcc agtcgcgtc gggcatggt cccgacgacc tgccggaaa 10620  
 gcccaacctt ccgtgtctgc tcggaggcga gtgcgcggg cgcatacgctg ccgtggcga 10680  
 gggcgtaac ggccctcggt tgggccaacc ggtatcgccctt cttcgccgg gagegttgc 10740  
 taccacgttc accacgtcg ctgcgttgt gctgcgtctgg ctcaggcgc ttcggcgat 10800  
 cgaggcggcc gccatgccc tcgcgtaccc gacggcatgg tacgcgtctg acagaatagc 10860  
 ccgccttcag cccgggggagc ggggtgtat gcatcgccg accggcgggg tccgtctcg 10920  
 cgcggtcgac tgggcccggc acgtgggagc cgaggccat ggcacggccg gcacgcccc 10980  
 gaaacgcgcc tacctggagt cgctgggctg gccgtatgtg agcgattccc gctcgacccg 11040  
 gttcgccgcgac gacgtgcgcg cgtggacggg cgagggtgg gtagacgtcg tgctcaactc 11100  
 gctctcgggc gagctgtatcg acaagagttt caatctctg cgatcgacg cccgggttgt 11160  
 ggagctcgac gacgtgcact gttacgcgga taaccagctc ggcgtgcggc ctttcctcg 11220  
 caatcttc ttttcgtcggt tggatctccg gggatgtat gtcgacggcc cggcgccggg 11280  
 ccgtcgctc ttggaggagc tccctggctt gatcgccgca ggcgtgttca cccctcccc 11340  
 catcgacg ctcggatcg cccgtgtcg cgtcgcttc cggagcatgg cgcaggcga 11400  
 gcatcttggg aagctcgatc tcaacgtcggt tgacccggag gtccagatcc gtattccaac 11460  
 ccacgacggc gccggcccggt ccacccggga tcgggacccctg ctcgacaggc tccgtctc 11520  
 tgcggccggc ggcgcggcggc cggcgctgg ggcgttccctc cgtacgcggg ttcgcaggt 11580  
 gctgcgcacg cccgaatca aggtcgccgc ggaggcgtg tccacccggc tcggcatgg 11640  
 ctcgcctatg gccgtggagc tgcgcacatcg tatcgaggcg agcctcaacg tgaagctgtc 11700  
 gacgacgttc ctgtccacgt ccccaatat cgccttgcgt gcccaaacc tggatgtgc 11760  
 tctcgccaca gctctctctt tggagcggtt ggcggcgag aacctacggg caggcgtgca 11820  
 aaacgactt gtcacatcg ggcgcacatcg agactggaa atcatggccc tatgacgatc 11880  
 aatcagctt taaacgacatcg cgagcacccg ggtatcaacg tggcgccgca tggggagcgc 11940  
 ctccgcatacg aggccccccaa gaacgcctg aacccggaaatc tgctcgctcg aatctccgag 12000  
 cacaaaagca cgatccgtac gatgcgtcgatc cagagactcc cccgacaaatc catcgcc 12060  
 gccccagccg agcggcaccgc tccgttccctc ctcacagaca tccaaagaaatc ctactggctg 12120  
 ggccggacag gagcggttac ggtccccagc gggatccacg cctatcgca atacgactgt 12180  
 acggatctcg acgtgcgcgc gctgagccgc gccttcggaa aagtgcgtcg gcggcacgac 12240  
 atgccttcggg cccacacgtc gcccggatcg atgcgggtga tcggacgttac agtgcacgac 12300  
 gacatcgatc tcatcgatcg ggcggggcc gacgggagca cacgggaaagc gaggctcg 12360  
 tgcgtcgccg atgcgtatgcg acggccatcgatc tgcacccgtt ggcggccctc gtttatcac 12420  
 gtcgtcgccg ttcggctggaa cgacggccaa acccgcttcg tgctcgtatcgatc tgcacccgtt 12480  
 aacgttggacc taggcacgtt gtcacatcgatc ttcaaggact ggctcagctt ctacgaagat 12540  
 cccgagaccc ctctccctgt cctggagctc tcgttcccg attatgtact cgcgttggag 12600  
 tctcgcaaga agtctcgaggc gcatcaacga tcgtatggatt actggaaagcg ggcacatcgcc 12660  
 gagctccac ctcggccgac gtcgtccgtatcg aaggccgtatcgatc ttcacccgtt gacggagatc 12720  
 cgctcccgcc acacggagca atggctccgc tcggacttctt ggggtcgatc gaagccggcgt 12780  
 gtcggggggc gccgggtcgatc cccgacggccgc gtcatctcggt tcgttccctt cgggtgtatc 12840  
 gggcgctggaa ggcgcggccccc cccgtttacg ttcaacataa cgcttccaa cccggcccc 12900  
 gtcacatccgc ggcgttacgatc ttcacccgtt gacttcacgt cgatggccctt ctcggacatc 12960  
 gacaccactc ggcacaaagag ctgcacaaatcg cgcgttacgatc gtattcaaga gcacgtgtgg 13020  
 gaagcgatgg atcaatcgatc cgtaaacggcgtt atcgagggtcc acgcggagggc cgccgggttc 13080  
 ctggggatcc aacggggcgcg attgttcccg tgggtgtatcgatc cggcgccgtt taaccagcaa 13140  
 gtcgttgggt tcacccgttgcgatc gacgggttc ggaactccgg tttacccaggc acgcacact 13200  
 ctcacatcgatc ttcacccgttgcgatc gacgggttc gacggatcgatc ctcggatcgatc 13260  
 gacatcgatc acgggttc gtcgttcccgatc ctcacccgttgcgatc acatgtcgatc acgtacgtc 13320  
 gtttttctcc ggcgttacatcgatc tgagaaacca tgggtgtatcgatc aggtgcgtcg ttcgttcccg 13380  
 ctcacccgttgcgatc tagaaacggcgcg ggcgttacatcgatc aacggatcgatc acgtacgtcgatc 13440  
 acgtgtcgatc gtcgttcccgatc ggcgttcccgatc gacggatcgatc ctcacccgttgcgatc 13500  
 tggcgccgca acacggatcgatc gacggatcgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13560  
 cggcgccgca acacggatcgatc gacggatcgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13620  
 tggcgccgca acacggatcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13680  
 gatggccgacc taccggccggaa gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13740  
 gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13800  
 ctcacatcgatc acacggatcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13860  
 acacccgttgcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13920  
 gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 13980  
 ataggcccgatc gacggatcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14040  
 gatgttcccgatc gacggatcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14100  
 cgcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14160  
 gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14220  
 aggttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14280  
 ctcacccgttgcgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc gtcgttcccgatc acgtacgtcgatc 14340

- 5 -

atctggtcca	tcgggtaccc	cgtgaggAAC	gtcgacccAT	cgtggggCAG	catcccTAC	14400
ggccgtccgc	tgcgcaacca	gacgttccac	gtgctcgtat	aggcgctcgA	accgcgcccG	14460
gtctgggttc	cggggcaact	ctacattggc	ggggtcgggc	tggactggg	ctactggcgc	14520
gatgaagaga	agacgcgcaa	gagttccctc	gtgcaccccg	agaccggggA	gcgcctctac	14580
aagaccggcg	atctgggccc	ctacctgccc	gatggaaaca	tgcagttcat	ggggcgtrgag	14640
gacaaccaaa	tcaagcttcg	cggataccgc	gttgagtcg	ggaaaatcgA	ggaaacgcct	14700
aagtgcgcac	cgAACgtacg	cgacgcgggt	attgtgcctc	tgggaacga	cgcggcgaac	14760
aagctccctc	tagccttatgt	ggtcccggag	ggcacaccca	gacgcgtgc	cgagcaggac	14820
gcgagcctca	agaccgagcg	gatcgacgcg	agagcacacg	ccggcgaagc	ggacggcttg	14880
agcgacggcg	agagggtgcA	gttcaagetc	gtctcgacacg	gactccggag	ggaccggac	14940
ggaaagcccc	tgcgtcgtat	gaccgggcag	gatggccggg	aggcggggc	ggacgtctac	15000
gcccgtcgcc	gtagegttcgg	aacgttccctt	gaggccccga	tccgttttgt	ttagtttgt	15060
cgatttcgt	gtctgttggag	cagcgtggag	cccgacggcg	cgacccttcc	caaattccgt	15120
tatccatcg	cgggcagcac	gtacccgggt	caaacctacg	cgatgtatcg	atccggccgc	15180
atcgaggggcg	tggacgaggg	cttctattat	taccacccgt	tcgagcacccg	tttgctgaag	15240
ctctccgatc	acgggatcgA	gcgcggagcg	cacggttccgc	aaaacttcga	cgtgttgcgt	15300
gaagcggcgt	tcaacccctc	gttcgtgggc	aggatcgacg	ccatcgagtc	gctgtatgga	15360
tcgctcgcc	gagaattttt	cctgtctggag	gccggatata	tggcgcgtct	cctgtatggag	15420
caggcgcctt	cctgtcaacat	cggcgtctgt	ccgggtggggc	aattcaattt	tgaacaggtt	15480
cggccgggttc	tgcacccgtcg	acattccggac	gtttacgtgc	acggcatgt	ggggcgggccc	15540
gtagacccgc	ggcagtccca	ggtctgtacg	ctcggcgtagg	atttctcacc	gaggcgcgccc	15600
acgacgcgcg	gcgcctccccc	cggccgcgag	cagcacttcg	ccgatatgt	tcgcgcacttc	15660
ttgaggacca	aactacccga	gtacatgggt	cctacagtc	tcgtggagct	cgatgcgttg	15720
ccgcgtacgt	ccaaacggcaa	gttgcgtatgt	aaggccctgc	gcegagcggaa	ggataccctcg	15780
tcgcgcggc	atccggggca	cacggcgcac	cgggacgcct	tggaggagat	cctcgtcgcc	15840
gtcgtaacgg	agggtgttcgg	gttggagggt	gtcgggtctc	ageagagctt	cgtcgatctt	15900
gggtgcgacat	cgttccatcat	gttcgtcat	aggaggctgt	tgcagaagag	gttggatagg	15960
gagatccca	tcacccgatgt	gttcccgat	ccgaacctcg	gttcgctggc	gtccgggttg	16020
cgccgagact	cgagagatct	agatcagcgg	ccgaacatgc	aggaccgagt	ggagggttcgg	16080
cgcaagggca	ggagacgtcg	ctaagagcgc	cgaacaaaac	caggccgagc	ggggccgtatga	16140
gccgcgaagc	cgcctcgctc	acccttggac	tcatctgtat	tgcgcgtggg	tacgcgtcgcc	16200
gggtgtcgcc	gtttagccgt	gttggttcga	cgttgaggaa	cgttgagtc	atggaaagaa	16260
aagatccctc	cgtatcgca	gtcatcgga	tgcggggcc	ttttccgggg	gcgcgggatc	16320
tggacgaatt	ctggagggaa	cttcgagacg	gcacggaggc	cgttcagcgc	tttcggcggc	16380
aggagctcgc	ggcggtccgg	gtcgaccccg	cgctgggtct	ggaccccgagc	tacgtccggg	16440
cgggcagcgt	gttggaaagac	gtcgaccgtt	tcgacgttc	tttcttcggc	atcagccccc	16500
gcgaggcaga	gttccatggat	ccgcagcacc	ggatcttcat	ggaatcgccc	tgggaggcgc	16560
tggadaacgc	cgatcgacac	ccgacggctt	acggggctt	tatcggtgt	tacgcggggc	16620
ccaacatcg	ctcgatctt	acgtcgaaat	tcacacgac	cccacggatc	atgcgggtggc	16680
ccggctgg	tcaacgttc	atccgcaac	acaaggatta	cctcgcgcacc	cacgtctcc	16740
acaggctgaa	tcttagaggg	ccgagatct	ccgttcaaac	tgcctgtctc	acctcgtctcg	16800
tggcggttca	cttggcgtgc	atgagccttc	tggaccgcga	gtgcgacatg	gcgcgtggccg	16860
gcgggattac	cggtccggatc	ccccatcgag	ccggctatgt	atatgtcgag	gggggcattt	16920
tctctcccg	cggtccattgc	cggtccatttc	acgcggaaagg	gaacggcaccg	atcatgggca	16980
acggctcgcc	cggtgttcc	ctgaaggccgc	tggaccgggc	gctctccgat	gttgcgtcccg	17040
tccgcgcgtt	tatcccttggg	tctggccacaa	aaacacgacg	agcggaggaa	atcgggtttca	17100
ctgcgccttc	tgggttgggc	caggcgcgaag	cgatcatgga	ggcgcgtggcg	ctggcagggg	17160
tgcaggcccg	gtccatccaa	tacatcgaga	cccacgggc	cggcacgcgt	ctcggagacg	17220
ccatcgagac	ggcgccgcct	cggtgggtgt	tgcgtcgca	cgcttcggcc	cgagggttt	17280
gcgcgatcg	ctccgtgaag	accggcatcg	gacacccctcg	atccggccgt	ggcatcgccc	17340
gtttgtatca	gacggcttc	cggtggaggc	accggcagat	gcccgcgcag	ctgaacttc	17400
aggctccat	cccatcgatc	gatcccggtt	cgacggccgtt	ctacgtcaat	accccttc	17460
aggatcgaa	tacccgttc	atcccgccgg	ggggccggct	cagctcgatc	gggatcgccg	17520
gcaccaacgc	ccatgtcg	ctggaggaa	cgccccggc	gaagttcca	ggccggccgc	17580
cggcgcgtc	tgcgcgttc	ttcgttcgtct	cgggccaaagag	cgcagcggcg	ctggatggcc	17640
cggcgcac	gttacgagat	catctgcagg	cgacccagg	gatttcgatc	ggcgcacgtcg	17700
ccttcagcc	ggcgacgacg	cgcagccca	tggagcaccg	gttcgcgtat	gccccggccgt	17760
cgcgcgaggc	gttgcgagag	gggttcgcac	cagcggcgcgc	aggccacacc	ccgcggggccg	17820
ccgtgcgtgg	ccgtcttc	ccaggcaac	tgcggaaagg	gttcttcgtc	tttccggccc	17880
agggttc	tgggttggc	atggggccgc	agctccgtgc	tgaggaaccc	gtttccac	17940
cggcgccttc	ggcggtgcac	cgggccatcc	aggccgaagc	tgtttgggtcg	ctgcgtcgcc	18000
agctcgccgc	cgacgaaagg	tcctccca	tcgagcgcac	cgacgtgggt	cagccggcgc	18060
tgttcgcct	cgcggtggc	tttgcggcgc	tgtggcggtc	gtgggggtgtc	gcgcggccac	18120
tgcgtatcg	ccacagcat	ggcgaggtt	ccgcccgcga	tgtggccccc	gcgcgtcgcc	18180
tcgaggatgc	ggtggcgtatc	atctggcggc	gcagccggct	gttcggccgc	atcagcggtc	18240

agggcgagat ggcgggtgacc gagctgtcgc tggccgaggc cgaggcggcg ctccgaggct 18300  
 acgaggatcg ggtgagcgtg gccgtgagca acagcccgcg ctcgacggtg ctctcggcg 18360  
 agccggcagc gatcggcgag gtgtgtcgt ccctgaacgc gaagggggtg ttctcgccgtc 18420  
 gggtaaggt ggtatgtcgcc agccacagcc cgcaggtcga cccgctgcg gaggacctct 18480  
 tggcagccct gggcgggctc cggccgggtg cggagctcg gacgaaattt ctggatgaac aacctcaggc 18540  
 cgggcggcat ggttagcgggc cccgtgtccagg cgcagttcca aggcggccac ggtctgttcg 18600  
 agccagtgcg ctgcggcag gtagtccagg cgcagttcca aggcggccac ggtctgttcg 18660  
 tggagatgag cccgcattcg atcttaacga cttcgtcga ggagatgccc cgcggggcc 18720  
 agcggggggg cgcagcggtg ggctcgctgc ggcggggca ggacgagcgc ccggcgatgc 18780  
 tggaggcgct gggcacgctg tggcgccagg gctaccctgt accctggggg cggctgtttc 18840  
 ccgcgggggg gccgggggtt cccgtgtccagg cctatccctg gcagcgcgag cggtaactgga 18900  
 tcgaagcgcc gggcaagagc gccgcggcg atcgcggcg cgtgcgtgcg ggccgttcacc 18960  
 cgctctcg taaaatgcag accctgtcaa cccagacgc acgcggcg tgggagacga 19020  
 cgctgtatcg caagcggtt cccgtgtccagg ggcggccaccgg ggtcgaggatg 19080  
 ttccgggcgc ggcgtacctg gagatggcg tttcgccggg ggcggaggct tggggcgatg 19140  
 gcccctttgc aataactgac gtgggtcgtc cccggggcgct ggcccttcgcg ggcgacgcgg 19200  
 cggtgtttgtt ccagggtggcg acgacggagc agccgtcggg gccggctgcag tttccagatcg 19260  
 cgagcggggc gccggggcgct ggccacgcgt cccctccgggtt ccacgcgtcgc ggcgcgttgc 19320  
 tcccgatggg ggcgcacccgg tccaggccat acgcggagc gacggatgatg gggctgcagt 19380  
 acggccctgc ctcccgagggg attgtcgacg tattgggggg tgaaggcgatg ggcgtgggac 19440  
 gggtaacgcct gcccgcacgcg gccggctcg cccggggatg tccgggttgcatt cctgcgtcgc 19500  
 tggacgcgtg ctcccgatcg tccggcagcc ttttcggccgg cccggggatg ggcgcgttgc 19560  
 gggtgcccgat gggatggggc tccatggccat acgcggatcg gacggatgatg gggctgcagt 19620  
 gccatcgccg cgtcgatgaa catggccacc aaaccccccga tccggcaggggc gccgactttt 19680  
 gggtgcccgat cagctcggtt gcatgggttgc cccggggatg cccggggatg ggcgcgttgc 19740  
 tttccggagg ggtgcggccgg cccggggatg aaggtaacg cccggggatg cccggggatg ggcgcgttgc 19800  
 cccggggatcc gggccgggtt gcatgggttgc cccggggatg cccggggatg ggcgcgttgc 19860  
 gtcgtcgccg cccggggatg cccggggatg cccggggatg cccggggatg ggcgcgttgc 19920  
 gtcgtcgccg cccggggatg cccggggatg cccggggatg cccggggatg ggcgcgttgc 19980  
 cggcagagaa caaacacgcg gtcgtcgccg tacgcgcgtt cccggggatg ggcgcgttgc 20040  
 gccaggctcc gacggcggtt gtcgtcgccg cccggggatg cccggggatg ggcgcgttgc 20100  
 cagggtcggtt ggcgcacggc gtcgtcgccg cccggggatg cccggggatg ggcgcgttgc 20160  
 cccctcgatcc ggcgtcggtt gtcgtcgccg acggatcgatg tccggaccgtg caggccctgg 20220  
 cccggatggg tttcgagac gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20280  
 tccggcccg ttcgtcgatcg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20340  
 ccatggatcg cccggatcg ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20400  
 gggagctcg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20460  
 ttcgtcgccg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20520  
 gggggaggat cgagatcgatg ttcgtcgccg acggatcgatg tttcgatggg tttcgatggg 20580  
 tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20640  
 gtcgtcgccg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 20700  
 cccggggatcc gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 20760  
 atcggggcgca gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 20820  
 gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 20880  
 ggtttcgatcc gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 20940  
 gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21000  
 cggggccaggg caatacgcc gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 21060  
 gggcgcagggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21120  
 cggccgcgcg ggaagatcgatg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 21180  
 cccgacgagggg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21240  
 ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21300  
 ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21360  
 acctgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21420  
 ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21480  
 ccccgatccat gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21540  
 aggccatcgatg gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21600  
 cccggggatcc gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21660  
 ccaccggccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21720  
 ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21780  
 gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 21840  
 ggcggaggatcg gacggatcgatg ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg 21900  
 cgggtcgccgat gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 21960  
 gtcgtcgccgat gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 22020  
 ggcggggatcc gtcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg 22080  
 ttcgtcgccg tttcgatggg tttcgatggg gtcgtcgccg tttcgatggg tttcgatggg 22140

gctcgaggac	gcccgtatcc	cgccccggtc	catcgacggg	agccgcaccg	gtgtgttcgt	22200
cggcgcttcc	acggcgact	acgcgcgcac	ggtcgttcgg	ctgcccgcgcg	aggagcgaga	22260
cgcgtacagc	gccaccggca	acatgtctag	catcgeggcc	ggacggctgt	cgtacacgct	22320
ggggttgcag	ggaccttgcc	tgaccgtcga	cacggcgtgc	tgcgtatcgc	tgggtggcgat	22380
tcacctcgcc	tgccgcagcc	tgcgcgagg	agagagcgt	ctcgcgttgg	cgggagggggt	22440
cagcgcgctc	ctctcccccg	acatgttgg	agccgcggcg	cgcacgcgaa	cgtgtcgcc	22500
cgtatgttcgt	tgccggacct	tgcgtcttc	ggccaacggg	tgcgtccgtg	gcgagggtctg	22560
tggcttggtc	gtcctcaaaac	ggctctccga	cgcgaacagg	gatggcgacc	gcatctggc	22620
gctgtatccgg	ggctcgggcca	tcaaccatga	tggccggctcg	accgggttga	ccgcgccccaa	22680
cgtgtcggt	caggagacgg	tcttgcgcga	ggcgctgccc	agcgcggccacg	tcgaagctgg	22740
ggccgtcgat	tacgtcgaga	cccacggaa	agggacccctcg	ctggggcgatc	ccatcgaggt	22800
cgaggcgctg	cgggcgacgg	tggggccggc	gcgcctccgac	ggcacacgcgt	gcgtgttggg	22860
cgcggtgaaag	accaacatcg	gcccattcga	ggccgcggca	ggcgttagcgg	gcctgtatcaa	22920
ggcgcggctt	tgcgtcgcc	acgagcgtac	ccccggaaaac	tccaaacctcc	gcacgcctcaa	22980
tccgcggatc	cggctcgagg	gcagcgcgtc	cgcgttggcg	accgagccgg	tgccgtggcc	23040
gcccacggac	cggccgcgtc	tgcgggggtt	gagctgttc	ggatgtgagcg	gaacgaacgc	23100
gcatgtggtg	cttggaaagagg	cgccggcggt	ggagctgtgg	cctggccgcgc	cggagcgctc	23160
ggcggagctt	tttgtgtctgt	cgggcaagag	cgagggggcg	tccgatgcgc	aggcggcgcg	23220
gctgcgcgag	cacctggaca	tgcacccgg	gctcggttc	ggggacgtgg	cgttcagcct	23280
ggcgacgcg	cgcagcgcga	ttagccaccc	gctcggtgt	gggtgtacgt	cgcgcgagggg	23340
gctgttggcg	gcgtctcggt	cggcgtcgca	ggggcagacag	ccggcgggggg	cggcgcgtc	23400
catcgcgagc	tcttcgcgcgc	gcaagcttgc	tttcctgttc	accggacagg	gcgcgcagac	23460
gcccggcatg	ggccggggggc	tttgcgcgc	gtggccagcg	tcccgggagg	cgttcgaccg	23520
gtgcgtggcg	ctgttcgacc	gggagcttga	ccggccgctg	cgcgagggtga	tgtgggcccga	23580
ggcggggggagc	gcccgtcggt	tgttgcgtga	ccagacggcg	tttaccccagc	ccgcgetctt	23640
cgcgggtggag	tacgcgtcgta	cggcgtgtgt	gcccgtgtgg	ggcgttagcgc	cggagctctt	23700
ggttggccat	agcatcgggg	agcttgggttgc	ggcgtcgctg	gggggggtgt	tccgtcgatgg	23760
agatgggggt	aggtctcggtt	cgggcgcgg	gggggtgtatg	cagggggtct	cgccggggcg	23820
cgcgtatgt	tcgctcgagg	cgccggaggc	ggagggtggcg	ggggcggtgg	cgccgcacgc	23880
ggcgtcggt	tcgatcgccgg	cggtaatgg	gccggagcag	gtgtgtatcg	cgggcgatgg	23940
gcaagcggt	caggcgatcg	cggcgggtt	cgcggcgcgc	ggcgcgcgc	ccaagcgct	24000
gcatgttctcg	cacgcgttcc	actcgccgt	gatgttgcac	atgtctggagg	agttcgggcg	24060
ggtgcggggcg	tcgggtgacgt	accggcgcc	aaggctttcg	cttgggtgagac	acctgagcgg	24120
gaagggtggc	acggacgcgc	ttagccgc	gggggtactgg	tgccggcacg	tgccggaggc	24180
ggtgcgttcc	ggcgacgggg	tgaaggcgct	gcacaaaggcc	ggcgccgggg	cgttcgatcg	24240
agttggcccg	aaggccgacgc	tgcgtcggt	gttggccagcc	tgcctgcccgg	agggggagcc	24300
gacgtgtcg	gctgtcggtc	gcgcggggcg	cgaggaggct	gggggggtgc	tcgaggcgct	24360
gggcaggctg	tggggccccc	gcggctcggt	cagctggccg	ggcgctttcc	ccacggctgg	24420
gcggccgggt	ccgtgtccga	ccataccgtg	gcagccggcag	cgttactgg	tcgaggcgcc	24480
ggcccaaggag	ctccggagcc	cgccgcgcga	tgcgtcggt	cgttgcgttgc	accgggttgg	24540
cggggcccgat	atgcctcgct	cattccgttgc	tgcgtcgatcg	ggccgttccgg	cggggttgct	24600
ggtgtcgccg	gaccgggggt	gagtccggga	ggggccggcg	ggggcgcttt	cgccgcagggg	24660
atgttcgtgc	gcccgtgtcc	atgcgtccgc	cgaggccctcc	gggtttggcg	agcagggtac	24720
ccaggccctc	gggtggccgca	acgactggca	gggggtgtcg	tacctgttgg	gtctggacgc	24780
cgtcggtggag	gcggggggcat	cgccgcgaaga	ggtcgcctaaa	gtcaaccatc	ttggccggcc	24840
gcccgtgtcc	gcgtgtatcc	aggcgctcg	cacggggcccg	cgctcaccacc	ggctcttgat	24900
cgtgaccccg	ggggccctgcg	cgggtggccg	cgaggctgc	gtctccccc	gtcaggccgg	24960
gctgtgggggt	atggggccgg	tcggggcgct	agagcatccc	ggctcttgg	gcgggctcg	25020
ggaccttggat	cccgaggagg	gcccgcacgg	ggtcgaggcc	cttgggtggccg	agctgttttc	25080
gccggacgccc	gaggatcagc	tggcatccg	ccaggggcgc	cggcgcgcag	cgccgttctgt	25140
ggccggccccc	ccggaggggaa	acgcagcgcc	gggtgtcgct	tctgtcgagg	ggagttactt	25200
ggtgacgggt	gggtgtggcg	cccttggcc	cctcttggcg	cggtgtttgg	tggagcgccgg	25260
ggcgccggcac	cttgtgtcgta	tcaagccgca	cggattggcc	gaccgcggagg	aatggggccg	25320
agatcagccg	ccagaggatgc	gcgcgcgc	tgcgcgtatcg	gaggcgctgg	aggcgcaggg	25380
cgcgcgggtc	accgttggcg	cggatcgatcg	ggccatgtcc	gaaggcatgg	cggegtcttt	25440
ggcgccgtc	gagccgcgc	tgcgggggg	atgtcgtcgcc	gcgggttctgc	tcgacgcacgg	25500
gctgtggcc	caccaggacg	ctgggtcgct	cgcccggttg	ttgcgccttca	agggtggaggg	25560
ggcatgggtg	ctgcacaccc	tttaccccgca	gcaggccgt	gaccccttcc	tactgttttc	25620
ctcggtcg	ggcgctttcg	gttcgtatcg	ccaggccgc	tacgcggcag	gcaatgcctt	25680
tttggacgcg	cttggggacc	ttcgccgaac	gcaggggctc	ggccgccttga	gcatcgctg	25740
gggcctgtgg	ggggagggggg	ggatgggg	gcaggcgcag	cccccggaa	acgaggcata	25800
gggaatcgg	ggcatgtccga	cgatcgccgc	cctggccggcg	atggaaatggc	tgctcggtac	25860
gcgcgcgacg	cagcgcgtgg	tcatcccaat	ggatggggcc	catgcggggag	cgccgcgcgc	25920
cgacgcgagc	cgaggcccg	tctggatcg	gtctggtaact	gccacgaaag	aggcctcttc	25980
cctggccgtg	ccagctgtgg	agcgcgtggc	caacgcgtct	gttgtggaga	cccgctcgcc	26040

gctctacgag cttgtgcgcg gcgtggtcgc cggggatcg ggcttaccg accagggcac 26100  
 gctcgcgtg cgacgaggct tcgcccagca gggccctcgac tccctgatgg ccgtggagat 26160  
 cccgaaacgg cttagggtg agctgggtat gccgcgtcg gcgacgctag cgttcgaacca 26220  
 tccgaccgtg gagcggctgg tggaaatactt gctgagccag gctggggcgc tgcaggacg 26280  
 caccgacgtg cggagcgttc ggttgcggc gacagaggac ccgatcgcca tctgtgggtgc 26340  
 cgcctgcgc ttcccggcg gggtcgagga cctggagtcc tactggcagc tggtaaccga 26400  
 gggctgtgg gtcagcaccg aggtgcccgc cgaccggat aatggggcag acggggcgct 26460  
 cccccggctcg ggagaggac agagacagac ctacgtcccc aggggtggct ttctgcccga 26520  
 ggtggagacg ttctatgcgg cgttcttcca catctcgcc cgggaggcga tgagcctgga 26580  
 cccgcacag cggctgcgtgc tggaaatgtg ctggaggaggc atcgagcgcc cggggccagga 26640  
 cccgtccggc ctgcgcgaga tgcccgatga ggcggggggg ctctacacgc gacccggcaa 26700  
 tgcccgacgg gtgcaggaaac catgtcgccg gacggctatac attttctctg ggctgcaacg ggcggaccct 26760  
 catgtcgac gttgcggcg gacggctatac attttctctg ggctgcaacg ggcggaccct 26820  
 ggctgtggat acggcgtgtc cttcgctcgt ggtggcgctg cacctcggtt gccagagctt 26880  
 gcgacggggc gagtcgcacc aagcccttgt tgccgggttc aacatgtcgcc tctcgccgaa 26940  
 gacccctcgcg ctgtcttcac ggatgcacgc actttcgccc ggcggggggg gcaagacgtt 27000  
 ctccggccgc gggacggctt acggcggggc cgagggtcgcc gccgtgggtgg tgctcaagcg 27060  
 getctccgac ggcgcggcg gacggctatac attttctctg ggctgcaacg ggcggaccct 27120  
 caatcatgt gggccgagca gcccggctgac aatgtccggc ggcggccggc gggccctgccc aggaggcgct 27180  
 gttacgcag ggcgtggcgcc acgcagggtt ggttccggcc gacgtcgatt tcgtggaaatg 27240  
 ccacgggacc gggacggcgcc tggccgaccc gatcgagggtg cgtgcgtcga ggcacgtgt 27300  
 cgggcaagcc cgcctcgccg gcacatggag cccggggcgcc cttgtcaag ggcgtgtcg cgcgtggggca 27360  
 agagcaaaat ccaaggccage gggggggggc ggcgtgggtt cttgtcaac ccgtcttcgc cgtggggaggc 27420  
 gtcgtccggt ggggtggggcc ggcgtgggtt cttgtcaac ccgtcttcgc cgcgtggggc 27480  
 cgcgggggtt agctcggtcg ggcgtgggtt cttgtcaag ggcgtgtcg cgggggggtt tggtaagggc 27540  
 gcccgggggtt gagctgtggc accgacgcgc catgtgggtgc ctggccgccc ggagcgctcg gggaggtttt 27600  
 tgcgtcgcc ggcggccggc ggcgtgggtt cttgtcaac ccgtcttcgc cgcgtggggca 27660  
 tgcgtcgca ggcggccggc tggccagcgcc gggacgtggc gtcgtggccg acctggacat 27720  
 gcaaccggag ctccgggtcg gttacgcgtt ggcacgcacgc gcaacgcgtat 27780  
 gaaccacccg ctgcgtggcc cgggtacgtc ggcggaggagg ctgcgtggccg cgctttcgcc 27840  
 cgtggcgca gggcagacgc cggccggggc ggcgtgggtt cttgtcaac ccgtcttcgc cgtcgccgg 27900  
 caagctggc tccctgttca cggcagacgg cgcgcagacg cccggcatgg gccgggggtt tggtaagggc 27960  
 ttgcgtggcg tggccagcgcc ggggggggtt cttgtcaac ccgtcttcgc cgcgtggggca 28020  
 ggagctggac cggccgcgtc ggcgtgggtt cttgtcaac ccgtcttcgc cgcgtggggca 28080  
 gttgtcgac cagacggcgcc tcacccagcc cgcgttcgtt acgggtggagt acgcgtgtac 28140  
 ggcgtcgcc ggcgtgtgg ggcgtgggtt cttgtcaac ccgtcttcgc cgcgtggggca 28200  
 gctgtggggcc cggcgtgtgg cgggggtgtt cttgtcaac ccgtcttcgc cgcgtggggca 28260  
 ggcgcggggg cggcgtgtgg cgggggtgtt cttgtcaac ccgtcttcgc cgcgtggggca 28320  
 ggcggggccg ggggtggccg tgggtatcgcc gggcgtggag caagcggtgc aggcgtatcg 28380  
 ggtcaatggg cccggagcagg ggcgggggtt cttgtcaac ccgtcttcgc acgcgtccca 28440  
 ggcgggggtt cttgtcaac ccgtcttcgc cgcgtggggca 28500  
 ctccggccgt atggaaaccga tgcgtggagga gttcggggccg gttcggggccgt cgggtacgt 28560  
 cccggccca agcggttcgc ggggtggccg tgggtatcgcc gggcgtggggca 28620  
 gagcgcggcc ggggtactggg tgcggcaccc ggggggggtt cttgtcaac ccgtcttcgc cggacgggg 28680  
 gaaggcgctg cacaaggccg gtcggccac cttcgctggaa gttggggccca agccgtacgt 28740  
 gtcggccgtg ttggccagccct gctgtccggg ggcggagccg acgtgtcgcc cgtcggtcg 28800  
 cggccggccg gaggaggctg cgggggtgtt cttgtcaac ccgtcttcgc cgcgtggggca 28860  
 cggcgtggcc agctggccgg ctatccgtcc cttcggttcc cttcggttcc cttcggttcc 28920  
 ctatccgtgg cttcggttcc ggtactggcc cttcggttcc cttcggttcc cttcggttcc 28980  
 agccgcggat cccggcccaag gtcggccat tgcgtggcc gtcgtggcc gtcgtggcc 29040  
 cttccagaaa tcaagaggagg cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29100  
 agtcggcgag cggcgtgtcc gttcggttcc cttcggttcc cttcggttcc cttcggttcc 29160  
 tgcgtggccgca gagacatccg cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29220  
 cgatttggccgat gttcggttcc cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29280  
 gatcgatggat accggcgacg cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29340  
 gtttctgagc accgtgtttt gttcgccccg acgtgtggcc gttcgccccg gggcatgtcat 29400  
 cttcggttcc gttcgccccg tggcccttgc tttcggttcc cttcggttcc cttcggttcc 29460  
 ggcggccgtc gggatccccg gggccctgggg cggggtcgcc gacgtggatcc cccgagcgag 29520  
 cccggcccaaa gcccggccgat tgcgtggcc gatgtcgcc accgtgtat tgcgtggcc 29580  
 gaccggaggat cttcggttcc cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29640  
 cccggccacag gggcaagcgcc cttcggttcc cttcggttcc cttcggttcc cttcggttcc 29700  
 gggaggccctc ggtggggctgg cttcggttcc gggccctgggg cttcggttcc cttcggttcc 29760  
 gcacccgggtt ctggaccagcc gggcgggggtt gcccggaccgg cttcggttcc cttcggttcc 29820  
 gcccggccgtg atccggccgcg gttcgaccggc gttcgaggccg cttcggttcc cttcggttcc 29880  
 ggtgaccggccg gttcgaccggc acgtggccgat cttcggttcc cttcggttcc cttcggttcc 29940

ggtcgagccc	ccgctgcgag	gggtggtgca	cgccgctggc	gtcagcgtca	tgcgtccact	30000
ggcggagacg	gacgagaccc	tgctcgagtc	ggtgcctccgt	cccaagggtgg	ccgggagctg	30060
gctgcgtgcac	cggtcgctgc	acggccggcc	tctcgaccctg	ttcgtgtctgt	tctcgctggg	30120
cgcagcggtg	tgggttagcc	atagccaggg	tgcgtaacgcg	gcggccaaacg	ctttccctcga	30180
cgggcgtcgc	catcttcggc	gttcgcaat	gtcgctcg	ttgagcgtcg	cgtggggtct	30240
gtggggccgag	ggaggcatgg	cggaacgcgga	ggctcatgc	cgtctgagcg	acatcgggg	30300
tctgccccatg	tcgacgtcg	cagcgttgtc	gggcgtccag	cgccctgggtgg	agaccggcgc	30360
ggctcagcgc	acggtgaccc	ggatggactg	ggcgccgttc	gcccgggtgt	acaccgctcg	30420
agggcgtcgc	aacctgtttt	cggcgttgtt	cgcagggcgc	gacatcatcg	cgccttcccc	30480
tccggcggca	gcaacccgg	actggcgtgg	cctgtccgtt	gccaaggccc	gcgtggctt	30540
gcacgagatc	gtccatgggg	ccgtcgctcg	gggtcggtggc	ttcctcgacc	cgagcgcgt	30600
cgtatctggg	atgggggttca	atgagcagg	cctcgactcg	ttgatggcg	tggagatccg	30660
caacccctt	caggctgagc	tggacgtcg	gcttcgtcg	acgtctggct	ttgatcatcc	30720
gacggtacag	cggtcggtgg	agcatctgt	cgtegatgta	ctgaagctgg	aggatcgag	30780
cgacacccag	catgttcgg	cggtggcg	agacgagccc	atcgccatcg	tggagccgc	30840
ctgcccgttc	ccggggcgggg	tggaggac	ggagtcttac	tggcagctat	tggccgaggg	30900
cgtgtgtggc	agcgccgagg	tgccggccga	ccgggtggat	gcccggact	ggtagcacc	30960
tgatccggag	atcccggcc	ggacttacgt	gaccaaaaggc	gccttcgtc	gcatggc	31020
gagatggat	gctggatctt	cccgatcc	gcttcgtcg	tgacatggcc	tcgacccgc	31080
gcagcgggtt	cttctggagg	taagctggga	agcgtcgag	agcggggta	tcgctccga	31140
tacgctgcga	gatagcccc	ccgggtgtt	ctgggggtcg	gggccccatg	agtactacac	31200
gcagcggctg	cgaggcttca	ccgacggagc	ggcagggttg	tacggccgca	ccgggaacat	31260
gctcagcgtt	acggctggac	ggctgtcg	tttctgggt	ctgcacggcc	cgacgctggc	31320
catggatacg	cgctgtcg	catccgtt	cgcgctgcac	ctcgccctgc	agagcctgc	31380
actgggcg	tgcgatcaag	cgctggtt	cggggtcaac	gtgtctcg	cgccggagac	31440
cctcgctg	cttcacgg	tgcgcgtc	tgcggccgac	gggggtgtca	agacgttctc	31500
ggccgacgcg	gacggctacg	cgcggtcg	gggggtcgcc	gtgggtggtgc	tcaagcggct	31560
gcmcgtcg	cagcgccgg	gcaactccat	cttggcgctg	atccggggaa	gcgcgggtgaa	31620
ccacgacggc	ccgagcagcg	ggctgaccgt	acccaacgg	cccggccagec	aagcatgt	31680
gcgcacggcg	cttcgcgaag	caggcg	tccgtcgac	gtgtatttt	tggagtgtca	31740
cgggacacgg	acggcgctgg	gcaacccat	cgaggtgcag	gcgtcgagcg	agggttatgg	31800
cccaggcgc	tccggggacc	gaccgtgtt	gtctggggcc	gccaaggcga	acgtcgccga	31860
tctggaggcg	gcatctggct	tggccaggtt	gtcaaggcc	gtgttgcgc	tgcggcacga	31920
gcagatcccc	gcccagccgg	agctgggg	gtcaaccc	cacttgcctg	gaaacacgt	31980
gccgggtggc	gtgcccacgt	aggcggtg	gtggggg	ggcgcacg	cgcgccggc	32040
cggcgtgagc	gcttcgtgggt	tgagcgaac	caacgtgcat	gtcgctgtcg	aggaggcacc	32100
ggaggtggag	ccggcgcccc	cggcgtccgc	gctgggggt	gagctggtgc	tgctatccgc	32160
caagacgcg	ggggcgctgg	acgcgcggc	ggcgcgggtc	tgccggcacc	tgcggcgca	32220
cccggagct	agccctcgccg	acgtggcgtt	cagccgtgg	acgcgcgc	gcccgtatgg	32280
gcacccgtc	gcccgtcg	cgacccgtc	cgaggccctg	cgaggcgcc	tggacccgc	32340
ggcgcagcaa	aaagacgcgc	agggcg	gcccggcaag	gcccgtgtct	cacgcggtaa	32400
gctggcttc	ctgttccacc	gacaggcgc	gcaaatggcc	ggcatggg	gtgggtgt	32460
cgaaaacgtgg	cctgcgttcc	gggaggcg	cgaccgg	gtggcgctt	tcgatcg	32520
gatcgaccag	cctctcgccg	aggtgtgt	ggctcgcc	ggcctcg	aggcggcg	32580
gctcgatcg	acccgcgtacg	cgccgc	tctcttgc	ctggagat	cgctggctgc	32640
cctgtggcg	tctggggcg	tggagccg	cgactgtc	ggctatagca	tcggcgagct	32700
ggtcggcc	tgcgtggcg	gctgttcc	gtcgaagat	gggggtgaggt	tgggtggccgc	32760
gcgcggccgg	ctgtgcagg	cgctacccgc	cggggtg	atggtagcc	tcgcagcgtc	32820
cgaggccag	gtggccgc	ccgtggc	ccacccgc	acgggtgc	tcgcccgggt	32880
caacggcc	gacggcg	tgatcg	cgccggat	cggtgtctcg	ccctcgccgc	32940
gacgttcgc	ggcgctggaa	tacgcacaa	gaggctcg	gtctccat	cgttccactc	33000
gcccgtatcg	gatccgtatgc	tggaaagat	ccaggggtc	gttcgtatgc	tcgcgttacc	33060
cgccgcacag	ccccgggtgg	tgcgaatgt	cacccg	gtcgaggcc	ccgagatcg	33120
cacccccc	tattgggtcc	ggcatgt	aaagcgcgt	cgcttcgg	acggggcaaa	33180
ggcgttgcat	gcccgggtgt	ccggc	cggtgtt	ggcccgaagc	cggtccctgt	33240
cgggtgtt	ccagcg	tcgggg	ggacgg	ggacgggtc	cgctacgcgc	33300
ggaccgtcg	gaatgcgagg	tggcc	gggcgtcg	ggcgtcg	cctgggggg	33360
tgcgtcgac	tgaagggcg	tgttcc	ggcgcg	gtttgtatg	tgcgtatgt	33420
tccatggc	ctgtgcgc	attggat	cctc	ccggat	cgccatgt	33480
gatcgagg	cgctggccgc	tggctgtt	cggtgt	atgccccgg	cgccatgc	33540
ccacgtc	tcgatcg	cacgc	cccttc	gtgtatcacc	tcgtgttgg	33600
caaggcggt	gtggccggcg	cctt	cgcg	ctcagcatcg	ccgcccagcg	33660
ctggcccg	cgggcgatcg	agctg	cggtgtt	ctgagatcg	tcgcgtatgg	33720
gcccggacc	gaggctcgagc	tccac	gtcacc	ctgaaggc	ggatgggct	33780
cctttcgag	ctggcgaccc	ggcg	ggcg	gaagccccc	ggatgggct	33840

- 10 -

ccgcggtcgg	gtgcagccga	cagacggcgc	gcccggcgcg	ttgcccggcgc	tcgagggtgct	33900
ggaggaccgc	gcatccage	ccctcgactt	cgccggattt	ctcgacaggt	tatcggcggt	33960
gcggatcggc	tgggtccgc	tttggcgatg	gctgcaggac	gggcgcgtcg	gcgacgagc	34020
ctcgcttgc	accctcgtgc	cgacctatcc	gaaccccac	gacgtggcgc	ccttgcaccc	34080
gatccctgtg	gacaacggct	ttgcggtgag	cctgtctca	accggagcg	agccggagga	34140
cgacgggacg	cccccgctgc	cgttcggcgt	ggaacgggtg	cggtgggtgce	gggcgcgggt	34200
tggaaagggtg	cggtgtggcg	gcgtgcggcg	tcgcgcggca	ttcggtgtct	cgagcttctgt	34260
gctgttcgac	aaaactggcg	agggtggcgc	cgaggtggag	ggatttgttt	gccgcggggc	34320
gccgcgagag	gtgttccctgc	ggcaggagtc	gggcgcgtcg	actgcagctt	tgtaccgcct	34380
cgactggccc	aaagcgcct	tgcggatgc	gcctgcggaa	cggtatcgagg	agagctgggt	34440
cgttgtggca	gcacccgtgc	cggagatggc	cgccggcgct	gcaacacgcgc	tcaaccgcgt	34500
cgtccctcg	gaaccccaaag	gcctcgaggc	ggccctcgcg	gggggtgtctc	ccgcagggtgt	34560
gatctgcctc	tggaggctg	gagccacaca	ggaagtcgc	gcggcgccgc	agcgtgtgyc	34620
gaccgaggc	ctctcggtgg	tgcaggcgct	cagggaccgc	gcgggtgcgc	tgtggtgggt	34680
gaccatggc	gcagtggccg	tcgaggccgg	tgagcgggtg	caggtcgcca	cagcgcgggt	34740
atggggcc	ggccggacag	tgcgcggat	gcccggag	ctcagctgca	ctctgggtgga	34800
tttggagccg	gaggccgatg	cagcgcgc	agctgacgtt	ctgttgcggg	agctcgggtcg	34860
cgctgacq	gagacacagg	tggcttccg	ttccggaaag	cgccgcgttag	cgccgcgtgt	34920
caaagcgc	accccccgaag	ggtccctgtt	ccctgacgca	gatctccatc	gactggagyc	34980
tgggcagaag	ggcacattgg	accagtcgg	cctcgcgcgg	gcacagcgc	gggcacccgg	35040
cccgccgag	gtcgagatca	aggttaaccgc	ctcggggctc	aacttccgga	ccgtccctcg	35100
tgtgttggga	atgtatccgg	gcaagcgcgg	gcccgtgggc	ggagattgtg	ccgggtgtcg	35160
cacggcggt	ggccaggggg	tgcggccacgt	cgccgtcgcc	gatgtgtca	tgacgcgtgg	35220
gacgttgc	catcgatca	cggtcgcacgc	gcggcggtgt	gtccggcagc	ctgcagggt	35280
gactcccg	caggcagcta	cgggtccgt	cgcgtrccct	acggccgtgc	tegetctgca	35340
cgacccgtgg	aatctgcggc	gcccgcgc	gggtgcgtatc	catgtcgccg	ccggcggtgt	35400
gggcgtggc	ggcgatggaaa	tcggccgtat	gatagggcc	gaggtgttgc	ccacggcgag	35460
cccgccca	ttggcagccg	ttcaggccat	ggcgtgcggc	cgacacgcaca	tcgcgcgtc	35520
gcggacgc	gagtttgcgt	agacgttccg	gcaggtcacc	ggcggccggg	gcgtggacgt	35580
gggtgttca	acgcgtggcc	gcgagttcgt	ggacgcgcgc	ctgtccctgc	tgtcgacggg	35640
ccggccgttc	tcgcagatgg	gcaagaccga	catacggtat	cgagccgcgg	tcgcggcgcc	35700
gcatcccg	gttcgttatac	gggtattcga	cattctggag	ctcgctccgg	atcgaactcg	35760
agagatcctc	gaggcgctgg	tgcaggccat	tgcgtgggaa	catcgccgc	cattggcggt	35820
gcatgcgtt	gcgatcacca	aggccgaggc	agcgttccg	ttatggcgc	aagcgcggca	35880
tcagggca	gtcgtgtgc	tcggccggcc	ctccgcagcg	cccttggcgc	cgacgggcac	35940
cgtactgc	accgggtggc	tgggagcggt	ggggccac	ttggcccgct	ggctcgccca	36000
gcagggcg	ccgcacatgg	tgctcacagg	tcggccgggc	ctggatacgc	cgggcgctgc	36060
caaaggcg	gcggagatcg	aagcgttccg	cgctcggtgt	aggatcgccg	cgtcggtatgt	36120
cgccgatcg	aatcgctgg	aggctgtgt	ccaggccat	ccggcgagg	ggccgttaca	36180
ggcggtgtc	catgcggcc	gagcgcgtca	tgcgtgtgt	tttgcgtatgc	agaccaccga	36240
ccgttctcg	cggtgtgtgg	caccgaaggt	gactggcgc	tggatctgc	atgagctcac	36300
ggcgggca	gatctcgctt	tcttcgtgt	tttctccctc	atgtcggggc	tcttgggccc	36360
ggccgggc	tccaactatg	ggccggccaa	caccccttcc	gacgcgtcg	ccgcgcacatcg	36420
ggggccgaa	ggcttggcg	cgcagagct	cgcggtgggc	ccatggtcgg	acggaggcat	36480
ggcaggcg	ctcagcgcgg	cgctcgacgc	cggggtcg	cgccatggga	tgggactct	36540
gtcgccgc	caggggcaccg	cgctgtcg	cgaggcgctg	gtcgccggcg	aaacgcagct	36600
cgggcgatg	tcgcgtcgac	tcgcgtcg	aagccaaatc	tccggagcg	cagtgcggcc	36660
tgtgttggc	gcgttgggtc	gcgcggaggc	gcgcataacg	ggggctgggg	cgcaggggggc	36720
attggcccg	cgctttgggg	cgctgcccga	ggcgcgcgc	gcccgcgc	tgcgcgttgc	36780
cgtgcaggcc	gagatcgcc	gcgtgttttc	atggagcgcc	gcgcgcgc	tgcgcgtcga	36840
tccggccgtc	tcggacttgg	gcctcgactc	gttcacggcg	ttgggactgc	gcaacgtgt	36900
cgccca	gtgggttgcga	cgctcgccgc	gacgttggca	ttcgatcacc	cgacggcgtca	36960
cgcgttccac	cgcttggctgc	tcgataaggt	cttggcggtg	gcccgcgc	cggtatcg	37020
cgcaaaatcg	tcgcgcgc	tcggccctcg	cgagccatt	gcatcggtcg	37080	
ccgttccca	ggcggcggtgg	ccgatccgg	gtcggtttgg	cgctgtcg	aagaggccag	37140
cgatggcg	gtcgagggtc	cgcatgagcg	atgggacatc	gacgcgttct	atgatccgga	37200
tccggatgt	cgccggcaaga	tgacgacacg	cttggcg	tttctgtcc	atatcgaccc	37260
gttcgatcc	gccttcttcg	gcgttcg	gcgcgaagcg	acgaccatgg	atccgcagca	37320
gcgggtgtc	ctggagacga	gctggggagc	tttcgcgc	ggccggatct	tgcccgcagc	37380
gctgtgtggc	agcgataccg	gcgtgttctgt	ggggcttcc	taccaggagt	acgctgtgt	37440
cgccggcg	atcgaggcg	tcgtgtgtca	tctaggcacc	ggcaccacgg	ccagcgctgc	37500
tccggccagg	atctttatg	tgctcggtt	aaaggggccg	agcgttgcacgg	tggacaccgc	37560
tggtgttcc	tcgtgtgtcg	cggtgcacct	ggcctgc	gcccgcgc	ggggcgagtg	37620
tccgggtggc	ctggccggcg	gcgtggcgct	gatgttgcacg	ccggcgacgt	tcgtggagtt	37680
cagccggcg	cgaggccctgg	ctcccgacgg	acgggtgcacag	agcttctcg	ccgcagccga	37740

- 11 -

cgccgtgggg	tggagcgaag	gctgcgccat	gctctgtcc	aaaccgcctt	gcgatgcga	37800
gcgcgtatgg	gatccgatcc	tgccgtgtat	ccggggcacc	gcggtaaacc	aggatggcg	37860
cagcaacggg	ctgacggcgc	ccaacgggtc	gtcgacgaa	gaggtgatcc	tcggggccct	37920
ggagcaggcg	gggctggctc	cgccggacgt	cagetacgtc	gagtgcacg	gcacccggac	37980
gacgttggc	gaccatcg	aatgtcaggc	cttggggccc	gtgcggcacc	agggggcgc	38040
ctcgccatgg	ccgctgtgt	tcgggtcggt	gaagttccat	atcgacata	cgcaggctgc	38100
ggccggcggt	gccccgtt	tcaagggtgc	gttggcgctc	gagcgcgggc	ttatcccgag	38160
gagcctgtat	ttcgtacgc	ccaatccgc	catttcgtgg	tcggagctcg	ccgtgcaggt	38220
ggccgcaaaa	cccgtcgaat	ggacgagaaa	cgccgtgccc	cgacgagccg	gggtgagctc	38280
gtttggcgtc	agcgggacca	acgcgcacgt	ggtgctggag	gaggcgccag	cgccggcggt	38340
cgcccccgcg	gccccgcgtt	cagcggagct	tttcgtgtct	tcggcgaaga	gcgcggcgcc	38400
gctggacgcg	caggcggcgc	ggcttcggc	gcacgtcgct	gcccacccgg	agctcgccct	38460
cgccgacctg	cggttcagcc	ttgcgcagac	ccgcagcccc	atgcacgtt	ggctcgccgt	38520
ggccggcgac	tcgcggagg	cgctgtcgac	cgcgctcgac	acagcggcgc	agggggcaggc	38580
gcccggcgca	gccccgtcg	gccacgcctt	cacaggcagc	gccccaaagg	ttgttttcgt	38640
ctttcttggc	cagggctccc	agtggctggg	catggggcaa	aagctccctt	cgaggagagcc	38700
cgctttccgc	gacgcgtct	ccgcgtgtga	ccgagcgtatt	caggccgaag	ccggctggtc	38760
gctgtcgccc	gagctcgccg	ccgatgagac	cacccgtcag	ctcggccgca	tccacgtgtgt	38820
gcagccggcg	ctgttcgcga	tcgaggtcgc	gtgttcggcg	ctgttcgggt	ctgtggggcggt	38880
cgagccggat	cgagtggtag	gcccacgat	ggcgaagt	gccccggcgc	acgtcgccgg	38940
cgccccgtcg	cicgaggat	ctgtagcgat	catctggccgg	ccgcacccgt	tgctcgccgc	39000
gatcagcggc	caaggcgaga	ttgcggctgt	cgagtttcc	ctggccgagg	ccgaggcagc	39060
gctcttggcc	tacgaagacc	ggctcagcgt	ggcgggtgagc	aacagcccc	gctcgacgg	39120
gctggcgccc	gagccggcag	cgctcgacaga	ggtgcggcg	atccctggcg	caaaggggg	39180
gtttctgcgt	cgagtcaagg	tgacgtcgcc	cagccacagc	ccacagatcg	acccgctgcg	39240
cgacgacta	ttggcagcat	ttggcgagat	cgacggcgcga	caagcgcacc	tgctcgatcg	39300
ctcgacgttg	acgacgcac	tcatggcggy	cccgagatct	gtggcgagat	actggggcga	39360
caacgttgc	cacgggttgtc	gtttcgccga	agcgggtgaca	tcgttgcgtt	aagacggtca	39420
tggttgcgtt	gtggagatga	gccccgcaccc	gatccgtacg	acatcggtcg	aggagatccg	39480
acggggcagc	aagccggagg	gagtgcgggt	gggctcggtt	ccgcgtggac	aggacgagcc	39540
cctgtccatg	ttggaggcgc	ttggagcgcet	ctgggtacac	ggccaggccgg	tgggtctggga	39600
gccccgttgc	tccgcggggc	gccccggccct	ccgtcgctgt	ccgtcgccga	ccatcccttc	39660
gcagcgcgag	cggtaactggg	tcgtatgcgc	gaccggccgc	gccccggggcg	gcagccgtt	39720
tgttcatcg	ggcgttcacc	cgcttcgtgg	tgaatcgag	accctgtcg	cccagaggag	39780
cacgcgcgt	ttggagacga	cgctggatct	caaacggctg	ccgtggctcg	gcgtatacc	39840
gggtcagggg	gccccgtgt	ttccggggcgc	ggcgtacctg	gagatggcgc	tttcgtccgg	39900
ggccgaggcc	ttgggtgacg	gtccgttccca	ggtcagcgat	gtgggtctcg	ccgaggcgct	39960
ggcccttcgcg	gttgtatcgc	cgccggccgtt	gcaggtcatg	gcgaccgagg	agcgaccagg	40020
ccgcctgcba	ttccacgttg	cgagccgggt	gcccggccac	ggccgtgtcg	cccttcgaag	40080
ccatggccgc	gggggtcgcc	gccagatcg	gcccgcgcag	gtccggcgca	ggctgtatct	40140
ggccgcgttt	cgtccccggc	ttccggccat	cgcacccgt	gcgcgttacc	atgcggcgct	40200
ggccgagatg	gggtcgatgt	acggcccgatc	gttccagggg	cttgcgagtc	tgtgggggg	40260
ggaggggcgag	gccccgtggac	gtgtcgccgt	ccccgaggcc	gccccgtccc	cagccgcgtt	40320
ccggctccac	ccccgcgtct	ttggatcgct	cttccacgt	agcagcgctt	tcgctgacc	40380
ccggcgaggcg	acgcacatggg	tacccgtgga	aatcggtct	ctgcgggtgt	tccagcgccc	40440
gtcggggggag	ctgtgtgtgc	atgcgcggag	tgtgaggccac	gaaagccaa	cacccgaccc	40500
gccccgttac	gacttcgtgg	ttgtcgacatc	cacggggcgc	atgcgtcccg	agatctccgg	40560
gctcggtcg	cagccgttcg	cgggggatgt	acgcggccgc	gaagaagacg	actgggttat	40620
ggagccggct	ttggaaaccga	ccccgggtcc	cgatcccgag	gtcatggcg	ggccgtgtgt	40680
gcttcatcg	tcggggcgcc	ggctcgccgc	tgcgttccac	tcggcgctga	ccgaagctgg	40740
ccattccgtc	gtccacgcga	cagggcgccgg	cacgagcgcc	gccccgttgc	aggcacttt	40800
gacggcgccc	ttcgacggcc	aggccccgac	gtccgttgg	cacctcgcc	gcctcgatga	40860
gcgtggcg	ctcgacgcgg	atggccctt	cgacgcggat	gcgttgcagg	agtcgtgt	40920
gcgcggcg	gacacgcgtc	tctggaccgt	gcaggccgt	gccccgggggg	gtttccgaga	40980
tcttcggcgg	ttgtggctcg	tgacacgcgg	cgcttccgg	atccggcccg	gcgcacgttc	41040
tgtggcgcc	gccccgttcc	ttggggctgg	ccgcgttate	gccttggage	acgcggagct	41100
gcccgtcgat	cgatcgacc	tcgtatccag	gccccgttgc	ggagaagtcg	atgagctgt	41160
tgcggagat	ttggccgacg	acgcggagg	ggaagtcgc	tttcgcggcg	gtgagcggcg	41220
cgtggccccc	ctcgccgaa	ggctgcccc	gaccgactgc	cgagagaaaa	tcgagccccc	41280
ggaaggccgg	ccgttccggc	tggagatcg	tgggtccggc	gtgtcgacgc	acctgtgtct	41340
ccgagccacg	gagccggcc	ctccctggcc	ggccggagg	gagatcgccg	tcgaggcggc	41400
ggggctcaac	tttcgtcgac	tgatggggc	catggggatc	tacccgttgc	ccggggacgg	41460
tccgggttgc	ctgggcgcgc	agtgtccgg	ccgaattgtc	gcgtatggcg	aagggtgtca	41520
gagccttgc	atcgccagg	acgtcggtgc	cgtcgccccc	ttcagtttcg	gcacccacgt	41580
caccatcgac	gccccqatgc	tcgcaccc	ccccgcggcc	ctgacggccg	cgcaggcagc	41640

cgccgtggcc gtcgcattca tgacggctcg gtacggcttc gtcacatctgg ggaggctccg 41700  
 ggccggcggag cgcgtgtca tccactcgcc gacggggggc accgggctcg ctgcgtgtca 41760  
 gatccggccgc cacctcgccg cggagatatt tgcgaccgt ggtacaccgg agaagcgggc 41820  
 gtggctgcgc gaggcaggga tcgcgcacgt gatggactcg cgttcgctgg acttcgccc 41880  
 gcaagtgtcg gcgcgcacga agggcgaggg ggtcgacgtc gtgttgaact cgctgtctgg 41940  
 cgccgcgttc gacgcggagcc ttccgaccct cgtgcggac gggcgcttc 42000  
 caagacggac atctatgcag atcgctcgct ggggctcgct cacttcagga agagccgtc 42060  
 ctacagcgcc gtcgatcttgcgggcttgc cgtgcgtcg cccgagcgcg tcgcagcgct 42120  
 gctggcggag gtgggtggacc tgctcgcacg gggagcgctg cagccgcttc cggtagagat 42180  
 ctcccccttc tgcggggccg cggacgcgtt ccggaaaatg ggcgaagcgc 42240  
 gaagctcggt ctgcgcgtgg aggacccgga cgtgcggatc cgccgttccgg 42300  
 cgccgcgttc cgcgcggacgc ggcgcctact cgtgacccggc ggtctggggg 42360  
 gagcgtgtcg ggtatggctgg cggagcagggg ggctggcat ctgtgtctgg tgggcccgtc 42420  
 cggcgggggt agcgcggagc agcagacgc tgcggccgc ctcgaggcgc acggcgcgc 42480  
 tgcacggta gcgagggcag acgtcgccga tcgggcgcag atggagcgg 42540  
 ggttaccgcg tccggggatgc cgctccgcgg cgtcgatccat gcccggggaa 42600  
 cgggctgcgt atgcagcaaa ccccccgcgc gttccgcgcg gtcatggcgc 42660  
 aggggccttc caccctgcgtc cgatggacacg cgaagcgcgc ctctcccttc 42720  
 cgcttcggga gcaagggtctt tgggtcgcc gggcaggggc aactacgcgc 42780  
 gttccctcgac gcaactggcac accaccggag ggcgcggggc ctgcgcgc 42840  
 ctggggcctg ttccgcggacg tgggtttgc cgcggggcgc caaaatcg 42900  
 ggttacccgc gggacgcggc gcttcacccc cgacgaaggg ctgtgggcgc 42960  
 gtcgcacggc gatcgacccccc aggccgggt catggcttc gacgtgcggc 43020  
 gtttaccccg gcccgggcat ctgcgggag gtttgcggg ctcatgcacgg 43080  
 ggcttcgggt cgctcgccg gggatcgga cctgtcgaa cggtcgcca 43140  
 gggcgcggg gcaagggtatgc tgcaggaggt cgtgcgcgc caggctcg 43200  
 ctttcggca gcaagctcg acgtggatgc ggcgcctacg agcctggggaa 43260  
 gatggggcta gagctgcgcgca accgcacatcg ggcgcgtgc ggcacatcc 43320  
 cctgtgtgg acctacccca cggtgccgc gctgagtg 43380  
 ctctacgggg gatggggatcg ccgcgcgccc gcccggataca gggagcgtgg 43440  
 ccacgaagtc gcttcgcgtcg acgaagacgg gtttgcgcg tgcattgtat 43500  
 ggcgcgggg aaggaggatcg tgcgtgcacg accgagaagg ccagctcc 43560  
 gtgagggtatc tctggggctt cggcaagacgc tgaacgaggc ctagatcc 43620  
 agaccgagcc gatcgccatc gtggggatcg gtcggcgtt cccgggggg 43680  
 cggaggcggtt ctggggagctg ctgcacgc ggcgcgcacgc gatccggccg 43740  
 gtcgggcgt cgttaggtgtc gaccggcgc acgacgtacc ggcgtggggc 43800  
 ccgaggccat cgacggcttc gacggccgt tttcggtat cggccccccgg 43860  
 cgctcgaccc gcaagatcg ctgtgtcg aggtcgctcg ggagggggtc 43920  
 gcatccggcc cagggtttcc tgcggggaccc gacccggcgtt gtctgcggc 43980  
 cggaggtacc ccacgcgcgc tgcgcgcacc agccgcgcga agagcgggc 44040  
 ccacccggcaa catgctcage atcgccggcc gacggctatc gtagacgc 44100  
 gacctgcct gaccgtcgat acggcggtcg ctgtatcgat ggtggccatt 44160  
 gcccggccct ggcgcgtcg gagagcgtac tcgcgtggc 44220  
 tctcccccggc caccgtcgca gtcgtggcgc gacccaggc 44280  
 gccagacccct cgacgcgtcg gccaacgggt tgcgtgtgg 44340  
 tgctcaagcg attggagcgc ggcgcgggg atggggaccg gatctggcg 44400  
 gatccggccat caatcaggac ggcgggtcgac cgggggtcgac 44460  
 agggggcgct ttgcgcgag ggcgtcggtt acgcggcggt cgaggccgag 44520  
 acatcgagac ccacggggcg gcaaccctcg tgggcgaccc 44580  
 ggcgtgtggt gggggccggcg cgagccgcacg gagcgcgcgt 44640  
 ccaacccctgg ccacccggatcg ggcgtcgccg ggcgtggggc 44700  
 cgctcatca cgacgcgcac ccgaggaaacc tcaatcc 44760  
 ggatcgagggg gaccgcgcac gctgtggcga cggacccgg 44820  
 ggacgcgttt cgccggagtg agtcgttcg ggtatggcgg 44880  
 tggaggaggc gcccgggtgt gacccgtgagg cggccggccc 44940  
 tcgttcgttc ggcgaagagc gccggcggcgc tggatgcgc 45000  
 acctggagaa gcaacgtcgag ttggccctcg gcgatgtggc 45060  
 gcagcgcgtt ggagcacccgg ctggcggtgg cggcgacgtc 45120  
 cgcttcggc cgcagcgcac gggcacacgc cgcggggagc 45180  
 gccgcagcgc gcccgaagggt gtcgtgtgt tttccggatcg 45240  
 tggggccgaaa gtcatggcc gaaagcgggg tttccgggc 45300  
 gggccatcgat ggcggaaagcg ggctggcgc gtcctccgc 45360  
 ctcgcacgt cggggcgcatc gacgtggttc agccgggtgt 45420  
 tttctgcgtt gtggcggtcg tggggatcg agccggaaac 45480  
 gcgagggttcg ggcggcgcac gtggccggcg cgtgtcgatc 45540

tctgcggcg cagccggctg ctgcggcggta tcagcggtaa gggggagatg gcgctggtcg 45600  
 agctgtcgct ggaggaggcc gaggcggcgc tgcgtggcca tgagggtcgg ctgagcgtgg 45660  
 cggtgagcaa cagcccgcgc tcgaccgtgc tcgccccgca gccggcggcg ctctcgagg 45720  
 tgctggcgcc gctgacggcc aagggggtgt tctggcgca ggtgaagggtg gacgtcgcca 45780  
 gccatagccc gcagggtcgac cgcgtcgcc aagagctgtat cgccggcgtcg ggagcgatcc 45840  
 ggcggcgagc ggctcggtgt ccgatgcgtc cgacggtgac gggcggggtg atcgcggttc 45900  
 cggagctcgg tgcgagctac tggggggaca accttggca gccgggtgcgc ttgcgtcgcc 45960  
 cggcgcaagc gctgctggag ggtggcccg cgctgttcat cgagatgagc ccgcacccga 46020  
 tcctggtgcc gcccctggac gagatccaga cggccggcga gcaagggggc gctgcggtgg 46080  
 gctcgctgctg gcgagggcag gacgagcgcg cgacgtgtg ggaggcgtcg gggacgtgt 46140  
 gggcgcccg ctatccggc agctgggtc ggctgttccc cgccggcggc aggccgggttc 46200  
 cgctcgccgac ctatccctgg cagcacgagc ggtgtggat cgaggtcgag cctgacgccc 46260  
 gccgcctcgc cgcagccgac cccacaagg actgggtcta ccaacggcagc tgccccgagg 46320  
 tgccccgccc cggcccgaaa tcggagacag ctcatggag ctggctgtg ttggccgaca 46380  
 ggggtgggt cggtgaggcg gtcgtcgag cgctgtcgac gcgcggactt tcctgcacccg 46440  
 tgcttcatgc gtcggctgac gcetccaccc tcgcccggca ggtatccgaa gctgccagtc 46500  
 gccgaaaacga ctggcaggga gtcctctacc tgggggggtc cgacggccgtc gtcgatgtg 46560  
 gggcatcgcc cgacgaaagt gacggaggtt cccggccgtc accggcaccgg gtccttgccc 46620  
 tggttcgatt ctctggcgctt gggcccgatc tcctcgctt ctgggtgggtg accccggggg 46680  
 catgcacggg gggggcgag ccagaggctt ctctttgcca agccgggttg tggggccctcg 46740  
 cgcgcgtcgc ggcgctggag ccccccgtg cctgggggtt ctcgtggac ctggatcttc 46800  
 agaagagccc gacggagatc gagcccccgg tggccggagct gctttcgccg gacggccgagg 46860  
 atccaactggc gttcccgagc ggtcgacggc acgcagcagc ccitgtagcc gccccgcgg 46920  
 agggcgacgt cgacccgata tcgtgttccg cggaggggag ctacctggtg acggggcgccc 46980  
 tgggtggctt tggctcgctc gtggctcggt ggctgttggg gcccggggatg cgacatctgg 47040  
 tgctcaccag cccgcacggg ctggcaggac gacaggcgtc gggggggagg cagccgcgg 47100  
 aggcccgccg cgcacatcgca ggggtcgagg ggctggaaagc gcagggcgcg cgggtgaccgg 47160  
 tggcagcggt ggtatcgcc gaggccgatc ccatgacggc gctgtggcc gcatcgagc 47220  
 ccccggtcgcc cgggggtgggtg cacggccggc ggttccccc cgtcggtcacc tggcgagaga 47280  
 cggacgaggc ctgtcggtgg tgggtcgctc gtcggatgggtt ggccggggagg tggctcgctc 47340  
 accggctgtc ggcgcacccgg ctcttcgacc tggctgtgtt gttctcgctc ggcgcggccgg 47400  
 tgtgggttggg caaaggccaa ggcgcatacg cccggcccaa tgcgttccctc gacgggtctc 47460  
 cgcacccatcg cccgcgcac gtcgtcgccgg ctggtagccct cgcctggggc ttatggggcc 47520  
 agggaggcat ggttgcatac aaggctcatg cacgtctgag cgacatcgccc gtcctgcaca 47580  
 tggccacggg gcccggcttg tcggcgctgg agccgttgggtaa gaacaccaggc gtcgtccagc 47640  
 gttcggtcac acggatggac tggcgccgt tgcgcgggtt ctatgcccgg cggggggggc 47700  
 gcaacttgtt ttcggctctg gtcggggagg acgagcgcgc tgcgtctccc cccgttccca 47760  
 cggccaaaccg gatctggcc ggccttggcc ttggggagag cgctcgaccg ctctacgagc 47820  
 tcgttcgccc catcgcccg cgggtgttccg gttttcccgca cccggggcgcg ctgcacgtcg 47880  
 gccgaggctt cgccgaggac gggctcgact ccctgtatggc tctggagatc cgtaacccgg 47940  
 ttcagcgcga gctgggggaa cgggtgttccg cgactctggc ttgcgaccac ccgacgggtgg 48000  
 ageggcttgtt ggcgcatactc ctacccgacg tgcgttgcgtt ggaggaccgg agcgacacccc 48060  
 ggcacatccg gtcgggtggcg gggatgacg acatcgccat cgctcggtcgc gcctggccgt 48120  
 tcccagggtgg ggtatggggcc ctggagacat actggggca tctggccgag ggcgttgggtg 48180  
 tcagcaccgg ggtggccagcc gacgggtggc ggcggccggta ctgttacgc cccgatccgg 48240  
 aggttccggg cccggacat tggccaaagg gtgcgttccctc cccgcgtatgtt cgcagcttgg 48300  
 atggggcggtt ttcggccatt tccccctcgat tggccatggcagg ctcggaccgg caacagggc 48360  
 tgggtcggtt ggttgcgttgg gaggcgatcg agcgtgttgg ccaggaccgg atggcgctc 48420  
 gcgagagcgc cacggggcggtt ttcgtgggca tgatcggtgg cgagcagcgc gagcgggtgc 48480  
 agggccctcgaa cgacgacgcgc ggcgttgcgtt acggcaccac cggcaacctt ctgcgtcg 48540  
 cccgtggacgc gctgtcggtt ttcctgggtt tgcacggcccc gacgtatgcg gtggacaccgg 48600  
 cctgtcggtt gtcgtcggttgg ggcgttgcacc tgcgttgcaca gagcgttgcga ttggggcagt 48660  
 ggcacccaggc ctcggccggc ggggtccagcg tgcgttgcgtt ggcgggtcga ttcgtcgccg 48720  
 cgtcgccat ggcgttgcgtt tcgcgcgtat ggcgttgcaca gacgttgcgtt gccgtcgcc 48780  
 acggcttgc gcccggccgag ggcgttgcgtt tgggtgtgtt caagcggttc cgtgcacgcgc 48840  
 agcgcgaccgg cgacccatcg ctggcggtgg tcaggagcacc ggcgtatcaac cacgtggcc 48900  
 cgacgcggcgg gtcacgggtt cccagcggtc ctgcggccagca ggcgttgcata cgccaggccgc 48960  
 tggcgcaagc gggcggtggcg cccggccggagg tcgatgttgcgtt ggagtgcacc gggacgggg 49020  
 cagcgctggg tgacccgatc gaggtgcagg cgctggggcgc ggtgtacggg cggggccggcc 49080  
 cccggggaggc gccgttgcgtt ctggcggtcg tcaaggccaa ctcggccac ctggaggccgg 49140  
 cgggggggtt gggccggcggtt ctcaagggtgc tcttgggttgcgtt ggagcagcagc cagattccgg 49200  
 ctcaaccggaa gtcgtcgacgatc ctcaaccggc acatcccgatg ggcgttgcgtt ccagtggccg 49260  
 ttgtccggcag ggcgttggccccc tggcccgccg ggcgttgcgtt ggcgttgcgtt ggcgttgcgtt 49320  
 ctttcggccctt gggccggacc aacgcgcatacg tgggtttggaa ggaggccggcc ggcgttgcgtt 49380  
 ctgtggccgcg gggcccccggag cgcgcagcgag agctgtcgat ctcgtcgccg aagagcgccgg 49440

cggcgctgga	tgcgcaggca	gcccggctgc	gggaccaccc	ggagaagcat	gtcgagcttg	49500
gcctcgcgta	tgtggcgttc	agcctggcga	cgacgcgcag	cgcgttggag	caccggctgg	49560
cggtgccgc	gagctcgcgc	gaggcgctgc	gagggggcgct	ttcggccgca	gcgcaggggc	49620
acacggccgc	gggagccgtg	cgtggggcggg	cctcggggcg	cagcgcggcc	aaggtggctt	49680
tcgtgtttcc	ggccaggggc	tcgcagtgg	tgggatggg	ccgaaagctc	atggccgaag	49740
agccgttctt	ccgggcggcg	ctggagggg	tcgcaccggc	catcgaggcg	gaagcgggct	49800
ggtcgtgtct	cggggagctc	tccggcgcacg	aggccgcctc	gcagctcggg	cgcacgcacg	49860
tggttcagcc	ggtgtgtttc	gccccatggaa	tagcgttttc	tcgcgtgtgg	cggtcgtggg	49920
gagtggagcc	ggaagcggtg	gtggggccaca	gcatggcga	ggttgcggcg	gcgcacgtgg	49980
ccggcgccgt	gtcgctcgag	gacgcgggtgg	cgatcatctg	ccggcgccgc	cggctgtcgc	50040
ggcggatcg	cggtcagggg	gagatggcgc	ttggcgatgg	gtcgctggag	gaggccgagg	50100
ccggctgcgt	tcggccatcg	ggtcggctga	gcgtggcggt	gagcaacacg	ccgcgttcga	50160
ccgtgtcgcc	cggcgagccg	gcggcgcttc	cgagggtgt	ggcggcgctg	acggccaagg	50220
gggtgttctg	ggccgcgggt	aagggtggacg	tcgcacggca	tagcccgacg	tcgcacccgc	50280
tgcgcaaga	gctgatcg	gcccgtggag	cgatccggcc	gcgagcggt	gcggtgccga	50340
tgcgctcgac	ggtgacgggc	gggggtgatcg	cggttccgg	gtcggtgtcg	agctactggg	50400
cgacaaacct	tccgcagccg	gtcgcttc	tcgcggccgc	gcaagcgctg	ctggagggtg	50460
gccccgcgt	gttcatcg	atgagccccc	acccgatctt	gttgcggcc	ctggacgaga	50520
tccagacggc	ggccgcggaa	ggggcgctg	cggtgggtcc	gtcgccggga	gggcaggacg	50580
agcgcgcgac	gctgtggag	gcccgtggga	cgctgtggc	gtccggctat	ccggtgagct	50640
gggctcggt	gttcccccg	ggccggcaggc	gggttccgt	gcccacat	ccctggcagc	50700
acgagcggt	ctggatcg	gacagcgtgc	atgggtcgaa	gcccctcgctg	cggttcggc	50760
agcttcgcaa	cggcgccacg	gaccatccgc	tgcgtggggc	tccattgtc	gtctcgccgc	50820
gaccggagc	tcacttgtgg	gagcaagcgc	tgagcgcacg	gaggtatcc	taccccttcgg	50880
aacatagggt	ccatggcga	gccgtgttgc	ccagcgccgc	gtatgttagag	atggcgctcg	50940
ccgeggcggt	agatctctat	ggcacggcgt	cgctgggtgt	ggagcagctg	gcgcgtcgac	51000
gagccctcgc	cgtggccctcc	gaaggcggtac	gcatcgatcg	agtggccctc	agcgaagaag	51060
gtccccgtcg	ggccctcattc	caggatcg	gtcgtgagga	ggcaggtagg	agctgggtgc	51120
ggcacccac	ggggcacgtg	tgtagcgccc	agagctcage	gttggggagcg	ttgaaggaag	51180
ctccgtggga	atttcacacgg	cgatgtccga	gcgtctgtc	gtcggaggcg	ctctatccgc	51240
tgctcaacga	gcacgcctc	gactatgttc	cctgttccca	gggcgtgggg	cagggtgtggc	51300
tcggcacccg	ggaggtgtcc	ggccgggtac	gtttggccagg	agacatggca	tcctcaagt	51360
gcgccttaccg	gttcatcccc	gccttgggt	atgcatgtt	tcagggtgtc	acagcgctgc	51420
tcaccacgc	ggaatccatc	gagatcg	ggccgtgtac	gatctccac	gaacccgatc	51480
tcccgggtc	cagggctcc	gtgaatcaag	cggtgagtga	cacctggctg	tgggacggcc	51540
cgctggacgg	tggacggcgc	cagagcgcga	gcgtgcccgt	cgacctggtg	ctcggcagct	51600
tccatgcgaa	gttgggagggtc	atggagcgc	tcgcgcaggc	gtacatcatc	ggcactctcc	51660
gcatatggaa	cgtcttcgtc	gtctgtggag	agcgttccac	gatagacgag	ttgtctcgta	51720
ggcttcaaatt	ctctgtcg	tacaggaagg	tcatacaagcg	atggatggaa	cacccctgtcg	51780
cgatcggtat	ctctgttaggg	gacggagac	atttttgtag	ctctcagccg	ctggcgagac	51840
ctgatttggc	ggcggtgtc	gaggaggccg	ggagggtgtt	cgccgcaccc	ccagtcctat	51900
ttgagtgggt	caagtttggc	ggggAACGGC	tcgcccacgt	attgaccgg	aagacgtcg	51960
cgctcgagat	cttccttc	gggtggctgt	tcgatatggc	ggagcgaatc	tatcgagatt	52020
cgccccatcg	ccgttactcg	aaacggcatcg	tcgcgggtgt	cgtcgagtcg	gcggcgccgg	52080
ttggtagcc	gtcgggaaatg	ttcagatctt	tggagatcg	agcagggacg	ggcgcgacca	52140
ccggcccggt	ctcccccgggt	ttgtcgctg	accggacgg	gttaccatcc	accgtgttt	52200
ctccgtctt	cttgcgtcg	ggcgagaaaa	gtttcgaga	ttatccatc	ctgaagtatg	52260
gcatttcgg	tgtcgaccag	gagccagtcg	gccagggata	cgcacatcag	aggtttgacg	52320
tcatcgctcg	ggccaatgtc	atccatcg	cccgcgat	aagagccacg	gcgaagcgctc	52380
tcctgtcg	gtctcgcc	ggaggcc	ttgtgtgt	cgagggcaca	gggcacatcga	52440
tctgtgtcg	tatcaccacg	ggatttattt	aggggtggca	gaagtacgaa	gtatgttcc	52500
gtatcgacca	tccgttc	cctgtcg	ccgtgtgt	cgctctcg	cgggtaggct	52560
ttcgccgacgc	cgtgatcg	ccaggcgacg	gtatccggc	ggggatcc	ggacagcacg	52620
tgatcttc	ggcgccgccc	ggcatagcag	gagccgtt	tgacagtc	gttggatcg	52680
cgacccaatc	gcccggccgc	cgtgcgtac	ggcaggaaat	ggccgtatggc	tccgctgacg	52740
tcgtccatcg	gatggcg	gagaggatgt	actttccacc	ccggccggggc	cgccaggttt	52800
gggtccacgg	tcgattgcgt	accgggtggag	gcccgttcc	gaaggcgctc	gttggagatc	52860
tgctcttgtt	cgaaagacacc	gggcagggtcg	ttggcagaggt	tcaggggctc	cgccctgcgc	52920
agctcgaggc	ttctgttttc	ggccggccgg	acccggggaa	agagtgggtt	tacgttttgg	52980
aatggcagcg	caaagaccc	ataccagagg	ctccggcagc	cgcgatctt	tcctccgggg	53040
gggttttgtt	cgtgtgtat	gaccaggggc	ggacaggcgc	tcgcgtcgta	tcgtgtcg	53100
aaggggcagg	cgaggcggtc	gtgcgcgtca	tcgcgggtac	ggcatacgcc	tcctcgccgc	53160
cggggctgt	tcaagtcgt	ccggcgccagc	cagatggctt	tcataccct	ctccgcgtat	53220
cattcgccg	ggaccggatt	tgtcgccg	tagtgcata	gtggagcc	gtgcgcacgg	53280
cagcagggg	gagggcgaca	cgggagtc	ttcaggccga	tcaactcc	gggagcc	53340

- 15 -

gcgccgtttc tctgggtgcag gcgctggtgc gccggagggtg ggcgaacatg ccgcggctt 53400  
 ggctcttgac ccgcgcgtg catgcgggtg ggcggaggta cgcaaggccc tcgggtggcgc 53460  
 aggccgcgtt gtggggccctc ggtcgacgc tcgcgcctca gcattccagag ctgcgggtgca 53520  
 cgcctgtgga cgtgaaccctg ggcgcgtctc cagaggacgc agccgcactg gcggtggagc 53580  
 tcggggcgag cgacagagag gaccaggctg cattgcgtc ggatggccgc tacgtggcgc 53640  
 gcctcggtcg gagctccctt tccggcaagc ctgcgtacggta ttgcggcatac cggccggacg 53700  
 gcagctatgt gatcacccat ggcatggggta gagtggggct ctcgggtcgca caatggatgg 53760  
 tgatgcaggg ggcccgcatt gtgggtctcg tggatccggc cggcgcttcc gaggcatccc 53820  
 gggatgcctt cccgtccatg gccgaggctg ggcggaggt gcagatcgta gaggccgacg 53880  
 tggctcggtcg cgacgatgtc gctcggtctt ctcgtaaagat cgaaccgtcg atgcggccgc 53940  
 ttcggggat cgtgtacgtg gacggggact tccggccgtg ctcctcgatg ctggagctgg 54000  
 atggccgtcg cttcaaggag tggatgtatc ccaaggctg cggagctgg aacctgcacg 54060  
 cgctgaccatg ggatagatcg ctggacttctc tgcgtccgtatc ttccctcgcc acctcgcttc 54120  
 tgggtctggcc accagcagggg atcaccgggtg caaggtgggc cttacagcga tggatcatca ctggggattt 54240  
 catcatcgcc gggacccctg aacgacggcg gggacccgt cgaataccgg gggatggaaag 54300  
 gcctcacgtt ggagcaggga gcccggccgc tcggggctt gctccgcacga cccaggccgc 54360  
 aggttaggggt gatggggctg aatctgcgtt gatgggttggat tttctatccc aacgcggccc 54420  
 gattggcgct gtggggcgag acgcgtcgaa ctttgcgtcgaa gggatggggatc ctttgcgtcg 54480  
 acgcgtcgaa ctttgcgtcgaa gggatggggatc ctttgcgtcgaa gggatggggatc ctttgcgtcg 54540  
 tggagaagca ctttgcgtcgaa aatctcggtt tggactcgatc gataggcctg gagatcccg 54600  
 agcggcacgt ggcgttcagc ggcgttcagc tggacaatcgatc tggactcgatc gataggcctg gagatcccg 54660  
 accgcacatcg gggccgcgtc ggcgttcagc tggactcgatc ctttgcgtcg 54720  
 acgtacgtc tcttgcgtcgaa agcttgcgtatc acatttcgtt tccgtatggc ggcgcgaccc 54780  
 acgcgtccggc caccgacggc gggatggggatc ctttgcgtcgaa gggatggggatc ctttgcgtcg 54840  
 tgcggggatc gacggacggc cggatggggatc ctttgcgtcgaa gggatggggatc ctttgcgtcg 54900  
 cgcagatcg tggatgtatc tggatgtatc ttccctcgcc accaccaatg cccggaaactg 54960  
 tggatcatcg ctttgcgtcgaa tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55020  
 gcgccggag cccatcgcca tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55080  
 tccggaggca ttcgtggggatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55140  
 gcgctggggcg ctgggtggccg tccatcccg cggatggggatc ctttgcgtcg 55200  
 caccggggatc gttggacggct tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55260  
 tgcgtcgat ctttgcgtcgaa tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55320  
 cggatcgca cccccgtccc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55380  
 cagcgtactac tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55440  
 caccggcaat acgtcgatcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55500  
 accctgcctg accgtcgaca tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55560  
 cccgagccgt cgccgtcgatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55620  
 ttcgttccaaatc acgtatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55680  
 cccggatccatc gacggccgtcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55740  
 gctcaaacgg ctttgcgtcgatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55800  
 ttcggccatc aatcaggatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55860  
 ggaggccgtc ttgcgtcgagg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55920  
 tgcgtcgaggacc cacggaaacgg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 55980  
 tgcgtcgatgg gggccggccg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56040  
 aaacctcgcc caccgtggggatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56100  
 tctgcaccac gaactgtatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56160  
 gatcgagggg accgtcgatcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56220  
 accgcgttcc gcccgggtcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56280  
 ggaggaggcg cccggccacgg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56340  
 ggtgtcgatcg gccaagaggcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56400  
 catcgcccgatc tacccggatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56460  
 tagcccgatc gacggccgtcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56520  
 gctggaggatc gcccggccgtcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56580  
 ctgcgtccggc aagctcgatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56640  
 cctgtgggtt gttggaggcgatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56700  
 ctttgcaccgg gagctccatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56760  
 cagggtcgatc ttgtcgatcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56820  
 cgcgtcgatcc ggcgttcccg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56880  
 cctcgcccgatc ctgggtggccg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 56940  
 ctttgggtgc gcccggggatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 57000  
 gatcgcccgatc cccggaggccg acgtggatcg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 57060  
 gatcgccggatc gtcaatggggatc cggagccgtcg tggatgtatc ttccctcgcc accaccaatg aattcgatcg 57120  
 gcagatcgatc gcccggatcccg tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 57180  
 cgcgtccac tggatccatc tggatgtatc ttccctcgcc accaccaatg tggatgtatc ttccctcgcc 57240

ggtgacgtac cgccggcctt cgatcgct ggtgagcaac ctgagcggga agccctgcac 57300  
 cgatgaggta agcgccggg ttactgggt gcgtcacgcg cgagaggcgg tgcgttcgc 57360  
 ggacggagtg aaggcgctgc acgcggccgg tgccggccctc ttccgtcgagg tggggccgaa 57420  
 gcccacgtc ctcggccctt tgccggctcg cctgcggat gccaggccgg tgctgtcccc 57480  
 agcgctcgcc gcggggcgta acgaggctcg gagcgcgctg gagggcgtcg tggggttctg 57540  
 ggtcgctgggt ggatcggtca cctggtcggg tgcgttcctc tcggggcgac ggcgggtacc 57600  
 gctgccaacc tatccccggc agcgcgagc ttactggatc gaagcgccgg tcgatcgta 57660  
 ggccggacggc accggccgtg ctccggccggg gggccacccc ttctcggtg aagtctttc 57720  
 cgtgtcgacc catgccccgtc tgccctgtg ggagacgacg ctggaccgaa agcggtcgcc 57780  
 gtggctcgcc gaggcaccggg cgcaggggga ggtcggttt cctggcgccg ggtacctgga 57840  
 gatggcgctc tcgtcggggg ccgagatctt gggcgatgga ccgatccccgg tcacggatgt 57900  
 ggtgctcatc gagacgtcg ctttcggggg cgatacgccg gacccgggtcc aggtggtgac 57960  
 gaccggaggag cgaccggggac ggctcggtt ccaggatcg agtggggagc cgggggaacg 58020  
 tcggccggccc ttccggatcc acgccccggg ctgtcgccg cggatcgggc gctgtcgagac 58080  
 cccggcgagg tcgaaccccg ccccccgtcg cgcccccgtt catggccggc tgcggcgctgc 58140  
 ggctatctat ggtgcgtcg ccgagatggg gtttcaatac gggccggcg tgcgggggct 58200  
 cgcccgagctg tggcgggggcg agggcgaggc gctgggcagg gtgagactgc ctgaggccgc 58260  
 cggctcccgcc acagccattacc agctgtatcc ggtgtcgctg gacgcgtcg tccaaatgat 58320  
 tggcgccggcg ttcggcgatc gcgatggggc gacggcggtt gggccgggggg aggtgggctc 58380  
 ggtgcccgtg tttccgggtt cccctggggg gctatggtc catgccccgg tcgtgaggcg 58440  
 tggtaaacag gcttccagcc ggtggaggcg cgacttttag ttatggacg gtacggggcg 58500  
 ggtggcgccc gagatctccc ggctgggtt ggagccggctt gcgagcggcg taccggccgc 58560  
 cgacgcagac gactggttcc tggagctgga ttggggagccc gccggcgctcg gtggggccaa 58620  
 gatcacaaggcc gggccgggtggc tgctgtcg ggggggttgtt ggctcgggc gtcgttgc 58680  
 ctcggcgctg aaggccggccg gccatgtcg ctgtccacgcg gccggggggac acacgagcac 58740  
 tgcaggatcg cgccgcgtcc tggccaaacgc gttcgacggc caggccccga cggccgtgg 58800  
 gcacctcagc agccctcgacg gggccggccca gtcggccccc gggctcgggg cgcaggccgc 58860  
 gtcgacgcg ccccgaggagcc cagatgtcg tgccgtatgcc ctgcataatcg cgctgtatcg 58920  
 tggtrgcgac agcggtcgatcc cccctggtcg agcggtcg ggcattggacc tccgaaacgc 58980  
 gcccggctg tggctcttga ccccgggggc tcaggcgccc gccgccccgg atgtctccgt 59040  
 ggtgcaagcg ccgctgttgg ggtctggggc caccatcgcc ttggagacg ccgagctcg 59100  
 ctgtatcagc gtcgaccccg atccagccga gcttgcggggaa gaaaggatcgatc ttttgcgtgc 59160  
 cgagctactt gcaaatcgatc cggaggaggat ggtcgccgtt cgggttgcggcc accggctcg 59220  
 tgcgcggctc gtccacccggc tgcccgacgc tcaggcgccc gagaaggatcg agccggccgg 59280  
 tgacaggccg ttccggcttag agatcgatcg accccggcgcc ctggaccaac tgggtctccg 59340  
 agccacgggg cggcgccgtc ctggtccggg cgaggatcgatc atcccgatcg aagcggccgg 59400  
 gtcgactcc atcgacatcc agctggcgatc gggcgatcgatc cccaaatgatc tgcctggaga 59460  
 agaaatcgag ccgttgggtgc tggaaaggcgatc gtcggccggg cgcattcgatc tggggcgca 59520  
 gggcgtgaac ggccttgggg tggccgacgc ggtgtatcgcc ctgcggcgcc gatgttttcg 59580  
 taccatgtc accacgtcgcc caacgtcgatc gttgcctcgatc cccctggggc tccctggcgac 59640  
 cgaggccggcc gcgatgtcccc tccgtatcc gacggccctgg tacggccctcg acaaggatcg 59700  
 ccacctcgatc gccccggggc ggggtcgatc ccatcgccgg gccgggtgggtg tgggtctttg 59760  
 cgcgtgcga tggcgccgc gcgatgtatcgatc ggcaccggcc acacggccca 59820  
 gaaccgtgccc tacctggatc cgctggggcg ggggtacgtt gacgtatcccc gtcggggccg 59880  
 gttcgatcgatc gacgtcgatcg catggacggc cggcgagggtt gtggacgtcg tgcgtcgatcc 59940  
 gcttcggggc gaggcgatcg acaaggatcgatc catgttccgt cgcggccgtt gtcgccttgc 60000  
 gaagctgggc aggccgcgacg actggccgatc caccgtatcc gggctggccgc cgctcttgc 60060  
 gaattttcc ttctcgatcg tggacttgcg gggaaatgtatcgatc cccgtatcgatc cggcgaggat 60120  
 ccgtcgatcgatc ttcgacgcgatc tggccgggtt ggtcgatcgatc gtcggccatca gcccactggg 60180  
 gtcgggggtt ggcgttggcg gatcccttac gccaccggccg gtcgagacatc tccctggatcc 60240  
 tgcgcgcgatc gaggatcgatcc gggaggatcgatc gcaaggacatcgatc tccctcgatcg 60300  
 cacgttggac gaccgggggg tggggatcgatc cgcggccggatcgatc gatcccgatcgatc tgcgttgc 60360  
 cgcggacggcc acatccatcgatc tggccggccg tggggatcgatc ctcggatcgatc gcgatgtatcgatc 60420  
 atggctggcc gaggccggccg cggggcaactt ggtgttggatcgatc ggcggccatcgatc gtcggccgag 60480  
 cgcagagcgatc cgaggccggcc tggccggatcgatc gggggccac ggcggccgcgc tcacggatcgatc 60540  
 gaaagcgatcgatc gtcggccatcgatc ggtatcgatc cgcggccatcgatc ttcaccggatcgatc 60600  
 gggatcgatcgatc tggggatcgatc ggcggccatcgatc ggcggccatcgatc ggcggccatcgatc 60660  
 gcagcagactt cccggcgccgtt tccgacacgtt gatggggatcgatc aaggatcgatc gggccatcgatc 60720  
 ctgcacacgtt tgcacacgtt aaggccatcgatc tcccttccgtt ggcgttgcgttccatcgatc 60780  
 tgggttttc ggcgttgcgtt gccaggatcgatc tccctcgatcgatc ggcggccatcgatc 60840  
 cccatcgatcgatc caccgtatcc ggcggccatcgatc ggcggccatcgatc ggcggccatcgatc 60900  
 cacggaggatcgatc gggatcgatcgatc tggccggatcgatc aaaccgttgcgatcgatc ggcggccatcgatc 60960  
 gatgcggggcc atcaccatcgatc atggggatcgatc tccctcgatcgatc ggcggccatcgatc 61020  
 tgcgtcgatcgatc acggggatcgatc tccctcgatcgatc tccctcgatcgatc tccctcgatcgatc 61080  
 aacagcgatcgatc tccctcgatcgatc ggcggccatcgatc ggcggccatcgatc tccctcgatcgatc 61140

gaccggccggg gatcgggacc tgctcgaaca gcttgcgtcg gctgagccga gcgcgcgggc 61200  
 ggggcgtctg caggacgtcg tgcgcggtca ggtctcgcat gtgcgtcg tccctgaaga 61260  
 caagatcgag gtggatgccc cgctctcgag catgggcattg gaetcgtcgta tgagcctgg 61320  
 gctgcgcac acgcacgtgg ctgcgtcgaaa cgtcggcccg cctgcagccct tggggtgac 61380  
 gtaccacaacg gttagcagcga taacgcgtcg gctgcgtcgac gacgcgcctcg tcgtccgg 61440  
 tggcgccggg tcggacacgg acgaatcgac ggcgagccgc gtttcgttcg tccacgtcc 61500  
 ccgcgttcgt cctgtcgta agccgcggg tcgtcttc tttttcacg gttctggcgg 61560  
 ctgcggccgg ggttccgtt cttgtcgaa gaagtcgtgg tgagcgtac tggaaaatcg 61620  
 ggccatgtgg cacgatcgca gcctcgccctc cgaggacgcg cttggtaaga agtacgtcca 61680  
 agaggcgcc tcgctgattc agcaactatgc agacgcacccg ttgcgttag taggggttcag 61740  
 cctgggtgtc cggttcgtca tggggacgc cgtggagctc gccagtcgtt ccggcgcacc 61800  
 ggctccgctg gccgtcttcg cgtggccgg cagctgttgc tcttcgttcg agatcacc 61860  
 ggagatggag accatataaa tagccaatgtt cttttcccgaa atgtccgcgg gtttcgtgc 61920  
 atccccccaa caatccagg ccgatgtcg cgcagacaaag gtcatcacag acaccatgg 61980  
 ggctccggcc cccggggact cgaaggagcc gccccgtgaag atccgcggtcc ctatcg 62040  
 catcgccggc tcggacgtcg tgcgtgtcc tccgagcgc gttcaggatc tacaatctcg 62100  
 caccacggag cgcttctata tgcacatccct tcccgagat cacgaatttc tcgtcgatcg 62160  
 agggcgcgag atcatgcaca tcgtcgactc gcatctcaat ccgctgtcg tccgcgaggac 62220  
 gacgtcgta gggcccgctg tcgaggcaaa atgtatggcag cttccctcg ggcgcgagaa 62280  
 tgggtggggc cagcggtggc gctggcgcc ggcggcaggc cggggaggcg catgaccc 62340  
 cctggacgtt tgcgtatag gagattttat gacacaggag caagcgtac agagtggagac 62400  
 gaagcctgtt ttgcacttca agccgttcgc gcctgggtac gccggaggacc cgttccccgc 62460  
 gatcgagcgc ctgagagagg caacccccc tttctactgg gatgaaggcc gtcctgggt 62520  
 cctccacccga taccacgacg tgcggcggt gttccgcgc gaaacgttcg cggtcagtcg 62580  
 agaagagtgg gaatcgagcg cggagactc gtcgcgtcc cccgagctca gcatatgaa 62640  
 gaagtacgga ttgttcgggc tgccgcgggaa ggatcacgtt cgggtccgcg agctcg 62700  
 cccgtcggtt acgtcacgcg ccacgtcgatc gtcgcgcgcgaaatacagc gcaccgtcg 62760  
 ccacgtcgatc gatgtcgatc ccggacaaga ggatgtcgac gttgtgcggg attacgcg 62820  
 gggaaatcccc atgcgcgcga tcagcgctct gttgaagggtt ccggccgagt gtgacgagaa 62880  
 gttccgtcg ttcggctcg cgactcgccg cgccgtcgcc ggggtttgg tgccccaggt 62940  
 cgatgaggag accaagaccc tggtcgcgtc cgtcaccggg gggctcgccg tgcctcatga 63000  
 cgccctccgt gageggcgca ggaacccgtt cgaaaatgtc gtcctgtac gtcgtgttca 63060  
 ggcgtggccc gacggcagca ggttgcgcac gaaggagctg tgcgcgttcg tgggtgcgat 63120  
 tattcgctgtt ggcacccata ccaatcgccg ttcgtgtgc tcaacctgtc 63180  
 gcggtcgccc gaggcgctcg agctggtaa ggccgagccc gggtcatga ggaacgcgt 63240  
 cgatgagggtt ctccgttcg acaatatctt cagaatagga actgtgcgtt tcgccaaggca 63300  
 ggaccttggg tactgcgggg catcgatcaa gaaaggggag atggcttttc tccgtatccc 63360  
 gagcgccctg agagatggga ctgtatttc cagggcagac gttttgtatc tgacgcggg 63420  
 cacggccgcg aggctcgccgt acggtagagg ccccatgtc tgccccgggg tgccttcgc 63480  
 tgcctcgag gggagatcg ccgtggccac catctccgtt aggtttcccg agatgaaatc 63540  
 gaaagaaatc cccgtgtttt gataccaccc cgcgttccgg aacatcgaaat cactcaacgt 63600  
 catctttaaag ccctccaaag ctggatagct cgcgggggtt tgccttcgg aacctcatcc 63660  
 cctcatgata cagctcgccg cgggtgtcg ttcggccggg gtgcgttcg atccagcg 63720  
 caagccatt gtcagcgccg gaagatcgaa tccacggccc ggagaagagc cgcgtccgg 63780  
 gacgtcgaa gaagtgcggg ggcggccctt gggagcgcgg agtcgtcg ttcgcgttc 63840  
 gcacgcgcgt cgtcatgtcc ggcgttgcac cgcggccggg gagcgcggccgg ccctgtatcg 63900  
 cggcctcacc gagcgccagg ttctgttc cgcgtcgcc ctcgcgttcg tccctctgac 63960  
 cgcgcgcgcc ttcggcagc tcgcgcggcg gtcgcgtccag cccgagggtgc tggcgagct 64020  
 cttccggccggtt gttgtgtccgg gcccgtccgt cgtcgccgcg ttcgcgttcg gttccatcg 64080  
 agtccctttt caggatccgg cggtcgggtt cgtgtcttc ggcacatctctt ggataggcgc 64140  
 gtcgtctgtt ctgtctatgg cgggtatcg gtcgtatgtg agtcgttcg gcaaggaggc 64200  
 ggcggccggg ggcgtctcg gtcgtcgccg gtcgtcgccc cgcgtcgcc cgcggggcc 64260  
 gctgggtcgag cgcgtcgagg ggcgttccac gtcgtcgatcg tgcgtcgcc cgcgcgtcc 64320  
 tgcgcgcagg tgcgtcgatcg ccgtgtccgt tgcgtcgatcg tgcgtcgcc cgcgcgtcc 64380  
 gacatccggc cgcggccgcg ggcggccgtc gacggccgtt cgcggccatgtg gacggccgc 64440  
 gaggccgacg aggcgctccg cccgttccgc gacgcgtactc cgcgtactc ggaggccgtt 64500  
 cggtggcgccagg aggccggcga cggccggcg gtcgtcgatcg tgcgtcgcc cgcgtcgcc 64560  
 cggcgtggca aggcgctcgaa caaggatccctt ttcgcgcaca cgcggccgg cgcgtcccg 64620  
 atcgccggca gactcccgaa cgtatcgatcg tgggtcgatcg tgcgtcgcc gtcgtcgatcg 64680  
 ttcggccggc cgcgtcgatcg cgcgtcgatcg gacgcgtccgt cgcgtcgatcg ggcgtcgcc 64740  
 gccggccggcgtt acccgccgtt gacggccgtt tccgtcgatcg tagggggatc tgggggggg 64800  
 gccggccggcc ttcaccccgcc ggcgtcgatcg cccgcgtcccg accagcgat ctcgaccgc 64860  
 ctcggccgcg cgcgtcgatcg gtcgtcgatcg ttcacactcg cttcgcccg tgcggatcg 64920  
 gtcgttcgttcccg ggcgtcgatcg agcggccggc gtcgtcgatcg tcccttcgttcccg caaccatcgac 64980  
 cggagccgcg ctcggatcgatcg gacgcgtccgt cgcgtcgatcg cggcgtccgtt cgcgtcgatcg 65040

- 18 -

acaggcgacg acccgccccga gggtgtcgaa cggattgcgg cagccctcat tgccgatccc 65100  
 ctccagacac tcgttcagct gcttggcgcc gatgcggcct gggcaactcgc cgaaggctcg 65160  
 ctgcgcgcgc cactcgatc ggatcttgcg cgagcacgcg tccttgctcg aataactcccg 65220  
 gtctttgtccg atgttgcgacc accgcgcctc gcggtcgac cgcggccgcca cgatgctatc 65280  
 gacggcgctg ccgactggca cggcgccctc cggcttgcgg ccacccgggg tttgcgcctc 65340  
 cccgcgtac cgcttttcgc cgccgcacgc cgccggcagg ctcattcccg acaccgagat 65400  
 cagccccacg accagcttcc cagcaatctt ttgcattggct tccccctccct cacgacacgt 65460  
 cacatcgag actctcccgct cggctcgctg ttgcacacgc cggcgcacggc cacgagcaga 65520  
 accgtccccg accagaacagc cccatgcgg gtttctcgca acatgcggcc acatccctgc 65580  
 gactactgtg ctcccgctcg tgccgagat ggctgttcctg tgccgacggc atatctgtcg 65640  
 atcggccggg caggaggatc cgacacgggc gcccggccgg aggtggccgc acgggctcga 65700  
 aatgtgtgc gcggaggcgcc tccatggccc cagccggaa cgcggccgccc ggccagccctc 65760  
 ggggtgacgc cgcacaaacggg agatgtccc ggagaggcgcc cgggcacagc cgagcgcctg 65820  
 caccacccgtg cgcactcgct agctccagct cctccggata gaagagaccc tcactcccg 65880  
 tccgtgtagg cgatcgctgat gatcagcgcg tctccgcct gacgcgagtc gagccgggta 65940  
 tgctgcacga caatgggaac gtccgatctg atcactgtgg catagtccgt atcggccggg 66000  
 atcggctcggt gtccgttcag atcgttgcac cggacatggcc gggtgccgcgct cgctgggacg 66060  
 gtcacccgggt acggccgggg ggggtcgccg tcgctgaatg acacgggtat ggcgacctgc 66120  
 gggccgggtt cccggcgtt cacaaggcgag gccgttccat ggtctcgatc ctgcggctcg 66180  
 ggtccgtgc tccggccggg gatgtggccc tctgcgattt cccagcgcgt cccggccgatc 66240  
 ggcttttcca tatgttccctc ctgctggctc ctctttggct gcctccctct gctgtccagg 66300  
 agcgcacggcc ttttctcccg acgcgcgttgg ggttccatgg ctgaggatcc tcgcccggc 66360  
 ctcccttgcgg accggcgccgc cgagcgcggc cgggtttaa aacgcacgcga cggacacatc 66420  
 gatgcggccgc cgacgaggcc gcccggcgtc tgatcccgat cgtgcacatcg cgacgtccgc 66480  
 cggcgccctt gcaggccggc ctgagcttg cgcggctatcg tgcgtccctcg cgtcaccggcc 66540  
 acccgccgtt tccatccca cccgcgcacgc acgcttgcctt aaacccggccg gagaacggccg 66600  
 gggggctgtg gtaccggcca gcccggacgc gaggccccgag agggacatgt ggtccggcctg 66660  
 gaagcagtga ggcgcacatcgat gtggcagatg aaacacgtt acacggggcc acgagtccgc 66720  
 cgccggatag ggctcacgtt cgggttccctc ggcgcacatgg cgcgcggccgg ctgtggccgg 66780  
 ccgagcgaga aatactgtgca gggcacgcgg ctgcgcggcc ggcggatgcgc gcaacgtccgc 66840  
 gcccgcgtcc accccggacgc cgcgcacacg cggctggccg tggacatcgatc tcaacctctcg 66900  
 cccggccggatc gcatcgaggc cggcgcgttgc tctggcgtcg tccgagctcc 66960  
 gagttccccgt gcaacgggtt cggagtgttc gactacaacg ctggcagccg aagaggcaag 67020  
 ctggccgaga cgaccgtgcc gcatgcacaa ttcgagctgc tcatcaccgt cgagaacgag 67080  
 agcagccctc agtctccatc ttctgcggcc gtcatcgggc cgacgtccgt cgggttaacat 67140  
 cgcgttatca gcaatcgatc gcccggccacg aggccccaga gcccgtccctc gategccttc 67200  
 tccatcatat cacccttgcg tacttccca ggcgcggccg cgtcgaagca accggccgtgc 67260  
 cggccgggtt ctacgtcgcc gacaggagag ctgcgttggcc cggccgtcgcc atcgctgaa 67320  
 ggatccgggg agcatggaga aagaatcgag gatcgccatc tacggcgcca tcgcagccaa 67380  
 cgtggcgatc gcccgggtca agttcatcgcc cgcgcggccgt accggcagct cggcgatgt 67440  
 ctcccgaggcc gtgcacttccc tcgtcgatc tgcagacggg ctccctccctc tgctcgccaa 67500  
 gcaccggagc gcacgcggcc cgcgcgcgcg gcatccgttc ggccacggca aggagctcta 67560  
 ttcttggacg ctgtatcgat ccatcatatg ctgcgcggcc ggcgcggccgg ttcgcgttca 67620  
 cgaagggtt tcgcacatcg tgcacccgcg ccagatcgat gatccgcacgt ggaactacgt 67680  
 cgtccctcgcc gcaggccggc ttttcgaggc gacgtcgctc atcatctcgatc tccacgatgt 67740  
 caagaagaag gacggacagg gtcacatcgatc ggcgcgttgc tccagcaagg accccgacac 67800  
 gttcacgatc tccctggagg actccgcggc gtcgcggccg ctcaccatcg ctttcctcg 67860  
 cgtctggctc gggcaccgcg tggaaacccc ctacatcgatc ggcgcggccgt cgatcgccat 67920  
 cggccctcggt ctgcgcgcgg tcgcgcgtt ctcgcgcgcg cagagccgtg ggtccctcg 67980  
 gggggagggc gcccggacaggc agtctccgcg cgcgcacccgc ggcgcgtcc ggcgcacatcc 68040  
 tggctgtcg cgggtggggc gggccctgcgatc gatcgacttc gtcgcgtcc acgtccctgg 68100  
 cgtctggccg atcgatcgatc acgcgcgtatc cgcgcgtcc ggggtcgccg agggtgcgt 68160  
 ggcgcacatcgatc accccggatc ggcgcgttgc accccgcgttgc aagcacatct acgtcgaggc 68220  
 caggctcgatc caccatcgatc cggggccgtg acgcgcgttgc gaggacccgc ggcgcggcc 68280  
 cgcgcacatcgatc cgcgcgcggcc gggctcgatc ggcgcgtcc gcaaggccgcg cttggccggc 68340  
 aaaccatcgatc gacgtcgatc ttcgcacgcgatc ggttgcgttgc ttcgcacatcgatc 68400  
 tccgcgggtc cggcgcacgcgc gggccggggc ggcgcacatcgatc ggcgcgtcc ggcgcacac 68460  
 caggctcgatc gggggccggc gtcatcgatc gggccggccg gcatggggccg atgtcgccgc 68520  
 ggcgcacatcgatc cggctggccgt cggccgtcc cggccggccgg cgcgcgtcc ggcgcgtcc 68580  
 acgcgcgtccg ttcgcgcgtatc ttcgcgcgttgc gcccgttgc ggcgcgtcc tccctcgccg 68640  
 ggcgcgcggc gatggcggtc gtcgcgttgc tccagatcgatc gatcatcgatc ggcgcgtcc 68700  
 atccctccgtt tccagggttgc gatcgccatc aggtgcacgc gtcgcgtcc 68750

&lt;210&gt; 2

&lt;211&gt; 1421

- 19 -

<212> PRT

<213> Sorangium cellulosum

<400> 2

Val Ala Asp Arg Pro Ile Glu Arg Ala Ala Glu Asp Pro Ile Ala Ile  
1 5 10 15

Val Gly Ala Ser Cys Arg Leu Pro Gly Gly Val Ile Asp Leu Ser Gly  
20 25 30

Phe Trp Thr Leu Leu Glu Gly Ser Arg Asp Thr Val Gly Arg Val Pro  
35 40 45

Ala Glu Arg Trp Asp Ala Ala Ala Trp Phe Asp Pro Asp Pro Asp Ala  
50 55 60

Pro Gly Lys Thr Pro Val Thr Arg Ala Ser Phe Leu Ser Asp Val Ala  
65 70 75 80

Cys Phe Asp Ala Ser Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Arg  
85 90 95

Met Asp Pro Ala His Arg Leu Leu Leu Glu Val Cys Trp Glu Ala Leu  
100 105 110

Glu Asn Ala Ala Ile Ala Pro Ser Ala Leu Val Gly Thr Glu Thr Gly  
115 120 125

Val Phe Ile Gly Ile Gly Pro Ser Glu Tyr Glu Ala Ala Leu Pro Gln  
130 135 140

Ala Thr Ala Ser Ala Glu Ile Asp Ala His Gly Gly Leu Gly Thr Met  
145 150 155 160

Pro Ser Val Gly Ala Gly Arg Ile Ser Tyr Ala Leu Gly Leu Arg Gly  
165 170 175

Pro Cys Val Ala Val Asp Thr Ala Tyr Ser Ser Ser Leu Val Ala Val  
180 185 190

His Leu Ala Cys Gln Ser Leu Arg Ser Gly Glu Cys Ser Thr Ala Leu  
195 200 205

Ala Gly Gly Val Ser Leu Met Leu Ser Pro Ser Thr Leu Val Trp Leu  
210 215 220

Ser Lys Thr Arg Ala Leu Ala Arg Asp Gly Arg Cys Lys Ala Phe Ser  
225 230 235 240

Ala Glu Ala Asp Gly Phe Gly Arg Gly Glu Gly Cys Ala Val Val Val  
245 250 255

Leu Lys Arg Leu Ser Gly Ala Arg Ala Asp Gly Asp Arg Ile Leu Ala  
260 265 270

Val Ile Arg Gly Ser Ala Ile Asn His Asp Gly Ala Ser Ser Gly Leu  
275 280 285

Thr Val Pro Asn Gly Ser Ser Gln Glu Ile Val Leu Lys Arg Ala Leu  
290 295 300

Ala Asp Ala Gly Cys Ala Ala Ser Ser Val Gly Tyr Val Glu Ala His  
305 310 315 320

Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ile Gln Ala Leu Asn

- 20 -

325	330	335
Ala Val Tyr Gly Leu Gly Arg Asp Val Ala Thr Pro Leu Leu Ile Gly		
340	345	350
Ser Val Lys Thr Asn Leu Gly His Pro Glu Tyr Ala Ser Gly Ile Thr		
355	360	365
Gly Leu Leu Lys Val Val Leu Ser Leu Gln His Gly Gln Ile Pro Ala		
370	375	380
His Leu His Ala Gln Ala Leu Asn Pro Arg Ile Ser Trp Gly Asp Leu		
385	390	395
Arg Leu Thr Val Thr Arg Ala Arg Thr Pro Trp Pro Asp Trp Asn Thr		
405	410	415
Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Met Ser Gly Thr Asn Ala		
420	425	430
His Val Val Leu Glu Glu Ala Pro Ala Ala Thr Cys Thr Pro Pro Ala		
435	440	445
Pro Glu Arg Pro Ala Glu Leu Leu Val Leu Ser Ala Arg Thr Ala Ser		
450	455	460
Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp His Leu Glu Thr Tyr		
465	470	475
Pro Ser Gln Cys Leu Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg		
485	490	495
Ser Ala Met Glu His Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Gly		
500	505	510
Leu Arg Ala Ala Leu Asp Ala Ala Ala Gln Gly Gln Thr Ser Pro Gly		
515	520	525
Ala Val Arg Ser Ile Ala Asp Ser Ser Arg Gly Lys Leu Ala Phe Leu		
530	535	540
Phe Thr Gly Gln Gly Ala Gln Thr Leu Gly Met Gly Arg Gly Leu Tyr		
545	550	555
Asp Val Trp Ser Ala Phe Arg Glu Ala Phe Asp Leu Cys Val Arg Leu		
565	570	575
Phe Asn Gln Glu Leu Asp Arg Pro Leu Arg Glu Val Met Trp Ala Glu		
580	585	590
Pro Ala Ser Val Asp Ala Ala Leu Leu Asp Gln Thr Ala Phe Thr Gln		
595	600	605
Pro Ala Leu Phe Thr Phe Glu Tyr Ala Leu Ala Ala Leu Trp Arg Ser		
610	615	620
Trp Gly Val Glu Pro Glu Leu Val Ala Gly His Ser Ile Gly Glu Leu		
625	630	635
Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu Asp Ala Val Phe		
645	650	655
Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu Pro Ala Gly Gly		
660	665	670

- 21 -

Ala Met Val Ser Ile Glu Ala Pro Glu Ala Asp Val Ala Ala Ala Val  
 675 680 685  
 Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val Asn Ala Pro Asp  
 690 695 700  
 Gln Val Val Ile Ala Gly Ala Gly Gln Pro Val His Ala Ile Ala Ala  
 705 710 715 720  
 Ala Met Ala Ala Arg Gly Ala Arg Thr Lys Ala Leu His Val Ser His  
 725 730 735  
 Ala Phe His Ser Pro Leu Met Ala Pro Met Leu Glu Ala Phe Gly Arg  
 740 745 750  
 Val Ala Glu Ser Val Ser Tyr Arg Arg Pro Ser Ile Val Leu Val Ser  
 755 760 765  
 Asn Leu Ser Gly Lys Ala Cys Thr Asp Glu Val Ser Ser Pro Gly Tyr  
 770 775 780  
 Trp Val Arg His Ala Arg Glu Val Val Arg Phe Ala Asp Gly Val Lys  
 785 790 795 800  
 Ala Leu His Ala Ala Gly Ala Gly Thr Phe Val Glu Val Gly Pro Lys  
 805 810 815  
 Ser Thr Leu Leu Gly Leu Val Pro Ala Cys Met Pro Asp Ala Arg Pro  
 820 825 830  
 Ala Leu Leu Ala Ser Ser Arg Ala Gly Arg Asp Glu Pro Ala Thr Val  
 835 840 845  
 Leu Glu Ala Leu Gly Gly Leu Trp Ala Val Gly Gly Leu Val Ser Trp  
 850 855 860  
 Ala Gly Leu Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr  
 865 870 875 880  
 Pro Trp Gln Arg Glu Arg Tyr Trp Ile Asp Thr Lys Ala Asp Asp Ala  
 885 890 895  
 Ala Arg Gly Asp Arg Arg Ala Pro Gly Ala Gly His Asp Glu Val Glu  
 900 905 910  
 Glu Gly Gly Ala Val Arg Gly Gly Asp Arg Arg Ser Ala Arg Leu Asp  
 915 920 925  
 His Pro Pro Pro Glu Ser Gly Arg Arg Glu Lys Val Glu Ala Ala Gly  
 930 935 940  
 Asp Arg Pro Phe Arg Leu Glu Ile Asp Glu Pro Gly Val Leu Asp His  
 945 950 955 960  
 Leu Val Leu Arg Val Thr Glu Arg Arg Ala Pro Gly Leu Gly Glu Val  
 965 970 975  
 Glu Ile Ala Val Asp Ala Ala Gly Leu Ser Phe Asn Asp Val Gln Leu  
 980 985 990  
 Ala Leu Gly Met Val Pro Asp Asp Leu Pro Gly Lys Pro Asn Pro Pro  
 995 1000 1005  
 Leu Leu Leu Gly Gly Glu Cys Ala Gly Arg Ile Val Ala Val Gly Glu  
 1010 1015 1020

- 22 -

Gly Val Asn Gly Leu Val Val Gly Gln Pro Val Ile Ala Leu Ser Ala  
 1025 1030 1035 1040

Gly Ala Phe Ala Thr His Val Thr Thr Ser Ala Ala Leu Val Leu Pro  
 1045 1050 1055

Arg Pro Gln Ala Leu Ser Ala Ile Glu Ala Ala Ala Met Pro Val Ala  
 1060 1065 1070

Tyr Leu Thr Ala Trp Tyr Ala Leu Asp Arg Ile Ala Arg Leu Gln Pro  
 1075 1080 1085

Gly Glu Arg Val Leu Ile His Ala Ala Thr Gly Gly Val Gly Leu Ala  
 1090 1095 1100

Ala Val Gln Trp Ala Gln His Val Gly Ala Glu Val His Ala Thr Ala  
 1105 1110 1115 1120

Gly Thr Pro Glu Lys Arg Ala Tyr Leu Glu Ser Leu Gly Val Arg Tyr  
 1125 1130 1135

Val Ser Asp Ser Arg Ser Asp Arg Phe Val Ala Asp Val Arg Ala Trp  
 1140 1145 1150

Thr Gly Gly Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Glu  
 1155 1160 1165

Leu Ile Asp Lys Ser Phe Asn Leu Leu Arg Ser His Gly Arg Phe Val  
 1170 1175 1180

Glu Leu Gly Lys Arg Asp Cys Tyr Ala Asp Asn Gln Leu Gly Leu Arg  
 1185 1190 1195 1200

Pro Phe Leu Arg Asn Leu Ser Phe Ser Leu Val Asp Leu Arg Gly Met  
 1205 1210 1215

Met Leu Glu Arg Pro Ala Arg Val Arg Ala Leu Leu Glu Glu Leu Leu  
 1220 1225 1230

Gly Leu Ile Ala Ala Gly Val Phe Thr Pro Pro Pro Ile Ala Thr Leu  
 1235 1240 1245

Pro Ile Ala Arg Val Ala Asp Ala Phe Arg Ser Met Ala Gln Ala Gln  
 1250 1255 1260

His Leu Gly Lys Leu Val Leu Thr Leu Gly Asp Pro Glu Val Gln Ile  
 1265 1270 1275 1280

Arg Ile Pro Thr His Ala Gly Ala Gly Pro Ser Thr Gly Asp Arg Asp  
 1285 1290 1295

Leu Leu Asp Arg Leu Ala Ser Ala Ala Pro Ala Ala Arg Ala Ala Ala  
 1300 1305 1310

Leu Glu Ala Phe Leu Arg Thr Gln Val Ser Gln Val Leu Arg Thr Pro  
 1315 1320 1325

Glu Ile Lys Val Gly Ala Glu Ala Leu Phe Thr Arg Leu Gly Met Asp  
 1330 1335 1340

Ser Leu Met Ala Val Glu Leu Arg Asn Arg Ile Glu Ala Ser Leu Lys  
 1345 1350 1355 1360

Leu Lys Leu Ser Thr Thr Phe Leu Ser Thr Ser Pro Asn Ile Ala Leu

- 23 -

1365	1370	1375
Leu Ala Gln Asn Leu Leu Asp Ala Leu Ala Thr Ala Leu Ser Leu Glu		
1380	1385	1390
Arg Val Ala Ala Glu Asn Leu Arg Ala Gly Val Gln Asn Asp Phe Val		
1395	1400	1405
Ser Ser Gly Ala Asp Gln Asp Trp Glu Ile Ile Ala Leu		
1410	1415	1420
<210> 3		
<211> 1410		
<212> PRT		
<213> Sorangium cellulosum		
<400> 3		
Met Thr Ile Asn Gln Leu Leu Asn Glu Leu Glu His Gln Gly Ile Lys		
1	5	10
15		
Leu Ala Ala Asp Gly Glu Arg Leu Gln Ile Gln Ala Pro Lys Asn Ala		
20	25	30
Leu Asn Pro Asn Leu Leu Ala Arg Ile Ser Glu His Lys Ser Thr Ile		
35	40	45
Leu Thr Met Leu Arg Gln Arg Leu Pro Ala Glu Ser Ile Val Pro Ala		
50	55	60
Pro Ala Glu Arg His Ala Pro Phe Pro Leu Thr Asp Ile Gln Glu Ser		
65	70	75
80		
Tyr Trp Leu Gly Arg Thr Gly Ala Phe Thr Val Pro Ser Gly Ile His		
85	90	95
Ala Tyr Arg Glu Tyr Asp Cys Thr Asp Leu Asp Val Pro Arg Leu Ser		
100	105	110
Arg Ala Phe Arg Lys Val Val Ala Arg His Asp Met Leu Arg Ala His		
115	120	125
Thr Leu Pro Asp Met Met Gln Val Ile Glu Pro Lys Val Asp Ala Asp		
130	135	140
Ile Glu Ile Ile Asp Leu Arg Gly Leu Asp Arg Ser Thr Arg Glu Ala		
145	150	155
160		
Arg Leu Val Ser Leu Arg Asp Ala Met Ser His Arg Ile Tyr Asp Thr		
165	170	175
Glu Arg Pro Pro Leu Tyr His Val Val Ala Val Arg Leu Asp Glu Arg		
180	185	190
Gln Thr Arg Leu Val Leu Ser Ile Asp Leu Ile Asn Val Asp Leu Gly		
195	200	205
Ser Leu Ser Ile Ile Phe Lys Asp Trp Leu Ser Phe Tyr Glu Asp Pro		
210	215	220
Glu Thr Ser Leu Pro Val Leu Glu Leu Ser Tyr Arg Asp Tyr Val Leu		
225	230	235
240		
Ala Leu Glu Ser Arg Lys Lys Ser Glu Ala His Gln Arg Ser Met Asp		
245	250	255

- 24 -

Tyr Trp Lys Arg Arg Ile Ala Glu Leu Pro Pro Pro Pro Thr Leu Pro  
 260 265 270  
 Met Lys Ala Asp Pro Ser Thr Leu Lys Glu Ile Arg Phe Arg His Thr  
 275 280 285  
 Glu Gln Trp Leu Pro Ser Asp Ser Trp Gly Arg Leu Lys Arg Arg Val  
 290 295 300  
 Gly Glu Arg Gly Leu Thr Pro Thr Gly Val Ile Leu Ala Ala Phe Ser  
 305 310 315 320  
 Glu Val Ile Gly Arg Trp Ser Ala Ser Pro Arg Phe Thr Leu Asn Ile  
 325 330 335  
 Thr Leu Phe Asn Arg Leu Pro Val His Pro Arg Val Asn Asp Ile Thr  
 340 345 350  
 Gly Asp Phe Thr Ser Met Val Leu Leu Asp Ile Asp Thr Thr Arg Asp  
 355 360 365  
 Lys Ser Phe Glu Gln Arg Ala Lys Arg Ile Gln Glu Gln Leu Trp Glu  
 370 375 380  
 Ala Met Asp His Cys Asp Val Ser Gly Ile Glu Val Gln Arg Glu Ala  
 385 390 395 400  
 Ala Arg Val Leu Gly Ile Gln Arg Gly Ala Leu Phe Pro Val Val Leu  
 405 410 415  
 Thr Ser Ala Leu Asn Gln Gln Val Val Gly Val Thr Ser Leu Gln Arg  
 420 425 430  
 Leu Gly Thr Pro Val Tyr Thr Ser Thr Gln Thr Pro Gln Leu Leu Leu  
 435 440 445  
 Asp His Gln Leu Tyr Glu His Asp Gly Asp Leu Val Leu Ala Trp Asp  
 450 455 460  
 Ile Val Asp Gly Val Phe Pro Pro Asp Leu Leu Asp Asp Met Leu Glu  
 465 470 475 480  
 Ala Tyr Val Val Phe Leu Arg Arg Leu Thr Glu Glu Pro Trp Gly Glu  
 485 490 495  
 Gln Val Arg Cys Ser Leu Pro Pro Ala Gln Leu Glu Ala Arg Ala Ser  
 500 505 510  
 Ala Asn Ala Thr Asn Ala Leu Leu Ser Glu His Thr Leu His Gly Leu  
 515 520 525  
 Phe Ala Ala Arg Val Glu Gln Leu Pro Met Gln Leu Ala Val Val Ser  
 530 535 540  
 Ala Arg Lys Thr Leu Thr Tyr Glu Glu Leu Ser Arg Arg Ser Arg Arg  
 545 550 555 560  
 Leu Gly Ala Arg Leu Arg Glu Gln Gly Ala Arg Pro Asn Thr Leu Val  
 565 570 575  
 Ala Val Val Met Glu Lys Gly Trp Glu Gln Val Val Ala Val Leu Ala  
 580 585 590  
 Val Leu Glu Ser Gly Ala Ala Tyr Val Pro Ile Asp Ala Asp Leu Pro

- 25 -

595	600	605
Ala Glu Arg Ile His Tyr Leu Leu Asp His Gly Glu Val Lys Leu Val		
610	615	620
Leu Thr Gln Pro Trp Leu Asp Gly Lys Leu Ser Trp Pro Pro Gly Ile		
625	630	635
Gln Arg Leu Leu Val Ser Glu Ala Gly Val Glu Gly Asp Gly Asp Gln		
645	650	655
Pro Pro Met Met Pro Ile Gln Thr Pro Ser Asp Leu Ala Tyr Val Ile		
660	665	670
Tyr Thr Ser Gly Ser Thr Gly Leu Pro Lys Gly Val Met Ile Asp His		
675	680	685
Arg Gly Ala Val Asn Thr Ile Leu Asp Ile Asn Glu Arg Phe Glu Ile		
690	695	700
Gly Pro Gly Asp Arg Val Leu Ala Leu Ser Ser Leu Ser Phe Asp Leu		
705	710	715
Ser Val Tyr Asp Val Phe Gly Ile Leu Ala Ala Gly Gly Thr Ile Val		
725	730	735
Val Pro Asp Ala Ser Lys Leu Arg Asp Pro Ala His Trp Ala Glu Leu		
740	745	750
Ile Glu Arg Glu Lys Val Thr Val Trp Asn Ser Val Pro Ala Leu Met		
755	760	765
Arg Met Leu Val Glu His Phe Glu Gly Arg Pro Asp Ser Leu Ala Arg		
770	775	780
Ser Leu Arg Leu Ser Leu Leu Ser Gly Asp Trp Ile Pro Val Gly Leu		
785	790	795
Pro Gly Glu Leu Gln Ala Ile Arg Pro Gly Val Ser Val Ile Ser Leu		
805	810	815
Gly Gly Ala Thr Glu Ala Ser Ile Trp Ser Ile Gly Tyr Pro Val Arg		
820	825	830
Asn Val Asp Leu Ser Trp Ala Ser Ile Pro Tyr Gly Arg Pro Leu Arg		
835	840	845
Asn Gln Thr Phe His Val Leu Asp Glu Ala Leu Glu Pro Arg Pro Val		
850	855	860
Trp Val Pro Gly Gln Leu Tyr Ile Gly Gly Val Gly Leu Ala Leu Gly		
865	870	875
Tyr Trp Arg Asp Glu Glu Lys Thr Arg Lys Ser Phe Leu Val His Pro		
885	890	895
Glu Thr Gly Glu Arg Leu Tyr Lys Thr Gly Asp Leu Gly Arg Tyr Leu		
900	905	910
Pro Asp Gly Asn Ile Glu Phe Met Gly Arg Glu Asp Asn Gln Ile Lys		
915	920	925
Leu Arg Gly Tyr Arg Val Glu Leu Gly Glu Ile Glu Glu Thr Leu Lys		
930	935	940

- 26 -

Ser His Pro Asn Val Arg Asp Ala Val Ile Val Pro Val Gly Asn Asp  
 945 950 955 960  
 Ala Ala Asn Lys Leu Leu Ala Tyr Val Val Pro Glu Gly Thr Arg  
 965 970 975  
 Arg Arg Ala Ala Glu Gln Asp Ala Ser Leu Lys Thr Glu Arg Ile Asp  
 980 985 990  
 Ala Arg Ala His Ala Ala Glu Ala Asp Gly Leu Ser Asp Gly Glu Arg  
 995 1000 1005  
 Val Gln Phe Lys Leu Ala Arg His Gly Leu Arg Arg Asp Leu Asp Gly  
 1010 1015 1020  
 Lys Pro Val Val Asp Leu Thr Gly Gln Asp Pro Arg Glu Ala Gly Leu  
 1025 1030 1035 1040  
 Asp Val Tyr Ala Arg Arg Ser Val Arg Thr Phe Leu Glu Ala Pro  
 1045 1050 1055  
 Ile Pro Phe Val Glu Phe Gly Arg Phe Leu Ser Cys Leu Ser Ser Val  
 1060 1065 1070  
 Glu Pro Asp Gly Ala Thr Leu Pro Lys Phe Arg Tyr Pro Ser Ala Gly  
 1075 1080 1085  
 Ser Thr Tyr Pro Val Gln Thr Tyr Ala Tyr Val Lys Ser Gly Arg Ile  
 1090 1095 1100  
 Glu Gly Val Asp Glu Gly Phe Tyr Tyr Tyr His Pro Phe Glu His Arg  
 1105 1110 1115 1120  
 Leu Leu Lys Leu Ser Asp His Gly Ile Glu Arg Gly Ala His Val Arg  
 1125 1130 1135  
 Gln Asn Phe Asp Val Phe Asp Glu Ala Ala Phe Asn Leu Leu Phe Val  
 1140 1145 1150  
 Gly Arg Ile Asp Ala Ile Glu Ser Leu Tyr Gly Ser Ser Arg Glu  
 1155 1160 1165  
 Phe Cys Leu Leu Glu Ala Gly Tyr Met Ala Gln Leu Leu Met Glu Gln  
 1170 1175 1180  
 Ala Pro Ser Cys Asn Ile Gly Val Cys Pro Val Gly Gln Phe Asn Phe  
 1185 1190 1195 1200  
 Glu Gln Val Arg Pro Val Leu Asp Leu Arg His Ser Asp Val Tyr Val  
 1205 1210 1215  
 His Gly Met Leu Gly Gly Arg Val Asp Pro Arg Gln Phe Gln Val Cys  
 1220 1225 1230  
 Thr Leu Gly Gln Asp Ser Ser Pro Arg Arg Ala Thr Thr Arg Gly Ala  
 1235 1240 1245  
 Pro Pro Gly Arg Glu Gln His Phe Ala Asp Met Leu Arg Asp Phe Leu  
 1250 1255 1260  
 Arg Thr Lys Leu Pro Glu Tyr Met Val Pro Thr Val Phe Val Glu Leu  
 1265 1270 1275 1280  
 Asp Ala Leu Pro Leu Thr Ser Asn Gly Lys Val Asp Arg Lys Ala Leu  
 1285 1290 1295

- 27 -

Arg Glu Arg Lys Asp Thr Ser Ser Pro Arg His Ser Gly His Thr Ala  
 1300 1305 1310  
 Pro Arg Asp Ala Leu Glu Glu Ile Leu Val Ala Val Val Arg Glu Val  
 1315 1320 1325  
 Leu Gly Leu Glu Val Val Gly Leu Gln Gln Ser Phe Val Asp Leu Gly  
 1330 1335 1340  
 Ala Thr Ser Ile His Ile Val Arg Met Arg Ser Leu Leu Gln Lys Arg  
 1345 1350 1355 1360  
 Leu Asp Arg Glu Ile Ala Ile Thr Glu Leu Phe Gln Tyr Pro Asn Leu  
 1365 1370 1375  
 Gly Ser Leu Ala Ser Gly Leu Arg Arg Asp Ser Arg Asp Leu Asp Gln  
 1380 1385 1390  
 Arg Pro Asn Met Gln Asp Arg Val Glu Val Arg Arg Lys Gly Arg Arg  
 1395 1400 1405  
 Arg Ser  
 1410  
  
 <210> 4  
 <211> 1832  
 <212> PRT  
 <213> Sorangium cellulosum  
  
 <400> 4  
 Met Glu Glu Gln Glu Ser Ser Ala Ile Ala Val Ile Gly Met Ser Gly  
 1 5 10 15  
 Arg Phe Pro Gly Ala Arg Asp Leu Asp Glu Phe Trp Arg Asn Leu Arg  
 20 25 30  
 Asp Gly Thr Glu Ala Val Gln Arg Phe Ser Glu Gln Glu Leu Ala Ala  
 35 40 45  
 Ser Gly Val Asp Pro Ala Leu Val Leu Asp Pro Ser Tyr Val Arg Ala  
 50 55 60  
 Gly Ser Val Leu Glu Asp Val Asp Arg Phe Asp Ala Ala Phe Phe Gly  
 65 70 75 80  
 Ile Ser Pro Arg Glu Ala Glu Leu Met Asp Pro Gln His Arg Ile Phe  
 85 90 95  
 Met Glu Cys Ala Trp Glu Ala Leu Glu Asn Ala Gly Tyr Asp Pro Thr  
 ... 100 105 110  
 Ala Tyr Glu Gly Ser Ile Gly Val Tyr Ala Gly Ala Asn Met Ser Ser  
 115 120 125  
 Tyr Leu Thr Ser Asn Leu His Glu His Pro Ala Met Met Arg Trp Pro  
 130 135 140  
 Gly Trp Phe Gln Thr Leu Ile Gly Asn Asp Lys Asp Tyr Leu Ala Thr  
 145 150 155 160  
 His Val Ser Tyr Arg Leu Asn Leu Arg Gly Pro Ser Ile Ser Val Gln  
 165 170 175

- 28 -

Thr Ala Cys Ser Thr Ser Leu Val Ala Val His Leu Ala Cys Met Ser  
 180 185 190  
 Leu Leu Asp Arg Glu Cys Asp Met Ala Leu Ala Gly Gly Ile Thr Val  
 195 200 205  
 Arg Ile Pro His Arg Ala Gly Tyr Val Tyr Ala Glu Gly Gly Ile Phe  
 210 215 220  
 Ser Pro Asp Gly His Cys Arg Ala Phe Asp Ala Lys Ala Asn Gly Thr  
 225 230 235 240  
 Ile Met Gly Asn Gly Cys Gly Val Val Leu Leu Lys Pro Leu Asp Arg  
 245 250 255  
 Ala Leu Ser Asp Gly Asp Pro Val Arg Ala Val Ile Leu Gly Ser Ala  
 260 265 270  
 Thr Asn Asn Asp Gly Ala Arg Lys Ile Gly Phe Thr Ala Pro Ser Glu  
 275 280 285  
 Val Gly Gln Ala Gln Ala Ile Met Glu Ala Leu Ala Leu Ala Gly Val  
 290 295 300  
 Glu Ala Arg Ser Ile Gln Tyr Ile Glu Thr His Gly Thr Gly Thr Leu  
 305 310 315 320  
 Leu Gly Asp Ala Ile Glu Thr Ala Ala Leu Arg Arg Val Phe Gly Arg  
 325 330 335  
 Asp Ala Ser Ala Arg Arg Ser Cys Ala Ile Gly Ser Val Lys Thr Gly  
 340 345 350  
 Ile Gly His Leu Glu Ser Ala Ala Gly Ile Ala Gly Leu Ile Lys Thr  
 355 360 365  
 Val Leu Ala Leu Glu His Arg Gln Leu Pro Pro Ser Leu Asn Phe Glu  
 370 375 380  
 Ser Pro Asn Pro Ser Ile Asp Phe Ala Ser Ser Pro Phe Tyr Val Asn  
 385 390 395 400  
 Thr Ser Leu Lys Asp Trp Asn Thr Gly Ser Thr Pro Arg Arg Ala Gly  
 405 410 415  
 Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala His Val Val Leu Glu  
 420 425 430  
 Glu Ala Pro Ala Ala Lys Leu Pro Ala Ala Ala Pro Ala Arg Ser Ala  
 435 440 445  
 Glu Leu Phe Val Val Ser Ala Lys Ser Ala Ala Ala Leu Asp Ala Ala  
 450 455 460  
 Ala Ala Arg Leu Arg Asp His Leu Gln Ala His Gln Gly Ile Ser Leu  
 465 470 475 480  
 Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Pro Met Glu His  
 485 490 495  
 Arg Leu Ala Met Ala Ala Pro Ser Arg Glu Ala Leu Arg Glu Gly Leu  
 500 505 510  
 Asp Ala Ala Ala Arg Gly Gln Thr Pro Pro Gly Ala Val Arg Gly Arg  
 515 520 525

- 29 -

Cys Ser Pro Gly Asn Val Pro Lys Val Val Phe Val Phe Pro Gly Gln  
530 535 540

Gly Ser Gln Trp Val Gly Met Gly Arg Gln Leu Leu Ala Glu Glu Pro  
545 550 555 560

Val Phe His Ala Ala Leu Ser Ala Cys Asp Arg Ala Ile Gln Ala Glu  
565 570 575

Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp Glu Gly Ser Ser  
580 585 590

Gln Leu Glu Arg Ile Asp Val Val Gln Pro Val Leu Phe Ala Leu Ala  
595 600 605

Val Ala Phe Ala Ala Leu Trp Arg Ser Trp Gly Val Ala Pro Asp Val  
610 615 620

Val Ile Gly His Ser Met Gly Glu Val Ala Ala Ala His Val Ala Gly  
625 630 635 640

Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys Arg Arg Ser Arg  
645 650 655

Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala Val Thr Glu Leu  
660 665 670

Ser Leu Ala Glu Ala Glu Ala Ala Leu Arg Gly Tyr Glu Asp Arg Val  
675 680 685

Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val Leu Ser Gly Glu  
690 695 700

Pro Ala Ala Ile Gly Glu Val Leu Ser Ser Leu Asn Ala Lys Gly Val  
705 710 715 720

Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His Ser Pro Gln Val  
725 730 735

Asp Pro Leu Arg Glu Asp Leu Leu Ala Ala Leu Gly Gly Leu Arg Pro  
740 745 750

Gly Ala Ala Ala Val Pro Met Arg Ser Thr Val Thr Gly Ala Met Val  
755 760 765

Ala Gly Pro Glu Leu Gly Ala Asn Tyr Trp Met Asn Asn Leu Arg Gln  
770 775 780

Pro Val Arg Phe Ala Glu Val Val Gln Ala Gln Leu Gln Gly His  
785 790 795 800

Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu Thr Thr Ser Val  
805 810 815

Glu Glu Met Arg Arg Ala Ala Gln Arg Ala Gly Ala Ala Val Gly Ser  
820 825 830

Leu Arg Arg Gly Gln Asp Glu Arg Pro Ala Met Leu Glu Ala Leu Gly  
835 840 845

Thr Leu Trp Ala Gln Gly Tyr Pro Val Pro Trp Gly Arg Leu Phe Pro  
850 855 860

Ala Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Glu

- 30 -

865	870	875	880
Arg Tyr Trp Ile Glu Ala Pro Ala Lys Ser Ala Ala Gly Asp Arg Arg			
885	890	895	
Gly Val Arg Ala Gly Gly His Pro Leu Leu Gly Glu Met Gln Thr Leu			
900	905	910	
Ser Thr Gln Thr Ser Thr Arg Leu Trp Glu Thr Thr Leu Asp Leu Lys			
915	920	925	
Arg Leu Pro Trp Leu Gly Asp His Arg Val Gln Gly Ala Val Val Phe			
930	935	940	
Pro Gly Ala Ala Tyr Leu Glu Met Ala Ile Ser Ser Gly Ala Glu Ala			
945	950	955	960
Leu Gly Asp Gly Pro Leu Gln Ile Thr Asp Val Val Leu Ala Glu Ala			
965	970	975	
Leu Ala Phe Ala Gly Asp Ala Ala Val Leu Val Gln Val Val Thr Thr			
980	985	990	
Glu Gln Pro Ser Gly Arg Leu Gln Phe Gln Ile Ala Ser Arg Ala Pro			
995	1000	1005	
Gly Ala Gly His Ala Ser Phe Arg Val His Ala Arg Gly Ala Leu Leu			
1010	1015	1020	
Arg Val Glu Arg Thr Glu Val Pro Ala Gly Leu Thr Leu Ser Ala Val			
1025	1030	1035	1040
Arg Ala Arg Leu Gln Ala Ser Ile Pro Ala Ala Ala Thr Tyr Ala Glu			
1045	1050	1055	
Leu Thr Glu Met Gly Leu Gln Tyr Gly Pro Ala Phe Gln Gly Ile Ala			
1060	1065	1070	
Glu Leu Trp Arg Gly Glu Gly Ala Leu Gly Arg Val Arg Leu Pro			
1075	1080	1085	
Asp Ala Ala Gly Ser Ala Ala Glu Tyr Arg Leu His Pro Ala Leu Leu			
1090	1095	1100	
Asp Ala Cys Phe Gln Ile Val Gly Ser Leu Phe Ala Arg Ser Gly Glu			
1105	1110	1115	1120
Ala Thr Pro Trp Val Pro Val Glu Leu Gly Ser Leu Arg Leu Leu Gln			
1125	1130	1135	
Arg Pro Ser Gly Glu Leu Trp Cys His Ala Arg Val Val Asn His Gly			
1140	1145	1150	
His Gln Thr Pro Asp Arg Gln Gly Ala Asp Phe Trp Val Val Asp Ser			
1155	1160	1165	
Ser Gly Ala Val Val Ala Glu Val Cys Gly Leu Val Ala Gln Arg Leu			
1170	1175	1180	
Pro Gly Gly Val Arg Arg Arg Glu Glu Asp Asp Trp Phe Leu Glu Leu			
1185	1190	1195	1200
Glu Trp Glu Pro Ala Ala Val Gly Thr Ala Lys Val Asn Ala Gly Arg			
1205	1210	1215	

- 31 -

Trp Leu Leu Leu Gly Gly Gly Gly Leu Gly Ala Ala Leu Arg Ala  
 1220 1225 1230  
 Met Leu Glu Ala Gly Gly His Ala Val Val His Ala Ala Glu Asn Asn  
 1235 1240 1245  
 Thr Ser Ala Ala Gly Val Arg Ala Leu Leu Ala Lys Ala Phe Asp Gly  
 1250 1255 1260  
 Gln Ala Pro Thr Ala Val Val His Leu Gly Ser Leu Asp Gly Gly  
 1265 1270 1275 1280  
 Glu Leu Asp Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala Pro Arg  
 1285 1290 1295  
 Ser Ala Asp Val Ser Pro Asp Ala Leu Asp Pro Ala Leu Val Arg Gly  
 1300 1305 1310  
 Cys Asp Ser Val Leu Trp Thr Val Gln Ala Leu Ala Gly Met Gly Phe  
 1315 1320 1325  
 Arg Asp Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln Ala Val  
 1330 1335 1340  
 Gly Ala Gly Asp Val Ser Val Thr Gln Ala Pro Leu Leu Gly Leu Gly  
 1345 1350 1355 1360  
 Arg Val Ile Ala Met Glu His Ala Asp Leu Arg Cys Ala Arg Val Asp  
 1365 1370 1375  
 Leu Asp Pro Ala Arg Pro Glu Gly Glu Leu Ala Ala Leu Leu Ala Glu  
 1380 1385 1390  
 Leu Leu Ala Asp Asp Ala Glu Ala Glu Val Ala Leu Arg Gly Gly Glu  
 1395 1400 1405  
 Arg Cys Val Ala Arg Ile Val Arg Arg Gln Pro Glu Thr Arg Pro Arg  
 1410 1415 1420  
 Gly Arg Ile Glu Ser Cys Val Pro Thr Asp Val Thr Ile Arg Ala Asp  
 1425 1430 1435 1440  
 Ser Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Ser Val  
 1445 1450 1455  
 Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly His Leu Val Leu Val Gly  
 1460 1465 1470  
 Arg Ser Gly Ala Ala Ser Val Glu Gln Arg Ala Ala Val Ala Ala Leu  
 1475 1480 1485  
 Glu Ala Arg Gly Ala Arg Val Thr Val Ala Lys Ala Asp Val Ala Asp  
 1490 1495 1500  
 Arg Ala Gln Leu Glu Arg Ile Leu Arg Glu Val Thr Thr Ser Gly Met  
 1505 1510 1515 1520  
 Pro Leu Arg Gly Val Val His Ala Ala Gly Ile Leu Asp Asp Gly Leu  
 1525 1530 1535  
 Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Lys Val Met Ala Pro Lys  
 1540 1545 1550  
 Val Gln Gly Ala Leu His Leu His Ala Leu Thr Arg Glu Ala Pro Leu  
 1555 1560 1565

- 32 -

Ser Phe Phe Val Leu Tyr Ala Ser Gly Val Gly Leu Leu Gly Ser Pro  
 1570 1575 1580  
 Gly Gln Gly Asn Tyr Ala Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala  
 1585 1590 1595 1600  
 His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Val Asp Trp Gly  
 1605 1610 1615  
 Leu Phe Ala Glu Val Gly Met Ala Ala Ala Gln Glu Asp Arg Gly Ala  
 1620 1625 1630  
 Arg Leu Val Ser Arg Gly Met Arg Ser Leu Thr Pro Asp Glu Gly Leu  
 1635 1640 1645  
 Ser Ala Leu Ala Arg Leu Leu Glu Ser Gly Arg Ala Gln Val Gly Val  
 1650 1655 1660  
 Met Pro Val Asn Pro Arg Leu Trp Val Glu Leu Tyr Pro Ala Ala Ala  
 1665 1670 1675 1680  
 Ser Ser Arg Met Leu Ser Arg Leu Val Thr Ala His Arg Ala Ser Ala  
 1685 1690 1695  
 Gly Gly Pro Ala Gly Asp Gly Asp Leu Leu Arg Arg Leu Ala Ala Ala  
 1700 1705 1710  
 Glu Pro Ser Ala Arg Ser Ala Leu Leu Glu Pro Leu Leu Arg Ala Gln  
 1715 1720 1725  
 Ile Ser Gln Val Leu Arg Leu Pro Glu Gly Lys Ile Glu Val Asp Ala  
 1730 1735 1740  
 Pro Leu Thr Ser Leu Gly Met Asn Ser Leu Met Gly Leu Glu Leu Arg  
 1745 1750 1755 1760  
 Asn Arg Ile Glu Ala Met Leu Gly Ile Thr Val Pro Ala Thr Leu Leu  
 1765 1770 1775  
 Trp Thr Tyr Pro Thr Val Ala Ala Leu Ser Gly His Leu Ala Arg Glu  
 1780 1785 1790  
 Ala Cys Glu Ala Ala Pro Val Glu Ser Pro His Thr Thr Ala Asp Ser  
 1795 1800 1805  
 Ala Val Glu Ile Glu Glu Met Ser Gln Asp Asp Leu Thr Gln Leu Ile  
 1810 1815 1820  
 Ala Ala Lys Phe Lys Ala Leu Thr  
 1825 1830  
 <210> 5  
 <211> 7257  
 <212> PPT  
 <213> Sorangium cellulosum  
 <400> 5  
 Met Thr Thr Arg Gly Pro Thr Ala Gln Gln Asn Pro Leu Lys Gln Ala  
 1 5 10 15  
 Ala Ile Ile Ile Gln Arg Leu Glu Glu Arg Leu Ala Gly Leu Ala Gln  
 20 25 30

- 33 -

Ala	Glu	Leu	Glu	Arg	Thr	Glu	Pro	Ile	Ala	Ile	Val	Gly	Ile	Gly	Cys	
35						40						45				
Arg	Phe	Pro	Gly	Gly	Ala	Asp	Ala	Pro	Glu	Ala	Phe	Trp	Glu	Leu	Leu	
50						55						60				
Asp	Ala	Glu	Arg	Asp	Ala	Val	Gln	Pro	Leu	Asp	Met	Arg	Trp	Ala	Leu	
65						70					75				80	
Val	Gly	Val	Ala	Pro	Val	Glu	Ala	Val	Pro	His	Trp	Ala	Gly	Leu	Leu	
						85				90				95		
Thr	Glu	Pro	Ile	Asp	Cys	Phe	Asp	Ala	Ala	Phe	Phe	Gly	Ile	Ser	Pro	
						100				105				110		
Arg	Glu	Ala	Arg	Ser	Leu	Asp	Pro	Gln	His	Arg	Leu	Leu	Glu	Val		
						115				120				125		
Ala	Trp	Glu	Gly	Leu	Glu	Asp	Ala	Gly	Ile	Pro	Pro	Arg	Ser	Ile	Asp	
						130				135				140		
Gly	Ser	Arg	Thr	Gly	Val	Phe	Val	Gly	Ala	Phe	Thr	Ala	Asp	Tyr	Ala	
						145				150				155		160
Arg	Thr	Val	Ala	Arg	Leu	Pro	Arg	Glu	Glu	Arg	Asp	Ala	Tyr	Ser	Ala	
						165				170				175		
Thr	Gly	Asn	Met	Leu	Ser	Ile	Ala	Ala	Gly	Arg	Leu	Ser	Tyr	Thr	Leu	
						180				185				190		
Gly	Leu	Gln	Gly	Pro	Cys	Leu	Thr	Val	Asp	Thr	Ala	Cys	Ser	Ser	Ser	
						195				200				205		
Leu	Val	Ala	Ile	His	Leu	Ala	Cys	Arg	Ser	Leu	Arg	Ala	Gly	Glu	Ser	
						210				215				220		
Asp	Leu	Ala	Leu	Ala	Gly	Gly	Val	Ser	Ala	Leu	Leu	Ser	Pro	Asp	Met	
						225				230				235		240
Met	Glu	Ala	Ala	Ala	Arg	Thr	Gln	Ala	Leu	Ser	Pro	Asp	Gly	Arg	Cys	
						245				250				255		
Arg	Thr	Phe	Asp	Ala	Ser	Ala	Asn	Gly	Phe	Val	Arg	Gly	Glu	Gly	Cys	
						260				265				270		
Gly	Leu	Val	Val	Leu	Lys	Arg	Leu	Ser	Asp	Ala	Gln	Arg	Asp	Gly	Asp	
						275				280				285		
Arg	Ile	Trp	Ala	Leu	Ile	Arg	Gly	Ser	Ala	Ile	Asn	His	Asp	Gly	Arg	
						290				295				300		
Ser	Thr	Gly	Leu	Thr	Ala	Pro	Asn	Val	Leu	Ala	Gln	Glu	Thr	Val	Leu	
						305				310				315		320
Arg	Glu	Ala	Leu	Arg	Ser	Ala	His	Val	Glu	Ala	Gly	Ala	Val	Asp	Tyr	
						325				330				335		
Val	Glu	Thr	His	Gly	Thr	Gly	Thr	Ser	Leu	Gly	Asp	Pro	Ile	Glu	Val	
						340				345				350		
Glu	Ala	Leu	Arg	Ala	Thr	Val	Gly	Pro	Ala	Arg	Ser	Asp	Gly	Thr	Arg	
						355				360				365		
Cys	Val	Leu	Gly	Ala	Val	Lys	Thr	Asn	Ile	Gly	His	Leu	Glu	Ala	Ala	
						370				375				380		

- 34 -

Ala Gly Val Ala Gly Leu Ile Lys Ala Ala Leu Ser Leu Thr His Glu  
 385 390 395 400  
 Arg Ile Pro Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg  
 405 410 415  
 Leu Glu Gly Ser Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro  
 420 425 430  
 Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser  
 435 440 445  
 Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Leu  
 450 455 460  
 Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu Leu Val Leu Ser Gly  
 465 470 475 480  
 Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Glu His  
 485 490 495  
 Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu  
 500 505 510  
 Ala Thr Thr Arg Ser Ala Met Ser His Arg Leu Ala Val Ala Val Thr  
 515 520 525  
 Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala Val Ala Gln Gly Gln  
 530 535 540  
 Thr Pro Ala Gly Ala Ala Arg Cys Ile Ala Ser Ser Ser Arg Gly Lys  
 545 550 555 560  
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Thr Pro Gly Met Gly  
 565 570 575  
 Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg  
 580 585 590  
 Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg Pro Leu Arg Glu Val  
 595 600 605  
 Met Trp Ala Glu Ala Gly Ser Ala Glu Ser Leu Leu Asp Gln Thr  
 610 615 620  
 Ala Phe Thr Gln Pro Ala Leu Phe Ala Val Glu Tyr Ala Leu Thr Ala  
 625 630 635 640  
 Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu Leu Val Gly His Ser  
 645 650 655  
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu  
 660 665 670  
 Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gly Leu  
 675 680 685  
 Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala Pro Glu Ala Glu Val  
 690 695 700  
 Ala Ala Ala Val Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val  
 705 710 715 720  
 Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val Glu Gln Ala Val Gln

- 35 -

725	730	735
Ala Ile Ala Ala Gly Phe Ala Ala Arg Gly Ala Arg Thr Lys Arg Leu		
740	745	750
His Val Ser His Ala Phe His Ser Pro Leu Met Glu Pro Met Leu Glu		
755	760	765
Glu Phe Gly Arg Val Ala Ala Ser Val Thr Tyr Arg Arg Pro Ser Val		
770	775	780
Ser Leu Val Ser Asn Leu Ser Gly Lys Val Val Thr Asp Glu Leu Ser		
785	790	795
Ala Pro Gly Tyr Trp Val Arg His Val Arg Glu Ala Val Arg Phe Ala		
805	810	815
Asp Gly Val Lys Ala Leu His Glu Ala Gly Ala Gly Thr Phe Val Glu		
820	825	830
Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Leu Pro Ala Cys Leu Pro		
835	840	845
Glu Ala Glu Pro Thr Leu Leu Ala Ser Leu Arg Ala Gly Arg Glu Glu		
850	855	860
Ala Ala Gly Val Leu Glu Ala Leu Gly Arg Leu Trp Ala Ala Gly Gly		
865	870	875
Ser Val Ser Trp Pro Gly Val Phe Pro Thr Ala Gly Arg Arg Val Pro		
885	890	895
Leu Pro Thr Tyr Pro Trp Gln Arg Gln Arg Tyr Trp Ile Glu Ala Pro		
900	905	910
Ala Glu Gly Leu Gly Ala Thr Ala Ala Asp Ala Leu Ala Gln Trp Phe		
915	920	925
Tyr Arg Val Asp Trp Pro Glu Met Pro Arg Ser Ser Val Asp Ser Arg		
930	935	940
Arg Ala Arg Ser Gly Gly Trp Leu Val Leu Ala Asp Arg Gly Gly Val		
945	950	955
Gly Glu Ala Ala Ala Ala Leu Ser Ser Gln Gly Cys Ser Cys Ala		
965	970	975
Val Leu His Ala Pro Ala Glu Ala Ser Ala Val Ala Glu Gln Val Thr		
980	985	990
Gln Ala Leu Gly Gly Arg Asn Asp Trp Gln Gly Val Leu Tyr Leu Trp		
995	1000	1005
Gly Leu Asp Ala Val Val Glu Ala Gly Ala Ser Ala Glu Glu Val Ala		
1010	1015	1020
Lys Val Thr His Leu Ala Ala Ala Pro Val Leu Ala Leu Ile Gln Ala		
1025	1030	1035
Leu Gly Thr Gly Pro Arg Ser Pro Arg Leu Trp Ile Val Thr Arg Gly		
1045	1050	1055
Ala Cys Thr Val Gly Gly Glu Pro Asp Ala Ala Pro Cys Gln Ala Ala		
1060	1065	1070

- 36 -

Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu His Pro Gly Ser Trp  
 1075 1080 1085  
 Gly Gly Leu Val Asp Leu Asp Pro Glu Glu Ser Pro Thr Glu Val Glu  
 1090 1095 1100  
 Ala Leu Val Ala Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala  
 1105 1110 1115 1120  
 Phe Arg Gln Gly Arg Arg Ala Ala Arg Leu Val Ala Ala Pro Pro  
 1125 1130 1135  
 Glu Gly Asn Ala Ala Pro Val Ser Leu Ser Ala Glu Gly Ser Tyr Leu  
 1140 1145 1150  
 Val Thr Gly Leu Gly Ala Leu Gly Leu Leu Val Ala Arg Trp Leu  
 1155 1160 1165  
 Val Glu Arg Gly Ala Gly His Leu Val Leu Ile Ser Arg His Gly Leu  
 1170 1175 1180  
 Pro Asp Arg Glu Glu Trp Gly Arg Asp Gln Pro Pro Glu Val Arg Ala  
 1185 1190 1195 1200  
 Arg Ile Ala Ala Ile Glu Ala Leu Glu Ala Gln Gly Ala Arg Val Thr  
 1205 1210 1215  
 Val Ala Ala Val Asp Val Ala Asp Ala Glu Gly Met Ala Ala Leu Leu  
 1220 1225 1230  
 Ala Ala Val Glu Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Leu  
 1235 1240 1245  
 Leu Asp Asp Gly Leu Leu Ala His Gln Asp Ala Gly Arg Leu Ala Arg  
 1250 1255 1260  
 Val Leu Arg Pro Lys Val Glu Gly Ala Trp Val Leu His Thr Leu Thr  
 1265 1270 1275 1280  
 Arg Glu Gln Pro Leu Asp Leu Phe Val Leu Phe Ser Ser Ala Ser Gly  
 1285 1290 1295  
 Val Phe Gly Ser Ile Gly Gln Gly Ser Tyr Ala Ala Gly Asn Ala Phe  
 1300 1305 1310  
 Leu Asp Ala Leu Ala Asp Leu Arg Arg Thr Gln Gly Leu Ala Ala Leu  
 1315 1320 1325  
 Ser Ile Ala Trp Gly Leu Trp Ala Glu Gly Gly Met Gly Ser Gln Ala  
 1330 1335 1340  
 Gln Arg Arg Glu His Glu Ala Ser Gly Ile Trp Ala Met Pro Thr Ser  
 1345 1350 1355 1360  
 Arg Ala Leu Ala Ala Met Glu Trp Leu Leu Gly Thr Arg Ala Thr Gln  
 1365 1370 1375  
 Arg Val Val Ile Gln Met Asp Trp Ala His Ala Gly Ala Ala Pro Arg  
 1380 1385 1390  
 Asp Ala Ser Arg Gly Arg Phe Trp Asp Arg Leu Val Thr Ala Thr Lys  
 1395 1400 1405  
 Glu Ala Ser Ser Ser Ala Val Pro Ala Val Glu Arg Trp Arg Asn Ala  
 1410 1415 1420

- 37 -

Ser Val Val Glu Thr Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Val  
 1425 1430 1435 1440  
 Val Ala Gly Val Met Gly Phe Thr Asp Gln Gly Thr Leu Asp Val Arg  
 1445 1450 1455  
 Arg Gly Phe Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile  
 1460 1465 1470  
 Arg Lys Arg Leu Gln Gly Glu Leu Gly Met Pro Leu Ser Ala Thr Leu  
 1475 1480 1485  
 Ala Phe Asp His Pro Thr Val Glu Arg Leu Val Glu Tyr Leu Leu Ser  
 1490 1495 1500  
 Gln Ala Leu Glu Leu Gln Asp Arg Thr Asp Val Arg Ser Val Arg Leu  
 1505 1510 1515 1520  
 Pro Ala Thr Glu Asp Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe  
 1525 1530 1535  
 Pro Gly Gly Val Glu Asp Leu Glu Ser Tyr Trp Gln Leu Leu Thr Glu  
 1540 1545 1550  
 Gly Val Val Val Ser Thr Glu Val Pro Ala Asp Arg Trp Asn Gly Ala  
 1555 1560 1565  
 Asp Gly Arg Val Pro Gly Ser Gly Glu Ala Gln Arg Gln Thr Tyr Val  
 1570 1575 1580  
 Pro Arg Gly Gly Phe Leu Arg Glu Val Glu Thr Phe Asp Ala Ala Phe  
 1585 1590 1595 1600  
 Phe His Ile Ser Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg  
 1605 1610 1615  
 Leu Leu Leu Glu Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp  
 1620 1625 1630  
 Pro Ser Ala Leu Arg Glu Ser Pro Thr Gly Val Phe Val Gly Ala Gly  
 1635 1640 1645  
 Pro Asn Glu Tyr Ala Glu Arg Val Gln Glu Leu Ala Asp Glu Ala Ala  
 1650 1655 1660  
 Gly Leu Tyr Ser Gly Thr Gly Asn Met Leu Ser Val Ala Ala Gly Arg  
 1665 1670 1675 1680  
 Leu Ser Phe Phe Leu Gly Leu His Gly Pro Thr Leu Ala Val Asp Thr  
 1685 1690 1695  
 Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Gly Cys Gln Ser Leu  
 1700 1705 1710  
 Arg Arg Gly Glu Cys Asp Gln Ala Leu Val Gly Val Asn Met Leu  
 1715 1720 1725  
 Leu Ser Pro Lys Thr Phe Ala Leu Leu Ser Arg Met His Ala Leu Ser  
 1730 1735 1740  
 Pro Gly Gly Arg Cys Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala  
 1745 1750 1755 1760  
 Arg Ala Glu Gly Cys Ala Val Val Leu Lys Arg Leu Ser Asp Ala

- 38 -

1765	1770	1775
Gln Arg Asp Arg Asp Pro Ile Leu Ala Val Ile Arg Gly Thr Ala Ile		
1780	1785	1790
Asn His Asp Gly Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala		
1795	1800	1805
Gln Glu Ala Leu Leu Arg Gln Ala Leu Ala His Ala Gly Val Val Pro		
1810	1815	1820
Ala Asp Val Asp Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly		
1825	1830	1835
Asp Pro Ile Glu Val Arg Ala Leu Ser Asp Val Tyr Gly Gln Ala Arg		
1845	1850	1855
Pro Ala Asp Arg Pro Leu Ile Leu Gly Ala Ala Lys Ala Asn Leu Gly		
1860	1865	1870
His Met Glu Pro Ala Ala Gly Leu Ala Gly Leu Leu Lys Ala Val Leu		
1875	1880	1885
Ala Leu Gly Gln Glu Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu		
1890	1895	1900
Asn Pro Leu Leu Pro Trp Glu Ala Leu Pro Val Ala Val Ala Arg Ala		
1905	1910	1915
Ala Val Pro Trp Pro Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser		
1925	1930	1935
Ser Phe Gly Met Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala		
1940	1945	1950
Pro Ala Val Glu Leu Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu		
1955	1960	1965
Leu Val Leu Ser Gly Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala		
1970	1975	1980
Arg Leu Arg Glu His Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp		
1985	1990	1995
Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Ala Met Asn His Arg Leu		
2005	2010	2015
Ala Val Ala Val Thr Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala		
2020	2025	2030
Val Ala Gln Gly Gln Thr Pro Pro Gly Ala Ala Arg Cys Ile Ala Ser		
2035	2040	2045
Ser Ser Arg Gly Lys Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln		
2050	2055	2060
Thr Pro Gly Met Gly Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg		
2065	2070	2075
Glu Ala Phe Asp Arg Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg		
2085	2090	2095
Pro Leu Arg Glu Val Met Trp Ala Glu Pro Gly Ser Ala Glu Ser Leu		
2100	2105	2110

- 39 -

Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu Phe Thr Val Glu  
 2115 2120 2125  
 Tyr Ala Leu Thr Ala Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu  
 2130 2135 2140  
 Val Ala Gly His Ser Ala Gly Glu Leu Val Ala Ala Cys Val Ala Gly  
 2145 2150 2155 2160  
 Val Phe Ser Leu Glu Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg  
 2165 2170 2175  
 Leu Met Gln Gly Leu Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala  
 2180 2185 2190  
 Pro Glu Ala Glu Val Ala Ala Val Ala Pro His Ala Ala Ser Val  
 2195 2200 2205  
 Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val  
 2210 2215 2220  
 Glu Gln Ala Val Gln Ala Ile Ala Ala Gly Phe Ala Ala Arg Gly Ala  
 2225 2230 2235 2240  
 Arg Thr Lys Arg Leu His Val Ser His Ala Ser His Ser Pro Leu Met  
 2245 2250 2255  
 Glu Pro Met Leu Glu Glu Phe Gly Arg Val Ala Ala Ser Val Thr Tyr  
 2260 2265 2270  
 Arg Arg Pro Ser Val Ser Leu Val Ser Asn Leu Ser Gly Lys Val Val  
 2275 2280 2285  
 Ala Asp Glu Leu Ser Ala Pro Gly Tyr Trp Val Arg His Val Arg Glu  
 2290 2295 2300  
 Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His Glu Ala Gly Ala  
 2305 2310 2315 2320  
 Gly Thr Phe Val Glu Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Leu  
 2325 2330 2335  
 Pro Ala Cys Leu Pro Glu Ala Glu Pro Thr Leu Leu Ala Ser Leu Arg  
 2340 2345 2350  
 Ala Gly Arg Glu Glu Ala Ala Gly Val Leu Glu Ala Leu Gly Arg Leu  
 2355 2360 2365  
 Trp Ala Ala Gly Gly Ser Val Ser Trp Pro Gly Val Phe Pro Thr Ala  
 2370 2375 2380  
 Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Gln Arg Tyr  
 2385 2390 2395 2400  
 Trp Pro Asp Ile Glu Pro Asp Ser Arg Arg His Ala Ala Ala Asp Pro  
 2405 2410 2415  
 Thr Gln Gly Trp Phe Tyr Arg Val Asp Trp Pro Glu Ile Pro Arg Ser  
 2420 2425 2430  
 Leu Gln Lys Ser Glu Glu Ala Ser Arg Gly Ser Trp Leu Val Leu Ala  
 2435 2440 2445  
 Asp Lys Gly Gly Val Gly Glu Ala Val Ala Ala Leu Ser Thr Arg  
 2450 2455 2460

- 40 -

Gly Leu Pro Cys Val Val Leu His Ala Pro Ala Glu Thr Ser Ala Thr  
 2465 2470 2475 2480  
 Ala Glu Leu Val Thr Glu Ala Ala Gly Gly Arg Ser Asp Trp Gln Val  
 2485 2490 2495  
 Val Leu Tyr Leu Trp Gly Leu Asp Ala Val Val Gly Ala Glu Ala Ser  
 2500 2505 2510  
 Ile Asp Glu Ile Gly Asp Ala Thr Arg Arg Ala Thr Ala Pro Val Leu  
 2515 2520 2525  
 Gly Leu Ala Arg Phe Leu Ser Thr Val Ser Cys Ser Pro Arg Leu Trp  
 2530 2535 2540  
 Val Val Thr Arg Gly Ala Cys Ile Val Gly Asp Glu Pro Ala Ile Ala  
 2545 2550 2555 2560  
 Pro Cys Gln Ala Ala Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu  
 2565 2570 2575  
 His Pro Gly Ala Trp Gly Gly Leu Val Asp Leu Asp Pro Arg Ala Ser  
 2580 2585 2590  
 Pro Pro Gln Ala Ser Pro Ile Asp Gly Glu Met Leu Val Thr Glu Leu  
 2595 2600 2605  
 Leu Ser Gln Glu Thr Glu Asp Gln Leu Ala Phe Arg His Gly Arg Arg  
 2610 2615 2620  
 His Ala Ala Arg Leu Val Ala Ala Pro Pro Gln Gly Gln Ala Ala Pro  
 2625 2630 2635 2640  
 Val Ser Leu Ser Ala Glu Ala Ser Tyr Leu Val Thr Gly Gly Leu Gly  
 2645 2650 2655  
 Gly Leu Gly Leu Ile Val Ala Gln Trp Leu Val Glu Leu Gly Ala Arg  
 2660 2665 2670  
 His Leu Val Leu Thr Ser Arg Arg Gly Leu Pro Asp Arg Gln Ala Trp  
 2675 2680 2685  
 Cys Glu Gln Gln Pro Pro Glu Ile Arg Ala Arg Ile Ala Ala Val Glu  
 2690 2695 2700  
 Ala Leu Glu Ala Arg Gly Ala Arg Val Thr Val Ala Ala Val Asp Val  
 2705 2710 2715 2720  
 Ala Asp Val Glu Pro Met Thr Ala Leu Val Ser Ser Val Glu Pro Pro  
 2725 2730 2735  
 Leu Arg Gly Val Val His Ala Ala Gly Val Ser Val Met Arg Pro Leu  
 2740 2745 2750  
 Ala Glu Thr Asp Glu Thr Leu Leu Glu Ser Val Leu Arg Pro Lys Val  
 2755 2760 2765  
 Ala Gly Ser Trp Leu Leu His Arg Leu Leu His Gly Arg Pro Leu Asp  
 2770 2775 2780  
 Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Ser His Ser  
 2785 2790 2795 2800  
 Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu Ala His

- 41 -

2805	2810	2815
Leu Arg Arg Ser Gln Ser Leu Pro Ala Leu Ser Val Ala Trp Gly Leu		
2820	2825	2830
Trp Ala Glu Gly Gly Met Ala Asp Ala Glu Ala His Ala Arg Leu Ser		
2835	2840	2845
Asp Ile Gly Val Leu Pro Met Ser Thr Ser Ala Ala Leu Ser Ala Leu		
2850	2855	2860
Gln Arg Leu Val Glu Thr Gly Ala Ala Gln Arg Thr Val Thr Arg Met		
2865	2870	2875
Asp Trp Ala Arg Phe Ala Pro Val Tyr Thr Ala Arg Gly Arg Arg Asn		
2885	2890	2895
Leu Leu Ser Ala Leu Val Ala Gly Arg Asp Ile Ile Ala Pro Ser Pro		
2900	2905	2910
Pro Ala Ala Ala Thr Arg Asn Trp Arg Gly Leu Ser Val Ala Glu Ala		
2915	2920	2925
Arg Val Ala Leu His Glu Ile Val His Gly Ala Val Ala Arg Val Leu		
2930	2935	2940
Gly Phe Leu Asp Pro Ser Ala Leu Asp Pro Gly Met Gly Phe Asn Glu		
2945	2950	2955
Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile Arg Asn Leu Leu Gln		
2965	2970	2975
Ala Glu Leu Asp Val Arg Leu Ser Thr Thr Leu Ala Phe Asp His Pro		
2980	2985	2990
Thr Val Gln Arg Leu Val Glu His Leu Leu Val Asp Val Leu Lys Leu		
2995	3000	3005
Glu Asp Arg Ser Asp Thr Gln His Val Arg Ser Leu Ala Ser Asp Glu		
3010	3015	3020
Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly Val Glu		
3025	3030	3035
Asp Leu Glu Ser Tyr Trp Gln Leu Leu Ala Glu Gly Val Val Ser		
3045	3050	3055
Ala Glu Val Pro Ala Asp Arg Trp Asp Ala Ala Asp Trp Tyr Asp Pro		
3060	3065	3070
Asp Pro Glu Ile Pro Gly Arg Thr Tyr Val Thr Lys Gly Ala Phe Leu		
3075	3080	3085
Arg Asp Leu Gln Arg Leu Asp Ala Thr Phe Phe Arg Ile Ser Pro Arg		
3090	3095	3100
Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu Val Ser		
3105	3110	3115
Trp Glu Ala Leu Glu Ser Ala Gly Ile Ala Pro Asp Thr Leu Arg Asp		
3125	3130	3135
Ser Pro Thr Gly Val Phe Val Gly Ala Gly Pro Asn Glu Tyr Tyr Thr		
3140	3145	3150

- 42 -

Gln Arg Leu Arg Gly Phe Thr Asp Gly Ala Ala Gly Leu Tyr Gly Gly  
3155 3160 3165

Thr Gly Asn Met Leu Ser Val Thr Ala Gly Arg Leu Ser Phe Phe Leu  
3170 3175 3180

Gly Leu His Gly Pro Thr Leu Ala Met Asp Thr Ala Cys Ser Ser Ser  
3185 3190 3195 3200

Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu Cys  
3205 3210 3215

Asp Gln Ala Leu Val Gly Gly Val Asn Val Leu Leu Ala Pro Glu Thr  
3220 3225 3230

Phe Val Leu Leu Ser Arg Met Arg Ala Leu Ser Pro Asp Gly Arg Cys  
3235 3240 3245

Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala Arg Gly Glu Gly Cys  
3250 3255 3260

Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Ala Gly Asp  
3265 3270 3275 3280

Ser Ile Leu Ala Leu Ile Arg Gly Ser Ala Val Asn His Asp Gly Pro  
3285 3290 3295

Ser Ser Gly Leu Thr Val Pro Asn Gly Pro Ala Gln Gln Ala Leu Leu  
3300 3305 3310

Arg Gln Ala Leu Ser Gln Ala Gly Val Ser Pro Val Asp Val Asp Phe  
3315 3320 3325

Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val  
3330 3335 3340

Gln Ala Leu Ser Glu Val Tyr Gly Pro Gly Arg Ser Gly Asp Arg Pro  
3345 3350 3355 3360

Leu Val Leu Gly Ala Ala Lys Ala Asn Val Ala His Leu Glu Ala Ala  
3365 3370 3375

Ser Gly Leu Ala Ser Leu Leu Lys Ala Val Leu Ala Leu Arg His Glu  
3380 3385 3390

Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu Asn Pro His Leu Pro  
3395 3400 3405

Trp Asn Thr Leu Pro Val Ala Val Pro Arg Lys Ala Val Pro Trp Gly  
3410 3415 3420

Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu Ser  
3425 3430 3435 3440

Gly Thr Asn Val His Val Val Leu Glu Glu Ala Pro Glu Val Glu Pro  
3445 3450 3455

Ala Pro Ala Ala Pro Ala Arg Pro Val Glu Leu Val Val Leu Ser Ala  
3460 3465 3470

Lys Ser Ala Ala Ala Leu Asp Ala Ala Ala Arg Leu Ser Ala His  
3475 3480 3485

Leu Ser Ala His Pro Glu Leu Ser Leu Gly Asp Val Ala Phe Ser Leu  
3490 3495 3500

- 43 -

Ala Thr Thr Arg Ser Pro Met Glu His Arg Leu Ala Ile Ala Thr Thr  
 3505 3510 3515 3520  
 Ser Arg Glu Ala Leu Arg Gly Ala Leu Asp Ala Ala Ala Gln Gln Lys  
 3525 3530 3535  
 Thr Pro Gln Gly Ala Val Arg Gly Lys Ala Val Ser Ser Arg Gly Lys  
 3540 3545 3550  
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Met Pro Gly Met Gly  
 3555 3560 3565  
 Arg Gly Leu Tyr Glu Thr Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg  
 3570 3575 3580  
 Cys Val Ala Leu Phe Asp Arg Glu Ile Asp Gln Pro Leu Arg Glu Val  
 3585 3590 3595 3600  
 Met Trp Ala Ala Pro Gly Leu Ala Gln Ala Ala Arg Leu Asp Gln Thr  
 3605 3610 3615  
 Ala Tyr Ala Gln Pro Ala Leu Phe Ala Leu Glu Tyr Ala Leu Ala Ala  
 3620 3625 3630  
 Leu Trp Arg Ser Trp Gly Val Glu Pro His Val Leu Leu Gly His Ser  
 3635 3640 3645  
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu  
 3650 3655 3660  
 Asp Ala Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu  
 3665 3670 3675 3680  
 Pro Ala Gly Gly Ala Met Val Ala Ile Ala Ala Ser Glu Ala Glu Val  
 3685 3690 3695  
 Ala Ala Ser Val Ala Pro His Ala Ala Thr Val Ser Ile Ala Ala Val  
 3700 3705 3710  
 Asn Gly Pro Asp Ala Val Val Ile Ala Gly Ala Glu Val Gln Val Leu  
 3715 3720 3725  
 Ala Leu Gly Ala Thr Phe Ala Ala Arg Gly Ile Arg Thr Lys Arg Leu  
 3730 3735 3740  
 Ala Val Ser His Ala Phe His Ser Pro Leu Met Asp Pro Met Leu Glu  
 3745 3750 3755 3760  
 Asp Phe Gln Arg Val Ala Ala Thr Ile Ala Tyr Arg Ala Pro Asp Arg  
 3765 3770 3775  
 Pro Val Val Ser Asn Val Thr Gly His Val Ala Gly Pro Glu Ile Ala  
 3780 3785 3790  
 Thr Pro Glu Tyr Trp Val Arg His Val Arg Ser Ala Val Arg Phe Gly  
 3795 3800 3805  
 Asp Gly Ala Lys Ala Leu His Ala Ala Gly Ala Ala Thr Phe Val Glu  
 3810 3815 3820  
 Val Gly Pro Lys Pro Val Leu Leu Gly Leu Leu Pro Ala Cys Leu Gly  
 3825 3830 3835 3840  
 Glu Ala Asp Ala Val Leu Val Pro Ser Leu Arg Ala Asp Arg Ser Glu

- 44 -

3845	3850	3855
Cys Glu Val Val Leu Ala Ala Leu Gly Ala Trp Tyr Ala Trp Gly Gly 3860	3865	3870
Ala Leu Asp Trp Lys Gly Val Phe Pro Asp Gly Ala Arg Arg Val Ala 3875	3880	3885
Leu Pro Met Tyr Pro Trp Gln Arg Glu Arg His Trp Met Asp Leu Thr 3890	3895	3900
Pro Arg Ser Ala Ala Pro Ala Gly Ile Ala Gly Arg Trp Pro Leu Ala 3905	3910	3915
Gly Val Gly Leu Cys Met Pro Gly Ala Val Leu His His Val Leu Ser 3925	3930	3935
Ile Gly Pro Arg His Gln Pro Phe Leu Gly Asp His Leu Val Phe Gly 3940	3945	3950
Lys Val Val Val Pro Gly Ala Phe His Val Ala Val Ile Leu Ser Ile 3955	3960	3965
Ala Ala Glu Arg Trp Pro Glu Arg Ala Ile Glu Leu Thr Gly Val Glu 3970	3975	3980
Phe Leu Lys Ala Ile Ala Met Glu Pro Asp Gln Glu Val Glu Leu His 3985	3990	3995
Ala Val Leu Thr Pro Glu Ala Ala Gly Asp Gly Tyr Leu Phe Glu Leu 4005	4010	4015
Ala Thr Leu Ala Ala Pro Glu Thr Glu Arg Arg Trp Thr Thr His Ala 4020	4025	4030
Arg Gly Arg Val Gln Pro Thr Asp Gly Ala Pro Gly Ala Leu Pro Arg 4035	4040	4045
Leu Glu Val Leu Glu Asp Arg Ala Ile Gln Pro Leu Asp Phe Ala Gly 4050	4055	4060
Phe Leu Asp Arg Leu Ser Ala Val Arg Ile Gly Trp Gly Pro Leu Trp 4065	4070	4075
Arg Trp Leu Gln Asp Gly Arg Val Gly Asp Glu Ala Ser Leu Ala Thr 4085	4090	4095
Leu Val Pro Thr Tyr Pro Asn Ala His Asp Val Ala Pro Leu His Pro 4100	4105	4110
Ile Leu Leu Asp Asn Gly Phe Ala Val Ser Leu Leu Ser Thr Arg Ser 4115	4120	4125
Glu Pro Glu Asp Asp Gly Thr Pro Pro Leu Pro Phe Ala Val Glu Arg 4130	4135	4140
Val Arg Trp Trp Arg Ala Pro Val Gly Arg Val Arg Cys Gly Gly Val 4145	4150	4155
Pro Arg Ser Gln Ala Phe Gly Val Ser Ser Phe Val Leu Val Asp Glu 4165	4170	4175
Thr Gly Glu Val Val Ala Glu Val Glu Gly Phe Val Cys Arg Arg Ala 4180	4185	4190

- 45 -

Pro Arg Glu Val Phe Leu Arg Gln Glu Ser Gly Ala Ser Thr Ala Ala  
4195 4200 4205

Leu Tyr Arg Leu Asp Trp Pro Glu Ala Pro Leu Pro Asp Ala Pro Ala  
4210 4215 4220

Glu Arg Ile Glu Glu Ser Trp Val Val Val Ala Ala Pro Gly Ser Glu  
4225 4230 4235 4240

Met Ala Ala Ala Leu Ala Thr Arg Leu Asn Arg Cys Val Leu Ala Glu  
4245 4250 4255

Pro Lys Gly Leu Glu Ala Ala Leu Ala Gly Val Ser Pro Ala Gly Val  
4260 4265 4270

Ile Cys Leu Trp Glu Ala Gly Ala His Glu Glu Ala Pro Ala Ala  
4275 4280 4285

Gln Arg Val Ala Thr Glu Gly Leu Ser Val Val Gln Ala Leu Arg Asp  
4290 4295 4300

Arg Ala Val Arg Leu Trp Trp Val Thr Met Gly Ala Val Ala Val Glu  
4305 4310 4315 4320

Ala Gly Glu Arg Val Gln Val Ala Thr Ala Pro Val Trp Gly Leu Gly  
4325 4330 4335

Arg Thr Val Met Gln Glu Arg Pro Glu Leu Ser Cys Thr Leu Val Asp  
4340 4345 4350

Leu Glu Pro Glu Ala Asp Ala Ala Arg Ser Ala Asp Val Leu Leu Arg  
4355 4360 4365

Glu Leu Gly Arg Ala Asp Asp Glu Thr Gln Val Ala Phe Arg Ser Gly  
4370 4375 4380

Lys Arg Arg Val Ala Arg Leu Val Lys Ala Thr Thr Pro Glu Gly Leu  
4385 4390 4395 4400

Leu Val Pro Asp Ala Glu Ser Tyr Arg Leu Glu Ala Gly Gln Lys Gly  
4405 4410 4415

Thr Leu Asp Gln Leu Arg Leu Ala Pro Ala Gln Arg Arg Ala Pro Gly  
4420 4425 4430

Pro Gly Glu Val Glu Ile Lys Val Thr Ala Ser Gly Leu Asn Phe Arg  
4435 4440 4445

Thr Val Leu Ala Val Leu Gly Met Tyr Pro Gly Asp Ala Gly Pro Met  
4450 4455 4460

Gly Gly Asp Cys Ala Gly Val Ala Thr Ala Val Gly Gln Gly Val Arg  
4465 4470 4475 4480

His Val Ala Val Gly Asp Ala Val Met Thr Leu Gly Thr Leu His Arg  
4485 4490 4495

Phe Val Thr Val Asp Ala Arg Leu Val Val Arg Gln Pro Ala Gly Leu  
4500 4505 4510

Thr Pro Ala Gln Ala Ala Thr Val Pro Val Ala Phe Leu Thr Ala Trp  
4515 4520 4525

Leu Ala Leu His Asp Leu Gly Asn Leu Arg Arg Gly Glu Arg Val Leu  
4530 4535 4540

- 46 -

Ile His Ala Ala Ala Gly Gly Val Gly Met Ala Ala Val Gln Ile Ala  
4545 4550 4555 4560  
Arg Trp Ile Gly Ala Glu Val Phe Ala Thr Ala Ser Pro Ser Lys Trp  
4565 4570 4575  
Ala Ala Val Gln Ala Met Gly Val Pro Arg Thr His Ile Ala Ser Ser  
4580 4585 4590  
Arg Thr Leu Glu Phe Ala Glu Thr Phe Arg Gln Val Thr Gly Gly Arg  
4595 4600 4605  
Gly Val Asp Val Val Leu Asn Ala Leu Ala Gly Glu Phe Val Asp Ala  
4610 4615 4620  
Ser Leu Ser Leu Leu Ser Thr Gly Gly Arg Phe Leu Glu Met Gly Lys  
4625 4630 4635 4640  
Thr Asp Ile Arg Asp Arg Ala Ala Val Ala Ala Ala His Pro Gly Val  
4645 4650 4655  
Arg Tyr Arg Val Phe Asp Ile Leu Glu Leu Ala Pro Asp Arg Thr Arg  
4660 4665 4670  
Glu Ile Leu Glu Arg Val Val Glu Gly Phe Ala Ala Gly His Leu Arg  
4675 4680 4685  
Ala Leu Pro Val His Ala Phe Ala Ile Thr Lys Ala Glu Ala Ala Phe  
4690 4695 4700  
Arg Phe Met Ala Gln Ala Arg His Gln Gly Lys Val Val Leu Leu Pro  
4705 4710 4715 4720  
Ala Pro Ser Ala Ala Pro Leu Ala Pro Thr Gly Thr Val Leu Leu Thr  
4725 4730 4735  
Gly Gly Leu Gly Ala Leu Gly Leu His Val Ala Arg Trp Leu Ala Gln  
4740 4745 4750  
Gln Gly Val Pro His Met Val Leu Thr Gly Arg Arg Gly Leu Asp Thr  
4755 4760 4765  
Pro Gly Ala Ala Lys Ala Val Ala Glu Ile Glu Ala Leu Gly Ala Arg  
4770 4775 4780  
Val Thr Ile Ala Ala Ser Asp Val Ala Asp Arg Asn Ala Leu Glu Ala  
4785 4790 4795 4800  
Val Leu Gln Ala Ile Pro Ala Glu Trp Pro Leu Gln Gly Val Ile His  
4805 4810 4815  
Ala Ala Gly Ala Leu Asp Asp Gly Val Leu Asp Glu Gln Thr Thr Asp  
4820 4825 4830  
Arg Phe Ser Arg Val Leu Ala Pro Lys Val Thr Gly Ala Trp Asn Leu  
4835 4840 4845  
His Glu Leu Thr Ala Gly Asn Asp Leu Ala Phe Phe Val Leu Phe Ser  
4850 4855 4860  
Ser Met Ser Gly Leu Leu Gly Ser Ala Gly Gln Ser Asn Tyr Ala Ala  
4865 4870 4875 4880  
Ala Asn Thr Phe Leu Asp Ala Leu Ala Ala His Arg Arg Ala Glu Gly

- 47 -

4885	4890	4895
Leu Ala Ala Gln Ser Leu Ala Trp Gly Pro Trp Ser Asp Gly Gly Met 4900	4905	4910
Ala Ala Gly Leu Ser Ala Ala Leu Gln Ala Arg Leu Ala Arg His Gly 4915	4920	4925
Met Gly Ala Leu Ser Pro Ala Gln Gly Thr Ala Leu Leu Gly Gln Ala 4930	4935	4940
Leu Ala Arg Pro Glu Thr Gln Leu Gly Ala Met Ser Leu Asp Val Arg 4945	4950	4955
Ala Ala Ser Gln Ala Ser Gly Ala Ala Val Pro Pro Val Trp Arg Ala 4965	4970	4975
Leu Val Arg Ala Glu Ala Arg His Thr Ala Ala Gly Ala Gln Gly Ala 4980	4985	4990
Leu Ala Ala Arg Leu Gly Ala Leu Pro Glu Ala Arg Arg Ala Asp Glu 4995	5000	5005
Val Arg Lys Val Val Gln Ala Glu Ile Ala Arg Val Leu Ser Trp Ser 5010	5015	5020
Ala Ala Ser Ala Val Pro Val Asp Arg Pro Leu Ser Asp Leu Gly Leu 5025	5030	5035
Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Val Leu Gly Gln Arg Val 5045	5050	5055
Gly Ala Thr Leu Pro Ala Thr Leu Ala Phe Asp His Pro Thr Val Asp 5060	5065	5070
Ala Leu Thr Arg Trp Leu Leu Asp Lys Val Leu Ala Val Ala Glu Pro 5075	5080	5085
Ser Val Ser Ser Ala Lys Ser Ser Pro Gln Val Ala Leu Asp Glu Pro 5090	5095	5100
Ile Ala Ile Ile Gly Ile Gly Cys Arg Phe Pro Gly Gly Val Ala Asp 5105	5110	5115
Pro Glu Ser Phe Trp Arg Leu Leu Glu Glu Gly Ser Asp Ala Val Val 5125	5130	5135
Glu Val Pro His Glu Arg Trp Asp Ile Asp Ala Phe Tyr Asp Pro Asp 5140	5145	5150
Pro Asp Val Arg Gly Lys Met Thr Thr Arg Phe Gly Gly Phe Leu Ser 5155	5160	5165
Asp Ile Asp Arg Phe Asp Pro Ala Phe Phe Gly Ile Ser Pro Arg Glu 5170	5175	5180
Ala Thr Thr Met Asp Pro Gln Gln Arg Leu Leu Leu Glu Thr Ser Trp 5185	5190	5195
Glu Ala Phe Glu Arg Ala Gly Ile Leu Pro Glu Arg Leu Met Gly Ser 5205	5210	5215
Asp Thr Gly Val Phe Val Gly Leu Phe Tyr Gln Glu Tyr Ala Ala Leu 5220	5225	5230

- 48 -

Ala Gly Gly Ile Glu Ala Phe Asp Gly Tyr Leu Gly Thr Gly Thr Thr  
5235 5240 5245

Ala Ser Val Ala Ser Gly Arg Ile Ser Tyr Val Leu Gly Leu Lys Gly  
5250 5255 5260

Pro Ser Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Val  
5265 5270 5275 5280

His Leu Ala Cys Gln Ala Leu Arg Arg Gly Glu Cys Ser Val Ala Leu  
5285 5290 5295

Ala Gly Gly Val Ala Leu Met Leu Thr Pro Ala Thr Phe Val Glu Phe  
5300 5305 5310

Ser Arg Leu Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ser Phe Ser  
5315 5320 5325

Ala Ala Ala Asp Gly Val Gly Trp Ser Glu Gly Cys Ala Met Leu Leu  
5330 5335 5340

Leu Lys Pro Leu Arg Asp Ala Gln Arg Asp Gly Asp Pro Ile Leu Ala  
5345 5350 5355 5360

Val Ile Arg Gly Thr Ala Val Asn Gln Asp Gly Arg Ser Asn Gly Leu  
5365 5370 5375

Thr Ala Pro Asn Gly Ser Ser Gln Gln Glu Val Ile Arg Arg Ala Leu  
5380 5385 5390

Glu Gln Ala Gly Leu Ala Pro Ala Asp Val Ser Tyr Val Glu Cys His  
5395 5400 5405

Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Gly  
5410 5415 5420

Ala Val Leu Ala Gln Gly Arg Pro Ser Asp Arg Pro Leu Val Ile Gly  
5425 5430 5435 5440

Ser Val Lys Ser Asn Ile Gly His Thr Gln Ala Ala Ala Gly Val Ala  
5445 5450 5455

Gly Val Ile Lys Val Ala Leu Ala Leu Glu Arg Gly Leu Ile Pro Arg  
5460 5465 5470

Ser Leu His Phe Asp Ala Pro Asn Pro His Ile Pro Trp Ser Glu Leu  
5475 5480 5485

Ala Val Gln Val Ala Ala Lys Pro Val Glu Trp Thr Arg Asn Gly Val  
5490 5495 5500

Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala  
5505 5510 5515 5520

His Val Val Leu Glu Glu Ala Pro Ala Ala Phe Ala Pro Ala Ala  
5525 5530 5535

Ala Arg Ser Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala Ala Ala  
5540 5545 5550

Leu Asp Ala Gln Ala Ala Arg Leu Ser Ala His Val Val Ala His Pro  
5555 5560 5565

Glu Leu Gly Leu Gly Asp Leu Ala Phe Ser Leu Ala Thr Thr Arg Ser  
5570 5575 5580

- 49 -

Pro Met Thr Tyr Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Ala Leu  
 5585 5590 5595 5600  
 Ser Ala Ala Leu Asp Thr Ala Ala Gln Gly Gln Ala Pro Pro Ala Ala  
 5605 5610 5615  
 Ala Arg Gly His Ala Ser Thr Gly Ser Ala Pro Lys Val Val Phe Val  
 5620 5625 5630  
 Phe Pro Gly Gln Gly Ser Gln Trp Leu Gly Met Gly Gln Lys Leu Leu  
 5635 5640 5645  
 Ser Glu Glu Pro Val Phe Arg Asp Ala Leu Ser Ala Cys Asp Arg Ala  
 5650 5655 5660  
 Ile Gln Ala Glu Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp  
 5665 5670 5675 5680  
 Glu Thr Thr Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro Ala Leu  
 5685 5690 5695  
 Phe Ala Ile Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp Gly Val  
 5700 5705 5710  
 Glu Pro Asp Ala Val Val Gly His Ser Met Gly Glu Val Ala Ala Ala  
 5715 5720 5725  
 His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys  
 5730 5735 5740  
 Arg Arg Ser Leu Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala  
 5745 5750 5755 5760  
 Val Val Glu Leu Ser Leu Ala Glu Ala Glu Ala Ala Leu Leu Gly Tyr  
 5765 5770 5775  
 Glu Asp Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val  
 5780 5785 5790  
 Leu Ala Gly Glu Pro Ala Ala Leu Ala Glu Val Leu Ala Ile Leu Ala  
 5795 5800 5805  
 Ala Lys Gly Val Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His  
 5810 5815 5820  
 Ser Pro Gln Ile Asp Pro Leu Arg Asp Glu Leu Leu Ala Ala Leu Gly  
 5825 5830 5835 5840  
 Glu Leu Glu Pro Arg Gln Ala Thr Val Ser Met Arg Ser Thr Val Thr  
 5845 5850 5855  
 Ser Thr Ile Met Ala Gly Pro Glu Leu Val Ala Ser Tyr Trp Ala Asp  
 5860 5865 5870  
 Asn Val Arg Gln Pro Val Arg Phe Ala Glu Ala Val Gln Ser Leu Met  
 5875 5880 5885  
 Glu Asp Gly His Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu  
 5890 5895 5900  
 Thr Thr Ser Val Glu Glu Ile Arg Arg Ala Thr Lys Arg Glu Gly Val  
 5905 5910 5915 5920  
 Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Leu Ser Met Leu

- 50 -

5925	5930	5935
Glu Ala Leu Gly Ala Leu Trp Val His	Gly Gln Ala Val	Gly Trp Glu
5940	5945	5950
Arg Leu Phe Ser Ala Gly Gly Ala	Gly Leu Arg Arg	Val Pro Leu Pro
5955	5960	5965
Thr Tyr Pro Trp Gln Arg Glu Arg	Tyr Trp Val Asp Ala	Pro Thr Gly
5970	5975	5980
Gly Ala Ala Gly Gly Ser Arg Phe Ala His	Ala Gly Ser His	Pro Leu
5985	5990	5995
Leu Gly Glu Met Gln Thr Leu Ser Thr Gln Arg Ser	Thr Arg Val Trp	
6005	6010	6015
Glu Thr Thr Leu Asp Leu Lys Arg Leu Pro Trp	Leu Gly Asp His Arg	
6020	6025	6030
Val Gln Gly Ala Val Val Phe Pro Gly Ala Ala	Tyr Leu Glu Met Ala	
6035	6040	6045
Leu Ser Ser Gly Ala Glu Ala Leu Gly Asp Gly	Pro Leu Gln Val Ser	
6050	6055	6060
Asp Val Val Leu Ala Glu Ala Leu Ala Phe Ala	Asp Asp Thr Pro Ala	
6065	6070	6075
Ala Val Gln Val Met Ala Thr Glu Glu Arg Pro	Gly Arg Leu Gln Phe	
6085	6090	6095
His Val Ala Ser Arg Val Pro Gly His Gly Gly	Ala Ala Phe Arg Ser	
6100	6105	6110
His Ala Arg Gly Val Leu Arg Gln Ile Glu Arg	Ala Glu Val Pro Ala	
6115	6120	6125
Arg Leu Asp Leu Ala Ala Leu Arg Ala Arg	Leu Gln Ala Ser Ala Pro	
6130	6135	6140
Ala Ala Ala Thr Tyr Ala Ala Leu Ala Glu Met	Gly Leu Glu Tyr Gly	
6145	6150	6155
Pro Ala Phe Gln Gly Leu Val Glu Leu Trp Arg	Gly Glu Gly Ala	
6165	6170	6175
Leu Gly Arg Val Arg Leu Pro Glu Ala Ala Gly	Ser Pro Ala Ala Cys	
6180	6185	6190
Arg Leu His Pro Ala Leu Leu Asp Ala Cys Phe	His Val Ser Ser Ala	
6195	6200	6205
Phe Ala Asp Arg Gly Glu Ala Thr Pro Trp Val	Pro Val Glu Ile Gly	
6210	6215	6220
Ser Leu Arg Trp Phe Gln Arg Pro Ser Gly Glu	Leu Trp Cys His Ala	
6225	6230	6235
Arg Ser Val Ser His Gly Lys Pro Thr Pro Asp	Arg Arg Ser Thr Asp	
6245	6250	6255
Phe Trp Val Val Asp Ser Thr Gly Ala Ile Val	Ala Glu Ile Ser Gly	
6260	6265	6270

- 51 -

Leu Val Ala Gln Arg Leu Ala Gly Gly Val Arg Arg Arg Glu Glu Asp  
 6275 6280 6285  
 Asp Trp Phe Met Glu Pro Ala Trp Glu Pro Thr Ala Val Pro Gly Ser  
 6290 6295 6300  
 Glu Val Met Ala Gly Arg Trp Leu Leu Ile Gly Ser Gly Gly Leu  
 6305 6310 6315 6320  
 Gly Ala Ala Leu His Ser Ala Leu Thr Glu Ala Gly His Ser Val Val  
 6325 6330 6335  
 His Ala Thr Gly Arg Gly Thr Ser Ala Ala Gly Leu Gln Ala Leu Leu  
 6340 6345 6350  
 Thr Ala Ser Phe Asp Gly Gln Ala Pro Thr Ser Val Val His Leu Gly  
 6355 6360 6365  
 Ser Leu Asp Glu Arg Gly Val Leu Asp Ala Asp Ala Pro Phe Asp Ala  
 6370 6375 6380  
 Asp Ala Leu Glu Glu Ser Leu Val Arg Gly Cys Asp Ser Val Leu Trp  
 6385 6390 6395 6400  
 Thr Val Gln Ala Val Ala Gly Ala Gly Phe Arg Asp Pro Pro Arg Leu  
 6405 6410 6415  
 Trp Leu Val Thr Arg Gly Ala Gln Ala Ile Gly Ala Gly Asp Val Ser  
 6420 6425 6430  
 Val Ala Gln Ala Pro Leu Leu Gly Leu Gly Arg Val Ile Ala Leu Glu  
 6435 6440 6445  
 His Ala Glu Leu Arg Cys Ala Arg Ile Asp Leu Asp Pro Ala Arg Arg  
 6450 6455 6460  
 Asp Gly Glu Val Asp Glu Leu Leu Ala Glu Leu Leu Ala Asp Asp Ala  
 6465 6470 6475 6480  
 Glu Glu Glu Val Ala Phe Arg Gly Gly Glu Arg Arg Val Ala Arg Leu  
 6485 6490 6495  
 Val Arg Arg Leu Pro Glu Thr Asp Cys Arg Glu Lys Ile Glu Pro Ala  
 6500 6505 6510  
 Glu Gly Arg Pro Phe Arg Leu Glu Ile Asp Gly Ser Gly Val Leu Asp  
 6515 6520 6525  
 Asp Leu Val Leu Arg Ala Thr Glu Arg Arg Pro Pro Gly Pro Gly Glu  
 6530 6535 6540  
 Val Glu Ile Ala Val Glu Ala Ala Gly Leu Asn Phe Leu Asp Val Met  
 6545 6550 6555 6560  
 Arg Ala Met Gly Ile Tyr Pro Gly Pro Gly Asp Gly Pro Val Ala Leu  
 6565 6570 6575  
 Gly Ala Glu Cys Ser Gly Arg Ile Val Ala Met Gly Glu Gly Val Glu  
 6580 6585 6590  
 Ser Leu Arg Ile Gly Gln Asp Val Val Ala Val Ala Pro Phe Ser Phe  
 6595 6600 6605  
 Gly Thr His Val Thr Ile Asp Ala Arg Met Leu Ala Pro Arg Pro Ala  
 6610 6615 6620

- 52 -

Ala Leu Thr Ala Ala Gln Ala Ala Ala Leu Pro Val Ala Phe Met Thr  
 6625 6630 6635 6640  
 Ala Trp Tyr Gly Leu Val His Leu Gly Arg Leu Arg Ala Gly Glu Arg  
 6645 6650 6655  
 Val Leu Ile His Ser Ala Thr Gly Gly Thr Gly Leu Ala Ala Val Gln  
 6660 6665 6670  
 Ile Ala Arg His Leu Gly Ala Glu Ile Phe Ala Thr Ala Gly Thr Pro  
 6675 6680 6685  
 Glu Lys Arg Ala Trp Leu Arg Glu Gln Gly Ile Ala His Val Met Asp  
 6690 6695 6700  
 Ser Arg Ser Leu Asp Phe Ala Glu Gln Val Leu Ala Ala Thr Lys Gly  
 6705 6710 6715 6720  
 Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Ala Ala Ile Asp  
 6725 6730 6735  
 Ala Ser Leu Ser Thr Leu Val Pro Asp Gly Arg Phe Ile Glu Leu Gly  
 6740 6745 6750  
 Lys Thr Asp Ile Tyr Ala Asp Arg Ser Leu Gly Leu Ala His Phe Arg  
 6755 6760 6765  
 Lys Ser Leu Ser Tyr Ser Ala Val Asp Leu Ala Gly Leu Ala Val Arg  
 6770 6775 6780  
 Arg Pro Glu Arg Val Ala Ala Leu Leu Ala Glu Val Val Asp Leu Leu  
 6785 6790 6795 6800  
 Ala Arg Gly Ala Leu Gln Pro Leu Pro Val Glu Ile Phe Pro Leu Ser  
 6805 6810 6815  
 Arg Ala Ala Asp Ala Phe Arg Lys Met Ala Gln Ala Gln His Leu Gly  
 6820 6825 6830  
 Lys Leu Val Leu Ala Leu Glu Asp Pro Asp Val Arg Ile Arg Val Pro  
 6835 6840 6845  
 Gly Glu Ser Gly Val Ala Ile Arg Ala Asp Gly Ala Tyr Leu Val Thr  
 6850 6855 6860  
 Gly Gly Leu Gly Gly Leu Gly Leu Ser Val Ala Gly Trp Leu Ala Glu  
 6865 6870 6875 6880  
 Gln Gly Ala Gly His Leu Val Leu Val Gly Arg Ser Gly Ala Val Ser  
 6885 6890 6895  
 Ala Glu Gln Gln Thr Ala Val Ala Ala Leu Glu Ala His Gly Ala Arg  
 6900 6905 6910  
 Val Thr Val Ala Arg Ala Asp Val Ala Asp Arg Ala Gln Met Glu Arg  
 6915 6920 6925  
 Ile Leu Arg Glu Val Thr Ala Ser Gly Met Pro Leu Arg Gly Val Val  
 6930 6935 6940  
 His Ala Ala Gly Ile Leu Asp Asp Gly Leu Leu Met Gln Gln Thr Pro  
 6945 6950 6955 6960  
 Ala Arg Phe Arg Ala Val Met Ala Pro Lys Val Arg Gly Ala Leu His

- 53 -

6965	6970	6975
Leu His Ala Leu Thr Arg Glu Ala Pro Leu Ser Phe Phe Val Leu Tyr		
6980	6985	6990
Ala Ser Gly Ala Gly Leu Leu Gly Ser Pro Gly Gln Gly Asn Tyr Ala		
6995	7000	7005
Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala His His Arg Arg Ala Gln		
7010	7015	7020
Gly Leu Pro Ala Leu Ser Ile Asp Trp Gly Leu Phe Ala Asp Val Gly		
7025	7030	7035
7040		
Leu Ala Ala Gly Gln Gln Asn Arg Gly Ala Arg Leu Val Thr Arg Gly		
7045	7050	7055
Thr Arg Ser Leu Thr Pro Asp Glu Gly Leu Trp Ala Leu Glu Arg Leu		
7060	7065	7070
Leu Asp Gly Asp Arg Thr Gln Ala Gly Val Met Pro Phe Asp Val Arg		
7075	7080	7085
Gln Trp Val Glu Phe Tyr Pro Ala Ala Ala Ser Ser Arg Arg Leu Ser		
7090	7095	7100
Arg Leu Met Thr Ala Arg Arg Val Ala Ser Gly Arg Leu Ala Gly Asp		
7105	7110	7115
7120		
Arg Asp Leu Leu Glu Arg Leu Ala Thr Ala Glu Ala Gly Ala Arg Ala		
7125	7130	7135
Gly Met Leu Gln Glu Val Val Arg Ala Gln Val Ser Gln Val Leu Arg		
7140	7145	7150
Leu Ser Glu Gly Lys Leu Asp Val Asp Ala Pro Leu Thr Ser Leu Gly		
7155	7160	7165
Met Asp Ser Leu Met Gly Leu Glu Leu Arg Asn Arg Ile Glu Ala Val		
7170	7175	7180
Leu Gly Ile Thr Met Pro Ala Thr Leu Leu Trp Thr Tyr Pro Thr Val		
7185	7190	7195
7200		
Ala Ala Leu Ser Ala His Leu Ala Ser His Val Val Ser Thr Gly Asp		
7205	7210	7215
Gly Glu Ser Ala Arg Pro Pro Asp Thr Gly Ser Val Ala Pro Thr Thr		
7220	7225	7230
His Glu Val Ala Ser Leu Asp Glu Asp Gly Leu Phe Ala Leu Ile Asp		
7235	7240	7245
Glu Ser Leu Ala Arg Ala Gly Lys Arg		
7250	7255	
<210> 6		
<211> 3798		
<212> PRT		
<213> Sorangium cellulosum		
<400> 6		
Val Thr Asp Arg Glu Gly Gln Leu Leu Glu Arg Leu Arg Glu Val Thr		
1	5	10
		15

- 54 -

Leu	Ala	Leu	Arg	Lys	Thr	Leu	Asn	Glu	Arg	Asp	Thr	Leu	Glu	Leu	Glu
		20				25						30			
Lys	Thr	Glu	Pro	Ile	Ala	Ile	Val	Gly	Ile	Gly	Cys	Arg	Phe	Pro	Gly
	35					40					45				
Gly	Ala	Gly	Thr	Pro	Glu	Ala	Phe	Trp	Glu	Leu	Leu	Asp	Asp	Gly	Arg
	50				55				60						
Asp	Ala	Ile	Arg	Pro	Leu	Glu	Glu	Arg	Trp	Ala	Leu	Val	Gly	Val	Asp
	65				70				75			80			
Pro	Gly	Asp	Asp	Val	Pro	Arg	Trp	Ala	Gly	Leu	Leu	Thr	Glu	Ala	Ile
	85					90						95			
Asp	Gly	Phe	Asp	Ala	Ala	Phe	Phe	Gly	Ile	Ala	Pro	Arg	Glu	Ala	Arg
	100					105				110					
Ser	Leu	Asp	Pro	Gln	His	Arg	Leu	Leu	Leu	Glu	Val	Ala	Trp	Glu	Gly
	115					120				125					
Phe	Glu	Asp	Ala	Gly	Ile	Pro	Pro	Arg	Ser	Leu	Val	Gly	Ser	Arg	Thr
	130					135				140					
Gly	Val	Phe	Val	Gly	Val	Cys	Ala	Thr	Glu	Tyr	Leu	His	Ala	Ala	Val
	145				150				155			160			
Ala	His	Gln	Pro	Arg	Glu	Glu	Arg	Asp	Ala	Tyr	Ser	Thr	Thr	Gly	Asn
	165					170			175						
Met	Leu	Ser	Ile	Ala	Ala	Gly	Arg	Leu	Ser	Tyr	Thr	Leu	Gly	Leu	Gln
	180					185			190						
Gly	Pro	Cys	Leu	Thr	Val	Asp	Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala
	195				200					205					
Ile	His	Leu	Ala	Cys	Arg	Ser	Leu	Arg	Ala	Arg	Glu	Ser	Asp	Leu	Ala
	210				215				220						
Leu	Ala	Gly	Gly	Val	Asn	Met	Leu	Leu	Ser	Pro	Asp	Thr	Met	Arg	Ala
	225					230				235			240		
Leu	Ala	Arg	Thr	Gln	Ala	Leu	Ser	Pro	Asn	Gly	Arg	Cys	Gln	Thr	Phe
	245					250				255					
Asp	Ala	Ser	Ala	Asn	Gly	Phe	Val	Arg	Gly	Glu	Gly	Cys	Gly	Leu	Ile
	260				265				270						
Val	Leu	Lys	Arg	Leu	Ser	Asp	Ala	Arg	Arg	Asp	Gly	Asp	Arg	Ile	Trp
	275				280				285						
Ala	Leu	Ile	Arg	Gly	Ser	Ala	Ile	Asn	Gln	Asp	Gly	Arg	Ser	Thr	Gly
	290				295				300						
Leu	Thr	Ala	Pro	Asn	Val	Leu	Ala	Gln	Gly	Ala	Leu	Leu	Arg	Glu	Ala
	305				310				315			320			
Leu	Arg	Asn	Ala	Gly	Val	Glu	Ala	Glu	Ala	Ile	Gly	Tyr	Ile	Glu	Thr
	325					330				335					
His	Gly	Ala	Ala	Thr	Ser	Leu	Gly	Asp	Pro	Ile	Glu	Ile	Glu	Ala	Leu
	340				345				350						
Arg	Ala	Val	Val	Gly	Pro	Ala	Arg	Ala	Asp	Gly	Ala	Arg	Cys	Val	Leu

- 55 -

355	360	365
Gly Ala Val Lys Thr Asn Leu Gly His Leu Glu Gly Ala Ala Gly Val		
370	375	380
Ala Gly Leu Ile Lys Ala Thr Leu Ser Leu His His Glu Arg Ile Pro		
385	390	395
400		
Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg Ile Glu Gly		
405	410	415
Thr Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro Arg Thr Gly		
420	425	430
Arg Thr Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser Gly Thr Asn		
435	440	445
Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Pro Glu Ala Ala		
450	455	460
Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala		
465	470	475
480		
Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp His Leu Glu Lys		
485	490	495
His Val Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu Ala Thr Thr		
500	505	510
Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala Ser Ser Arg Glu		
515	520	525
Ala Leu Arg Gly Ala Leu Ser Ala Ala Ala Gln Gly His Thr Pro Pro		
530	535	540
Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala Pro Lys Val Val		
545	550	555
560		
Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly Met Gly Arg Lys		
565	570	575
Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu Glu Gly Cys Asp		
580	585	590
Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu Gly Glu Leu Ser		
595	600	605
Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro		
610	615	620
Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp		
625	630	635
640		
Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met Gly Glu Val Ala		
645	650	655
Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile		
660	665	670
Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu		
675	680	685
Met Ala Leu Val Glu Leu Ser Leu Glu Glu Ala Ala Leu Arg		
690	695	700

- 56 -

Gly	His	Glu	Gly	Arg	Leu	Ser	Val	Ala	Val	Ser	Asn	Ser	Pro	Arg	Ser
705					710					715					720
Thr	Val	Leu	Ala	Gly	Glu	Pro	Ala	Ala	Leu	Ser	Glu	Val	Leu	Ala	Ala
					725					730					735
Leu	Thr	Ala	Lys	Gly	Val	Phe	Trp	Arg	Gln	Val	Lys	Val	Asp	Val	Ala
					740				745						750
Ser	His	Ser	Pro	Gln	Val	Asp	Pro	Leu	Arg	Glu	Glu	Leu	Ile	Ala	Ala
					755				760						765
Leu	Gly	Ala	Ile	Arg	Pro	Arg	Ala	Ala	Ala	Val	Pro	Met	Arg	Ser	Thr
					770				775						780
Val	Thr	Gly	Gly	Val	Ile	Ala	Gly	Pro	Glu	Leu	Gly	Ala	Ser	Tyr	Trp
					785				790						800
Ala	Asp	Asn	Leu	Arg	Gln	Pro	Val	Arg	Phe	Ala	Ala	Ala	Ala	Gln	Ala
					805				810						815
Leu	Leu	Glu	Gly	Gly	Pro	Ala	Leu	Phe	Ile	Glu	Met	Ser	Pro	His	Pro
					820				825						830
Ile	Leu	Val	Pro	Pro	Leu	Asp	Glu	Ile	Gln	Thr	Ala	Ala	Glu	Gln	Gly
					835				840						845
Gly	Ala	Ala	Ala	Val	Gly	Ser	Leu	Arg	Arg	Gly	Gln	Asp	Glu	Arg	Ala
					850				855						860
Leu	Leu	Glu	Ala	Leu	Gly	Thr	Leu	Trp	Ala	Ser	Gly	Tyr	Pro	Val	Ser
					865				870						880
Trp	Ala	Arg	Leu	Phe	Pro	Ala	Gly	Gly	Arg	Arg	Val	Pro	Leu	Pro	Thr
					885				890						895
Tyr	Pro	Trp	Gln	His	Glu	Arg	Cys	Trp	Ile	Glu	Val	Glu	Pro	Asp	Ala
					900				905						910
Arg	Arg	Leu	Ala	Ala	Ala	Asp	Pro	Thr	Lys	Asp	Trp	Phe	Tyr	Arg	Thr
					915				920						925
Asp	Trp	Pro	Glu	Val	Pro	Arg	Ala	Ala	Pro	Lys	Ser	Glu	Thr	Ala	His
					930				935						940
Gly	Ser	Trp	Leu	Leu	Leu	Ala	Asp	Arg	Gly	Gly	Val	Gly	Glu	Ala	Val
					945				950						960
Ala	Ala	Ala	Leu	Ser	Thr	Arg	Gly	Leu	Ser	Cys	Thr	Val	Leu	His	Ala
					965				970						975
Ser	Ala	Asp	Ala	Ser	Thr	Val	Ala	Glu	Gln	Val	Ser	Glu	Ala	Ala	Ser
					980				985						990
Arg	Arg	Asn	Asp	Trp	Gln	Gly	Val	Leu	Tyr	Leu	Trp	Gly	Leu	Asp	Ala
					995				1000						1005
Val	Val	Asp	Ala	Gly	Ala	Ser	Ala	Asp	Glu	Val	Ser	Glu	Ala	Thr	Arg
					1010				1015						1020
Arg	Ala	Thr	Ala	Pro	Val	Leu	Gly	Leu	Val	Arg	Phe	Leu	Ser	Ala	Ala
					1025				1030						1040
Pro	His	Pro	Pro	Arg	Phe	Trp	Val	Val	Thr	Arg	Gly	Ala	Cys	Thr	Val
					1045				1050						1055

- 57 -

Gly Gly Glu Pro Glu Ala Ser Leu Cys Gln Ala Ala Leu Trp Gly Leu  
 1060 1065 1070  
 Ala Arg Val Ala Ala Leu Glu His Pro Ala Ala Trp Gly Gly Leu Val  
 1075 1080 1085  
 Asp Leu Asp Pro Gln Lys Ser Pro Thr Glu Ile Glu Pro Leu Val Ala  
 1090 1095 1100  
 Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala Phe Arg Ser Gly  
 1105 1110 1115 1120  
 Arg Arg His Ala Ala Arg Leu Val Ala Ala Pro Pro Glu Gly Asp Val  
 1125 1130 1135  
 Ala Pro Ile Ser Leu Ser Ala Glu Gly Ser Tyr Leu Val Thr Gly Gly  
 1140 1145 1150  
 Leu Gly Gly Leu Gly Leu Leu Val Ala Arg Trp Leu Val Glu Arg Gly  
 1155 1160 1165  
 Ala Arg His Leu Val Leu Thr Ser Arg His Gly Leu Pro Glu Arg Gln  
 1170 1175 1180  
 Ala Ser Gly Gly Glu Gln Pro Pro Glu Ala Arg Ala Arg Ile Ala Ala  
 1185 1190 1195 1200  
 Val Glu Gly Leu Glu Ala Gln Gly Ala Arg Val Thr Val Ala Ala Val  
 1205 1210 1215  
 Asp Val Ala Glu Ala Asp Pro Met Thr Ala Leu Leu Ala Ala Ile Glu  
 1220 1225 1230  
 Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Val Phe Pro Val Arg  
 1235 1240 1245  
 His Leu Ala Glu Thr Asp Glu Ala Leu Leu Glu Ser Val Leu Arg Pro  
 1250 1255 1260  
 Lys Val Ala Gly Ser Trp Leu Leu His Arg Leu Leu Arg Asp Arg Pro  
 1265 1270 1275 1280  
 Leu Asp Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Gly  
 1285 1290 1295  
 Lys Gly Gin Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu  
 1300 1305 1310  
 Ala His His Arg Arg Ala His Ser Leu Pro Ala Leu Ser Leu Ala Trp  
 1315 1320 1325  
 Gly Leu Trp Ala Glu Gly Gly Met Val Asp Ala Lys Ala His Ala Arg  
 1330 1335 1340  
 Leu Ser Asp Ile Gly Val Leu Pro Met Ala Thr Gly Pro Ala Leu Ser  
 1345 1350 1355 1360  
 Ala Leu Glu Arg Leu Val Asn Thr Ser Ala Val Gln Arg Ser Val Thr  
 1365 1370 1375  
 Arg Met Asp Trp Ala Arg Phe Ala Pro Val Tyr Ala Ala Arg Gly Arg  
 1380 1385 1390  
 Arg Asn Leu Leu Ser Ala Leu Val Ala Glu Asp Glu Arg Ala Ala Ser

- 58 -

1395	1400	1405
Pro Pro Val Pro Thr Ala Asn Arg Ile Trp Arg Gly Leu Ser Val Ala		
1410	1415	1420
Glu Ser Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Ile Val Ala Arg		
1425	1430	1435
1440		
Val Leu Gly Phe Ser Asp Pro Gly Ala Leu Asp Val Gly Arg Gly Phe		
1445	1450	1455
Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Leu Glu Ile Arg Asn Arg		
1460	1465	1470
Leu Gln Arg Glu Leu Gly Glu Arg Leu Ser Ala Thr Leu Ala Phe Asp		
1475	1480	1485
His Pro Thr Val Glu Arg Leu Val Ala His Leu Leu Thr Asp Val Leu		
1490	1495	1500
Lys Leu Glu Asp Arg Ser Asp Thr Arg His Ile Arg Ser Val Ala Ala		
1505	1510	1515
1520		
Asp Asp Asp Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly		
1525	1530	1535
Asp Glu Gly Leu Glu Thr Tyr Trp Arg His Leu Ala Glu Gly Met Val		
1540	1545	1550
Val Ser Thr Glu Val Pro Ala Asp Arg Trp Arg Ala Ala Asp Trp Tyr		
1555	1560	1565
Asp Pro Asp Pro Glu Val Pro Gly Arg Thr Tyr Val Ala Lys Gly Ala		
1570	1575	1580
Phe Leu Arg Asp Val Arg Ser Leu Asp Ala Ala Phe Phe Ala Ile Ser		
1585	1590	1595
1600		
Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Glu		
1605	1610	1615
Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp Pro Met Ala Leu		
1620	1625	1630
Arg Glu Ser Ala Thr Gly Val Phe Val Gly Met Ile Gly Ser Glu His		
1635	1640	1645
Ala Glu Arg Val Gln Gly Leu Asp Asp Asp Ala Ala Leu Leu Tyr Gly		
1650	1655	1660
Thr Thr Gly Asn Leu Leu Ser Val Ala Ala Gly Arg Leu Ser Phe Phe		
1665	1670	1675
1680		
Leu Gly Leu His Gly Pro Thr Met Thr Val Asp Thr Ala Cys Ser Ser		
1685	1690	1695
Ser Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu		
1700	1705	1710
Cys Asp Gln Ala Leu Ala Gly Gly Ser Ser Val Leu Leu Ser Pro Arg		
1715	1720	1725
Ser Phe Val Ala Ala Ser Arg Met Arg Leu Leu Ser Pro Asp Gly Arg		
1730	1735	1740

- 59 -

Cys Lys Thr Phe Ser Ala Ala Ala Asp Gly Phe Ala Arg Ala Glu Gly  
 1745 1750 1755 1760  
 Cys Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Asp Arg  
 1765 1770 1775  
 Asp Pro Ile Leu Ala Val Val Arg Ser Thr Ala Ile Asn His Asp Gly  
 1780 1785 1790  
 Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala Gln Gln Ala Leu  
 1795 1800 1805  
 Leu Arg Gln Ala Leu Ala Gln Ala Gly Val Ala Pro Ala Glu Val Asp  
 1810 1815 1820  
 Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu  
 1825 1830 1835 1840  
 Val Gln Ala Leu Gly Ala Val Tyr Gly Arg Gly Arg Pro Ala Glu Arg  
 1845 1850 1855  
 Pro Leu Trp Leu Gly Ala Val Lys Ala Asn Leu Gly His Leu Glu Ala  
 1860 1865 1870  
 Ala Ala Gly Leu Ala Gly Val Leu Lys Val Leu Leu Ala Leu Glu His  
 1875 1880 1885  
 Glu Gln Ile Pro Ala Gln Pro Glu Leu Asp Glu Leu Asn Pro His Ile  
 1890 1895 1900  
 Pro Trp Ala Glu Leu Pro Val Ala Val Val Arg Arg Ala Val Pro Trp  
 1905 1910 1915 1920  
 Pro Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu  
 1925 1930 1935  
 Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu  
 1940 1945 1950  
 Pro Val Ala Ala Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser  
 1955 1960 1965  
 Ala Lys Ser Ala Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp  
 1970 1975 1980  
 His Leu Glu Lys His Val Glu Leu Gly Asp Val Ala Phe Ser  
 1985 1990 1995 2000  
 Leu Ala Thr Thr Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala  
 2005 2010 2015  
 Ser Ser Arg Glu Ala Leu Arg Gly Ala Leu Ser Ala Ala Gln Gly  
 2020 2025 2030  
 His Thr Pro Pro Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala  
 2035 2040 2045  
 Pro Lys Val Val Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly  
 2050 2055 2060  
 Met Gly Arg Lys Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu  
 2065 2070 2075 2080  
 Glu Gly Cys Asp Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu  
 2085 2090 2095

- 60 -

Gly Glu Leu Ser Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp  
2100 2105 2110

Val Val Gln Pro Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu  
2115 2120 2125

Trp Arg Ser Trp Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met  
2130 2135 2140

Gly Glu Val Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp  
2145 2150 2155 2160

Ala Val Ala Ile Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser  
2165 2170 2175

Gly Gln Gly Glu Met Ala Leu Val Glu Leu Ser Leu Glu Ala Glu  
2180 2185 2190

Ala Ala Leu Arg Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn  
2195 2200 2205

Ser Pro Arg Ser Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu  
2210 2215 2220

Val Leu Ala Ala Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys  
2225 2230 2235 2240

Val Asp Val Ala Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu  
2245 2250 2255

Leu Ile Ala Ala Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro  
2260 2265 2270

Met Arg Ser Thr Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly  
2275 2280 2285

Ala Ser Tyr Trp Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala  
2290 2295 2300

Ala Ala Gln Ala Leu Leu Glu Gly Pro Ala Leu Phe Ile Glu Met  
2305 2310 2315 2320

Ser Pro His Pro Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala  
2325 2330 2335

Ala Glu Gln Gly Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp  
2340 2345 2350

Glu Arg Ala Thr Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly  
2355 2360 2365

Tyr Pro Val Ser Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val  
2370 2375 2380

Pro Leu Pro Thr Tyr Pro Trp Gln His Glu Arg Tyr Trp Ile Glu Asp  
2385 2390 2395 2400

Ser Val His Gly Ser Lys Pro Ser Leu Arg Leu Arg Gln Leu Arg Asn  
2405 2410 2415

Gly Ala Thr Asp His Pro Leu Leu Gly Ala Pro Leu Leu Val Ser Ala  
2420 2425 2430

Arg Pro Gly Ala His Leu Trp Glu Gln Ala Leu Ser Asp Glu Arg Leu

- 61 -

2435	2440	2445
Ser Tyr Leu Ser Glu His Arg Val His Gly Glu Ala Val Leu Pro Ser		
2450	2455	2460
Ala Ala Tyr Val Glu Met Ala Leu Ala Ala Gly Val Asp Leu Tyr Gly		
2465	2470	2475
Thr Ala Thr Leu Val Leu Glu Gln Leu Ala Leu Glu Arg Ala Leu Ala		
2485	2490	2495
Val Pro Ser Glu Gly Gly Arg Ile Val Gln Val Ala Leu Ser Glu Glu		
2500	2505	2510
Gly Pro Gly Arg Ala Ser Phe Gln Val Ser Ser Arg Glu Glu Ala Gly		
2515	2520	2525
Arg Ser Trp Val Arg His Ala Thr Gly His Val Cys Ser Gly Gln Ser		
2530	2535	2540
Ser Ala Val Gly Ala Leu Lys Glu Ala Pro Trp Glu Ile Gln Arg Arg		
2545	2550	2555
Cys Pro Ser Val Leu Ser Ser Glu Ala Leu Tyr Pro Leu Leu Asn Glu		
2565	2570	2575
His Ala Leu Asp Tyr Gly Pro Cys Phe Gln Gly Val Glu Gln Val Trp		
2580	2585	2590
Leu Gly Thr Gly Glu Val Leu Gly Arg Val Arg Leu Pro Gly Asp Met		
2595	2600	2605
Ala Ser Ser Ser Gly Ala Tyr Arg Ile His Pro Ala Leu Leu Asp Ala		
2610	2615	2620
Cys Phe Gln Val Leu Thr Ala Leu Leu Thr Thr Pro Glu Ser Ile Glu		
2625	2630	2635
Ile Arg Arg Arg Leu Thr Asp Leu His Glu Pro Asp Leu Pro Arg Ser		
2645	2650	2655
Arg Ala Pro Val Asn Gln Ala Val Ser Asp Thr Trp Leu Trp Asp Ala		
2660	2665	2670
Ala Leu Asp Gly Gly Arg Arg Gln Ser Ala Ser Val Pro Val Asp Leu		
2675	2680	2685
Val Leu Gly Ser Phe His Ala Lys Trp Glu Val Met Glu Arg Leu Ala		
2690	2695	2700
Gln Ala Tyr Ile Ile Gly Thr Leu Arg Ile Trp Asn Val Phe Cys Ala		
2705	2710	2715
Ala Gly Glu Arg His Thr Ile Asp Glu Leu Leu Val Arg Leu Gln Ile		
2725	2730	2735
Ser Val Val Tyr Arg Lys Val Ile Lys Arg Trp Met Glu His Leu Val		
2740	2745	2750
Ala Ile Gly Ile Leu Val Gly Asp Gly Glu His Phe Val Ser Ser Gln		
2755	2760	2765
Pro Leu Pro Glu Pro Asp Leu Ala Ala Val Leu Glu Glu Ala Gly Arg		
2770	2775	2780

- 62 -

Val Phe Ala Asp Leu Pro Val Leu Phe Glu Trp Cys Lys Phe Ala Gly  
 2785                    2790                    2795                    2800  
 Glu Arg Leu Ala Asp Val Leu Thr Gly Lys Thr Leu Ala Leu Glu Ile  
 2805                    2810                    2815  
 Leu Phe Pro Gly Gly Ser Phe Asp Met Ala Glu Arg Ile Tyr Arg Asp  
 2820                    2825                    2830  
 Ser Pro Ile Ala Arg Tyr Ser Asn Gly Ile Val Arg Gly Val Val Glu  
 2835                    2840                    2845  
 Ser Ala Ala Arg Val Val Ala Pro Ser Gly Met Phe Ser Ile Leu Glu  
 2850                    2855                    2860  
 Ile Gly Ala Gly Thr Gly Ala Thr Thr Ala Ala Val Leu Pro Val Leu  
 2865                    2870                    2875                    2880  
 Leu Pro Asp Arg Thr Glu Tyr His Phe Thr Asp Val Ser Pro Leu Phe  
 2885                    2890                    2895  
 Leu Ala Arg Ala Glu Gln Arg Phe Arg Asp Tyr Pro Phe Leu Lys Tyr  
 2900                    2905                    2910  
 Gly Ile Leu Asp Val Asp Gln Glu Pro Ala Gly Gln Gly Tyr Ala His  
 2915                    2920                    2925  
 Gln Arg Phe Asp Val Ile Val Ala Ala Asn Val Ile His Ala Thr Arg  
 2930                    2935                    2940  
 Asp Ile Arg Ala Thr Ala Lys Arg Leu Leu Ser Leu Leu Ala Pro Gly  
 2945                    2950                    2955                    2960  
 Gly Leu Leu Val Leu Val Glu Gly Thr Gly His Pro Ile Trp Phe Asp  
 2965                    2970                    2975  
 Ile Thr Thr Gly Leu Ile Glu Gly Trp Gln Lys Tyr Glu Asp Asp Leu  
 2980                    2985                    2990  
 Arg Ile Asp His Pro Leu Leu Pro Ala Arg Thr Trp Cys Asp Val Leu  
 2995                    3000                    3005  
 Arg Arg Val Gly Phe Ala Asp Ala Val Ser Leu Pro Gly Asp Gly Ser  
 3010                    3015                    3020  
 Pro Ala Gly Ile Leu Gly Gln His Val Ile Leu Ser Arg Ala Pro Gly  
 3025                    3030                    3035                    3040  
 Ile Ala Gly Ala Ala Cys Asp Ser Ser Gly Glu Ser Ala Thr Glu Ser  
 3045                    3050                    3055  
 Pro Ala Ala Arg Ala Val Arg Gln Glu Trp Ala Asp Gly Ser Ala Asp  
 3060                    3065                    3070  
 Val Val His Arg Met Ala Leu Glu Arg Met Tyr Phe His Arg Arg Pro  
 3075                    3080                    3085  
 Gly Arg Gln Val Trp Val His Gly Arg Leu Arg Thr Gly Gly Ala  
 3090                    3095                    3100  
 Phe Thr Lys Ala Leu Ala Gly Asp Leu Leu Leu Phe Glu Asp Thr Gly  
 3105                    3110                    3115                    3120  
 Gln Val Val Ala Glu Val Gln Gly Leu Arg Leu Pro Gln Leu Glu Ala  
 3125                    3130                    3135

- 63 -

Ser Ala Phe Ala Pro Arg Asp Pro Arg Glu Glu Trp Leu Tyr Ala Leu  
 3140 3145 3150  
 Glu Trp Gln Arg Lys Asp Pro Ile Pro Glu Ala Pro Ala Ala Ala Ser  
 3155 3160 3165  
 Ser Ser Ser Ala Gly Ala Trp Leu Val Leu Met Asp Gln Gly Gly Thr  
 3170 3175 3180  
 Gly Ala Ala Leu Val Ser Leu Leu Glu Gly Arg Gly Glu Ala Cys Val  
 3185 3190 3195 3200  
 Arg Val Ile Ala Gly Thr Ala Tyr Ala Cys Leu Ala Pro Gly Leu Tyr  
 3205 3210 3215  
 Gln Val Asp Pro Ala Gln Pro Asp Gly Phe His Thr Leu Leu Arg Asp  
 3220 3225 3230  
 Ala Phe Gly Glu Asp Arg Ile Cys Arg Ala Val Val His Met Trp Ser  
 3235 3240 3245  
 Leu Asp Ala Thr Ala Ala Gly Glu Arg Ala Thr Ala Glu Ser Leu Gln  
 3250 3255 3260  
 Ala Asp Gln Leu Leu Gly Ser Leu Ser Ala Leu Ser Leu Val Gln Ala  
 3265 3270 3275 3280  
 Leu Val Arg Arg Arg Trp Arg Asn Met Pro Arg Leu Trp Leu Leu Thr  
 3285 3290 3295  
 Arg Ala Val His Ala Val Gly Ala Glu Asp Ala Ala Ala Ser Val Ala  
 3300 3305 3310  
 Gln Ala Pro Val Trp Gly Leu Gly Arg Thr Leu Ala Leu Glu His Pro  
 3315 3320 3325  
 Glu Leu Arg Cys Thr Leu Val Asp Val Asn Pro Ala Pro Ser Pro Glu  
 3330 3335 3340  
 Asp Ala Ala Ala Leu Ala Val Glu Leu Gly Ala Ser Asp Arg Glu Asp  
 3345 3350 3355 3360  
 Gln Val Ala Leu Arg Ser Asp Gly Arg Tyr Val Ala Arg Leu Val Arg  
 3365 3370 3375  
 Ser Ser Phe Ser Gly Lys Pro Ala Thr Asp Cys Gly Ile Arg Ala Asp  
 3380 3385 3390  
 Gly Ser Tyr Val Ile Thr Asp Gly Met Gly Arg Val Gly Leu Ser Val  
 3395 3400 3405  
 Ala Gin Trp Met Val Met Gln Gly Ala Arg His Val Val Leu Val Asp  
 3410 3415 3420  
 Arg Gly Gly Ala Ser Glu Ala Ser Arg Asp Ala Leu Arg Ser Met Ala  
 3425 3430 3435 3440  
 Glu Ala Gly Ala Glu Val Gln Ile Val Glu Ala Asp Val Ala Arg Arg  
 3445 3450 3455  
 Asp Asp Val Ala Arg Leu Leu Ser Lys Ile Glu Pro Ser Met Pro Pro  
 3460 3465 3470  
 Leu Arg Gly Ile Val Tyr Val Asp Gly Thr Phe Gln Gly Asp Ser Ser

- 64 -

3475	3480	3485
Met Leu Glu Leu Asp Ala Arg Arg Phe Lys Glu Trp Met Tyr Pro Lys		
3490	3495	3500
Val Leu Gly Ala Trp Asn Leu His Ala Leu Thr Arg Asp Arg Ser Leu		
3505	3510	3515
Asp Phe Phe Val Leu Tyr Ser Ser Gly Thr Ser Leu Leu Gly Leu Pro		
3525	3530	3535
Gly Gln Gly Ser Arg Ala Ala Gly Asp Ala Phe Leu Asp Ala Ile Ala		
3540	3545	3550
His His Arg Cys Lys Val Gly Leu Thr Ala Met Ser Ile Asn Trp Gly		
3555	3560	3565
Leu Leu Ser Glu Ala Ser Ser Pro Ala Thr Pro Asn Asp Gly Gly Ala		
3570	3575	3580
Arg Leu Glu Tyr Arg Gly Met Glu Gly Leu Thr Leu Glu Gln Gly Ala		
3585	3590	3595
Ala Ala Leu Gly Arg Leu Leu Ala Arg Pro Arg Ala Gln Val Gly Val		
3605	3610	3615
Met Arg Leu Asn Leu Arg Gln Trp Leu Glu Phe Tyr Pro Asn Ala Ala		
3620	3625	3630
Arg Leu Ala Leu Trp Ala Glu Leu Leu Lys Glu Arg Asp Arg Ala Asp		
3635	3640	3645
Arg Gly Ala Ser Asn Ala Ser Asn Leu Arg Glu Ala Leu Gln Ser Ala		
3650	3655	3660
Arg Pro Glu Asp Arg Gln Leu Ile Leu Glu Lys His Leu Ser Glu Leu		
3665	3670	3675
Leu Gly Arg Gly Leu Arg Leu Pro Pro Glu Arg Ile Glu Arg His Val		
3685	3690	3695
Pro Phe Ser Asn Leu Gly Met Asp Ser Leu Ile Gly Leu Glu Leu Arg		
3700	3705	3710
Asn Arg Ile Glu Ala Ala Leu Gly Ile Thr Val Pro Ala Thr Leu Leu		
3715	3720	3725
Trp Thr Tyr Pro Asn Val Ala Ala Leu Ser Gly Ser Leu Leu Asp Ile		
3730	3735	3740
Leu Phe Pro Asn Ala Gly Ala Thr His Ala Pro Ala Thr Glu Arg Glu		
3745	3750	3755
Lys Ser Phe Glu Asn Asp Ala Ala Asp Leu Glu Ala Leu Arg Gly Met		
3765	3770	3775
Thr Asp Glu Gln Lys Asp Ala Leu Leu Ala Glu Lys Leu Ala Gln Leu		
3780	3785	3790
Ala Gln Ile Val Gly Glu		
3795		

- 65 -

<212> PRT

<213> Sorangium cellulosum

<400> 7

Met Ala Thr Thr Asn Ala Gly Lys Leu Glu His Ala Leu Leu Leu Met  
1 5 10 15

Asp Lys Leu Ala Lys Lys Asn Ala Ser Leu Glu Gln Glu Arg Thr Glu  
20 25 30

Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly Gly Ala Asp  
35 40 45

Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Ser Gly Arg Asp Ala Val  
50 55 60

Gln Pro Leu Asp Arg Arg Trp Ala Leu Val Gly Val His Pro Ser Glu  
65 70 75 80

Glu Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Val Asp Gly Phe  
85 90 95

Asp Ala Ala Phe Phe Gly Thr Ser Pro Arg Glu Ala Arg Ser Leu Asp  
100 105 110

Pro Gin Gln Arg Leu Leu Leu Glu Val Thr Trp Glu Gly Leu Glu Asp  
115 120 125

Ala Gly Ile Ala Pro Gln Ser Leu Asp Gly Ser Arg Thr Gly Val Phe  
130 135 140

Leu Gly Ala Cys Ser Ser Asp Tyr Ser His Thr Val Ala Gln Gln Arg  
145 150 155 160

Arg Glu Glu Gln Asp Ala Tyr Asp Ile Thr Gly Asn Thr Leu Ser Val  
165 170 175

Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln Gly Pro Cys Leu  
180 185 190

Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala  
195 200 205

Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala Leu Ala Gly Gly  
210 215 220

Val Asn Met Leu Leu Ser Ser Lys Thr Met Ile Met Leu Gly Arg Ile  
225 230 235 240

Gln Ala Leu Ser Pro Asp Gly His Cys Arg Thr Phe Asp Ala Ser Ala  
245 250 255

Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Met Val Val Leu Lys Arg  
260 265 270

Leu Ser Asp Ala Gln Arg His Gly Asp Arg Ile Trp Ala Leu Ile Arg  
275 280 285

Gly Ser Ala Met Asn Gln Asp Gly Arg Ser Thr Gly Leu Met Ala Pro  
290 295 300

Asn Val Leu Ala Gln Glu Ala Leu Leu Arg Glu Ala Leu Gln Ser Ala  
305 310 315 320

Arg Val Asp Ala Gly Ala Ile Gly Tyr Val Glu Thr His Gly Thr Gly

- 66 -

325	330	335
Thr Ser Leu Gly Asp Pro Ile Glu Val Glu Ala Leu Arg Ala Val Leu		
340	345	350
Gly Pro Ala Arg Ala Asp Gly Ser Arg Cys Val Leu Gly Ala Val Lys		
355	360	365
Thr Asn Leu Gly His Leu Glu Gly Ala Ala Gly Val Ala Gly Leu Ile		
370	375	380
Lys Ala Ala Leu Ala Leu His His Glu Leu Ile Pro Arg Asn Leu His		
385	390	395
Phe His Thr Leu Asn Pro Arg Ile Arg Ile Glu Gly Thr Ala Leu Ala		
405	410	415
Leu Ala Thr Glu Pro Val Pro Trp Pro Arg Ala Gly Arg Pro Arg Phe		
420	425	430
Ala Gly Val Ser Ala Phe Gly Leu Ser Gly Thr Asn Val His Val Val		
435	440	445
Leu Glu Glu Ala Pro Ala Thr Val Leu Ala Pro Ala Thr Pro Gly Arg		
450	455	460
Ser Ala Glu Leu Leu Val Leu Ser Ala Lys Ser Ala Ala Ala Leu Asp		
465	470	475
Ala Gln Ala Ala Arg Leu Ser Ala His Ile Ala Ala Tyr Pro Glu Gln		
485	490	495
Gly Leu Gly Asp Val Ala Phe Ser Leu Val Ser Thr Arg Ser Pro Met		
500	505	510
Glu His Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Ala Leu Arg Ser		
515	520	525
Ala Leu Glu Val Ala Ala Gln Gly Gln Thr Pro Ala Gly Ala Ala Arg		
530	535	540
Gly Arg Ala Ala Ser Ser Pro Gly Lys Leu Ala Phe Leu Phe Ala Gly		
545	550	555
560		
Gln Gly Ala Gln Val Pro Gly Met Gly Arg Gly Leu Trp Glu Ala Trp		
565	570	575
Pro Ala Phe Arg Glu Thr Phe Asp Arg Cys Val Thr Leu Phe Asp Arg		
580	585	590
Glu Leu His Gln Pro Leu Cys Glu Val Met Trp Ala Glu Pro Gly Ser		
595	600	
605		
Ser Arg Ser Ser Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu		
610	615	
620		
Phe Ala Leu Glu Tyr Ala Leu Ala Ala Leu Phe Arg Ser Trp Gly Val		
625	630	
635		
640		
Glu Pro Glu Leu Val Ala Gly His Ser Leu Gly Glu Leu Val Ala Ala		
645	650	
655		
Cys Val Ala Gly Val Phe Ser Leu Glu Asp Ala Val Arg Leu Val Val		
660	665	
670		

- 67 -

Ala Arg Gly Arg Leu Met Gln Ala Leu Pro Ala Gly Gly Ala Met Val  
 675 680 685  
 Ser Ile Ala Ala Pro Glu Ala Asp Val Ala Ala Ala Val Ala Pro His  
 690 695 700  
 Ala Ala Leu Val Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val  
 705 710 715 720  
 Ile Ala Gly Ala Glu Lys Phe Val Gln Gln Ile Ala Ala Ala Phe Ala  
 725 730 735  
 Ala Arg Gly Ala Arg Thr Lys Pro Leu His Val Ser His Ala Phe His  
 740 745 750  
 Ser Pro Leu Met Asp Pro Met Leu Glu Ala Phe Arg Arg Val Thr Glu  
 755 760 765  
 Ser Val Thr Tyr Arg Arg Pro Ser Ile Ala Leu Val Ser Asn Leu Ser  
 770 775 780  
 Gly Lys Pro Cys Thr Asp Glu Val Ser Ala Pro Gly Tyr Trp Val Arg  
 785 790 795 800  
 His Ala Arg Glu Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His  
 805 810 815  
 Ala Ala Gly Ala Gly Leu Phe Val Glu Val Gly Pro Lys Pro Thr Leu  
 820 825 830  
 Leu Gly Leu Val Pro Ala Cys Leu Pro Asp Ala Arg Pro Val Leu Leu  
 835 840 845  
 Pro Ala Ser Arg Ala Gly Arg Asp Glu Ala Ala Ser Ala Leu Glu Ala  
 850 855 860  
 Leu Gly Gly Phe Trp Val Val Gly Gly Ser Val Thr Trp Ser Gly Val  
 865 870 875 880  
 Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln  
 885 890 895  
 Arg Glu Arg Tyr Trp Ile Glu Ala Pro Val Asp Arg Glu Ala Asp Gly  
 900 905 910  
 Thr Gly Arg Ala Arg Ala Gly Gly His Pro Leu Leu Gly Glu Val Phe  
 915 920 925  
 Ser Val Ser Thr His Ala Gly Leu Arg Leu Trp Glu Thr Thr Leu Asp  
 930 935 940  
 Arg Lys Arg Leu Pro Trp Leu Gly Glu His Arg Ala Gln Gly Glu Val  
 945 950 955 960  
 Val Phe Pro Gly Ala Gly Tyr Leu Glu Met Ala Leu Ser Ser Gly Ala  
 965 970 975  
 Glu Ile Leu Gly Asp Gly Pro Ile Gln Val Thr Asp Val Val Leu Ile  
 980 985 990  
 Glu Thr Leu Thr Phe Ala Gly Asp Thr Ala Val Pro Val Gln Val Val  
 995 1000 1005  
 Thr Thr Glu Glu Arg Pro Gly Arg Leu Arg Phe Gln Val Ala Ser Arg  
 1010 1015 1020

- 68 -

Glu Pro Gly Glu Arg Arg Ala Pro Phe Arg Ile His Ala Arg Gly Val  
1025 1030 1035 1040

Leu Arg Arg Ile Gly Arg Val Glu Thr Pro Ala Arg Ser Asn Leu Ala  
1045 1050 1055

Ala Leu Arg Ala Arg Leu His Ala Ala Val Pro Ala Ala Ala Ile Tyr  
1060 1065 1070

Gly Ala Leu Ala Glu Met Gly Leu Gln Tyr Gly Pro Ala Leu Arg Gly  
1075 1080 1085

Leu Ala Glu Leu Trp Arg Gly Glu Gly Ala Leu Gly Arg Val Arg  
1090 1095 1100

Leu Pro Glu Ala Ala Gly Ser Ala Thr Ala Tyr Gln Leu His Pro Val  
1105 1110 1115 1120

Leu Leu Asp Ala Cys Val Gln Met Ile Val Gly Ala Phe Ala Asp Arg  
1125 1130 1135

Asp Glu Ala Thr Pro Trp Ala Pro Val Glu Val Gly Ser Val Arg Leu  
1140 1145 1150

Phe Gln Arg Ser Pro Gly Glu Leu Trp Cys His Ala Arg Val Val Ser  
1155 1160 1165

Asp Gly Gln Gln Ala Ser Ser Arg Trp Ser Ala Asp Phe Glu Leu Met  
1170 1175 1180

Asp Gly Thr Gly Ala Val Val Ala Glu Ile Ser Arg Leu Val Val Glu  
1185 1190 1195 1200

Arg Leu Ala Ser Gly Val Arg Arg Asp Ala Asp Asp Trp Phe Leu  
1205 1210 1215

Glu Leu Asp Trp Glu Pro Ala Ala Leu Gly Gly Pro Lys Ile Thr Ala  
1220 1225 1230

Gly Arg Trp Leu Leu Leu Gly Glu Gly Gly Leu Gly Arg Ser Leu  
1235 1240 1245

Cys Ser Ala Leu Lys Ala Ala Gly His Val Val Val His Ala Ala Gly  
1250 1255 1260

Asp Asp Thr Ser Thr Ala Gly Met Arg Ala Leu Leu Ala Asn Ala Phe  
1265 1270 1275 1280

Asp Gly Gln Ala Pro Thr Ala Val Val His Leu Ser Ser Leu Asp Gly  
1285 1290 1295

Gly Gly Gln Leu Gly Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala  
1300 1305 1310

Pro Arg Ser Pro Asp Val Asp Ala Asp Ala Leu Glu Ser Ala Leu Met  
1315 1320 1325

Arg Gly Cys Asp Ser Val Leu Ser Leu Val Gln Ala Leu Val Gly Met  
1330 1335 1340

Asp Leu Arg Asn Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln  
1345 1350 1355 1360

Ala Ala Ala Ala Gly Asp Val Ser Val Val Gln Ala Pro Leu Leu Gly

- 69 -

1365	1370	1375
Leu Gly Arg Thr Ile Ala Leu Glu His Ala Glu Leu Arg Cys Ile Ser		
1380	1385	1390
Val Asp Leu Asp Pro Ala Glu Pro Glu Gly Glu Ala Asp Ala Leu Leu		
1395	1400	1405
Ala Glu Leu Leu Ala Asp Asp Ala Glu Glu Glu Val Ala Leu Arg Gly		
1410	1415	1420
Gly Asp Arg Leu Val Ala Arg Leu Val His Arg Leu Pro Asp Ala Gln		
1425	1430	1435
Arg Arg Glu Lys Val Glu Pro Ala Gly Asp Arg Pro Phe Arg Leu Glu		
1445	1450	1455
Ile Asp Glu Pro Gly Ala Leu Asp Gln Leu Val Leu Arg Ala Thr Gly		
1460	1465	1470
Arg Arg Ala Pro Gly Pro Gly Glu Val Glu Ile Ser Val Glu Ala Ala		
1475	1480	1485
Gly Leu Asp Ser Ile Asp Ile Gln Leu Ala Leu Gly Val Ala Pro Asn		
1490	1495	1500
Asp Leu Pro Gly Glu Glu Ile Glu Pro Leu Val Leu Gly Ser Glu Cys		
1505	1510	1515
Ala Gly Arg Ile Val Ala Val Gly Glu Gly Val Asn Gly Leu Val Val		
1525	1530	1535
Gly Gln Pro Val Ile Ala Leu Ala Ala Gly Val Phe Ala Thr His Val		
1540	1545	1550
Thr Thr Ser Ala Thr Leu Val Leu Pro Arg Pro Leu Gly Leu Ser Ala		
1555	1560	1565
Thr Glu Ala Ala Ala Met Pro Leu Ala Tyr Leu Thr Ala Trp Tyr Ala		
1570	1575	1580
Leu Asp Lys Val Ala His Leu Gln Ala Gly Glu Arg Val Leu Ile His		
1585	1590	1595
Ala Glu Ala Gly Gly Val Gly Leu Cys Ala Val Arg Trp Ala Gln Arg		
1605	1610	1615
Val Gly Ala Glu Val Tyr Ala Thr Ala Asp Thr Pro Glu Asn Arg Ala		
1620	1625	1630
Tyr Leu Glu Ser Leu Gly Val Arg Tyr Val Ser Asp Ser Arg Ser Gly		
1635	1640	1645
Arg Phe Val Thr Asp Val His Ala Trp Thr Asp Gly Glu Gly Val Asp		
1650	1655	1660
Val Val Leu Asp Ser Leu Ser Gly Glu Arg Ile Asp Lys Ser Leu Met		
1665	1670	1675
Val Leu Arg Ala Cys Gly Arg Leu Val Lys Leu Gly Arg Arg Asp Asp		
1685	1690	1695
Cys Ala Asp Thr Gln Pro Gly Leu Pro Pro Leu Leu Arg Asn Phe Ser		
1700	1705	1710

- 70 -

Phe Ser Gln Val Asp Leu Arg Gly Met Met Leu Asp Gln Pro Ala Arg  
 1715 1720 1725

Ile Arg Ala Leu Leu Asp Glu Leu Phe Gly Leu Val Ala Ala Gly Ala  
 1730 1735 1740

Ile Ser Pro Leu Gly Ser Gly Leu Arg Val Gly Gly Ser Leu Thr Pro  
 1745 1750 1755 1760

Pro Pro Val Glu Thr Phe Pro Ile Ser Arg Ala Ala Glu Ala Phe Arg  
 1765 1770 1775

Arg Met Ala Gln Gly Gln His Leu Gly Lys Leu Val Leu Thr Leu Asp  
 1780 1785 1790

Asp Pro Glu Val Arg Ile Arg Ala Pro Ala Glu Ser Ser Val Ala Val  
 1795 1800 1805

Arg Ala Asp Gly Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly  
 1810 1815 1820

Leu Arg Val Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly Gln Leu Val  
 1825 1830 1835 1840

Leu Val Gly Arg Ser Gly Ala Ala Ser Ala Glu Gln Arg Ala Ala Val  
 1845 1850 1855

Ala Ala Leu Glu Ala His Gly Ala Arg Val Thr Val Ala Lys Ala Asp  
 1860 1865 1870

Val Ala Asp Arg Ser Gln Ile Glu Arg Val Leu Arg Glu Val Thr Ala  
 1875 1880 1885

Ser Gly Met Pro Leu Arg Gly Val Val His Ala Ala Gly Leu Val Asp  
 1890 1895 1900

Asp Gly Leu Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Thr Val Met  
 1905 1910 1915 1920

Gly Pro Lys Val Gln Gly Ala Leu His Leu His Thr Leu Thr Arg Glu  
 1925 1930 1935

Ala Pro Leu Ser Phe Phe Val Leu Tyr Ala Ser Ala Ala Gly Leu Phe  
 1940 1945 1950

Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp  
 1955 1960 1965

Ala Leu Ser His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Ile  
 1970 1975 1980

Asp Trp Gly Met Phe Thr Glu Val Gly Met Ala Val Ala Gln Glu Asn  
 1985 1990 1995 2000

Arg Gly Ala Arg Gln Ile Ser Arg Gly Met Arg Gly Ile Thr Pro Asp  
 2005 2010 2015

Glu Gly Leu Ser Ala Leu Ala Arg Leu Leu Glu Gly Asp Arg Val Gln  
 2020 2025 2030

Thr Gly Val Ile Pro Ile Thr Pro Arg Gln Trp Val Glu Phe Tyr Pro  
 2035 2040 2045

Ala Thr Ala Ala Ser Arg Arg Leu Ser Arg Leu Val Thr Thr Gln Arg  
 2050 2055 2060

- 71 -

Ala Val Ala Asp Arg Thr Ala Gly Asp Arg Asp Leu Leu Glu Gln Leu  
 2065 2070 2075 2080  
 Ala Ser Ala Glu Pro Ser Ala Arg Ala Gly Leu Leu Gln Asp Val Val  
 2085 2090 2095  
 Arg Val Gln Val Ser His Val Leu Arg Leu Pro Glu Asp Lys Ile Glu  
 2100 2105 2110  
 Val Asp Ala Pro Leu Ser Ser Met Gly Met Asp Ser Leu Met Ser Leu  
 2115 2120 2125  
 Glu Leu Arg Asn Arg Ile Glu Ala Ala Leu Gly Val Ala Ala Pro Ala  
 2130 2135 2140  
 Ala Leu Gly Trp Thr Tyr Pro Thr Val Ala Ala Ile Thr Arg Trp Leu  
 2145 2150 2155 2160  
 Leu Asp Asp Ala Leu Val Val Arg Leu Gly Gly Ser Asp Thr Asp  
 2165 2170 2175  
 Glu Ser Thr Ala Ser Ala Gly Ser Phe Val His Val Leu Arg Phe Arg  
 2180 2185 2190  
 Pro Val Val Lys Pro Arg Ala Arg Leu Phe Cys Phe His Gly Ser Gly  
 2195 2200 2205  
 Gly Ser Pro Glu Gly Phe Arg Ser Trp Ser Glu Lys Ser Glu Trp Ser  
 2210 2215 2220  
 Asp Leu Glu Ile Val Ala Met Trp His Asp Arg Ser Leu Ala Ser Glu  
 2225 2230 2235 2240  
 Asp Ala Pro Gly Lys Lys Tyr Val Gln Glu Ala Ala Ser Leu Ile Gln  
 2245 2250 2255  
 His Tyr Ala Asp Ala Pro Phe Ala Leu Val Gly Phe Ser Leu Gly Val  
 2260 2265 2270  
 Arg Phe Val Met Gly Thr Ala Val Glu Leu Ala Ser Arg Ser Gly Ala  
 2275 2280 2285  
 Pro Ala Pro Leu Ala Val Phe Thr Leu Gly Gly Ser Leu Ile Ser Ser  
 2290 2295 2300  
 Ser Glu Ile Thr Pro Glu Met Glu Thr Asp Ile Ile Ala Lys Leu Phe  
 2305 2310 2315 2320  
 Phe Arg Asn Ala Ala Gly Phe Val Arg Ser Thr Gln Gln Val Gln Ala  
 2325 2330 2335  
 Asp Ala Arg Ala Asp Lys Val Ile Thr Asp Thr Met Val Ala Pro Ala  
 2340 2345 2350  
 Pro Gly Asp Ser Lys Glu Pro Pro Val Lys Ile Ala Val Pro Ile Val  
 2355 2360 2365  
 Ala Ile Ala Gly Ser Asp Asp Val Ile Val Pro Pro Ser Asp Val Gln  
 2370 2375 2380  
 Asp Leu Gln Ser Arg Thr Thr Glu Arg Phe Tyr Met His Leu Leu Pro  
 2385 2390 2395 2400  
 Gly Asp His Glu Phe Leu Val Asp Arg Gly Arg Glu Ile Met His Ile

- 72 -

2405	2410	2415
Val Asp Ser His Leu Asn Pro Leu Leu Ala Ala Arg Thr Thr Ser Ser		
2420	2425	2430
Gly Pro Ala Phe Glu Ala Lys		
2435		
<210> 8		
<211> 419		
<212> PRT		
<213> Sorangium cellulosum		
<400> 8		
Met Thr Gln Glu Gln Ala Asn Gln Ser Glu Thr Lys Pro Ala Phe Asp		
1	5	10
Phe Lys Pro Phe Ala Pro Gly Tyr Ala Glu Asp Pro Phe Pro Ala Ile		
20	25	30
Glu Arg Leu Arg Glu Ala Thr Pro Ile Phe Tyr Trp Asp Glu Gly Arg		
35	40	45
Ser Trp Val Leu Thr Arg Tyr His Asp Val Ser Ala Val Phe Arg Asp		
50	55	60
Glu Arg Phe Ala Val Ser Arg Glu Glu Trp Glu Ser Ser Ala Glu Tyr		
65	70	75
Ser Ser Ala Ile Pro Glu Leu Ser Asp Met Lys Lys Tyr Gly Leu Phe		
85	90	95
Gly Leu Pro Pro Glu Asp His Ala Arg Val Arg Lys Leu Val Asn Pro		
100	105	110
Ser Phe Thr Ser Arg Ala Ile Asp Leu Leu Arg Ala Glu Ile Gln Arg		
115	120	125
Thr Val Asp Gln Leu Leu Asp Ala Arg Ser Gly Gln Glu Glu Phe Asp		
130	135	140
Val Val Arg Asp Tyr Ala Glu Gly Ile Pro Met Arg Ala Ile Ser Ala		
145	150	155
160		
Leu Leu Lys Val Pro Ala Glu Cys Asp Glu Lys Phe Arg Arg Phe Gly		
165	170	175
Ser Ala Thr Ala Arg Ala Leu Gly Val Gly Leu Val Pro Gln Val Asp		
180	185	190
Glu Glu Thr Lys Thr Leu Val Ala Ser Val Thr Glu Gly Leu Ala Leu		
195	200	205
Leu His Asp Val Leu Asp Glu Arg Arg Asn Pro Leu Glu Asn Asp		
210	215	220
Val Leu Thr Met Leu Leu Gln Ala Glu Ala Asp Gly Ser Arg Leu Ser		
225	230	235
240		
Thr Lys Glu Leu Val Ala Leu Val Gly Ala Ile Ile Ala Ala Gly Thr		
245	250	255
Asp Thr Thr Ile Tyr Leu Ile Ala Phe Ala Val Leu Asn Leu Leu Arg		
260	265	270

- 73 -

Ser Pro Glu Ala Leu Glu Leu Val Lys Ala Glu Pro Gly Leu Met Arg  
 275                    280                    285  
 Asn Ala Leu Asp Glu Val Leu Arg Phe Asp Asn Ile Leu Arg Ile Gly  
 290                    295                    300  
 Thr Val Arg Phe Ala Arg Gln Asp Leu Glu Tyr Cys Gly Ala Ser Ile  
 305                    310                    315                    320  
 Lys Lys Gly Glu Met Val Phe Leu Leu Ile Pro Ser Ala Leu Arg Asp  
 325                    330                    335  
 Gly Thr Val Phe Ser Arg Pro Asp Val Phe Asp Val Arg Arg Asp Thr  
 340                    345                    350  
 Gly Ala Ser Leu Ala Tyr Gly Arg Gly Pro His Val Cys Pro Gly Val  
 355                    360                    365  
 Ser Leu Ala Arg Leu Glu Ala Glu Ile Ala Val Gly Thr Ile Phe Arg  
 370                    375                    380  
 Arg Phe Pro Glu Met Lys Leu Lys Glu Thr Pro Val Phe Gly Tyr His  
 385                    390                    395                    400  
 Pro Ala Phe Arg Asn Ile Glu Ser Leu Asn Val Ile Leu Lys Pro Ser  
 405                    410                    415  
 Lys Ala Gly

<210> 9  
 <211> 607  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 9  
 Ala Ser Leu Asp Ala Leu Phe Ala Arg Ala Thr Ser Ala Arg Val Leu  
 1                    5                        10                    15  
 Asp Asp Gly His Gly Arg Ala Thr Glu Arg His Val Leu Ala Glu Ala  
 20                    25                        30  
 Arg Gly Ile Glu Asp Leu Arg Ala Leu Arg Glu His Leu Arg Ile Gln  
 35                    40                        45  
 Glu Gly Gly Pro Ser Phe His Cys Met Cys Leu Gly Asp Leu Thr Val  
 50                    55                        60  
 Glu Leu Leu Ala His Asp Gln Pro Leu Ala Ser Ile Ser Phe His His  
 65                    70                        75                    80  
 Ala Arg Ser Leu Arg His Pro Asp Trp Thr Ser Asp Ala Met Leu Val  
 85                    89                        95  
 Asp Gly Pro Ala Leu Val Arg Trp Leu Ala Ala Arg Gly Ala Pro Gly  
 100                    105                      110  
 Pro Leu Arg Glu Tyr Glu Glu Glu Arg Glu Arg Ala Arg Thr Ala Gln  
 115                    120                      125  
 Glu Ala Arg Arg Leu Trp Leu Ala Ala Ala Pro Pro Cys Phe Ala Pro  
 130                    135                      140

- 74 -

Asp Leu Pro Arg Phe Glu Asp Asp Ala Asn Gly Leu Pro Leu Gly Pro  
 145 150 155 160  
 Met Ser Pro Glu Val Ala Glu Ala Glu Arg Arg Leu Arg Ala Ser Tyr  
 165 170 175  
 Ala Thr Pro Glu Leu Ala Cys Ala Ala Leu Leu Ala Trp Leu Gly Thr  
 180 185 190  
 Gly Ala Gly Pro Trp Ser Gly Tyr Pro Ala Tyr Glu Met Leu Pro Glu  
 195 200 205  
 Asn Leu Leu Leu Gly Phe Gly Leu Pro Thr Ala Ile Ala Ala Ala Ser  
 210 215 220  
 Ala Pro Gly Thr Ser Glu Ala Ala Leu Arg Gly Ala Ala Arg Leu Phe  
 225 230 235 240  
 Ala Ser Trp Glu Val Val Ser Ser Lys Lys Ser Gln Leu Gly Asn Ile  
 245 250 255  
 Pro Glu Ala Leu Trp Glu Arg Leu Arg Thr Ile Val Arg Ala Met Gly  
 260 265 270  
 Asn Ala Asp Asn Leu Ser Arg Phe Glu Arg Ala Glu Ala Ile Ala Ala  
 275 280 285  
 Glu Val Arg Arg Leu Arg Ala Gln Pro Ala Pro Phe Ala Ala Gly Ala  
 290 295 300  
 Gly Leu Ala Val Ala Gly Val Ser Ser Ser Gly Arg Leu Ser Gly Leu  
 305 310 315 320  
 Val Thr Asp Gly Asp Ala Leu Tyr Ser Gly Asp Gly Asn Asp Ile Val  
 325 330 335  
 Met Phe Gln Pro Gly Arg Ile Ser Pro Val Val Leu Leu Ala Gly Thr  
 340 345 350  
 Asp Pro Phe Phe Glu Leu Ala Pro Pro Leu Ser Gln Met Leu Phe Val  
 355 360 365  
 Ala His Ala Asn Ala Gly Thr Ile Ser Lys Val Leu Thr Glu Gly Ser  
 370 375 380  
 Pro Leu Ile Val Met Ala Arg Asn Gln Ala Arg Pro Met Ser Leu Val  
 385 390 395 400  
 His Ala Arg Gly Phe Met Ala Trp Val Asn Gln Ala Met Val Pro Asp  
 405 410 415  
 Pro Glu Arg Gly Ala Pro Phe Val Val Gln Arg Ser Thr Ile Met Glu  
 420 425 430  
 Phe Glu His Pro Thr Pro Arg Cys Leu His Glu Pro Ala Gly Ser Ala  
 435 440 445  
 Phe Ser Leu Ala Cys Asp Glu Glu His Leu Tyr Trp Cys Glu Leu Ser  
 450 455 460  
 Ala Gly Arg Leu Glu Leu Trp Arg His Pro His His Arg Pro Gly Ala  
 465 470 475 480  
 Pro Ser Arg Phe Ala Tyr Leu Gly Glu His Pro Ile Ala Ala Thr Trp  
 485 490 495

- 75 -

Tyr Pro Ser Leu Thr Leu Asn Ala Thr His Val Leu Trp Ala Asp Pro  
 500 505 510

Asp Arg Arg Ala Ile Leu Gly Val Asp Lys Arg Thr Gly Val Glu Pro  
 515 520 525

Ile Val Leu Ala Glu Thr Arg His Pro Pro Ala His Val Val Ser Glu  
 530 535 540

Asp Arg Asp Ile Phe Ala Leu Thr Gly Gln Pro Asp Ser Arg Asp Trp  
 545 550 555 560

His Val Glu His Ile Arg Ser Gly Ala Ser Thr Val Val Ala Asp Tyr  
 565 570 575

Gln Arg Gln Leu Trp Asp Arg Pro Asp Met Val Leu Asn Arg Arg Gly  
 580 585 590

Leu Phe Phe Thr Thr Asn Asp Arg Ile Leu Thr Leu Ala Arg Ser  
 595 600 605

<210> 10

<211> 423

<212> PRT

<213> Sorangium cellulosum

<400> 10

Met Gly Ala Leu Ile Ser Val Ala Ala Pro Gly Cys Ala Leu Gly Gly  
 1 5 10 15

Ala Glu Glu Glu Gly Gln Pro Gly Gln Asp Ala Gly Ala Gly Ala Leu  
 20 25 30

Ala Pro Ala Arg Glu Val Met Ala Ala Glu Val Ala Ala Gly Gln Met  
 35 40 45

Pro Gly Ala Val Trp Leu Val Ala Arg Gly Asp Asp Val His Val Asp  
 50 55 60

Ala Val Gly Val Thr Glu Leu Gly Gly Ser Ala Pro Met Arg Arg Asp  
 65 70 75 80

Thr Ile Phe Arg Ile Ala Ser Met Thr Lys Ala Val Thr Ala Thr Ala  
 85 90 95

Val Met Met Leu Val Glu Glu Gly Lys Leu Asp Leu Asp Ser Pro Val  
 100 105 110

Asp Arg Trp Leu Pro Glu Leu Ala Asn Arg Lys Val Leu Ala Arg Ile  
 115 120 125

Asp Gly Pro Ile Asp Glu Thr Val Pro Ala Glu Arg Pro Ile Thr Val  
 130 135 140

Arg Asp Leu Met Thr Phe Thr Met Gly Phe Gly Ile Ser Phe Asp Ala  
 145 150 155 160

Ser Ser Pro Ile Gln Arg Ala Ile Asp Glu Leu Gly Leu Val Asn Ala  
 165 170 175

Gln Pro Val Pro Met Thr Pro His Gly Pro Asp Glu Trp Ile Arg Arg  
 180 185 190

- 76 -

Leu Gly Thr Leu Pro Leu Met His Gln Pro Gly Ala Gln Trp Met Tyr  
 195 200 205  
 Asn Thr Gly Ser Leu Val Gln Gly Val Leu Val Gly Arg Ala Ala Asp  
 210 215 220  
 Gln Gly Phe Asp Ala Phe Val Arg Glu Arg Ile Leu Ala Pro Leu Gly  
 225 230 235 240  
 Met Arg Asp Thr Asp Phe His Val Pro Ala Asp Lys Leu Ala Arg Phe  
 245 250 255  
 Ala Gly Cys Gly Tyr Phe Thr Asp Glu Gln Thr Gly Glu Lys Thr Arg  
 260 265 270  
 Met Asp Arg Asp Gly Ala Glu Ser Ala Tyr Ala Ser Pro Pro Ala Phe  
 275 280 285  
 Pro Ser Gly Ala Ala Gly Leu Val Ser Thr Val Asp Asp Tyr Leu Leu  
 290 295 300  
 Phe Ala Arg Met Leu Met Asn Gly Gly Val His Glu Gly Arg Arg Leu  
 305 310 315 320  
 Leu Ser Ala Ala Ser Val Arg Glu Met Thr Ala Asp His Leu Thr Pro  
 325 330 335  
 Ala Gln Lys Ala Ala Ser Ser Phe Phe Pro Gly Phe Phe Glu Thr His  
 340 345 350  
 Gly Trp Gly Tyr Gly Met Ala Val Val Thr Ala Pro Asp Ala Val Ser  
 355 360 365  
 Glu Val Pro Gly Arg Tyr Gly Trp Asp Gly Gly Phe Gly Thr Ser Trp  
 370 375 380  
 Ile Asn Asp Pro Gly Arg Glu Leu Ile Gly Ile Val Met Thr Gln Ser  
 385 390 395 400  
 Ala Gly Phe Leu Phe Ser Gly Ala Leu Glu Arg Phe Trp Arg Ser Val  
 405 410 415  
 Tyr Val Ala Thr Glu Ser Ala  
 420

<210> 11  
 <211> 7:3  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 11  
 Met His Gly Leu Thr Glu Arg Gln Val Leu Leu Ser Leu Val Thr Leu  
 1 5 10 15  
 Ala Leu Ile Leu Val Thr Ala Arg Ala Ser Gly Glu Leu Ala Arg Arg  
 20 25 30  
 Leu Arg Gln Pro Glu Val Leu Gly Glu Leu Phe Gly Gly Val Val Leu  
 35 40 45  
 Gly Pro Ser Val Val Gly Ala Leu Ala Pro Gly Phe His Arg Ala Leu  
 50 55 60  
 Phe Gln Glu Pro Ala Val Gly Val Val Leu Ser Gly Ile Ser Trp Ile

- 77 -

65	70	75	80
Gly Ala Leu Leu Leu Leu Met Ala Gly Ile Glu Val Asp Val Gly			
85	90	95	
Ile Leu Arg Lys Glu Ala Arg Pro Gly Ala Leu Ser Ala Leu Gly Ala			
100	105	110	
Ile Ala Pro Pro Leu Ala Ala Gly Ala Ala Phe Ser Ala Leu Val Leu			
115	120	125	
Asp Arg Pro Leu Pro Ser Gly Leu Phe Leu Gly Ile Val Leu Ser Val			
130	135	140	
Thr Ala Val Ser Val Ile Ala Lys Val Leu Ile Glu Arg Glu Ser Met			
145	150	155	160
Arg Arg Ser Tyr Ala Gln Val Thr Leu Ala Ala Gly Val Val Ser Glu			
165	170	175	
Val Ala Ala Trp Val Leu Val Ala Met Thr Ser Ser Ser Tyr Gly Ala			
180	185	190	
Ser Pro Ala Leu Ala Val Ala Arg Ser Ala Leu Leu Ala Ser Gly Phe			
195	200	205	
Leu Leu Phe Met Val Leu Val Gly Arg Arg Leu Thr His Leu Ala Met			
210	215	220	
Arg Trp Val Ala Asp Ala Thr Arg Val Ser Lys Gly Gln Val Ser Leu			
225	230	235	240
Val Leu Val Leu Thr Phe Leu Ala Ala Leu Thr Gln Arg Leu Gly			
245	250	255	
Leu His Pro Leu Leu Gly Ala Phe Ala Leu Gly Val Leu Leu Asn Ser			
260	265	270	
Ala Pro Arg Thr Asn Arg Pro Leu Leu Asp Gly Val Gln Thr Leu Val			
275	280	285	
Ala Gly Leu Phe Ala Pro Val Phe Phe Val Leu Ala Gly Met Arg Val			
290	295	300	
Asp Val Ser Gln Leu Arg Thr Pro Ala Ala Trp Gly Thr Val Ala Leu			
305	310	315	320
Leu Leu Ala Thr Ala Thr Ala Ala Lys Val Val Pro Ala Ala Leu Gly			
325	330	335	
Ala Arg Leu Gly Gly Leu Arg Gly Ser Glu Ala Ala Leu Val Ala Val			
340	345	350	
Gly Leu Asn Met Lys Gly Gly Thr Asp Leu Ile Val Ala Ile Val Gly			
355	360	365	
Val Glu Leu Gly Leu Leu Ser Asn Glu Ala Tyr Thr Met Tyr Ala Val			
370	375	380	
Val Ala Leu Val Thr Val Thr Ala Ser Pro Ala Leu Leu Ile Trp Leu			
385	390	395	400
Glu Lys Arg Ala Pro Pro Thr Gln Glu Glu Ser Ala Arg Leu Glu Arg			
405	410	415	

- 78 -

Glu Glu Ala Ala Arg Arg Ala Tyr Ile Pro Gly Val Glu Arg Ile Leu  
 420 425 430  
 Val Pro Ile Val Ala His Ala Leu Pro Gly Phe Ala Thr Asp Ile Val  
 435 440 445  
 Glu Ser Ile Val Ala Ser Lys Arg Lys Leu Gly Glu Thr Val Asp Ile  
 450 455 460  
 Thr Glu Leu Ser Val Glu Gln Gln Ala Pro Gly Pro Ser Arg Ala Ala  
 465 470 475 480  
 Gly Glu Ala Ser Arg Gly Leu Ala Arg Leu Gly Ala Arg Leu Arg Val  
 485 490 495  
 Gly Ile Trp Arg Gln Arg Arg Glu Leu Arg Gly Ser Ile Gln Ala Ile  
 500 505 510  
 Leu Arg Ala Ser Arg Asp His Asp Leu Leu Val Ile Gly Ala Arg Ser  
 515 520 525  
 Pro Ala Arg Ala Arg Gly Met Ser Phe Gly Arg Leu Gln Asp Ala Ile  
 530 535 540  
 Val Gln Arg Ala Glu Ser Asn Val Leu Val Val Val Gly Asp Pro Pro  
 545 550 555 560  
 Ala Ala Glu Arg Ala Ser Ala Arg Arg Ile Leu Val Pro Ile Ile Gly  
 565 570 575  
 Leu Glu Tyr Ser Phe Ala Ala Ala Asp Leu Ala Ala His Val Ala Leu  
 580 585 590  
 Ala Trp Asp Ala Glu Leu Val Leu Leu Ser Ser Ala Gln Thr Asp Pro  
 595 600 605  
 Gly Ala Val Val Trp Arg Asp Arg Glu Pro Ser Arg Val Arg Ala Val  
 610 615 620  
 Ala Arg Ser Val Val Asp Glu Ala Val Phe Arg Gly Arg Arg Leu Gly  
 625 630 635 640  
 Val Arg Val Ser Ser Arg Val His Val Gly Ala His Pro Ser Asp Glu  
 645 650 655  
 Ile Thr Arg Glu Leu Ala Arg Ala Pro Tyr Asp Leu Leu Val Leu Gly  
 660 665 670  
 Cys Tyr Asp His Gly Pro Leu Gly Arg Leu Tyr Leu Gly Ser Thr Val  
 675 680 685  
 Glu Ser Val Val Val Arg Ser Arg Val Pro Val Ala Leu Leu Val Ala  
 690 695 700  
 His Gly Gly Thr Arg Glu Gln Val Arg  
 705 710

<210> 12  
 <211> 126  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 12  
 Met Asp Lys Pro Ile Gly Arg Thr Arg Cys Ala Ile Ala Glu Gly Tyr

- 79 -

1	5	10	15
Ile Pro Gly Gly Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu			
20	25	30	
Thr Ala Cys Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile			
35	40	45	
Thr Val Tyr Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr			
50	55	60	
Val Pro Ala Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu			
65	70	75	80
Pro Glu Pro Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser			
85	90	95	
Asp Ala Pro Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala			
100	105	110	
Glu Asn Ala Leu Leu Ser Thr Ile Ala Tyr Thr Asp Arg Glu			
115	120	125	
 <210> 13			
<211> 149			
<212> PRT			
<213> Sorangium cellulosum			
 <400> 13			
Met Lys His Val Asp Thr Gly Arg Arg Phe Gly Arg Arg Ile Gly His			
1	5	10	15
Thr Leu Gly Leu Leu Ala Ser Met Ala Leu Ala Gly Cys Gly Pro			
20	25	30	
Ser Glu Lys Thr Val Gln Gly Thr Arg Leu Ala Pro Gly Ala Asp Ala			
35	40	45	
Arg Val Thr Ala Asp Val Asp Pro Asp Ala Ala Thr Thr Arg Leu Ala			
50	55	60	
Val Asp Val Val His Leu Ser Pro Pro Glu Arg Leu Glu Ala Gly Ser			
65	70	75	80
Glu Arg Phe Val Val Trp Gln Arg Pro Ser Pro Glu Ser Pro Trp Arg			
85	90	95	
Arg Val Gly Val Leu Asp Tyr Asn Ala Asp Ser Arg Arg Gly Lys Leu			
100	105	110	
Ala Glu Thr Thr Val Pro Tyr Ala Asn Phe Glu Leu Leu Ile Thr Ala			
115	120	125	
Glu Lys Gln Ser Ser Pro Gln Ser Pro Ser Ser Ala Ala Val Ile Gly			
130	135	140	
Pro Thr Ser Val Gly			
145			
 <210> 14			
<211> 184			
<212> PRT			
<213> Sorangium cellulosum			

- 80 -

<400> 14  
 Val Thr Ser Glu Glu Val Pro Gly Ala Ala Leu Gly Ala Gln Ser Ser  
 1 5 10 15  
 Leu Val Arg Ala Gln His Ala Ala Arg His Val Arg Pro Cys Thr Arg  
 20 25 30  
 Ala Glu Glu Pro Pro Ala Leu Met His Gly Leu Thr Glu Arg Gln Val  
 35 40 45  
 Leu Leu Ser Leu Val Ala Leu Ala Leu Val Leu Leu Thr Ala Arg Ala  
 50 55 60  
 Phe Gly Glu Leu Ala Arg Arg Leu Arg Gln Pro Glu Val Leu Gly Glu.  
 65 70 75 80  
 Leu Phe Gly Gly Val Val Leu Gly Pro Ser Val Val Gly Ala Leu Ala  
 85 90 95  
 Pro Gly Phe His Arg Val Leu Phe Gln Asp Pro Ala Val Gly Val Val  
 100 105 110  
 Leu Ser Gly Ile Ser Trp Ile Gly Ala Leu Val Leu Leu Met Ala  
 115 120 125  
 Gly Ile Glu Val Asp Val Ser Ile Leu Arg Lys Glu Ala Arg Pro Gly  
 130 135 140  
 Ala Leu Ser Ala Leu Gly Ala Ile Ala Pro Pro Leu Arg Thr Pro Gly  
 145 150 155 160  
 Pro Leu Val Gln Arg Met Gln Gly Ala Phe Thr Trp Asp Leu Asp Val  
 165 170 175  
 Ser Pro Arg Arg Ser Ala Gln Ala  
 180

<310> 15  
<311> 145  
<212> PRT  
<213> Sorangium cellulosum

<400> 15  
 Val Asn Ala Pro Cys Met Arg Cys Thr Ser Gly Pro Gly Val Arg Ser  
 1 5 10 15  
 Gly Gly Ala Ile Ala Pro Ser Ala Glu Ser Ala Pro Gly Arg Ala Ser  
 20 25 30  
 Leu Arg Arg Met Leu Thr Ser Thr Ser Ile Pro Ala Met Ser Ser Arg  
 35 40 45  
 Thr Ser Ala Pro Ile Gln Glu Met Pro Glu Ser Thr Thr Pro Thr Ala  
 50 55 60  
 Gly Ser Trp Lys Arg Thr Arg Trp Asn Pro Gly Ala Ser Ala Pro Thr  
 65 70 75 80  
 Thr Asp Gly Pro Ser Thr Thr Pro Pro Lys Ser Ser Pro Ser Thr Ser  
 85 90 95  
 Gly Trp Arg Ser Arg Arg Ala Ser Ser Pro Lys Ala Arg Ala Val Arg  
 100 105 110

- 81 -

Arg Thr Ser Ala Arg Ala Thr Ser Glu Ser Arg Thr Cys Arg Ser Val  
 115 120 125

Arg Pro Cys Ile Arg Ala Gly Gly Ser Ser Ala Arg Val Gln Gly Arg  
 130 135 140

Thr  
 145

<210> 16  
 <211> 185  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 16  
 Val Leu Ala Pro Pro Ala Asp Ile Arg Pro Pro Ala Ala Ala Gln Leu  
 1 5 10 15

Glu Pro Asp Ser Pro Asp Asp Glu Ala Asp Glu Ala Asp Glu Ala Leu  
 20 25 30

Arg Pro Phe Arg Asp Ala Ile Ala Ala Tyr Ser Glu Ala Val Arg Trp  
 35 40 45

Ala Glu Ala Ala Gln Arg Pro Arg Leu Glu Ser Leu Val Arg Leu Ala  
 50 55 60

Ile Val Arg Leu Gly Lys Ala Leu Asp Lys Val Pro Phe Ala His Thr  
 65 70 75 80

Thr Ala Gly Val Ser Gln Ile Ala Gly Arg Leu Gln Asn Asp Ala Val  
 85 90 95

Trp Phe Asp Val Ala Ala Arg Tyr Ala Ser Phe Arg Ala Ala Thr Glu  
 100 105 110

His Ala Leu Arg Asp Ala Ala Ser Ala Met Glu Ala Leu Ala Ala Gly  
 115 120 125

Pro Tyr Arg Gly Ser Ser Arg Val Ser Ala Ala Val Gly Glu Phe Arg  
 130 135 140

Gly Glu Ala Ala Arg Leu His Pro Ala Asp Arg Val Pro Ala Ser Asp  
 145 150 155 160

Gln Gln Ile Leu Thr Ala Leu Arg Ala Ala Glu Arg Ala Leu Ile Ala  
 165 170 175

Leu Tyr Thr Ala Phe Ala Arg Glu Glu  
 180 185

<210> 17  
 <211> 146  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 17  
 Met Ala Asp Ala Ala Ser Arg Ser Ala Cys Ser Val Ala Ala Arg Lys  
 1 5 10 15

Leu Ala Tyr Arg Ala Ala Thr Ser Asn Gln Thr Ala Ser Phe Trp Ser  
 20 25 30

- 82 -

Leu Pro Ala Ile Trp Glu Thr Pro Ala Val Val Cys Ala Lys Gly Thr  
 35                   40                   45

Leu Ser Ser Ala Leu Pro Ser Arg Thr Ile Ala Ser Arg Thr Arg Leu  
 50                   55                   60

Ser Ser Arg Gly Arg Cys Ala Ala Ser Ala His Arg Thr Ala Ser Glu  
 65                   70                   75                   80

Tyr Ala Ala Ile Ala Ser Arg Asn Gly Arg Ser Ala Ser Ser Ala Ser  
 85                   90                   95

Ser Ala Ser Ser Ser Gly Glu Ser Gly Ser Ser Trp Ala Ala Ala Gly  
 100               105               110

Gly Arg Met Ser Ala Gly Gly Ala Ser Thr Gly Glu Val Tyr Glu Gln  
 115               120               125

Ala Pro Arg Leu Arg Leu Ala Gln Ser Val Ala Ala Arg Arg Arg Asp  
 130               135               140

Pro Thr  
 145

<210> 18

<211> 288

<212> PRT

<213> Sorangium cellulosum

<400> 18

Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr  
 1               5               10               15

Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser  
 20               25               30

Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu  
 35               40               45

Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His  
 50               55               60

Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg  
 65               70               75               80

Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr  
 85               90               95

Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala  
 100              105              110

Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn  
 115              120              125

Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly  
 130              135              140

Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser  
 145              150              155              160

Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser  
 165              170              175

- 83 -

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val  
 180 185 190

Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg  
 195 200 205

Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys  
 210 215 220

Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr  
 225 230 235 240

Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys  
 245 250 255

Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu  
 260 265 270

Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg  
 275 280 285

<210> 19  
<211> 288  
<212> PRT  
<213> Sorangium cellulosum

<400> 19  
Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr  
 1 5 10 15

Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser  
 20 25 30

Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu  
 35 40 45

Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His  
 50 55 60

Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg  
 65 70 75 80

Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr  
 85 90 95

Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala  
 100 105 110

Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn  
 115 120 125

Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly  
 130 135 140

Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser  
 145 150 155 160

Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser  
 165 170 175

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val

- 84 -

180	185	190	
Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg			
195	200	205	
Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys			
210	215	220	
Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr			
225	230	235	240
Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys			
245	250	255	
Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu			
260	265	270	
Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg			
275	280	285	

<210> 20  
 <211> 155  
 <212> PRT  
 <213> Sorangium cellulosum

 <400> 20  
 Met Asp Pro Arg Ala Arg Arg Glu Lys Arg Pro Ser Leu Leu Asp Ser  
     1               5                         10                         15  
 Arg Gly Arg Gln Pro Lys Arg Ser Gln Gln Gly Gly His Met Glu Lys  
     20  25                         30  
 Pro Ile Gly Arg Thr Arg Trp Ala Ile Ala Glu Gly Tyr Ile Pro Gly  
     35  40                         45  
 Arg Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu Thr Ala Cys  
     50  55                         60  
 Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile Thr Val Tyr  
     65  70                         75                         80  
 Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr Val Pro Ala  
     85  90                         95  
 Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu Pro Glu Pro  
     100                                      105                         110  
 Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser Asp Val Pro  
     115                                      120                         125  
 Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala Glu Asn Ala  
     130                                      135                         140  
 Leu Ile Ser Thr Ile Ala Tyr Thr Asp Arg Glu  
     145                                      150                         155

 <210> 21  
 <211> 156  
 <212> PRT  
 <213> Sorangium cellulosum

- 85 -

<400> 21  
 Val Arg Arg Ser Arg Trp Gln Met Lys His Val Asp Thr Gly Arg Arg  
 1 5 10 15  
 Val Gly Arg Arg Ile Gly Leu Thr Leu Gly Leu Leu Ala Ser Met Ala  
 20 25 30  
 Leu Ala Gly Cys Gly Gly Pro Ser Glu Lys Ile Val Gln Gly Thr Arg  
 35 40 45  
 Leu Ala Pro Gly Ala Asp Ala His Val Ala Ala Asp Val Asp Pro Asp  
 50 55 60  
 Ala Ala Thr Thr Arg Leu Ala Val Asp Val Val His Leu Ser Pro Pro  
 65 70 75 80  
 Glu Arg Ile Glu Ala Gly Ser Glu Arg Phe Val Val Trp Gln Arg Pro  
 85 90 95  
 Ser Ser Glu Ser Pro Trp Gln Arg Val Gly Val Leu Asp Tyr Asn Ala  
 100 105 110  
 Ala Ser Arg Arg Gly Lys Leu Ala Glu Thr Thr Val Pro His Ala Asn  
 115 120 125  
 Phe Glu Leu Leu Ile Thr Val Glu Lys Gln Ser Ser Pro Gln Ser Pro  
 130 135 140  
 Ser Ser Ala Ala Val Ile Gly Pro Thr Ser Val Gly  
 145 150 155

<210> 22  
<211> 305  
<212> PRT  
<213> Sorangium cellulosum

<400> 22  
 Met Glu Lys Glu Ser Arg Ile Ala Ile Tyr Gly Ala Ile Ala Ala Asn  
 1 5 10 15  
 Val Ala Ile Ala Ala Val Lys Phe Ile Ala Ala Ala Val Thr Gly Ser  
 20 25 30  
 Ser Ala Met Leu Ser Glu Gly Val His Ser Leu Val Asp Thr Ala Asp  
 35 40 45  
 Gly Leu Leu Leu Leu Gly Lys His Arg Ser Ala Arg Pro Pro Asp  
 50 55 60  
 Ala Glu His Pro Phe Gly His Gly Lys Glu Leu Tyr Phe Trp Thr Leu  
 65 70 75 80  
 Ile Val Ala Ile Met Ile Phe Ala Ala Gly Gly Val Ser Ile Tyr  
 85 90 95  
 Glu Gly Ile Leu His Leu Leu His Pro Arg Gln Ile Glu Asp Pro Thr  
 100 105 110  
 Trp Asn Tyr Val Val Leu Gly Ala Ala Ala Val Phe Glu Gly Thr Ser  
 115 120 125  
 Leu Ile Ile Ser Ile His Glu Phe Lys Lys Lys Asp Gly Gln Gly Tyr  
 130 135 140

- 86 -

Leu Ala Ala Met Arg Ser Ser Lys Asp Pro Thr Thr Phe Thr Ile Val  
 145 150 155 160  
 Leu Glu Asp Ser Ala Ala Leu Ala Gly Leu Thr Ile Ala Phe Leu Gly  
 165 170 175  
 Val Trp Leu Gly His Arg Leu Gly Asn Pro Tyr Leu Asp Gly Ala Ala  
 180 185 190  
 Ser Ile Gly Ile Gly Leu Val Leu Ala Ala Val Ala Val Phe Leu Ala  
 195 200 205  
 Ser Gln Ser Arg Gly Leu Leu Val Gly Glu Ser Ala Asp Arg Glu Leu  
 210 215 220  
 Leu Ala Ala Ile Arg Ala Leu Ala Ser Ala Asp Pro Gly Val Ser Ala  
 225 230 235 240  
 Val Gly Arg Pro Leu Thr Met His Phe Gly Pro His Glu Val Leu Val  
 245 250 255  
 Val Leu Arg Ile Glu Phe Asp Ala Ala Leu Thr Ala Ser Gly Val Ala  
 260 265 270  
 Glu Ala Ile Glu Arg Ile Glu Thr Arg Ile Arg Ser Glu Arg Pro Asp  
 275 280 285  
 Val Lys His Ile Tyr Val Glu Ala Arg Ser Leu His Gln Arg Ala Arg  
 290 295 300  
 Ala  
 305

<210> 23  
 <211> 135  
 <212> PRT  
 <213> Sorangium cellulosum

<400> 23  
 Val Gln Thr Ser Ser Phe Asp Ala Arg Tyr Ala Gly Cys Lys Ser Ser  
 1 5 10 15  
 Arg Arg Ile Ala Arg Ser Gly Ser Ala Gly Ala Arg Ala Gly Arg Ala  
 20 25 30  
 His Glu Gly Ala Ala Ser Ala Gly Phe Glu Gly Gly Asp Val Met Arg  
 35 40 45  
 Lys Ala Arg Ala His Gly Ala Met Leu Gly Gly Arg Asp Asp Gly Trp  
 50 55 60  
 Arg Arg-Gly Leu Pro Gly Ala Gly Ala Leu Arg Ala Ala Leu Gln Arg  
 65 70 75 80  
 Gly Arg Ser Arg Asp Leu Ala Arg Arg Arg Leu Ile Ala Ser Val Ser  
 85 90 95  
 Leu Ala Gly Gly Ala Ser Met Ala Val Val Ser Leu Phe Gln Leu Gly  
 100 105 110  
 Ile Ile Glu Arg Leu Pro Asp Pro Pro Leu Pro Gly Phe Asp Ser Ala  
 115 120 125

- 87 -

Lys Val Thr Ser Ser Asp Ile  
130 135

<210> 24  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: universal  
reverse primer

<400> 24  
ggaaaacagct atgaccatg

19

<210> 25  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: universal  
forward primer

<400> 25  
gtaaaaacgac ggccagt

17

<210> 26  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer  
NH24 end "B"

<400> 26  
gtgactggcg cctggaatct gcatgagc

28

<210> 27  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer NH2  
end "A"

<400> 27  
agcggagct tgcttagacat tctgtttc

28

<210> 28  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer NH2  
end "B"

<400> 28  
gacgcgcctc gggcagcgcc ccaa

24

<210> 29

- 88 -

<211> 25  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
pEPO15-NH6 end "B"

<400> 29  
caccgaagcg tcgatctggc ccatc 25

<210> 30  
<211> 25  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
pEPO15H2.7 end "A"

<400> 30  
cggtcagatc gacgacgggc tttcc 25



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>C12N 15/52, C07D 493/00, C07K 14/535</b>	A3	(11) International Publication Number: <b>WO 99/66028</b> (43) International Publication Date: <b>23 December 1999 (23.12.1999)</b>						
<p>(21) International Application Number: <b>PCT/EP99/04171</b></p> <p>(22) International Filing Date: <b>16 June 1999 (16.06.1999)</b></p> <p>(30) Priority Data:</p> <table> <tr> <td>09/099,504</td> <td>18 June 1998 (18.06.1998) US</td> </tr> <tr> <td>60/101,631</td> <td>24 September 1998 (24.09.1998) US</td> </tr> <tr> <td>60/118,906</td> <td>05 February 1999 (05.02.1999) US</td> </tr> </table> <p>(60) Parent Application or Grant</p> <p>NOVARTIS AG [/]; (.) NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [/]; (.) SCHUPP, Thomas [/]; (.) LIGON, James, Madison [/]; (.) MOLNAR, Istvan [/]; (.) ZIRKLE, Ross [/]; (.) GÖRLACH, Jörn [/]; (.) CYR, Devon [/]; (.) SCHUPP, Thomas [/]; (.) LIGON, James, Madison [/]; (.) MOLNAR, Istvan [/]; (.) ZIRKLE, Ross [/]; (.) GÖRLACH, Jörn [/]; (.) CYR, Devon [/]; (.) BECKER, Konrad ; (.)</p>		09/099,504	18 June 1998 (18.06.1998) US	60/101,631	24 September 1998 (24.09.1998) US	60/118,906	05 February 1999 (05.02.1999) US	Published
09/099,504	18 June 1998 (18.06.1998) US							
60/101,631	24 September 1998 (24.09.1998) US							
60/118,906	05 February 1999 (05.02.1999) US							

(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES  
 (54) Titre: GENES POUR LA BIOSYNTHÈSE D'EPOTHILONES

## (57) Abstract

Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

## (57) Abrégé

L'invention porte: sur des molécules d'acide nucléique isolées à partir de Sorangium cellulosum et codant pour des polypeptides nécessaires à la biosynthèse de l'épothilone; sur des procédés de production d'épothilone dans des hôtes de recombinaison transformés au moyen des gènes de l'invention. On peut ainsi produire l'épothilone en quantités suffisantes pour permettre sa purification et son utilisation dans des préparation pharmaceutiques telles que celles utilisées pour le traitement du cancer.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/52, C07K 14/535, C07D 493/00</b>		A3	(11) International Publication Number: <b>WO 99/66028</b> (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: <b>PCT/EP99/04171</b>		[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US).	
(22) International Filing Date: 16 June 1999 (16.06.99)		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	
(30) Priority Data: 09/099,504 18 June 1998 (18.06.98) US 60/101,631 24 September 1998 (24.09.98) US 60/118,906 5 February 1999 (05.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except AT/US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).		(88) Date of publication of the international search report: 29 June 2000 (29.06.00)	
(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES			
(57) Abstract			
<p>Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
RJ	Reina	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KR	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Cote d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**INTERNATIONAL SEARCH REPORT**

International Application No PCT/EP 99/04171
---

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/52 C07K14/535 C07D493/00
---

According to International Patent Classification (IPC) or to both national classification and IPC
---

<b>B. FIELDS SEARCHED</b>
---------------------------

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K C07D
---

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
---

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>
---

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 22461 A (BIOTECHNOLOG FORSCHUNG GMBH ;GERTH KLAUS (DE); HOEFLER GERHARD (DE)) 28 May 1998 (1998-05-28) the whole document	1-10
Y	SCHUPP T. ET AL.: "A Sorangium cellulosum (myxobacterium) gene cluster for the biosynthesis of the macrolide antibiotic soraphen A: cloning, characterization and homology to polyketide synthase genes from actinomycetes" J. BACTERIOL., vol. 177, no. 13, 1995, pages 3673-3679, XP000893003 the whole document	1-10

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
--	--

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"C" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the International search	Date of mailing of the International search report
---	--

17 April 2000

03/05/2000

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentstaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx: 31 651 epo nl Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

Panzica, G

## INTERNATIONAL SEARCH REPORT

Inte xnat Application No  
PCT/EP 99/04171

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MOLNAR I. ET AL.: "The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from <i>Sorangium cellulosum</i> So ce90" CHEM. BIOL., vol. 7, 2000, pages 97-109, XP000904734 the whole document	1-93
T	TANG LI, ET AL.: "Cloning and heterologous expression of the epothilone gene cluster." SCIENCE, vol. 287, 28 January 2000 (2000-01-28), pages 640-642, XP002135841 the whole document	1-93

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Int'l	Int'l Application No
PCT/EP 99/04171	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9822461	A 28-05-1998	AU	5483798 A	10-06-1998
		CN	1237970 A	08-12-1999
		CZ	9901750 A	15-09-1999
		EP	0941227 A	15-09-1999
		NO	992338 A	14-05-1999
		PL	333435 A	06-12-1999